<SEC-DOCUMENT>0001144204-12-044299.txt : 20120810
<SEC-HEADER>0001144204-12-044299.hdr.sgml : 20120810
<ACCEPTANCE-DATETIME>20120810115450
ACCESSION NUMBER:		0001144204-12-044299
CONFORMED SUBMISSION TYPE:	POS EX
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20120810
DATE AS OF CHANGE:		20120810
EFFECTIVENESS DATE:		20120810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS EX
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-180562
		FILM NUMBER:		121023451

	BUSINESS ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE,
		STREET 2:		SUITE 200
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE,
		STREET 2:		SUITE 200
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS EX
<SEQUENCE>1
<FILENAME>v319529_posex.htm
<DESCRIPTION>POST-EFFECTIVE AMENDMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>AS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION ON AUGUST 10, 2012 REGISTRATION NO. 333-180562</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="text-align: right; margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POST-EFFECTIVE AMENDMENT NO. 2  TO
FORM S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ON</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B> <B>UNDER</B>
<B>THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SYNTHETIC BIOLOGICS, INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nevada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or Other Jurisdiction of Incorporation
or Organization)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2834</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">(Primary Standard Industrial
Classification Code Number)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>13-3808303</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer Identification No.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>617 Detroit Street, Suite 100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ann Arbor, MI 48104</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(734)&nbsp;332-7800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address and telephone number of principal
executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Copy to:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Leslie Marlow, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Hank Gracin, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Gracin &amp; Marlow, LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Chrysler Building</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>405 Lexington Avenue, 26th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10174<BR>
(212) 907-6457</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address and telephone number of agent
for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximate Date of Proposed Sale to the
Public: From time to time after the date this registration statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following box. </FONT><FONT STYLE="font-family: Wingdings">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the
same offering. </FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT STYLE="font-family: Wingdings">&thorn;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;(File
No. 333-180562)</FONT><FONT STYLE="font-family: Wingdings"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the Registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.&nbsp;&nbsp;See the
definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41%">Large accelerated filer</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD STYLE="width: 39%">Accelerated filer</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Wingdings">o</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Non-accelerated filer</TD>
    <TD><FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD>Smaller reporting company</TD>
    <TD><FONT STYLE="font-family: Wingdings">&thorn;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(Do not check if a smaller reporting company)</TD>
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Post-Effective Amendment No.
2 to Form S-3 on Form S-1 Registration Statement (File No. 333-180562) is filed pursuant to Rule 462(d) solely to add XBRL
exhibits not previously filed with respect to such registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II - INFORMATION NOT REQUIRED IN
PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 16. EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.1</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Certificate of Incorporation, as amended (Incorporated by reference to (i)&nbsp;Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed October 16, 2008, (ii)&nbsp;Exhibit&nbsp;3.1 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2001 filed August 14, 2001 and (iii)&nbsp;Exhibits 3.1, 4.1 and 4.2 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 1998 filed August 14, 1998)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.2</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Articles of Merger (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed October 19, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.3</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Certificate of Merger filed with the Secretary of State of Delaware (Incorporated by reference to Exhibit 3.2 of the Registrant&rsquo;s Current Report on Form 8-K filed October 19, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.4</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Articles of Incorporation filed with the Nevada Secretary of State (Incorporated by reference to Exhibit 3.3 of the Registrant&rsquo;s Current Report on Form 8-K filed October 19, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.5</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">By-Laws (Incorporated by reference to (i) Exhibit 3.4 of the Registrant&rsquo;s Current Report on Form 8-K filed October 19, 2009 and (ii) Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed June 3, 2010. )</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.6</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Amended and Restated Bylaws Adopted and Effective October 31, 2011 (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed November 2, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">3.7</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Certificate of Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed February 16, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">4.1</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Form of Warrant Certificate (Incorporated by reference to Exhibit 4.1 to the Registrant&rsquo;s Current Report on Form 8-K filed December 1, 2006.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*4.2</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">2001 Stock Incentive Plan (Incorporated by reference to Exhibit 4.1 of the Registrant&rsquo;s Registration Statement on Form S-8 filed January 18, 2008.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*4.3</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">2007 Stock Incentive Plan (Incorporated by reference to Exhibit 4.2 of the Registrant&rsquo;s Registration Statement on Form S-8 filed January 18, 2008.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*4.4</TD>
    <TD STYLE="width: 92%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">2010 Stock Incentive Plan (Incorporated by reference
        to Exhibit 4.1 of the Registrant&rsquo;s Registration Statement on Form S-8 filed November 29, 2010.)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">4.5</TD>
    <TD STYLE="padding-right: 0.8pt">Form of Warrant Certificate issued to Enclave Capital LLC (Incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form 8-K filed July 6, 2010.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">4.6</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Form of Warrant to Purchase Common Stock issued January 2011(Incorporated by reference to Exhibit 10.3 of the Registrant&rsquo;s Current Report on Form 8-K filed February 2, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">4.7</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Form of Warrant to Purchase Common Stock issued April 2011(Incorporated by reference to Exhibit 10.3 of the Registrant&rsquo;s Current Report on Form 8-K filed April 6, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">4.8</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Form of Exchange Warrant to Purchase Common Stock issued in exchange of the Warrant issued April 2011(Incorporated by reference to Exhibit 4.1 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 filed August 15, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">4.9</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Form of Exchange Warrant to Purchase Common Stock issued in exchange of the Warrant issued February 2011(Incorporated by reference to Exhibit 4.2 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 filed August 15, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">4.10</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify">Form of Warrant to Purchase Common Stock issued February 2012 (Incorporated by reference to Exhibit 4.10 of the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2011 filed March 30, 2012.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">4.11</TD>
    <TD STYLE="padding-right: 0.8pt">Form of Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.10 of the Registrant&rsquo;s Annual Report on Form 10-K filed March 30, 2012.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">5.1</TD>
    <TD STYLE="padding-right: 0.8pt">Legal Opinion of Gracin &amp; Marlow, LLP **</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">10.1</TD>
    <TD STYLE="padding-right: 0.8pt">Unit Purchase Agreement (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Current Report on Form 8-K filed December 1, 2006.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.2</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">License Agreement between The Regents of the University of California and Epitope Pharmaceuticals, Inc. (Incorporated by reference to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2008 filed November 14, 2008.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*10.3</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify">Form of Director/Officer Indemnification Agreement (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed January 6, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.4</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Warrant Cancellation and Registration Rights Agreement between Accredited Adventures Capital LLC and Adeona (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed January 20, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.5</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Stock Purchase Agreement with Neil O. Colwell and Connie Colwell&nbsp;&nbsp;(Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed April 16, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.6</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Escrow Agreement Nayaran Torke (Incorporated by reference to Exhibit 10.5 of the Registrant&rsquo;s Current Report on Form 8-K filed July 16, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.7</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Consulting Agreement with Nayaran Torke (Incorporated by reference to Exhibit 10.4 of the Registrant&rsquo;s Current Report on Form 8-K filed July 16, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.8</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Purchase Agreement 1st Amendment HartLab LLC (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed July 16, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.9</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Purchase Agreement 2nd Amendment Hartlab LLC (Incorporated by reference to Exhibit 10.3 of the Registrant&rsquo;s Current Report on Form 8-K filed July 16, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.10</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Agreement and Plan of Reincorporation Merger (Incorporated by reference to Exhibit 1.1 of the Registrant&rsquo;s Current Report on Form 8-K filed October 19, 2009.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*10.11</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Employment Agreement with James S. Kuo, M.D., (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed February 9, 2010.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*10.12</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Separation Agreement with Max Lyons (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed February 9, 2010.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">10.13</TD>
    <TD STYLE="padding-right: 0.8pt">Sublicense Agreement between Meda AB, Adeona Pharamaceuticals, Inc. and Pipex Therapeutics, Inc. (Incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K filed May 11, 2010.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.14</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Non-Disturbance Agreement among Pipex Therapeutics, Inc., Mclean Hospital Corp and Meda AB (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed May 11, 2010.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.15</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify">Placement Agent Agreement with Enclave Capital LLC (Incorporated by reference to Exhibit 1.1 of the Registrant&rsquo;s Current Report on Form 8-K filed July 6, 2010.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.16</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify">Common Stock Purchase Agreement with Seaside 88,LP (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed July 6, 2010.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.17</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify">Agreement with Chardan Capital Markets, LLC (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed February 2, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.18</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Securities Purchase Agreement with investors (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed February 2, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.19</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">McLean Hospital Corporation Exclusive License Agreement (Incorporated by reference to Exhibit 10.21 of the Registrant&rsquo;s Annual Report on Form 10-K filed March 31, 2011)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.20</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Agreement with Chardan Capital Markets, LLC (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed April 6, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.21</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Securities Purchase Agreement with investors (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed April 6, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.22</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Exchange Agreement with respect to Warrant issued April 2011(Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 filed August 15, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.23</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Exchange Agreement with respect to Warrant issued February 2011(Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 filed August 15, 2011.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">10.24</TD>
    <TD STYLE="padding-right: 0.8pt">Exclusive Channel Collaboration Agreement with Intrexon Corporation (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed November 21, 2011.)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.25</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Stock Purchase Agreement with Intrexon Corporation (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed November 21, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.26</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Registration Rights Agreement with Intrexon Corporation (Incorporated by reference to Exhibit 10.3 of the Registrant&rsquo;s Current Report on Form 8-K filed November 21, 2011.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*10.27</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Employment Agreement with Jeffrey Riley (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed February 6, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.28</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Consulting Agreement with Dr. James Kuo (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed February 6, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*10.29</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Employment Agreement with C. Evan Ballantyne (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed February 7, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">*10.30</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Employment Agreement with Steve H. Kanzer (1)Incorporated by reference to Exhibit 10.304 of the Registrant's Annual&nbsp; Report on Form 10-K for the year ended December 31, 2011 filed March 30, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.31</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Membership Interest Purchase Agreement by and among Synthetic Biologics, Inc., Hartlab LLC, and Adeona Clinical Laboratory, LLC, dated as of March 7, 2012 (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed March 12, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.32</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Pledge and Security Agreement between Synthetic Biologics, Inc. and Hartlab, LLC dated as of March 7, 2012 (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed March 12, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-right: 0.8pt">10.33</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Non-Recourse Promissory Note between Synthetic Biologics, Inc. and Hartlab, LLC dated as of March 7, 2012 (Incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K filed March 12, 2012.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">10.34</TD>
    <TD STYLE="padding-right: 0.8pt">Financial Advisory Agreement with Griffin Securities, Inc. (Incorporated by reference to Exhibit 10.34 of the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2011 filed March 30, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">21</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">List of Subsidiaries (Incorporated by reference to Exhibit 10.34 of the Registrant&rsquo;s Annual Report on Form 10-K filed March 30, 2012.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">23.1</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">Consent of Independent Registered Accounting Firm **</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">23.2</TD>
    <TD STYLE="width: 92%">Consent of Gracin &amp; Marlow, LLP (Included in its opinion filed as Exhibit 5)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>24</TD>
    <TD>Power of Attorney (Included on signature page)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.INS</TD>
    <TD>XBRL Instance Document ***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.SCH</TD>
    <TD>XBRL Taxonomy Extension Schema Document ***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.CAL</TD>
    <TD>XBRL Taxonomy Calculation Linkbase Document ***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.LAB</TD>
    <TD>XBRL Taxonomy Extension Label Linkbase Document ***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.PRE</TD>
    <TD>XBRL Taxonomy Extension Presentation Linkbase Document ***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.DEF</TD>
    <TD>XBRL Taxonomy Extension Definition Linkbase Document ***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Management contract or compensatory plan or arrangement required
to be identified pursuant to Item 15(a)(3) of this report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">** Previously filed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*** Filed herewith</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
on the Post-Effective Amendment No. 2 to Form S-3 on Form&nbsp;S-1 and has duly caused this registration statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of Ann Arbor, State of Michigan, August 10, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">SYNTHETIC BIOLOGICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="width: 31%; padding-right: 0.8pt; border-bottom: Black 1pt solid">/s/ Jeffrey Riley</TD>
    <TD STYLE="width: 15%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Chief Executive Officer and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">(Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Date: August 10, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">By:</TD>
    <TD STYLE="width: 31%; border-bottom: black 1pt solid; padding-right: 0.8pt">/s/ C. Evan Ballantyne</TD>
    <TD STYLE="width: 15%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">(Principal Financial and Principal Accounting Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Date: August 10, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the
dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">By:</TD>
    <TD STYLE="width: 42%; border-bottom: black 1pt solid; padding-right: 0.8pt">/s/ Jeffrey Riley</TD>
    <TD STYLE="width: 35%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Date: August 10, 2012</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Chief Executive Officer and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">(Principal Executive Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%; padding-right: 0.8pt; padding-bottom: 1pt">Date: August 10, 2012</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="width: 42%; padding-right: 0.8pt; border-bottom: Black 1pt solid">/s/ Jeffrey J. Kraws *</TD>
    <TD STYLE="width: 35%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Jeffrey J. Kraws</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Chairman</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%; padding-right: 0.8pt; padding-bottom: 1pt">Date: August 10, 2012</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="width: 42%; padding-right: 0.8pt; border-bottom: Black 1pt solid">/s/ Steve H. Kanzer *</TD>
    <TD STYLE="width: 35%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Steve H. Kanzer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%; padding-right: 0.8pt; padding-bottom: 1pt">Date: August 10, 2012</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="width: 42%; padding-right: 0.8pt; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="width: 35%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">James S. Kuo</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">Date: August 10, 2012</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="padding-right: 0.8pt; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Nelson K. Stacks</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">Date: August 10, 2012</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="padding-right: 0.8pt; border-bottom: Black 1pt solid">/s/ Scott L. Tarriff *</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Scott L. Tarriff</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">Date: August 10, 2012</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">By:</TD>
    <TD STYLE="padding-right: 0.8pt; border-bottom: Black 1pt solid">/s/ Jeffrey Wolf *</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0.8pt; padding-bottom: 1pt">Jeffrey Wolf</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0.8pt; padding-bottom: 1pt">Director</TD>
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt"></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; padding-bottom: 1pt; font-size: 10pt">*By:<U>/s/Jeffrey Riley&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt">Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt">Chief Executive Officer and President</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt">Attorney-in-fact</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>2
<FILENAME>syn-20120331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- XBRL document created with Ez-XBRL version 5.0.1.0 [07/27/2012 03:20:35 PM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.3.6 on Thursday, August 09, 2012 08:36:39 PM -->
<xbrli:xbrl xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:syn="http://www.adeonapharma.com/20120331">
	<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="syn-20120331.xsd"/>
	<!-- Context Section  -->
	<xbrli:context id="Context_FYE_31-Dec-2010">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2010-01-01
</xbrli:startDate>
			<xbrli:endDate>
2010-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2010-01-01
</xbrli:startDate>
			<xbrli:endDate>
2010-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2010-01-01
</xbrli:startDate>
			<xbrli:endDate>
2010-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2010-01-01
</xbrli:startDate>
			<xbrli:endDate>
2010-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_SubscriptionReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">syn:SubscriptionReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2010-01-01
</xbrli:startDate>
			<xbrli:endDate>
2010-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2010">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2010-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_3ME_31-Mar-2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2011-01-01
</xbrli:startDate>
			<xbrli:endDate>
2011-03-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2011-01-01
</xbrli:startDate>
			<xbrli:endDate>
2011-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2011-01-01
</xbrli:startDate>
			<xbrli:endDate>
2011-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2011-01-01
</xbrli:startDate>
			<xbrli:endDate>
2011-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2011-01-01
</xbrli:startDate>
			<xbrli:endDate>
2011-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_SubscriptionReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">syn:SubscriptionReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2011-01-01
</xbrli:startDate>
			<xbrli:endDate>
2011-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_3ME_31-Mar-2012">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2012-01-01
</xbrli:startDate>
			<xbrli:endDate>
2012-03-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Mar-2012">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2012-03-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2009">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2009-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2009-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2010-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2009-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2010-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2009-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2010-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_SubscriptionReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">syn:SubscriptionReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2009-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_SubscriptionReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">syn:SubscriptionReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2010-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Mar-2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-03-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_SubscriptionReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">syn:SubscriptionReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<!-- Unit Section  -->
	<!--
I~1\FVPHexeD5678YReqi>XUI~\FVPYwivc444c555cT{h>6<HE<4GG1FH<:18F651FFH;1:=H5=G<6G96I -->
	<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
	<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
	<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
	<!-- Element Section  -->
	<dei:EntityRegistrantName contextRef="Context_3ME_31-Mar-2012">Synthetic Biologics, Inc.</dei:EntityRegistrantName>
	<dei:EntityCentralIndexKey contextRef="Context_3ME_31-Mar-2012">0000894158</dei:EntityCentralIndexKey>
	<dei:EntityFilerCategory contextRef="Context_3ME_31-Mar-2012">Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:DocumentType contextRef="Context_3ME_31-Mar-2012">Other</dei:DocumentType>
	<dei:AmendmentFlag contextRef="Context_3ME_31-Mar-2012">false</dei:AmendmentFlag>
	<dei:DocumentPeriodEndDate contextRef="Context_3ME_31-Mar-2012">2012-03-31</dei:DocumentPeriodEndDate>
	<us-gaap:Cash contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">2649000</us-gaap:Cash>
	<us-gaap:Cash contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">6678000</us-gaap:Cash>
	<us-gaap:Cash contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">6802000</us-gaap:Cash>
	<us-gaap:Cash contextRef="Context_As_Of_31-Dec-2009" unitRef="USD" decimals="-3">2715000</us-gaap:Cash>
	<us-gaap:Cash contextRef="Context_As_Of_31-Mar-2011" unitRef="USD" decimals="-3">6080000</us-gaap:Cash>
	<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">339000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">405000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">440000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">343000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">16000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">83000</us-gaap:OtherAssetsCurrent>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">214000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">23000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">3545000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7122000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">7325000</us-gaap:AssetsCurrent>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">475000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">323000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">303000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:NotesAndLoansReceivableNetNoncurrent>
	<us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">700000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
	<syn:DepositsAndOtherAssetsNoncurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">91000</syn:DepositsAndOtherAssetsNoncurrent>
	<syn:DepositsAndOtherAssetsNoncurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">31000</syn:DepositsAndOtherAssetsNoncurrent>
	<syn:DepositsAndOtherAssetsNoncurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">21000</syn:DepositsAndOtherAssetsNoncurrent>
	<us-gaap:Assets contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">4111000</us-gaap:Assets>
	<us-gaap:Assets contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7476000</us-gaap:Assets>
	<us-gaap:Assets contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">8349000</us-gaap:Assets>
	<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">266000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">388000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">316000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">210000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">29000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">127000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">500000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">417000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">443000</us-gaap:LiabilitiesCurrent>
	<us-gaap:Liabilities contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">532000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">417000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">443000</us-gaap:Liabilities>
	<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
	<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">23000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">31000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">33000</us-gaap:CommonStockValue>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">47280000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">58901000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">60946000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">-43724000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">-51873000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">-53073000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">3579000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7059000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">7906000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2009" unitRef="USD" decimals="-3">3545000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">22000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">23000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">45553000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">47280000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-42013000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-43724000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">-17000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">31000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">58901000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-51873000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">4111000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7476000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">8349000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2010" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2011" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Mar-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2010" unitRef="shares" decimals="0">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31-Mar-2012" unitRef="shares" decimals="0">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31-Dec-2010" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31-Mar-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2010" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31-Mar-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2010" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2011" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Mar-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2010" unitRef="shares" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Mar-2012" unitRef="shares" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Dec-2010" unitRef="shares" decimals="0">23420189</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">31374002</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Mar-2012" unitRef="shares" decimals="0">32857609</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2010" unitRef="shares" decimals="0">23338707</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">31292520</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Mar-2012" unitRef="shares" decimals="0">32776127</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">2117000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">1233000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">2588000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">1468000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">1580000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">231000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">3340000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">386000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:OperatingExpenses contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">3697000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">1464000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">5928000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">1854000</us-gaap:OperatingExpenses>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-1083000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-1464000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-5928000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">-1854000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<syn:WarrantExpenses contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</syn:WarrantExpenses>
	<syn:WarrantExpenses contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">716000</syn:WarrantExpenses>
	<syn:WarrantExpenses contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">1492000</syn:WarrantExpenses>
	<syn:WarrantExpenses contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</syn:WarrantExpenses>
	<syn:ChangeInFairValueOfWarrantLiability contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</syn:ChangeInFairValueOfWarrantLiability>
	<syn:ChangeInFairValueOfWarrantLiability contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">94000</syn:ChangeInFairValueOfWarrantLiability>
	<syn:ChangeInFairValueOfWarrantLiability contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">242000</syn:ChangeInFairValueOfWarrantLiability>
	<syn:ChangeInFairValueOfWarrantLiability contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</syn:ChangeInFairValueOfWarrantLiability>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-5000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnDispositionOfProperty contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-5000</us-gaap:GainLossOnDispositionOfProperty>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnDispositionOfProperty contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnDispositionOfProperty>
<us-gaap:OtherNonoperatingIncome contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">9000</us-gaap:OtherNonoperatingIncome>
	<us-gaap:OtherNonoperatingIncome contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">56000</us-gaap:OtherNonoperatingIncome>
	<us-gaap:OtherNonoperatingIncome contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">22000</us-gaap:OtherNonoperatingIncome>
	<us-gaap:OtherNonoperatingIncome contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">5000</us-gaap:OtherNonoperatingIncome>
	<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-112000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-759000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-1698000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">5000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-1195000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-2223000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-7626000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">-1849000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-516000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">37000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-523000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">649000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-1711000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-1711000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-2186000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-8149000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-8149000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">-1200000</us-gaap:NetIncomeLoss>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="Context_FYE_31-Dec-2010" unitRef="USD_per_Share" decimals="2">-0.06</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="Context_3ME_31-Mar-2011" unitRef="USD_per_Share" decimals="2">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="Context_FYE_31-Dec-2011" unitRef="USD_per_Share" decimals="2">-0.27</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="Context_3ME_31-Mar-2012" unitRef="USD_per_Share" decimals="2">-0.06</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="Context_FYE_31-Dec-2010" unitRef="USD_per_Share" decimals="2">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="Context_3ME_31-Mar-2011" unitRef="USD_per_Share" decimals="0">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="Context_FYE_31-Dec-2011" unitRef="USD_per_Share" decimals="2">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="Context_3ME_31-Mar-2012" unitRef="USD_per_Share" decimals="2">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_31-Dec-2010" unitRef="USD_per_Share" decimals="2">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_31-Mar-2011" unitRef="USD_per_Share" decimals="2">-0.09</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_31-Dec-2011" unitRef="USD_per_Share" decimals="2">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_31-Mar-2012" unitRef="USD_per_Share" decimals="2">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
	<syn:WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive contextRef="Context_FYE_31-Dec-2010" unitRef="shares" decimals="0">22393568</syn:WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive>
	<syn:WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive contextRef="Context_3ME_31-Mar-2011" unitRef="shares" decimals="0">25220694</syn:WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive>
	<syn:WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive contextRef="Context_FYE_31-Dec-2011" unitRef="shares" decimals="0">27710428</syn:WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive>
	<syn:WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive contextRef="Context_3ME_31-Mar-2012" unitRef="shares" decimals="0">32003164</syn:WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive>
	<us-gaap:ShareBasedCompensation contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">400000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">768000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">973000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">508000</us-gaap:ShareBasedCompensation>
	<syn:StockIssuedAsCompensation contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">47000</syn:StockIssuedAsCompensation>
	<syn:StockIssuedAsCompensation contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">76000</syn:StockIssuedAsCompensation>
	<syn:StockIssuedAsCompensation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">94000</syn:StockIssuedAsCompensation>
	<syn:StockIssuedAsCompensation contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</syn:StockIssuedAsCompensation>
	<syn:StockIssuedForConsultingFees contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">214000</syn:StockIssuedForConsultingFees>
	<syn:StockIssuedForConsultingFees contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">58000</syn:StockIssuedForConsultingFees>
	<syn:StockIssuedForConsultingFees contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">165000</syn:StockIssuedForConsultingFees>
	<syn:StockIssuedForConsultingFees contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</syn:StockIssuedForConsultingFees>
	<us-gaap:Depreciation contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">346000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">80000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">144000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">20000</us-gaap:Depreciation>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">130000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">21000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">414000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">8000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:GainLossOnSaleOfAccountsReceivable contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnSaleOfAccountsReceivable>
	<us-gaap:GainLossOnSaleOfAccountsReceivable contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">63000</us-gaap:GainLossOnSaleOfAccountsReceivable>
	<us-gaap:GainLossOnSaleOfAccountsReceivable contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">63000</us-gaap:GainLossOnSaleOfAccountsReceivable>
	<us-gaap:GainLossOnSaleOfAccountsReceivable contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnSaleOfAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">438000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">111000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">480000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">43000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">335000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-268000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-327000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">67000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInNotesReceivableCurrent contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInNotesReceivableCurrent>
	<us-gaap:IncreaseDecreaseInNotesReceivableCurrent contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">700000</us-gaap:IncreaseDecreaseInNotesReceivableCurrent>
	<syn:IncreaseDecreaseInDepositsAndOtherAssets contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</syn:IncreaseDecreaseInDepositsAndOtherAssets>
	<syn:IncreaseDecreaseInDepositsAndOtherAssets contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-68000</syn:IncreaseDecreaseInDepositsAndOtherAssets>
	<syn:IncreaseDecreaseInDepositsAndOtherAssets contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-60000</syn:IncreaseDecreaseInDepositsAndOtherAssets>
	<syn:IncreaseDecreaseInDepositsAndOtherAssets contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">-10000</syn:IncreaseDecreaseInDepositsAndOtherAssets>
	<syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">13000</syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">3000</syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">191000</syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">23000</syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-196000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">154000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">153000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">-72000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">202000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-192000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-181000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">98000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">5000</syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
	<syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">40000</syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
	<syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">24000</syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
	<syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-1145000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-281000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-2875000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">-1415000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">77000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">1000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">65000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">1000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-75000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">129000</syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises>
	<syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">8000</syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises>
	<syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">15000</syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises>
	<syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">68000</syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises>
	<syn:ProceedsFromIssuanceOfCommonStockForWarrantExercises contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">0</syn:ProceedsFromIssuanceOfCommonStockForWarrantExercises>
	<syn:ProceedsFromIssuanceOfCommonStockForWarrantExercises contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">1471000</syn:ProceedsFromIssuanceOfCommonStockForWarrantExercises>
	<syn:ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">1000000</syn:ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises>
	<syn:ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">4000000</syn:ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises>
	<syn:ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">7500000</syn:ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises>
	<syn:ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</syn:ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises>
	<us-gaap:RecoveryOfDirectCosts contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">115000</us-gaap:RecoveryOfDirectCosts>
	<us-gaap:RecoveryOfDirectCosts contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">296000</us-gaap:RecoveryOfDirectCosts>
	<us-gaap:RecoveryOfDirectCosts contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">539000</us-gaap:RecoveryOfDirectCosts>
	<us-gaap:RecoveryOfDirectCosts contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:RecoveryOfDirectCosts>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">1014000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">3712000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">6979000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">1539000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-66000</us-gaap:CashPeriodIncreaseDecrease>
	<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">3432000</us-gaap:CashPeriodIncreaseDecrease>
	<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">4029000</us-gaap:CashPeriodIncreaseDecrease>
	<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">124000</us-gaap:CashPeriodIncreaseDecrease>
	<us-gaap:InterestPaid contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">10000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">0</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:InterestPaid>
	<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
	<us-gaap:NatureOfOperations contextRef="Context_3ME_31-Mar-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;1.&amp;#160;&amp;#160;&amp;#160;Organization&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Synthetic Biologics, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Synthetic Biologics&amp;#8221;), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. In the area of synthetic biology, the Company is initially developing a product candidate to treat pulmonary arterial hypertension (PAH). The Company also intends to expand new and existing collaborations in the synthetic biology area. In addition, Synthetic Biologics has several clinical-stage programs that are being funded, or partially funded, by grants, charitable organizations and corporate partners. In this area we are developing, or have partnered the development of, product candidates to treat relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS).&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 23%; font-weight: bold; text-decoration: none;"&gt;&lt;b&gt;Medical Indication&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; width: 2%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 23%; font-weight: bold; text-decoration: none;"&gt;&lt;b&gt;Product Candidate&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; width: 2%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 50%; font-weight: bold; text-decoration: none;"&gt;&lt;b&gt;Status&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;PAH&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Synthetic DNA-based therapy&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Preclinical&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;Relapsing-remitting MS&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Trimesta&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;All patients enrolled in Phase II clinical trial;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;(oral estriol)&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;dosing and monitoring underway&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;Cognitive dysfunction in&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Trimesta&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Patient enrollment underway in Phase II&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;MS&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;(oral estriol)&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;clinical trial&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;Fibromyalgia&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Effirma&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Partnered with Meda AB&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;(oral flupirtine)&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;ALS&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;AEN-100&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Phase II/III clinical trial preparation underway&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;(gastroretentive zinc acetate)&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:NatureOfOperations>
	<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;2.&amp;#160;&amp;#160;&amp;#160;Basis of Presentation&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The accompanying unaudited consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The financial information as of December 31, 2011, is derived from the audited financial statements presented in the Company&amp;#8217;s Annual Report on Form 10-K/A for the year ended December 31, 2011. The unaudited consolidated interim financial statements should be read in conjunction with the Company&amp;#8217;s Annual Report on Form 10-K/A, which contains the audited financial statements and notes thereto, together with the Management&amp;#8217;s Discussion and Analysis, for the year ended December 31, 2011.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been consolidated or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the period ended March 31, 2012, are not necessarily indicative of results for the full year.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has seven subsidiaries, Pipex Therapeutics, Inc. (&amp;#8220;Pipex Therapeutics&amp;#8221;), Effective Pharmaceuticals, Inc. (&amp;#8220;EPI&amp;#8221;), Solovax, Inc. (&amp;#8220;Solovax&amp;#8221;), CD4 Biosciences, Inc. (&amp;#8220;CD4&amp;#8221;), Epitope Pharmaceuticals, Inc. (&amp;#8220;Epitope&amp;#8221;), Healthmine, Inc. (&amp;#8220;Healthmine&amp;#8221;) and Putney Drug Corp. (&amp;#8220;Putney&amp;#8221;). As of March 31, 2012, EPI, Healthmine and Putney are wholly owned and Pipex Therapeutics, Solovax, CD4 and Epitope are majority-owned.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;div&gt;
&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in; text-align: left;"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;All inter-company transactions and accounts have been eliminated in consolidation.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Emerging from the Development Stage&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;During the second quarter of 2010, the Company emerged from the development stage.&amp;#160;&amp;#160;&amp;#160;A development-stage enterprise is one in which planned principle operations have not commenced or if its operations have commenced, there has been no significant revenue.&amp;#160;&amp;#160; The Company&amp;#8217;s strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration.&amp;#160;&amp;#160;On May 6, 2010, the Company entered into a Sublicense Agreement (the &amp;#8220;Meda Agreement&amp;#8221;) with Meda&amp;#160;AB of Sweden (&amp;#8220;Meda&amp;#8221;) and received an up-front payment of $2.5 million. The execution of the Meda Agreement combined with revenues from Adeona Clinical Laboratory were an indication of the commencement of principal operations, and therefore development-stage reporting was no longer required.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Accounts receivable were reported at realizable value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded. The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables deemed uncollectible were charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&amp;#160;&amp;#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&amp;#160;&amp;#160;For the year ended December 31, 2011, the Company&amp;#8217;s only stream of revenue was laboratory revenue. During the year ended December 31, 2010, the Company&amp;#8217;s streams of revenue were license revenue, laboratory revenue and grant revenue.&amp;#160;&amp;#160;&amp;#160;Laboratory revenues are a component of discontinued operations for the years ended December 31, 2011 and 2010. See
 Note 3 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;License Revenues&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company&amp;#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&amp;#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On May 6, 2010, the Company entered into the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&amp;#160; As consideration for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment was recorded as license revenue in 2010. Pursuant to the Company&amp;#8217;s license agreement with McLean Hospital, the Company paid 15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and $10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of 7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.&amp;#160;The Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. Pursuant to the terms of the Company&amp;#8217;s agreement with McLean Hospital, the Company is obligated to pay half of all future royalties the Company receives.&amp;#160;&amp;#160;Future milestone payments will be recorded as revenue when payment is received as there are no future deliverables, and it is non-refundable.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160; &lt;i&gt;Laboratory Revenues&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company primarily recognized revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company maintained a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looked at several factors, the most significant of which is the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The allowance taken was the averaged yearly average adjustment amount for these prior periods and multiplied by the period&amp;#8217;s actual gross sales to determine the actual sales allowance for each period.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company generated reimbursement from&amp;#160;three significant insurance providers in 2011 and 2010.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table align="center" style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;Customer&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 31%; text-align: center;"&gt;A&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 31%; text-align: right;"&gt;70&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
&lt;td style="width:
 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 30%; text-align: right;"&gt;65&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;B&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;11&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;C&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;19&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;14&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&lt;i&gt;Grant Revenues&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On November 4, 2010, the Company was awarded two grants totaling $489,000 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company&amp;#8217;s clinical programs. The QTDP Grants Program was included in the healthcare reform legislation and established a one-time pool of $1 billion for grants to small biotechnology companies developing novel therapeutics which show potential to: (a)&amp;#160;result in new therapies that either treat areas of unmet medical need, or prevent, detect, or treat chronic or acute diseases and conditions; (b)&amp;#160;reduce long-term health care costs in the U.S.; or (c)&amp;#160;significantly advance the goal of curing cancer within a 30-year period.&amp;#160;&amp;#160;All grant income was recognized in 2010 and there are no future obligations associated with these grants.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;During 2010 and March 2011, all amounts awarded under these grants had been received. See Note 9 regarding the taxability of grant revenues.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&lt;i&gt;Revenues, net (in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;December&amp;#160;31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 64%; text-align: left;"&gt;License revenue&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;2,500&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;License fees&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(375&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;License revenue, net&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,125&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Grant revenue&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;489&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total revenues, net&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,614&lt;/td&gt;
&lt;td style="padding-bottom:
 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company's operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast and plan future business activities.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three months or less.&amp;#160;&amp;#160;At December 31, 2011 and 2010, respectively, the Company had no cash equivalents.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Classification of Marketable Securities as Held to Maturity, Trading, and Available for Sale&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Debt securities are classified as held to maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available for sale. Held to maturity securities are recorded as either short-term or long-term on the balance sheet, based on contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held to maturity or as trading, are classified as available for sale, and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders&amp;#8217; equity. At December 31, 2011 and 2010, respectively, the Company had no marketable securities.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;During the year ended December 31, 2011, the Company held investments in marketable securities that were classified as held to maturity and consisted of corporate bonds and certificates of deposits as follows &lt;i&gt;(in thousands)&lt;/i&gt; :&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 60%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;December 31, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 78%; text-align: justify;"&gt;Purchase of short-term investments&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 19%; text-align: right;"&gt;(4,370&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: justify;"&gt;Amortization of premium on investments&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;57&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: justify;"&gt;Proceeds from short-term investments&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4,293&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt;"&gt;Loss on sale of short-term investments&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;20&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Fair value&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated
 useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 49%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center;"&gt;Asset&amp;#160;Description&lt;/td&gt;
&lt;td style="width: 4%; padding-right: 0.8pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 47%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center;"&gt;Estimated&amp;#160;Useful&amp;#160;Life&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;Office equipment and furniture&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"&gt;5&amp;#160;&amp;#160;years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"&gt;7-10 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;Manufacturing equipment&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"&gt;10 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt;" nowrap="nowrap"&gt;Leasehold improvements and fixtures&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;Lesser of estimated useful or life of lease&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Depreciation expense was approximately $144,000 and $346,000 for the years ended December 31, 2011 and 2010, respectively. When assets are disposed of, the cost and accumulated depreciation are removed from the accounts. Repairs and maintenance are charged to expense as incurred.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;During 2010, the Company reviewed property and equipment for impairment and determined that certain items had been impaired due to obsolescence. As a result of this review, the Company recorded an impairment loss of approximately $121,000. For the year ended December 31, 2011, there were no significant events or changes in circumstances identified by the Company that would indicate that the carrying value of an asset was not recoverable.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Goodwill was not amortized, and was tested for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was assigned.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;ASC No. 350 requires a two-step approach to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit, and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially affected by changes in these estimates and assumptions.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;At December 31, 2011, in connection with the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired. See Note 3 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Beneficial Conversion Feature&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;For conventional convertible debt where the rate of conversion is below market value, the Company records a "beneficial conversion feature" (BCF) and related debt
 discount.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;When the Company records a BCF, the relative fair value of the BCF would be recorded as a debt discount against the face amount of the respective debt instrument. The discount would be amortized to interest expense over the life of the debt.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Derivative Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In&amp;#160;determining the appropriate fair value, the Company uses the Black-Scholes option pricing model. In&amp;#160;assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In&amp;#160;addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option pricing model.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Debt Issue Costs and Debt Discount&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company may pay debt issue costs, and record debt discounts in connection with raising funds through the issuance of convertible debt.&amp;#160;&amp;#160;These costs are amortized over the life of the debt to interest expense. If&amp;#160;a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Original Issue Discount&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;For certain convertible debt issued, the Company may provide the debt holder with an original issue discount.&amp;#160;&amp;#160;&amp;#160;The original issue discount was recorded to debt discount reducing the face amount of the note and is being amortized to interest expense over the life of the debt.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Net Earnings (Loss) per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Net earnings (loss) per share is computed by dividing net earnings (loss) less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends by the weighted average number of common shares outstanding including the effect of common share equivalents.&amp;#160;Since the Company reported a net loss for the years ended December 31, 2011 and 2010, all common equivalent shares would be anti-dilutive; as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the year ended December 31, 2011 were 2,979,010 and 3,259,186, respectively, and for the year ended December 31, 2010 were 1,990,444 and 1,070,472, respectively.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company expenses research and development costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&amp;#8217;s product candidates.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market
 participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 3%; padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 94%; padding-right: 0.8pt; text-align: justify;"&gt;Level 1 inputs: Quoted prices (unadjusted)&amp;#160;for identical assets or liabilities in active markets;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 3%; padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 94%; padding-right: 0.8pt; text-align: justify;"&gt;Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 3%; padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 94%; padding-right: 0.8pt; text-align: justify;"&gt;Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The carrying amounts of the Company&amp;#8217;s short-term financial instruments, including accounts receivable, other current assets, accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Payment Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&amp;#8217; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company accounts for income taxes in accordance with accounting guidance now codified as FASB ASC Topic 740, &amp;#8220; &lt;i&gt;Income Taxes&lt;/i&gt; ,&amp;#8221; which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Accounting guidance now codified as FASB ASC Topic 740-20, &lt;i&gt;&amp;#8220;Income Taxes &amp;#8211; Intraperiod Tax Allocation,&amp;#8221;&lt;/i&gt; clarifies the accounting for uncertainties in income taxes recognized in accordance with FASB ASC Topic 740-20 by prescribing guidance for the recognition, de-recognition and measurement in financial statements of income tax positions taken in previously filed tax returns or tax positions expected to be taken in tax returns, including a decision whether to file or not to file in a particular jurisdiction. FASB ASC Topic 740-20 requires that any liability created for unrecognized tax benefits is disclosed. The application of FASB ASC Topic 740-20 may also affect the tax bases of assets and liabilities and therefore may change or create deferred tax liabilities or assets. The Company would recognize interest and penalties related to unrecognized tax benefits in income tax expense. At December 31, 2011 and 2010, respectively, the Company did not record any liabilities for uncertain tax positions.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting
 Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;In May 2011, the FASB issued guidance in regard to fair value measurement. The new guidance results in a consistent definition of fair value and common requirements for measurement of and disclosure about fair value between GAAP and International Financial Reporting Standards (IFRS). This guidance is effective for interim and annual periods beginning after December 15, 2011. The adoption of this guidance is not expected to have a material impact on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;In September 2011, the FASB issued guidance in regard to goodwill impairment. The new guidance is intended to reduce the cost and complexity of the annual goodwill impairment test by providing entities with the option of performing a "qualitative" assessment to determine whether further impairment testing is necessary. An entity can choose to perform the qualitative assessment on none, some, or all of its reporting units. Moreover, an entity can bypass the qualitative assessment for any reporting unit in any period and proceed directly to step one of the impairment test, and then perform the qualitative assessment in any subsequent period. The new guidance is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;To conform prior period amounts to current year classifications, the Company has reclassified assets, liabilities, revenues and expenses associated with the sale of Adeona Clinical Laboratory to discontinued operations. These reclassifications had no impact on the Company&amp;#8217;s previously reported financial condition, results of operations or cash flows.&lt;/p&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;3.&amp;#160;&amp;#160;&amp;#160;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;All inter-company transactions and accounts have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Accounts receivable were reported at realizable value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded. The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables deemed uncollectible were charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&amp;#160;&amp;#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&amp;#160;&amp;#160;For the three months ended March 31, 2012 and 2011, the Company&amp;#8217;s only stream of revenue was laboratory revenue.&amp;#160;Laboratory revenues are a component of discontinued operations for the three months ended March 31, 2012 and 2011. &lt;i&gt;See Note 4 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory and Note Receivable.&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;License Revenues&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company&amp;#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&amp;#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date,
 the Company has not received any royalty revenues.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On May 6, 2010, the Company entered into the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&amp;#160; As consideration for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment was recorded as license revenue in 2010. Pursuant to the Company&amp;#8217;s license agreement with McLean Hospital, the Company paid 15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and $10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of 7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.&amp;#160;The Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. Pursuant to the terms of the Company&amp;#8217;s agreement with McLean Hospital, the Company is obligated to pay half of all future royalties the Company receives.&amp;#160;&amp;#160;Future milestone payments will be recorded as revenue when payment is received as there are no future deliverables, and it is non-refundable.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Laboratory Revenues&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company primarily recognized revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company maintained a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looked at several factors, the most significant of which is the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The allowance taken was the averaged yearly average adjustment amount for these prior periods and multiplied by the period&amp;#8217;s actual gross sales to determine the actual sales allowance for each period.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company generated reimbursements from&amp;#160;3 significant insurance providers in March 31, 2012 and 2011, as follows:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;table style="width: 88%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;"&gt;Customer&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; width: 33%;"&gt;A&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 34%;"&gt;68&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;%&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 33%;"&gt;69&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;B&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;18&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;C&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company's operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast and plan future business activities.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p
 style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three months or less.&amp;#160;&amp;#160;At March 31, 2012 and 2011, respectively, the Company had no cash equivalents.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Goodwill was not amortized, and was tested for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was assigned.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;ASC No. 350 requires a two-step approach to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit, and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially affected by changes in these estimates and assumptions.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;At December 31, 2011, in connection with the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired. &lt;i&gt;See Note 4 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory and Note Receivable&lt;/i&gt;.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Net Earnings (Loss) per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Net earnings (loss) per share is computed by dividing net earnings (loss) less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends by the weighted average number of common shares outstanding including the effect of common share equivalents.&amp;#160;Since the Company reported a net loss for the three months ended March 31, 2012 and 2011, all common equivalent shares would be anti-dilutive; as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the three months ended March 31, 2012 were 3,843,465 and 2,414,922, respectively, and for the three months ended March 31, 2011 were 2,273,072 and 2,554,650, respectively.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company expenses research and development costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&amp;#8217;s product candidates.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Payment Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&amp;#8217; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;To conform prior period amounts to current year classifications, the Company has reclassified assets, liabilities, revenues and expenses associated with the sale of Adeona Clinical Laboratory to discontinued operations. These reclassifications had no impact on the Company&amp;#8217;s previously reported financial condition, results of operations or cash
 flows.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;div&gt;
&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in; text-align: left;"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Discontinued Operations of Adeona Clinical Laboratory&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &amp;#8220;Lab&amp;#8221;) to Hartlab, LLC, an entity controlled by the Lab&amp;#8217;s former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&amp;#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year non-recourse promissory note secured by all of the assets of the Lab.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;In accordance with ASC Topic 205-20 &amp;#8220;&lt;i&gt;Presentation of Financial Statements&amp;#8212;Discontinued Operations&lt;/i&gt;&amp;#8221; (ASC 205-20), the Company determined that the sale of the Lab should be classified as &amp;#8220;held for sale&amp;#8221; at December 31, 2011. In accordance with ACS 205-20 all of the following criteria must be met for an entity to be classified as &amp;#8220;held for sale&amp;#8221;:&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 6%; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6%; padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 88%; padding-right: 0.8pt; text-align: justify;"&gt;Management, having the authority to approve the action, commits to a plan to sell the asset.&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: justify;"&gt;The asset is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets.&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: justify;"&gt;An active program to locate a buyer and other actions required to complete the plan to sell the asset have been initiated.&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: justify;"&gt;The sale of the asset is probable, and transfer of the asset is expected to qualify for recognition as a complete sale within one year.&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: justify;"&gt;The asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company determined that all the criteria had been met and has classified the Lab as discontinued operations and its results of operations, financial position and cash flows are separately reported for all periods presented. The assets and liabilities of the discontinued operations are presented separately under the captions &amp;#8220;Assets of discontinued operations&amp;#8221; and &amp;#8220;Liabilities of discontinued operations,&amp;#8221; respectively, in the accompanying Consolidated Balance Sheets at December 31, 2011, and December 31, 2010, and consist of the following &lt;i&gt;(in thousands&lt;/i&gt; &lt;i&gt;):&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Assets of discontinued operations:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 64%; text-align: left; padding-left: 9pt;"&gt;Property and equipment, net&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;23&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;36&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 9pt;"&gt;Goodwill&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align:
 right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;178&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Total assets&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;23&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;214&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Liabilities of discontinued operations:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"&gt;Current portion of capital lease&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;24&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Total liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;24&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;The summarized statement of operations data for Adeona Clinical Laboratory for the years ended December 31, 2011 and December 31, 2010 are as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 64%; text-align: left;"&gt;Laboratory fees, net&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;1,169&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;551&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Operating Costs and Expenses:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;General and administrative&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;539&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;599&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Cost of&amp;#160; laboratory services&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;975&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;468&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"&gt;Impairment loss on
 goodwill&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;178&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"&gt;Total operating costs and expenses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;1,692&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;1,067&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Loss from discontinued operations&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(523&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(516&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
	<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;4.&amp;#160;&amp;#160;&amp;#160;Discontinued Operations of Adeona Clinical Laboratory and Note Receivable&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &amp;#8220;Lab&amp;#8221;) to Hartlab, LLC, an entity controlled by the Lab&amp;#8217;s former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&amp;#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year non-recourse promissory note bearing interest at 5.7% per annum secured by all of the assets of the Lab. The note and all unpaid interest are due on March 1, 2014.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In accordance with ASC Topic 205-20 &amp;#8220; &lt;i&gt;Presentation of Financial Statements&amp;#8212;Discontinued Operations&lt;/i&gt; &amp;#8221; (ASC 205-20), the Company determined that all the criteria had been met and classified the Lab as discontinued operations and its results of operations, financial position and cash flows are separately reported for all periods presented. The assets of the discontinued operations are presented separately under the caption &amp;#8220;Assets of discontinued operations&amp;#8221; in the accompanying Consolidated Balance Sheets at March 31, 2012, and December 31, 2011, and consist of the following &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;table style="width: 88%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;December 31, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Assets of discontinued operations:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt; width: 70%;"&gt;Property and equipment, net&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 12%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 12%;"&gt;23&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Total assets&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;23&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The summarized statement of operations data for Adeona Clinical Laboratory for the three months ended March 31, 2012 and March 31, 2011 are as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;table style="width: 88%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"&gt;March 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 70%;"&gt;Laboratory fees, net&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;115&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;323&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Operating Costs and Expenses:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align:
 right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.24in;"&gt;General and administrative&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;27&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;35&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.24in;"&gt;Cost of&amp;#160; laboratory services&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;116&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;251&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.24in;"&gt;Total operating costs and expenses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;143&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;286&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Income (loss) from discontinued operations&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(28&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;37&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Other Income:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.12in;"&gt;Gain on the sale of Adeona Clinical Laboratory&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;677&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Net income from discontinued operations&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;649&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;37&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;div&gt;
&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in; text-align: left;"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&lt;b&gt;&lt;i&gt;Stock Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;During 2001, the Company&amp;#8217;s Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the &amp;#8220;2001 Stock Plan&amp;#8221;). As of the date of the merger, there were 1,489,353 options issued and outstanding under the 2001 plan. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&amp;#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &amp;#8220;Awards&amp;#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of December 31, 2011, there were 1,320,354 options issued and outstanding under the 2001 Stock Plan.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On March 20, 2007, the Company&amp;#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &amp;#8220;2007 Stock Plan&amp;#8221;) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of December 31, 2011, there are 1,201,156 options issued and outstanding under the 2007 Stock Plan.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&amp;#8220;2010 Stock Plan&amp;#8221;) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. Options become exercisable over various period from the date of grant, and generally expire ten years after the grant date. As of December 31, 2011, there are 457,500 options issued and outstanding under the 2010 Stock Plan.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;In the event of an employee&amp;#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes assumptions used in the years ended December 31, 2011 and 2010 are as follows:&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6"&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align:
 bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Exercise price&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.49 - $2.22&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.56 - $0.87&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 64%; text-align: left;"&gt;Expected dividends&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15%; text-align: center;"&gt;0%&lt;/td&gt;
&lt;td style="width: 1%; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15%; text-align: center;"&gt;0%&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;175% - 188%&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;187% - 207%&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Risk fee interest rate&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;1.30% - 3.58%&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;2.54% - 3.63%&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Expected life of option&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;5 - 7 years&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;10 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Expected forfeitures&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;0%&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;0%&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company records stock-based compensation based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.75in;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0.5in; padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;immediate vesting,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;half vesting immediately and the remainder over three years,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;quarterly over three years,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;annually over three years,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;one-third immediate vesting and remaining annually over two years,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;one half immediate vesting with remaining vesting over nine months,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;one quarter immediate vesting with the remaining over three years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;one quarter immediate vesting with the remaining over 33 months; and&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;monthly over three years.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;During 2011, the Company granted 557,002 options to employees and consultants having an approximate fair value of $609,000 based upon the Black-Scholes option pricing model.&amp;#160; During 2010, the Company granted 743,332 options to employees and consultants having an approximate fair value of $597,000 based upon the Black-Scholes option pricing model.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2"
 nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;Aggregate&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;Average&amp;#160;Exercise&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;Contractual&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;Intrinsic&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 40%; padding-bottom: 2.5pt;"&gt;Balance &amp;#8211; December 31, 2009&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; padding-bottom: 2.5pt; text-align: right;"&gt;2,561,332&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; padding-bottom: 2.5pt; text-align: right;"&gt;1.26&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; border-bottom: black 2.5pt double; text-align: right;"&gt;7.16 years&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; border-bottom: black 2.5pt double; text-align: right;"&gt;304,000&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;743,332&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(255,954&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.44&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Forfeited&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align:
 right;"&gt;(509,619&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;0.69&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Balance &amp;#8211; December 31, 2010&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;2,539,091&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;1.32&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;6.97 years&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,028,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;557,002&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.26&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(23,333&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.57&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Forfeited&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(93,750&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;0.59&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Balance &amp;#8211; December 31, 2011 &amp;#8211; outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,979,010&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.34&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;6.01 years&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Balance &amp;#8211; December 31, 2011 &amp;#8211; exercisable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,454,607&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.46&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;5.62 years&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Grant date fair value of options granted &amp;#8211; 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;609,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Weighted average grant date fair value &amp;#8211; 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.09&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Grant date fair value of options granted &amp;#8211; 2010&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;597,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Weighted average grant date fair value &amp;#8211; 2010&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;0.80&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Outstanding options held by related parties &amp;#8211; 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,283,160&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Exercisable options held by related parties &amp;#8211; 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,070,660&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Outstanding options held by related parties &amp;#8211; 2010&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,083,160&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Exercisable options held by related parties &amp;#8211; 2010&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;858,160&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;The options outstanding and exercisable at December 31, 2011 are as follows:&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="11" nowrap="nowrap"&gt;Options&amp;#160;Outstanding&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="9" nowrap="nowrap"&gt;Options&amp;#160;Exercisable&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Range&amp;#160;of&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" nowrap="nowrap"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" nowrap="nowrap"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 14%; text-align: center;"&gt;$0.09 -
 $4.57&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;2,889,011&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;1.20&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14%; text-align: right;"&gt;6.11 years&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;2,364,608&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;1.29&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14%; text-align: right;"&gt;5.72 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;"&gt;$4.58 - $9.05&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;89,999&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5.93&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;2.76 years&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;89,999&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5.93&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;2.76 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt;"&gt;$0.09 - $9.05&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,979,010&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.34&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 2.5pt double;"&gt;6.01 years&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,454,607&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.46&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 2.5pt double;"&gt;5.62 years&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;The options outstanding and exercisable at December 31, 2010 are as follows:&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="11" nowrap="nowrap"&gt;Options&amp;#160;Outstanding&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="9" nowrap="nowrap"&gt;Options&amp;#160;Exercisable&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Range&amp;#160;of&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2"
 nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" nowrap="nowrap"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" nowrap="nowrap"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 14%; text-align: center;"&gt;$0.09 - $4.57&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;2,449,092&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;1.16&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14%; text-align: right;"&gt;7.09 years&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;1,900,445&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;1.28&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14%; text-align: right;"&gt;6.47 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;"&gt;$4.58 - $9.05&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;89,999&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5.93&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;3.76 years&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;89,999&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5.93&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;3.76 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt;"&gt;$0.09 - $9.05&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,539,091&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.32&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 2.5pt double;"&gt;6.97 years&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,990,444&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.48&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 2.5pt double;"&gt;6.35 years&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;The following is a summary of the Company&amp;#8217;s non-vested stock options at December 31, 2011:&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;b&gt;Unvested&lt;/b&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;b&gt;Grant&lt;/b&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Stock&amp;#160;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Date&amp;#160;Fair&amp;#160;Value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr
 style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 64%;"&gt;Non-vested&amp;#160;&amp;#8211;&amp;#160;December&amp;#160;31,&amp;#160;2010&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;548,647&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;0.77&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;557,002&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.09&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Vested/Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(528,017&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.07&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Forfeited/Cancelled&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(53,229&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;0.57&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Non-vested &amp;#8211; December 31, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;524,403&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;0.82&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Weighted average remaining period for vesting&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.67 years&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Stock Warrants and Derivative Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On July 2, 2010, the Company entered into a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.32 and a life of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As of December 31, 2011, 30,303 of these warrants remained outstanding.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On January 28, 2011, the Company entered into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants to purchase 1,428,572 shares of common stock. Each warrant was exercisable&amp;#160;for thirteen months&amp;#160;at $2.00 per share and subsequently exchanged for new warrants with substantially the same&amp;#160;terms as the original warrants except that the expiration date was extended for two months. The original warrants had an anti-dilution price protection feature; if the Company issues securities at a price per share that is less than $2.00 per share, the warrant holders will be ratcheted down to the lower offering price. However, the Company had instituted a floor price of $1.40 per share in connection with the price protection.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On April 6, 2011, the Company entered into another Common Stock Purchase Agreement that triggered the ratchet provision and re-set the price of these warrants to $1.40 per share. Due to the re-set to the floor price, the warrant liability was marked-to-market and reclassified to additional paid-in capital since it ceased to contain the provisions of a derivative liability. As of December 31, 2011, all of these warrants remained outstanding.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The warrants were initially recorded as liabilities at their estimated fair value on the commitment date, which was $716,000 with subsequent changes in estimated fair value recorded as a warrant expense&amp;#160;in the Company&amp;#8217;s statement of operations at each subsequent reporting period. On April 6, 2011, the fair value of the warrant liability was $1.5 million, which represented an increase in fair value of $765,000. The fair value was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align:
 justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Remeasurement&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Commitment&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Date&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Date&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;April&amp;#160;6,&amp;#160;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%;"&gt;Closing stock price&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;1.39&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;2.08&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Expected dividend rate&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Expected stock price volatility&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;117.1&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;104.6&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.28&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.29&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Expected life (years)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.08&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.85&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On August 10, 2011, the Company entered into an agreement to exchange the warrants issued in connection with the January 28, 2011 financing for new warrants with substantially the same terms as the original warrants except that in the new warrants the expiration date was&amp;#160;extended by two months.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On April 6, 2011, the Company entered into a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase 844,391 shares of common stock. The warrant was initially exercisable&amp;#160;for thirteen months&amp;#160;at $2.0725 per share. The warrant had an anti-dilution price protection feature; that provided if the Company issues securities at a price per share that is less than $2.0725 per share,&amp;#160;the&amp;#160;exercise price of the warrant&amp;#160;will be ratcheted down to the lower offering price.&amp;#160;On July 28, 2011, the warrant was exchanged for a new warrant with substantially similar terms except that in the new warrant (i) the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00, (iii) the expiration date was extended for an additional&amp;#160;three months to August 12, 2012,&amp;#160;and (iv) the warrant&amp;#8217;s initial exercise date was changed to January 2012. Due to this warrant exchange, the warrant liability was marked-to-market and reclassified to additional paid-in capital since it ceased to contain the provisions of a derivative liability. As of December 31, 2011, all of these warrants remained outstanding.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The warrant is&amp;#160;initially recorded as a liability at&amp;#160;its estimated fair value on the commitment date, which was $776,000 with subsequent changes in estimated fair value recorded as a warrant expense&amp;#160;in the Company&amp;#8217;s statement of operations at each subsequent period. On July 28, 2011, the fair value of the warrant liability was $253,000, which represented a decrease in fair value of $523,000. The fair value is measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Remeasurement&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td
 nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Commitment&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Date&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Date&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;July&amp;#160;28,&amp;#160;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%; text-indent: -0.25in; padding-left: 0.25in;"&gt;Closing stock price&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;2.08&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;0.84&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"&gt;Expected dividend rate&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"&gt;Expected stock price volatility&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;112.1&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;105.6&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.29&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.21&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"&gt;Expected life (years)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.08&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.04&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;The following table summarizes the estimated fair value of the warrant liabilities &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-indent: -0.25in; padding-left: 0.25in;"&gt;Balance at December 31, 2010&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 85%; text-align: left; text-indent: -0.25in; padding-left: 0.25in;"&gt;Warrant liability&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;1,492&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"&gt;Change in fair value of warrant liability&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;242&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;"&gt;Reclassification to additional paid-in capital&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(1,734&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.25in;"&gt;Balance at December 31, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;A summary of warrant activity for the Company for the year ended December 31, 2010 and for the year ended December 31, 2011 is as follows:&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"
 nowrap="nowrap"&gt;Number&amp;#160;of&amp;#160;Warrants&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%;"&gt;Balance at December 31, 2009&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;1,070,472&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;3.27&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;60,606&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.32&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Forfeited&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Balance as December 31, 2010&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,131,078&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3.49&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,272,963&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.25&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(15,615&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.03&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Forfeited&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(129,240&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2.08&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Balance as December 31, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;3,259,186&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.95&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;A summary of all outstanding and exercisable warrants as of December 31, 2011 is as follows:&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Exercise&lt;br /&gt;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Warrants&lt;br /&gt;Outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Warrants&lt;br /&gt;Exercisable&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Aggregate &lt;br /&gt;Intrinsic&amp;#160;Value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 18%; text-align: right;"&gt;1.00&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 17%; text-align: right;"&gt;844,391&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;
 text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 17%; text-align: right;"&gt;844,391&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 17%; text-align: right;"&gt;0.61 years&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 17%; text-align: right;"&gt;219,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.32&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;30,303&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;30,303&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4.00 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.40&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,428,572&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,428,572&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.33 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2.22&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;517,257&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;517,257&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4.91 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3.30&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;61,207&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;61,207&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3.41 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3.75&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;50,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;50,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4.13 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;6.36&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;327,456&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;327,456&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;0.86 years&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.95&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;3,259,186&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;3,259,186&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.33 years&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;219,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&lt;b&gt;&lt;i&gt;Options of Subsidiaries&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;As of December 31, 2011, CD4 Biosciences, Inc., a majority-owned subsidiary of Synthetic Biologics, has a total of 20,000 stock options outstanding and exercisable.&amp;#160;&amp;#160;These stock options have an exercise price of $0.20 and a remaining contractual life of 0.37 years.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;As of December 31, 2011, Epitope, a majority-owned subsidiary of Synthetic Biologics, has 50,000 stock options outstanding and 20,000 stock options exercisable. These stock options have an exercise price of $0.001 and a remaining contractual life of 6.50 years.&lt;/p&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;6.&amp;#160;&amp;#160;&amp;#160;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During 2001, Pipex Therapeutics&amp;#8217; board of directors and stockholders adopted the 2001 Stock Incentive Plan (the &amp;#8220;2001 Stock Plan&amp;#8221;). This plan was assumed by Pipex in the October 2006 merger with Sheffield. As of the date of the merger, there were 1,489,353 options issued and outstanding under the 2001 plan. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&amp;#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &amp;#8220;Awards&amp;#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of March 31, 2012, there were 1,066,007 options issued and outstanding under the 2001 Stock Plan.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On March 20, 2007, the Company&amp;#8217;s board of directors approved the Company&amp;#8217;s 2007 Stock Incentive Plan (the &amp;#8220;2007 Stock Plan&amp;#8221;) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2012, there are 1,031,394 options issued and outstanding under the 2007 Stock Plan.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On November 2, 2010, the board of directors and stockholders adopted the 2010 Stock Incentive Plan (&amp;#8220;2010 Stock Plan&amp;#8221;) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire seven to ten years after the grant date. As of March 31, 2012, there are 1,746,064 options issued and outstanding under the 2010 Stock Plan.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In the event of an employee&amp;#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used in the months ended March 31, 2012 and 2011 are as follows:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;table style="width: 88%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;Exercise price&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$1.14 &amp;#8211; $2.47&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$1.21 &amp;#8211; $2.22&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align:
 left; width: 64%;" nowrap="nowrap"&gt;Expected dividends&lt;/td&gt;
&lt;td style="width: 1%;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 1%;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 15%;" nowrap="nowrap"&gt;0%&lt;/td&gt;
&lt;td style="text-align: center; width: 1%;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 1%;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 1%;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 15%;" nowrap="nowrap"&gt;0%&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;Expected volatility&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;108% &amp;#8211; 174%&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;185% &amp;#8211; 188%&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;Risk free interest rates&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;0.37% &amp;#8211; 1.98%&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;2.81% &amp;#8211; 3.58%&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;Expected life options&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;10 years&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;5 years &amp;#8211; 7 years&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;Expected forfeitures&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;0%&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;0%&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company records stock-based compensation based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 94%;"&gt;&lt;font style="font-size: 10pt;"&gt;immediate vesting,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;one-half vesting immediately and the remainder over three years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 94%;"&gt;&lt;font style="font-size: 10pt;"&gt;monthly over three years,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;quarterly over three years,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;annually over three years,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;one-third immediate vesting and remaining annually over two years,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;one-eighth immediate vesting with remaining vesting over two years,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;one-half immediate vesting with remaining vesting over nine months; and&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;one quarter immediate vesting with the remaining over three years.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During the three months ended March 31, 2012, the Company granted 1,300,000 options to employees and consultants having a fair value of approximately $3 million based upon the Black-Scholes option pricing model.&amp;#160; During the same period of 2011, the Company granted 324,502 options to employees having a fair value of approximately $433,000 based upon the Black-Scholes option pricing model.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;A summary of stock option
 activities as of March 31, 2012, and for the year ended December 31, 2011, is as follows:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Aggregate&lt;br /&gt;Intrinsic&lt;br /&gt;Value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 52%;"&gt;Balance &amp;#8211; December 31, 2010&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 9%;"&gt;2,539,091&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 9%;"&gt;1.32&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;557,002&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.26&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(23,333&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.57&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Forfeited or expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(93,750&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;0.59&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;Balance &amp;#8211; December 31, 2011&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,979,010&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.34&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,300,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2.35&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(289,343&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.23&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Forfeited or expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(146,202&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom:
 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Balance &amp;#8211; March 31, 2012 &amp;#8211; outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;3,843,465&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.79&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="text-underline-style: double;"&gt;7.18 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,230,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Balance &amp;#8211; March 31, 2012 &amp;#8211; exercisable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,323,320&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.62&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="text-underline-style: double;"&gt;5&lt;/font&gt;.73 years&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,814,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The options outstanding and exercisable as of March 31, 2012, are as follows:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="13"&gt;Options&amp;#160;Outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="10"&gt;Options&amp;#160;Exercisable&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Weighted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Weighted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;Range&amp;#160;of&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Average&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Remaining&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Average&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Remaining&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom:
 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; width: 16%;"&gt;$0.09 - $4.57&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;3,753,466&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;1.69&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 11%;"&gt;7.29 years&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;2,233,321&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;1.44&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 11%;"&gt;5.86 years&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;"&gt;$4.58 - $9.05&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;89,999&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5.93&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;"&gt;2.51 years&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;89,999&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5.93&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;"&gt;2.51 years&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt;"&gt;$0.09 - $9.05&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;3,843,465&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.79&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: center;"&gt;&lt;font style="text-underline-style: double;"&gt;7.18 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,323,320&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.62&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: center;"&gt;&lt;font style="text-underline-style: double;"&gt;5.73 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The options outstanding and exercisable as of March 31, 2011, are as follows:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="13"&gt;Options&amp;#160;Outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="10"&gt;Options&amp;#160;Exercisable&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Weighted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Weighted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;Range&amp;#160;of&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"
 colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Average&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Remaining&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Average&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;Remaining&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; width: 16%;"&gt;$0.09 - $4.57&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;2,721,921&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;1.22&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 11%;"&gt;6.75 years&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;2,183,073&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;1.32&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 11%;"&gt;6.27 years&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;"&gt;$4.58 - $9.05&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;89,999&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5.93&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;"&gt;3.51 years&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;89,999&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5.93&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;"&gt;3.51 years&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt;"&gt;$0.09 - $9.05&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,811,926&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.37&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: center;"&gt;&lt;font style="text-underline-style: double;"&gt;6.65 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,273,072&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.50&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: center;"&gt;&lt;font style="text-underline-style: double;"&gt;6.16 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;div style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Options of Subsidiary&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;
&lt;div style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/div&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times,
 serif;"&gt;During 2004 and 2007, CD4 granted 30,000 options. On August 5, 2009, 10,000 of these options expired. As of March 31, 2012, a total of 20,000 options were outstanding and exercisable with an exercise price of $0.20 and a remaining contractual life of 0.12 years.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;As of March 31, 2012, Epitope has 50,000 options outstanding and 20,000 options exercisable with an exercise price of $0.001 and a remaining contractual life of 6.25 years.&amp;#160;&amp;#160;These options were granted during 2008, vest annually over 5 years, and have a fair value of $50, which was determined using the Black-Scholes model with the following assumptions: expected dividend yield of 0%; expected volatility of 200%, risk free interest rate of 2.47% and an expected life of 10 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<syn:StockPurchaseWarrantsTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;div&gt;
&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in; text-align: left;"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Stock Repurchase Program&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On April 3, 2009, the Company&amp;#8217;s Board of Directors approved a Stock Repurchase Program authorizing the Company to repurchase, from time-to-time and through December 31, 2009, up to $1 million of its common stock, up to a maximum of four million shares at prices of up to $5 per share. As of December 31, 2011, the Company had repurchased 81,482 shares for approximately $50,000 ($0.61 per share), based upon the quoted closing trading price.&amp;#160;&amp;#160;These treasury shares are not included in the computation of earnings (loss) per share and are deemed to be canceled and retired.&lt;/p&gt;
&lt;/div&gt;</syn:StockPurchaseWarrantsTextBlock>
	<syn:StockPurchaseWarrantsTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif; margin-left: 0in;"&gt;&lt;b&gt;7.&amp;#160;&amp;#160;&amp;#160;Stock Purchase Warrants&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On March 15, 2012, the Company entered into a consulting agreement for a financial communications program, for a period of twelve months that began on February 20, 2012. As compensation for such program, the consultant is paid a monthly fee and will be issued a performance warrant exercisable for 250,000 shares of the Company&amp;#8217;s common stock based on achievement of certain milestones. Upon initiation of the program, 50,000 of the performance warrants vested. The performance warrant is exercisable for a period of two years from the date the agreement was executed for an exercise price equal to the price of the Company&amp;#8217;s common stock on the date of execution. The fair value of the warrant approximated $61,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 85%;"&gt;Exercise price&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;2.20&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected dividends&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;108&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.37&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected life of warrant&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected forfeitures&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On December 20, 2011, the Company entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services, the consultant is paid a monthly fee and on February 2, 2012, was issued a warrant exercisable for 100,000 shares of the Company&amp;#8217;s common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal to the price of the Company&amp;#8217;s common stock on the date of issue. The fair value of the warrant approximated $200,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 85%;"&gt;Exercise price&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;1.14&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected dividends&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;174&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.71&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected life of warrant&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected forfeitures&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On April 6, 2011, the Company entered into a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase 844,391 shares of common stock. The warrants have an exercise price of $1.00 and a life of fifteen months. The warrants vested immediately and expire August 10, 2012. As of March 31, 2012, 344,391 of these warrants remained outstanding.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On January 28, 2011, the Company entered into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants to purchase 1,428,572 shares of common stock. The warrants have an exercise price of $1.40 and a life of fifteen months. The warrants vested immediately and expire May 1, 2012. As of March 31, 2012, 746,429 of these warrants remained outstanding.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times,
 serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On July 2, 2010, the Company entered into a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.32 and a life of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As of March 31, 2012, 18,182 of these warrants remained outstanding.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;A summary of warrant activities as of March 31, 2012, and for the year ended December 31, 2011, is as follows:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Warrants&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;br /&gt;Average&amp;#160;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 70%;"&gt;Balance &amp;#8211; December 31, 2010&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;1,131,078&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;3.49&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,272,963&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.25&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(15,615&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.03&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(129,240&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2.08&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;Balance &amp;#8211; December 31, 2011&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3,259,186&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.95&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;350,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.90&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,194,264&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.24&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Balance &amp;#8211; March 31, 2012 - outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,414,922&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2.36&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Balance &amp;#8211; March 31, 2012 &amp;#8211; exercisable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,214,922&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2.37&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The warrants outstanding as of March 31, 2012, are as follows:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Exercise&lt;br /&gt;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Warrants&lt;br /&gt;Outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Warrants&lt;br /&gt;Exercisable&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Aggregate&lt;br /&gt;Intrinsic&amp;#160;Value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 18%;"&gt;1.00&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 17%;"&gt;344,391&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 17%;"&gt;344,391&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 17%;"&gt;0.36 years&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 17%;"&gt;443,000&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.14&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;100,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;100,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4.84 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;106,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.32&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;18,182&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;18,182&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3.75 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;16,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.40&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;746,429&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;721,429&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.08 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;577,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2.20&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;250,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;50,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.96 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2.22&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;517,257&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;517,257&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4.66 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3.30&lt;/td&gt;
&lt;td style="text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;61,207&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;61,207&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3.30 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3.75&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;50,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;50,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3.88 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;6.36&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;327,456&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;327,456&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;u style="text-decoration: none;"&gt;0.61 years&lt;/u&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,414,922&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,214,922&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="text-underline-style: double;"&gt;&lt;u style="text-decoration: none;"&gt;1.81 years&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,142,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</syn:StockPurchaseWarrantsTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;div&gt;
&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in; text-align: left;"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Stockholders&amp;#8217; Equity&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Year Ended December 31, 2010&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On July 2, 2010, the Company sold 1,212,121 shares of the Company&amp;#8217;s common stock at a closing price of $0.825 for gross proceeds of $1 million.&amp;#160;&amp;#160;The Company paid direct offering costs of $115,000.&amp;#160;&amp;#160;See Note 5 regarding warrants granted with this offering.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;During the year ended December 31, 2010, the Company issued 255,954 shares of common stock, in connection with the exercise of stock options, for proceeds of $130,000. The Company also issued 279,724 shares of common stock for consulting services, having a fair value of $214,000 ($0.76 per share), 81,035 shares of common stock for license fees, having a fair value of $70,000 ($0.87 per share), and 60,521 shares of common stock for employment service, having a fair value of $47,000 ($0.77 per share). The fair value of these issuances were based upon the quoted closing trading prices.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Year Ended December 31, 2011&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;During the year ended December 31, 2011, the Company issued 28,333 shares of common stock in connection with the exercise of stock options and warrants for proceeds of $15,000 and 10,615 shares of common stock related to a cashless exercise of warrants. The Company issued 73,585 shares of common stock for employment service, having a fair value of $94,000 ($1.29 average per share) and 171,796 shares of common stock for consulting services, having a fair value of $165,000 ($0.96 average per share), based on the quoted closing trading prices. The Company also issued 3,123,558 shares of common stock as consideration for the Channel Agreement with Intrexon, having a fair value of $1.7 million ($0.54 average per share), based on the quoted closing trading price.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On January 28, 2011, the Company sold 2,857,144 shares of common stock and warrants exercisable for&amp;#160;1,428,572 shares of common stock&amp;#160;for $4 million. Direct offering costs were approximately $296,000.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On April 6, 2011, the Company sold 1,688,782 shares of common stock and a warrant exercisable for 844,391 shares of common stock&amp;#160;for $3.5 million. Direct offering costs were approximately $243,000.&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif; margin-left: 0in;"&gt;&lt;b&gt;8.&amp;#160;&amp;#160;&amp;#160;Stockholders&amp;#8217; Equity&lt;/b&gt;&lt;/p&gt;
&lt;div style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif; margin-left: 0in;"&gt;During the three months ended March 31, 2012, the Company issued 289,343 shares of common stock, in connection with the exercise of stock options, for proceeds of approximately $68,000. The Company also issued 1,194,264 shares of common stock in connection with the exercise of warrants, for proceeds of approximately $1.5 million.&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;10. Subsequent Event&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On December 20, 2011, the Company entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services, the consultant will be paid a monthly fee of $10,000 and was issued a warrant exercisable for 100,000 shares of the Company&amp;#8217;s common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal to the price of the Company&amp;#8217;s common stock on the date of issue. The issue date of the warrant is February 2, 2012.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The fair value of the warrant approximated $200,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;table style="width: 50%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 75%;"&gt;Exercise price&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 22%; text-align: right;"&gt;1.14&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Expected dividends&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;174&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.71&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Expected life of warrant&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Expected forfeitures&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On May 1, 2012, the Company was informed by Berman &amp;amp; Company, P.A. (&amp;#8220;Berman &amp;amp; Company&amp;#8221;), the Company&amp;#8217;s independent registered accounting firm, that during a regular Public Company Accounting Oversight Board (&amp;#8220;PCAOB&amp;#8221;) inspection of Berman &amp;amp; Company, the PCAOB issued a comment that the audit opinion included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2011 was issued by a partner at Berman &amp;amp; Company who was not authorized under the PCAOB rules to issue the opinion or act as our named engagement partner with respect to the Form 10-K audit (or prior 2011 Form 10-Q interim reviews) after the original engagement partner rotated off the account under the Securities and Exchange Commission&amp;#8217;s independence rules as it pertains to partner rotation (S-X Rule 2-01 - Qualifications of Accountants).&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company believes that the previously filed financial statements for the year ended December 31, 2011 are accurate. In addition, the Company has not been informed by Berman &amp;amp; Company or the PCAOB, that the previously filed financial statements for the year ended December 31, 2011 are not accurate or otherwise invalid. As a matter of precaution the new engagement partner at Berman &amp;amp; Company has since: (i) taken full responsibility for the audit as the lead engagement partner on the audit, (ii) performed a detailed review of all audit procedures related to the original audit for sufficiency and (iii) reissued the audit opinion. The review performed by the new audit partner did not result in any changes to the Company&amp;#8217;s financial statements or notes to the financial statements for the year ended December 31, 2011, other than the addition of the May 1, 2012 and May 10, 2012 disclosures in this subsequent event note to the financial statements.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On May 10, 2012, Jeffrey J. Kraws was appointed as the independent, non-executive Chairman of the Board. For his service as independent, non-executive Chairman of the Board, Mr. Kraws will be issued options exercisable for 100,000 shares of the Company&amp;#8217;s common stock and will receive annual compensation of $150,000. The fair value of these options will be measured using the Black-Scholes valuation model.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif; margin-left: 0in;"&gt;&lt;b&gt;9.&amp;#160;&amp;#160;&amp;#160;Subsequent Events&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On May 1, 2012, the Company was informed by Berman &amp;amp; Company, P.A. (&amp;#8220;Berman &amp;amp; Company&amp;#8221;), the Company&amp;#8217;s independent registered accounting firm, that during a regular Public Company Accounting Oversight Board (&amp;#8220;PCAOB&amp;#8221;) inspection of Berman &amp;amp; Company, the PCAOB issued a comment that the audit opinion included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2011 was issued by a partner at Berman &amp;amp; Company who was not authorized under the PCAOB rules to issue the opinion or act as our named engagement partner with respect to the Form 10-K audit (or prior 2011 Form 10-Q interim reviews) after the original engagement partner rotated off the account under the Securities and Exchange Commission&amp;#8217;s independence rules as it pertains to partner rotation (S-X Rule 2-01 - Qualifications of Accountants).&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company received funds from the exercise of warrants but will not issue any shares under any of its outstanding registration statements on Form S-3 until such time as it receives guidance from the SEC whether the issue disclosed herein affects the Company&amp;#8217;s ability to continue to issue securities thereunder. The Company intends to return all of the funds to the warrant holders. The Company has sought guidance from the SEC staff regarding this matter and intends to file a waiver request to the extent it becomes necessary.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On May 10, 2012, Jeffrey J. Kraws was appointed as the independent, non-executive Chairman of the Board. For his service as independent, non-executive Chairman of the Board, Mr. Kraws will receive annual compensation of $150,000. Additionally, Mr. Kraws was granted options to purchase 100,000 shares of the Company&amp;#8217;s common stock with an exercise price equal to our per share market price on the date of issue. These options will vest pro rata, quarterly over a two year period with the first quarterly issuance of 12,500 options vesting immediately. The Company measured the fair value of the stock options at approximately $166,000 using a Black-Scholes valuation model; these warrants were indexed to the Company&amp;#8217;s own stock.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Black-Scholes assumptions used in calculating the fair value of the stock options are as follows:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 50%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 77%;"&gt;Exercise price&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 20%;"&gt;1.70&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected dividends&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;171&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.28&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected life of options&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;7 years&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected forfeitures&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">24000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">32000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
	<us-gaap:LicensesRevenue contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">2125000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:LicensesRevenue>
	<us-gaap:RevenueFromGrants contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">489000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:RevenueFromGrants>
	<us-gaap:SalesRevenueNet contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">2614000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:SalesRevenueNet>
	<us-gaap:InvestmentIncomeInterest contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">14000</us-gaap:InvestmentIncomeInterest>
	<syn:StockIssuedForLicenseFee contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">70000</syn:StockIssuedForLicenseFee>
	<syn:StockIssuedForLicenseFee contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</syn:StockIssuedForLicenseFee>
	<syn:IssueOfStockForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</syn:IssueOfStockForExclusiveChannelCollaborationAgreement>
	<syn:IssueOfStockForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">1684000</syn:IssueOfStockForExclusiveChannelCollaborationAgreement>
	<us-gaap:AdjustmentForAmortization contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentForAmortization>
	<us-gaap:AdjustmentForAmortization contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">57000</us-gaap:AdjustmentForAmortization>
	<us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments>
	<us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">20000</us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments>
	<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireMarketableSecurities>
	<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">4370000</us-gaap:PaymentsToAcquireMarketableSecurities>
	<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
	<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">4293000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">12000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<syn:StockIssuedForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</syn:StockIssuedForExclusiveChannelCollaborationAgreement>
	<syn:StockIssuedForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-3000</syn:StockIssuedForExclusiveChannelCollaborationAgreement>
	<syn:ExchangeOfEquipment contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">64000</syn:ExchangeOfEquipment>
	<syn:ExchangeOfEquipment contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</syn:ExchangeOfEquipment>
	<syn:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</syn:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
	<syn:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">1734000</syn:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
	<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">21449352</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">23338707</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">31292520</us-gaap:SharesOutstanding>
	<syn:StockIssuedDuringPeriodValueLicenseFees contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">70000</syn:StockIssuedDuringPeriodValueLicenseFees>
	<syn:StockIssuedDuringPeriodValueLicenseFees contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueLicenseFees>
	<syn:StockIssuedDuringPeriodValueLicenseFees contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">70000</syn:StockIssuedDuringPeriodValueLicenseFees>
	<syn:StockIssuedDuringPeriodValueLicenseFees contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueLicenseFees>
	<syn:StockIssuedDuringPeriodValueLicenseFees contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueLicenseFees>
	<syn:StockIssuedDuringPeriodSharesLicenseFees contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">81035</syn:StockIssuedDuringPeriodSharesLicenseFees>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">47000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">47000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">94000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">94000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">60521</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">73585</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
	<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">213000</syn:StockIssuedDuringPeriodValueConsultingFees>
	<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueConsultingFees>
	<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">213000</syn:StockIssuedDuringPeriodValueConsultingFees>
	<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueConsultingFees>
	<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueConsultingFees>
	<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">165000</syn:StockIssuedDuringPeriodValueConsultingFees>
	<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueConsultingFees>
	<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">165000</syn:StockIssuedDuringPeriodValueConsultingFees>
	<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueConsultingFees>
	<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueConsultingFees>
	<syn:StockIssuedDuringPeriodSharesConsultingFees contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">279724</syn:StockIssuedDuringPeriodSharesConsultingFees>
	<syn:StockIssuedDuringPeriodSharesConsultingFees contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">171796</syn:StockIssuedDuringPeriodSharesConsultingFees>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">130000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">113000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">17000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">255954</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">885000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">884000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">6961000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">6956000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">1212121</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">4545926</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">1687000</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
	<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">3000</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
	<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">1684000</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
	<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
	<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
	<syn:StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">3123558</syn:StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement>
	<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">15000</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
	<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
	<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">15000</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
	<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
	<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
	<syn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">38948</syn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">973000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">973000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<syn:StockIssuanceCost contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">115000</syn:StockIssuanceCost>
	<syn:StockIssuanceCost contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">539000</syn:StockIssuanceCost>
	<syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">1734000</syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified>
	<syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified>
	<syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">1734000</syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified>
	<syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified>
	<syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="-3">0</syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in; text-align: left;"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Organization and Nature of Operations and Basis of Presentation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Description of Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Synthetic Biologics, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Synthetic Biologics&amp;#8221;), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. In the area of synthetic biology, the Company is initially developing a product candidate to treat PAH. The Company also intends to expand new and existing collaborations in the synthetic biology area. In addition, Synthetic Biologics has several clinical-stage programs that are being funded, or partially funded, by grants, charitable organizations and corporate partners. In this area we are developing, or have partnered the development of, product candidates to treat relapsing-remitting MS, cognitive dysfunction in MS, fibromyalgia and ALS.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 24%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center;" nowrap="nowrap"&gt;Medical Indication&lt;/td&gt;
&lt;td style="width: 2%; padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 24%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center;" nowrap="nowrap"&gt;Product Candidate&lt;/td&gt;
&lt;td style="width: 2%; padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 48%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center;" nowrap="nowrap"&gt;Status&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;PAH&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;Synthetic DNA-based therapy&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;Preclinical&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;Relapsing-remitting MS&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;Trimesta&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;All patients enrolled in Phase II clinical trial;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;(estriol)&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;dosing and monitoring underway&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;Cognitive dysfunction in&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;Trimesta&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;Patient enrollment underway in Phase II&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;MS&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;(estriol)&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;clinical trial&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;Fibromyalgia&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;Effirma&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;Partnered with Meda AB&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"
 nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;(oral flupirtine)&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;ALS&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;AEN-100&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;Clinical trial preparation underway&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;(gastroretentive zinc acetate)&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On December 21, 2011, Synthetic Biologics announced that the Board of Directors had taken several actions to prioritize its focus on our entry into the emerging field of synthetic biology. The Company also announced that it intends to seek marketing partners for its zinc-based products &lt;i&gt;reaZin&lt;/i&gt; &amp;#8482; and &lt;i&gt;wellZin&lt;/i&gt; &amp;#8482;.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation and Corporate Structure&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;As of December 31, 2011, the Company had eight active subsidiaries, Pipex Therapeutics, Inc. (&amp;#8220;Pipex Therapeutics&amp;#8221;), Adeona Clinical Laboratory (formerly Hart Lab, LLC), Effective Pharmaceuticals, Inc. (&amp;#8220;EPI&amp;#8221;), Solovax, Inc. (&amp;#8220;Solovax&amp;#8221;), CD4 Biosciences, Inc. (&amp;#8220;CD4&amp;#8221;), Epitope Pharmaceuticals, Inc. (&amp;#8220;Epitope&amp;#8221;), Healthmine, Inc. (&amp;#8220;Healthmine&amp;#8221;) and Putney Drug Corp. (&amp;#8220;Putney&amp;#8221;). As of December 31, 2011, EPI, Adeona Clinical Laboratory, Healthmine and Putney are wholly owned and Pipex Therapeutics, Solovax, CD4 and Epitope are majority-owned.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;For financial reporting purposes, the outstanding common stock of the Company is that of Synthetic Biologics, Inc. All statements of operations, stockholders&amp;#8217; equity and cash flows for each of the entities are presented as consolidated. All subsidiaries were formed under the laws of the State of Delaware on January 8, 2001, except for EPI, which was incorporated in Delaware on December 12, 2000, Epitope which was incorporated in Delaware in January of 2002, Putney which was incorporated in Delaware in November of 2006, Healthmine which was formed in Delaware in December of 2007 and Adeona Clinical Laboratory which was incorporated in Illinois as a limited liability company on August 8, 2005.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &amp;#8220;Lab&amp;#8221;) to Hartlab, LLC, an entity controlled by the Lab&amp;#8217;s former owner, in consideration for (i) the immediate assignment of the Lab&amp;#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year non-recourse promissory note secured by all the assets of the Lab. Accordingly, this business has been presented in the consolidated financial statements as discontinued operations. This transaction is described in more detail in Note 3 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in; text-align: left;"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Selected Balance Sheet Information&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Accounts receivable (in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 64%; text-align: justify;"&gt;Accounts receivable&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;692&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;472&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Bad debt allowance - customer&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(287&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(133&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;405&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;339&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;Other current assets (in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" border="0" cellspacing="0" cellpadding="0"  &gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 64%; text-align: justify;"&gt;Grant receivable&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;320&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Prepaid expenses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;16&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;23&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;16&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;343&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Property and equipment (in thousands)&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 64%; text-align: justify;"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;863&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: justify;"&gt;Manufacturing equipment&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;400&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;333&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: justify;"&gt;Computer and office equipment&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;159&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;160&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt;"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;136&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;214&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;695&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,570&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Less accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(372&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(1,095&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;323&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;475&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&lt;i&gt;Accrued expenses (in thousands)&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 64%; text-align: justify;"&gt;Accrued vendor payments&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;1&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;105&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Bonus&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;100&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Compensation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;28&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;29&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;210&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;5.&amp;#160;&amp;#160;&amp;#160;Selected Balance Sheet Information&lt;/b&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Accounts receivable consisted of the following at March 31, 2012 and December 31, 2011 &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 88%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;December 31, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 70%;"&gt;Accounts receivable&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;736&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;692&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Bad debt allowance - customer&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(296&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(287&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Accounts receivable, net&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;440&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;405&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Property and Equipment consisted of the following at March 31, 2012, and December 31, 2011 &lt;i&gt;(in thousands)&lt;/i&gt; :&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 88%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;March&amp;#160;31,&amp;#160;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;December&amp;#160;31, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 70%;"&gt;Manufacturing equipment&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;400&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;400&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Computer and office equipment&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;159&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;159&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;136&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;136&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-left: 9pt;"&gt;Total&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;695&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;695&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Less accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(392&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(372&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;
 padding-bottom: 2.5pt;"&gt;Property and equipment, net&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;303&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;323&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Depreciation expense for the three months ended March 31, 2012 and 2011 was $20,000 and $80,000, respectively.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;div&gt;
&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in; text-align: left;"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;License, Collaborative and Employment Agreements and Commitments&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;License Agreements&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company has entered into various option and license agreements for the use of patents and their corresponding applications. These agreements have been entered into with various educational institutions and hospitals. These agreements contain payment schedules or stated amounts due for (a) option and license fees, (b) expense reimbursements, and (c) achievement of success milestones. All expenses related to these agreements have been recorded as research and development.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Research Agreement&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;In September&amp;#160;of 2005, the Company entered into a three-year research agreement with the University of Michigan. Pursuant to that agreement, the Company sponsored research of approximately $460,000 per year.&amp;#160;&amp;#160;On March 20, 2008, the Company terminated the agreement.&amp;#160;&amp;#160;On March 24, 2009, the Company entered into a payment plan with the University of Michigan to pay the outstanding balance of $197,000.&amp;#160;&amp;#160;The Company agreed to pay $5,000 per month, until the balance is paid in full. At December 31, 2011, the balance is approximately $32,000 and is recorded as a short-term accounts payable&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Employment Agreements&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;On February 6, 2010, the Company executed a three-year employment agreement with James S. Kuo, M.D., Chairman, Chief Executive Officer and President.&amp;#160;&amp;#160;The agreement provided for an annual base salary of $199,000, discretionary performance and transactional bonus payments, and 400,000 stock options with an exercise price equal to the market price on the date of grant.&amp;#160;&amp;#160;Of these stock options, 100,000 vested immediately upon grant and the remainder will vest pro rata, on a monthly basis, over the following thirty-six months. The fair value of the options totaled $328,000 and was determined using the Black-Scholes model with the following assumptions: expected dividend yield of 0%, expected volatility of 204.5%; risk free interest rate of 3.59% and an expected life of 10 years.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Effective February 3, 2012, Dr. Kuo resigned from his positions as President and Chief Executive Officer. In connection with his resignation, Dr. Kuo entered into a nine-month consulting agreement with the Company (the &amp;#8220;Consulting Agreement&amp;#8221;). Pursuant to the Consulting Agreement, Dr. Kuo will be entitled to a consulting fee of $17,000 per month and retain the right to exercise the stock options held by him that have vested (324,999) as of the effective date of the Consulting Agreement for a period expiring on the date that is one year from the effective date of the Consulting Agreement.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Effective February 3, 2012, Jeffrey Riley was appointed to serve as the Company&amp;#8217;s Chief Executive Officer and President. In connection with his appointment, Mr. Riley entered into a three-year employment agreement with the Company (the &amp;#8220;Riley Employment Agreement&amp;#8221;). Pursuant to the Riley Employment Agreement, Mr. Riley will be entitled to an annual base salary of $348,000 and will be eligible for discretionary performance and transactional bonus payments. Additionally, Mr. Riley was granted options to purchase 750,000 shares of the Company&amp;#8217;s common stock with an exercise price equal to the per share market price on the date of issue. These options will vest pro rata, on a monthly basis, over thirty-six months. The Company measured the fair value of the stock options at approximately $1.7 million using a Black-Scholes valuation model; these warrants were indexed to the Company&amp;#8217;s own stock.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;Effective February 6, 2012, C. Evan Ballantyne was appointed the Company&amp;#8217;s Chief Financial Officer. In connection with his appointment, Mr. Ballantyne entered into a three-year employment agreement with the Company (the &amp;#8220;Ballantyne Employment Agreement&amp;#8221;). Pursuant to the Ballantyne Employment Agreement, Mr. Ballantyne will be entitled to an annual base salary of $298,000 and will be eligible for discretionary performance and transactional bonus payments. Additionally, Mr. Ballantyne was granted options to purchase 425,000 shares of our common stock with an exercise price equal to our per share market price on the date of issue. These options will vest pro rata, on a monthly basis, over thirty-six months. The Company measured the fair value of the stock options at approximately $1 million using a Black-Scholes valuation model; these warrants were indexed to the Company&amp;#8217;s own stock.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;
 text-align: justify;"&gt;The Black-Scholes assumptions used in calculating the fair value of the stock options are as follows:&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 60%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; background-color: #ccffcc;"&gt;
&lt;td style="width: 54%; padding-right: 0.8pt;"&gt;Exercise price&lt;/td&gt;
&lt;td style="width: 4%; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 39%; padding-right: 0.8pt; text-align: center;"&gt;$2.30 - $2.47&lt;/td&gt;
&lt;td style="width: 3%; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top; background-color: white;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;Expected dividends&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"&gt;0%&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top; background-color: #ccffcc;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;Expected volatility&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"&gt;174%&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top; background-color: white;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"&gt;1.93% - 1.97%&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top; background-color: #ccffcc;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;Expected life of options&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"&gt;10 years&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top; background-color: white;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;Expected forfeitures&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"&gt;0%&lt;/td&gt;
&lt;td style="padding-right: 0.8pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Other Commitments&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;As of December 31, 2011, amounts due for license agreements are as follows &lt;i&gt;(in thousands)&lt;/i&gt; :&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table align="center" style="width: 60%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;Year&amp;#160;Ending&amp;#160;December&amp;#160;31,&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 79%; text-align: left; padding-left: 17.3pt;"&gt;2012&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 18%; text-align: right;"&gt;37&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-left: 17.3pt;"&gt;2013&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-left: 17.3pt;"&gt;2014&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-left: 17.3pt;"&gt;2015&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 17.3pt;"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt; padding-left: 8.65pt; text-align: left;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;57&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&lt;i&gt;Operating Lease&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;During 2007, the Company entered into a non-cancelable operating lease for office, laboratory and production space in Ann Arbor, Michigan.&amp;#160;This lease expired on February 28, 2011. In March 2011, the Company entered into a month-to-month lease, at a different location, in Ann Arbor, Michigan.&amp;#160;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;During the years ended December 31, 2011 and 2010 the Company recognized rent expense of $64,000 and $214,000, respectively.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Capital Lease&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;In June 2006, the Company acquired $65,000 of equipment under a non-cancelable capital lease. The Company agreed to guarantee and to release the seller from the seller&amp;#8217;s personal guarantee of the remaining balance and the amount was placed in
 escrow.&amp;#160;&amp;#160;The effective interest rate of the lease was 8.51%.&amp;#160; Related monthly payments of principal and interest were $1,400 over a period of sixty months.&amp;#160; In September 2008, the lessor extended the term for repayment by eight months, with a final maturity date of January 2012.&amp;#160;&amp;#160;The remaining balance of this capital lease at December 31, 2010 was $24,000. In January 2011, this capital lease was paid in full and the funds were released from escrow. See Note 3 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;div&gt;
&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in; text-align: left;"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;There was no income tax expense for the years ended December 31, 2011 and 2010 due to the Company&amp;#8217;s net losses.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The Company&amp;#8217;s tax expense differs from the &amp;#8220;expected&amp;#8221; tax expense for the years ended December 31, 2011 and 2010, (computed by applying the Federal Corporate tax rate of 34% to loss before taxes and 5.5% for Michigan State Corporate taxes, the blended rate used was 37.63%), as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%; text-align: left;"&gt;Computed &amp;#8220;expected&amp;#8221; tax benefit - Federal&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;(2,618&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;(550&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Computed &amp;#8220;expected&amp;#8221; tax benefit - State&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(448&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(94&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Non-taxable federal grant&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(184&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Meals, entertainment and other&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Non-deductible stock-based compensation&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;366&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;150&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Warrant expense&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;56&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Change in fair value of warrant expense&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;91&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Realized loss on debt securities&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;7&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Change in valuation allowance&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2,035&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;673&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The effects of temporary differences that gave rise to
 significant portions of deferred tax assets at December 31, 2011 and 2010 are as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;Deferred&amp;#160;tax&amp;#160;assets:&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 70%; text-align: left;"&gt;Stock issued for services&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;(321&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;(223&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Bad debt &amp;#8211; change in allowance&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(205&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(49&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Net operating loss carry-forward&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(10,425&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(8,644&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Total gross deferred tax assets&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(10,951&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(8,916&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Less valuation allowance&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;10,951&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;8,916&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Net deferred tax assets&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;At December 31, 2011, the Company has a net operating loss carry-forward of approximately $27.7 million available to offset future taxable income expiring through 2031. Utilization of these net operating losses may be limited due to potential ownership changes under Section 382 of the Internal Revenue Code.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;The valuation allowance at December 31, 2010 was approximately $8.9 million. The net change in valuation allowance during the year ended December 31, 2011 was an increase of approximately $2 million. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, Management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2011.&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;During 2010, the Company received grant revenue of $489,000.&amp;#160;&amp;#160;Under the terms of the grant, this revenue is not taxable.&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<!-- Footnote Section -->
	<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
	</link:footnoteLink>
	<syn:EquipmentImpairmentLoss contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</syn:EquipmentImpairmentLoss>
	<syn:EquipmentImpairmentLoss contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">121000</syn:EquipmentImpairmentLoss>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnDispositionOfProperty contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-6000</us-gaap:GainLossOnDispositionOfProperty>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnDispositionOfProperty contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">3000</us-gaap:GainLossOnDispositionOfProperty>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>syn-20120331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, August 08, 2012 09:40:52 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, August 08, 2012 09:45:41 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.3.6 on Thursday, August 09, 2012 08:36:40 PM -->
<schema elementFormDefault="qualified" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric" targetNamespace="http://www.adeonapharma.com/20120331" xmlns:syn="http://www.adeonapharma.com/20120331">
	<annotation><appinfo>
			<link:roleType roleURI="http://www.adeonapharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
				<link:definition>001 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified" id="StatementOfFinancialPositionClassified">
				<link:definition>002 - Statement - Consolidated Balance Sheets</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/Balancesheetparenthetical" id="Balancesheetparenthetical">
				<link:definition>003 - Statement - Consolidated Balance Sheets [Parenthetical]</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/StatementOfIncomeAlternative" id="StatementOfIncomeAlternative">
				<link:definition>004 - Statement - Consolidated Statements of Operations</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect" id="StatementOfCashFlowsIndirect">
				<link:definition>007 - Statement - Consolidated Statements of Cash Flows</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/Organization" id="Organization">
				<link:definition>008 - Disclosure - Organization</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/BasisOfPresentation" id="BasisOfPresentation">
				<link:definition>009 - Disclosure - Basis of Presentation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
				<link:definition>011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable" id="DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable">
				<link:definition>012 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/SelectedBalanceSheetInformation" id="SelectedBalanceSheetInformation">
				<link:definition>013 - Disclosure - Selected Balance Sheet Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/StockBasedCompensation" id="StockBasedCompensation">
				<link:definition>014 - Disclosure - Stock-Based Compensation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/StockPurchaseWarrants" id="StockPurchaseWarrants">
				<link:definition>015 - Disclosure - Stock Purchase Warrants</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/StockholdersEquity" id="StockholdersEquity">
				<link:definition>016 - Disclosure - Stockholders' Equity</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/SubsequentEvent" id="SubsequentEvent">
				<link:definition>019 - Disclosure - Subsequent Event</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" id="ConsolidatedStatementsOfChangesInStockholdersEquity">
				<link:definition>005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
				<link:definition>006 - Statement - Consolidated Statements of Changes in Stockholders' Equity [Parenthetical]</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation" id="OrganizationAndNatureOfOperationsAndBasisOfPresentation">
				<link:definition>010 - Disclosure - Organization and Nature of Operations and Basis of Presentation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/IncomeTaxes" id="IncomeTaxes">
				<link:definition>018 - Disclosure - Income Taxes</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitments" id="LicenseCollaborativeAndEmploymentAgreementsAndCommitments">
				<link:definition>017 - Disclosure - License, Collaborative and Employment Agreements and Commitments</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:linkbaseRef xlink:type="simple" xlink:href="syn-20120331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="syn-20120331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="syn-20120331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="syn-20120331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
		</appinfo></annotation>
	<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
	<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
	<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
	<import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/currency/2011-01-31" schemaLocation="http://xbrl.sec.gov/currency/2011/currency-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/exch/2011-01-31" schemaLocation="http://xbrl.sec.gov/exch/2011/exch-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
	<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
	<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
	<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
	<import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
	<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
	<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
	<element name="DocumentAndEntityInformationAbstract" id="syn_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="DepositsAndOtherAssetsNoncurrent" id="syn_DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="BalanceSheetParentheticalAbstract" id="syn_BalanceSheetParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="WarrantExpenses" id="syn_WarrantExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ChangeInFairValueOfWarrantLiability" id="syn_ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" id="syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedAsCompensation" id="syn_StockIssuedAsCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedForLicenseFee" id="syn_StockIssuedForLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="IssueOfStockForExclusiveChannelCollaborationAgreement" id="syn_IssueOfStockForExclusiveChannelCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedForConsultingFees" id="syn_StockIssuedForConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="EquipmentImpairmentLoss" id="syn_EquipmentImpairmentLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="IncreaseDecreaseInDepositsAndOtherAssets" id="syn_IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" id="syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" id="syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ProceedsFromIssuanceOfCommonStockForStockOptionExercises" id="syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ProceedsFromIssuanceOfCommonStockForWarrantExercises" id="syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedForExclusiveChannelCollaborationAgreement" id="syn_StockIssuedForExclusiveChannelCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" id="syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ExchangeOfEquipment" id="syn_ExchangeOfEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" id="syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockPurchaseWarrantsAbstract" id="syn_StockPurchaseWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockPurchaseWarrantsTextBlock" id="syn_StockPurchaseWarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="SubscriptionReceivableMember" id="syn_SubscriptionReceivableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedDuringPeriodValueLicenseFees" id="syn_StockIssuedDuringPeriodValueLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedDuringPeriodSharesLicenseFees" id="syn_StockIssuedDuringPeriodSharesLicenseFees" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" id="syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" id="syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedDuringPeriodValueConsultingFees" id="syn_StockIssuedDuringPeriodValueConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedDuringPeriodSharesConsultingFees" id="syn_StockIssuedDuringPeriodSharesConsultingFees" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" id="syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" id="syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" id="syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ConsolidatedStatementsOfChangesInStockholdersEquityParentheticalAbstract" id="syn_ConsolidatedStatementsOfChangesInStockholdersEquityParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuanceCost" id="syn_StockIssuanceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>syn-20120331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, August 08, 2012 09:40:52 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, August 08, 2012 09:45:41 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.3.6 on Thursday, August 09, 2012 08:36:40 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfFinancialPositionClassified" roleURI="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified"/>
	<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" order="10" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" order="30" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="20" use="optional" weight="1"/></calculationLink>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfIncomeAlternative" roleURI="http://www.adeonapharma.com/role/StatementOfIncomeAlternative"/>
	<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueNet" xlink:to="loc_us-gaap_LicensesRevenue" order="10" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueNet" xlink:to="loc_us-gaap_RevenueFromGrants" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_SalesRevenueNet" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingExpenses" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="20" use="optional" weight="1"/></calculationLink>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfCashFlowsIndirect" roleURI="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect"/>
	<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations" order="10" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="30" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedAsCompensation" xlink:label="loc_syn_StockIssuedAsCompensation"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_StockIssuedAsCompensation" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForLicenseFee" xlink:label="loc_syn_StockIssuedForLicenseFee"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_StockIssuedForLicenseFee" order="50" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForConsultingFees" xlink:label="loc_syn_StockIssuedForConsultingFees"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_StockIssuedForConsultingFees" order="70" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_WarrantExpenses" order="80" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability" order="90" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" order="100" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts" order="110" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AdjustmentForAmortization" order="120" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" order="130" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfProperty" xlink:label="loc_us-gaap_GainLossOnDispositionOfProperty"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfProperty" order="140" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_EquipmentImpairmentLoss" order="150" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfAccountsReceivable" order="160" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" order="170" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="180" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" order="190" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" order="200" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" order="210" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="220" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="230" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" order="240" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/><loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedForExclusiveChannelCollaborationAgreement"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_syn_StockIssuedForExclusiveChannelCollaborationAgreement" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RecoveryOfDirectCosts" order="50" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/></calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>syn-20120331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, August 08, 2012 09:40:52 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, August 08, 2012 09:45:41 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.3.6 on Thursday, August 09, 2012 08:36:40 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#DocumentAndEntityInformation" roleURI="http://www.adeonapharma.com/role/DocumentAndEntityInformation"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfFinancialPositionClassified" roleURI="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#Balancesheetparenthetical" roleURI="http://www.adeonapharma.com/role/Balancesheetparenthetical"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfIncomeAlternative" roleURI="http://www.adeonapharma.com/role/StatementOfIncomeAlternative"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfCashFlowsIndirect" roleURI="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.adeonapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.adeonapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"/>
	<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/DocumentAndEntityInformation">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_3" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_4" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_5" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_6" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_7" order="60" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Cash_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_OtherAssetsCurrent_5" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_7" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_9" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent_10" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Assets_11" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccountsPayableCurrent_13" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_14" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_15" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_16" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_17" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_17" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_18" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_Liabilities_19" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_StockholdersEquityAbstract_20" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_PreferredStockValue_21" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_22"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_CommonStockValue_22" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_25"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_StockholdersEquity_25" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_26"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_26" order="70" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/Balancesheetparenthetical">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_8" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9" order="80" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RevenuesAbstract_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LicensesRevenue_3" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RevenueFromGrants_4" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SalesRevenueNet_5" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_OperatingExpenses_9" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_10" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11" xlink:to="loc_syn_WarrantExpenses_12" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_13" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_14" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11" xlink:to="loc_us-gaap_InvestmentIncomeInterest_16" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11" xlink:to="loc_us-gaap_OtherNonoperatingIncome_17" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_18" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_19" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_20" order="90" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_21" order="100" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_22"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_22" order="110" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_23"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_22" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_23" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_24"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_22" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_24" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_25"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_25" order="120" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xlink:label="loc_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive_26"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive_26" order="130" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11" xlink:to="loc_syn_EquipmentImpairmentLoss" order="30" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_4" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ShareBasedCompensation_6" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedAsCompensation" xlink:label="loc_syn_StockIssuedAsCompensation_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_StockIssuedAsCompensation_7" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForLicenseFee" xlink:label="loc_syn_StockIssuedForLicenseFee_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_StockIssuedForLicenseFee_8" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement_9" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForConsultingFees" xlink:label="loc_syn_StockIssuedForConsultingFees_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_StockIssuedForConsultingFees_10" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_WarrantExpenses_11" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_12" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_Depreciation_13" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_14" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_AdjustmentForAmortization_15" order="90" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_16" order="100" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfProperty" xlink:label="loc_us-gaap_GainLossOnDispositionOfProperty_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnDispositionOfProperty_17" order="110" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_EquipmentImpairmentLoss_18" order="120" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_19" order="130" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" order="140" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_21" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_22"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_22" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_23"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_23" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_24"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_24" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation_25"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation_25" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_26"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_26" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_27"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_27" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_28"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_28" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_31"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_31" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_32"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_32" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_33"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_33" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_34"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_34" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_37"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_37" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises_38"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises_38" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedForExclusiveChannelCollaborationAgreement_39"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" xlink:to="loc_syn_StockIssuedForExclusiveChannelCollaborationAgreement_39" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises_40"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises_40" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_41"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_41" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_43"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_43" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_44"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_Cash_44" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_45"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_45" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_46"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_45" xlink:to="loc_us-gaap_InterestPaid_46" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_47"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_45" xlink:to="loc_us-gaap_IncomeTaxesPaid_47" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_48"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_48" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ExchangeOfEquipment" xlink:label="loc_syn_ExchangeOfEquipment_49"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ExchangeOfEquipment_49" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_50"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_50" order="90" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_SubscriptionReceivableMember" xlink:label="loc_syn_SubscriptionReceivableMember_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_syn_SubscriptionReceivableMember_7" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_8" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_9" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_10" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_11" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_12" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodValueLicenseFees" xlink:label="loc_syn_StockIssuedDuringPeriodValueLicenseFees_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodValueLicenseFees_13" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodSharesLicenseFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesLicenseFees_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesLicenseFees_14" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement_15" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement_16" order="90" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodValueConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodValueConsultingFees_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodValueConsultingFees_17" order="100" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodSharesConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesConsultingFees_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesConsultingFees_18" order="110" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19" order="120" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20" order="130" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_21" order="140" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_22"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_22" order="150" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_23"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_23" order="160" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_24"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_24" order="170" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xlink:label="loc_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified_25"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified_25" order="180" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_26"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_26" order="190" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuanceCost" xlink:label="loc_syn_StockIssuanceCost_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuanceCost_4" order="10" use="optional"/>
	</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>syn-20120331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, August 08, 2012 09:40:52 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, August 08, 2012 09:45:41 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.3.6 on Thursday, August 09, 2012 08:36:40 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_DocumentAndEntityInformationAbstract" xlink:label="loc_syn_DocumentAndEntityInformationAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DocumentAndEntityInformationAbstract" xlink:to="lab_syn_DocumentAndEntityInformationAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash at the beginning of period</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash at the end of period</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets Of Discontinued Operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets of discontinued operations</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xml:lang="en-US">Notes, Loans and Financing Receivable, Net, Noncurrent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xml:lang="en-US">Long-term note receivable</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and Other Assets Noncurrent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and other assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and other assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DepositsAndOtherAssetsNoncurrent" xlink:to="lab_syn_DepositsAndOtherAssetsNoncurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders Equity [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Liabilities Of Disposal Group, Including Discontinued Operation, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Liabilities of discontinued operations</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Long Term Liabilities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Noncurrent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xml:lang="en-US">Accounts payable</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity Attributable To Parent [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized, 28,127,644 issued and 28,209,126 outstanding and 23,420,189 issued and 23,338,707 outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized, 31,374,002 issued and 31,292,520 outstanding and 23,420,189 issued and 23,338,707 outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid In Capital, Common Stock</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable To Parent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Stockholders Equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_BalanceSheetParentheticalAbstract" xlink:label="loc_syn_BalanceSheetParentheticalAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_BalanceSheetParentheticalAbstract" xlink:to="lab_syn_BalanceSheetParentheticalAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par Or Stated Value Per Share</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicensesRevenue" xml:lang="en-US">Licenses Revenue</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LicensesRevenue" xml:lang="en-US">License revenue, net</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue" xlink:to="lab_us-gaap_LicensesRevenue"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromGrants" xml:lang="en-US">Revenue From Grants</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromGrants" xml:lang="en-US">Grant revenue</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromGrants" xlink:to="lab_us-gaap_RevenueFromGrants"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue, Net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Total Revenues</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Total Revenues</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet" xlink:to="lab_us-gaap_SalesRevenueNet"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Costs and Expenses:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Costs and Expenses</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Costs and Expenses</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss from Continuing Operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss from Continuing Operations</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income (Expense):</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantExpenses" xml:lang="en-US">Warrant Expenses</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantExpenses" xml:lang="en-US">Warrant expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantExpenses" xml:lang="en-US">The amount of expenses incurred for warrant during the period.</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_WarrantExpenses" xml:lang="en-US">Warrant expense</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantExpenses" xlink:to="lab_syn_WarrantExpenses"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change In Fair Value Of Warrant Liability</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair value of warrant liability</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair value of warrant liability</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ChangeInFairValueOfWarrantLiability" xlink:to="lab_syn_ChangeInFairValueOfWarrantLiability"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) On Sale Of Property Plant Equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on the sale of equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Sale of Property Plant Equipment, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (loss) on the sale of equipment</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income (expense)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Income (Expense), net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Income (Expense), net</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Income (Loss) From Continuing Operations Attributable To Parent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net Loss from Continuing Operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net Loss from Continuing Operations</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income (Loss) From Discontinued Operations, Net Of Tax, Attributable To Parent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Net Income (Loss) from Discontinued Operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Net Income (Loss) from Discontinued Operations</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable To Parent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net Income (Loss) Per Share - Basic and Dilutive:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) From Continuing Operations, Per Basic and Diluted Share</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Continuing Operations (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) From Discontinued Operations, Net Of Tax, Per Basic and Diluted Share</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Discontinued Operations (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net Loss Per Share</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net Income (Loss) Per Share - Basic and Dilutive (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xlink:label="loc_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xml:lang="en-US">Weighted Average Number Of Common Shares Outstanding During Period Basic and Dilutive</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xml:lang="en-US">Weighted average number of common shares outstanding during the year Basic and Dilutive (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xml:lang="en-US">Weighted average number of common shares outstanding during the period - Basic and Dilutive (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xml:lang="en-US">The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xlink:to="lab_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedAsCompensation" xlink:label="loc_syn_StockIssuedAsCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedAsCompensation" xml:lang="en-US">Stock Issued As Compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedAsCompensation" xml:lang="en-US">Stock issued as employee compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedAsCompensation" xml:lang="en-US">The noncash expense that accounts for the value of stock options distributed to employees as compensation.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedAsCompensation" xlink:to="lab_syn_StockIssuedAsCompensation"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForLicenseFee" xlink:label="loc_syn_StockIssuedForLicenseFee"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedForLicenseFee" xml:lang="en-US">Stock Issued For License Fee</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedForLicenseFee" xml:lang="en-US">Stock issued for license fee</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedForLicenseFee" xml:lang="en-US">issued of stock based on license fee During the period.</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_StockIssuedForLicenseFee" xml:lang="en-US">Stock issued for license fee</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedForLicenseFee" xlink:to="lab_syn_StockIssuedForLicenseFee"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Issue Of Stock For Exclusive Channel Collaboration Agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Stock issued for exclusive channel collaboration agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Stock issued for exclusive channel collaboration agreement during the period.</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Stock issued for exclusive channel collaboration agreement</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xlink:to="lab_syn_IssueOfStockForExclusiveChannelCollaborationAgreement"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForConsultingFees" xlink:label="loc_syn_StockIssuedForConsultingFees"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedForConsultingFees" xml:lang="en-US">Stock Issued For Consulting Fees</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedForConsultingFees" xml:lang="en-US">Stock issued for consulting fees</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedForConsultingFees" xml:lang="en-US">The fair value of restricted stock or stock options granted to nonemployees as payment for consulting fees.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedForConsultingFees" xlink:to="lab_syn_StockIssuedForConsultingFees"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision For Doubtful Accounts</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for uncollectible accounts receivable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for Doubtful Accounts</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization of premium on investments</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization of premium on investments</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xml:lang="en-US">Held-To-Maturity Securities, Sold Security, Realized Gain (Loss), Excluding Other Than Temporary Impairments</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xml:lang="en-US">Loss on sale of short-term investment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xml:lang="en-US">Loss on sale of short-term investment</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EquipmentImpairmentLoss" xml:lang="en-US">Equipment Impairment Loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_EquipmentImpairmentLoss" xml:lang="en-US">Impairment loss on equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_EquipmentImpairmentLoss" xml:lang="en-US">Impairment loss on equipment during the period.</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_EquipmentImpairmentLoss" xml:lang="en-US">Impairment loss on equipment</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EquipmentImpairmentLoss" xlink:to="lab_syn_EquipmentImpairmentLoss"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfAccountsReceivable" xml:lang="en-US">Gain (Loss) On Sale Of Accounts Receivable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfAccountsReceivable" xml:lang="en-US">Gain on the settlement of accounts payable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfAccountsReceivable" xml:lang="en-US">Gain on the settlement of accounts payable</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:to="lab_us-gaap_GainLossOnSaleOfAccountsReceivable"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) In Accounts Receivable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase (Decrease) In Other Current Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xml:lang="en-US">Increase (Decrease) In Notes Receivable, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xml:lang="en-US">Note receivable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xml:lang="en-US">Note receivable</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Increase Decrease In Deposits and Other Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Increase (Decrease) In Assets Of Disposal Group Including Discontinued Operation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Assets of discontinued operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">The increase (decrease) during the reporting period in assets of discontinued operations.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) In Accounts Payable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Increase (Decrease) In Liabilities Of Disposal Group Including Discontinued Operation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Liabilities of discontinued operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">The increase (decrease) during the reporting period in liabilities of discontinued operations.</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Liabilities of discontinued operations</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Payments To Acquire Marketable Securities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Purchase of short-term investments</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Purchase of short-term investments</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds From Sale, Maturity and Collection Of Investments</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from short-term investments</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds From Sale Of Property, Plant, and Equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from the sale of equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from the sale of equipment</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xml:lang="en-US">Proceeds From Issuance Of Common Stock For Stock Option Exercises</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xml:lang="en-US">Proceeds from issuance of common stock for stock option and warrant exercises</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity for stock option exercised.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:to="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xml:lang="en-US">Proceeds From Issuance Of Common Stock For Warrant Exercises</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xml:lang="en-US">Proceeds from issuance of common stock for warrant exercises</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xml:lang="en-US">Proceeds from issuance of common stock for warrant exercises</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity for warrant exercises.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xlink:to="lab_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedForExclusiveChannelCollaborationAgreement"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Stock Issued For Exclusive Channel Collaboration Agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Proceeds from issuance of common stock for exclusive channel collaboration agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Stock Issued For Exclusive Channel Collaboration Agreement during the period.</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_StockIssuedForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Proceeds from issuance of common stock for exclusive channel collaboration agreement</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedForExclusiveChannelCollaborationAgreement" xlink:to="lab_syn_StockIssuedForExclusiveChannelCollaborationAgreement"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xml:lang="en-US">Proceeds From Issuance Of Common Stock Excluding Stock Option and Warrant Exercises</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xml:lang="en-US">Proceeds from the issuance of common stock</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity excluding stock option and warrant exercised during the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xlink:to="lab_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xml:lang="en-US">Recovery Of Direct Costs</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xml:lang="en-US">Cash paid as direct offering costs</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xml:lang="en-US">Cash paid as direct offering costs</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecoveryOfDirectCosts" xlink:to="lab_us-gaap_RecoveryOfDirectCosts"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Cash Period Increase Decrease</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashPeriodIncreaseDecrease"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ExchangeOfEquipment" xlink:label="loc_syn_ExchangeOfEquipment"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExchangeOfEquipment" xml:lang="en-US">Exchange Of Equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExchangeOfEquipment" xml:lang="en-US">Exchange of equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ExchangeOfEquipment" xml:lang="en-US">Equipment Exchanged during the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExchangeOfEquipment" xlink:to="lab_syn_ExchangeOfEquipment"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xml:lang="en-US">Reclassification Of Derivative Liability To Additional Paid In Capital</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xml:lang="en-US">Reclassification of warrant liability to additional paid-in capital</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xml:lang="en-US">Reclassification of warrant liability to additional paid-in capital for the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:to="lab_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature Of Operations [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis Of Presentation [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureTextBlockSupplementAbstract" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureTextBlockSupplementAbstract" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="lab_us-gaap_DisclosureTextBlockSupplementAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsAbstract" xml:lang="en-US">Stock Purchase Warrants [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPurchaseWarrantsAbstract" xml:lang="en-US">Stock Purchase Warrants [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsAbstract" xlink:to="lab_syn_StockPurchaseWarrantsAbstract"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockPurchaseWarrantsTextBlock" xlink:label="loc_syn_StockPurchaseWarrantsTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsTextBlock" xml:lang="en-US">Stock Purchase Warrants [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPurchaseWarrantsTextBlock" xml:lang="en-US">Stock Purchase Warrants [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockPurchaseWarrantsTextBlock" xml:lang="en-US">The entire disclosure for stock purchase warrants.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsTextBlock" xlink:to="lab_syn_StockPurchaseWarrantsTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders Equity Note [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement Of Stockholders' Equity [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Statement, Equity Components [Axis]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Statement, Equity Components [Axis]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-In Capital [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_SubscriptionReceivableMember" xlink:label="loc_syn_SubscriptionReceivableMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_SubscriptionReceivableMember" xml:lang="en-US">Subscription Receivable [Member]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_SubscriptionReceivableMember" xml:lang="en-US">Subscription Receivable during the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_SubscriptionReceivableMember" xlink:to="lab_syn_SubscriptionReceivableMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Adjustments To Additional Paid In Capital, Share-Based Compensation, Stock Options, Requisite Service Period Recognition</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Stock-based compensation</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Value, Share-Based Compensation, Net Of Forfeitures</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Issuance of common stock for employee compensation</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Shares, Share-Based Compensation, Net Of Forfeitures</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Issuance of common stock for employee compensation (in shares)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodValueLicenseFees" xlink:label="loc_syn_StockIssuedDuringPeriodValueLicenseFees"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodValueLicenseFees" xml:lang="en-US">Stock Issued During Period Value License Fees</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodValueLicenseFees" xml:lang="en-US">Issuance of common stock for license fees</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodValueLicenseFees" xml:lang="en-US">Value of stock issued during the period as a result of licence fee.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodValueLicenseFees" xlink:to="lab_syn_StockIssuedDuringPeriodValueLicenseFees"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodSharesLicenseFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesLicenseFees"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodSharesLicenseFees" xml:lang="en-US">Stock Issued During Period Shares License Fees</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodSharesLicenseFees" xml:lang="en-US">Issuance of common stock for license fees (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodSharesLicenseFees" xml:lang="en-US">Number of shares issued during the period as a result of licence fees.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodSharesLicenseFees" xlink:to="lab_syn_StockIssuedDuringPeriodSharesLicenseFees"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Stock Issued During Period Value For Exclusive Channel Collaboration Agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Issuance of common stock for exclusive channel collaboration agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Value of stock issued during the period For Exclusive Channel Collaboration Agreement.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xlink:to="lab_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Stock Issued During Period Shares For Exclusive Channel Collaboration Agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Issuance of common stock for exclusive channel collaboration agreement (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Number of shares issued during the period For Exclusive Channel Collaboration Agreement.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xlink:to="lab_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodValueConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodValueConsultingFees"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodValueConsultingFees" xml:lang="en-US">Stock Issued During Period Value Consulting Fees</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodValueConsultingFees" xml:lang="en-US">Issuance of common stock for consulting fees</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodValueConsultingFees" xml:lang="en-US">Value of stock issued during the period as a result of consulting fee.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodValueConsultingFees" xlink:to="lab_syn_StockIssuedDuringPeriodValueConsultingFees"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodSharesConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesConsultingFees"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodSharesConsultingFees" xml:lang="en-US">Stock Issued During Period Shares Consulting Fees</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodSharesConsultingFees" xml:lang="en-US">Issuance of common stock for consulting fees (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodSharesConsultingFees" xml:lang="en-US">Number of shares issued during the period as a result of consulting fee.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodSharesConsultingFees" xlink:to="lab_syn_StockIssuedDuringPeriodSharesConsultingFees"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Issuance of common stock for options exercised</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Issuance of common stock for options exercised (in shares)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common stock, net of issuance costs</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xml:lang="en-US">Stock Issued During Period Value Stock Options and Warrants Exercised</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xml:lang="en-US">Issuance of common stock for options and warrants exercised</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xml:lang="en-US">Value stock issued during the period as a result of the stock options and warrants exercised.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:to="lab_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xml:lang="en-US">Stock Issued During Period Shares Stock Options and Warrants Exercised</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xml:lang="en-US">Issuance of common stock for options and warrants exercised (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xml:lang="en-US">Number of share options and warrants exercised during the current period..</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:to="lab_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xlink:label="loc_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xml:lang="en-US">Adjustments To Additional Paid In Capital Warrants Liability Reclassified</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xml:lang="en-US">Warrant liability reclassified to stockholders' equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xml:lang="en-US">Increase in additional paid in capital due to warrants liability reclassified to stockholders equity during the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xlink:to="lab_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ConsolidatedStatementsOfChangesInStockholdersEquityParentheticalAbstract" xlink:label="loc_syn_ConsolidatedStatementsOfChangesInStockholdersEquityParentheticalAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ConsolidatedStatementsOfChangesInStockholdersEquityParentheticalAbstract" xml:lang="en-US">Consolidated Statements Of Changes In Stockholders' Equity [Parenthetical] [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ConsolidatedStatementsOfChangesInStockholdersEquityParentheticalAbstract" xml:lang="en-US">Consolidated Statements Of Changes In Stockholders' Equity [Parenthetical] [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ConsolidatedStatementsOfChangesInStockholdersEquityParentheticalAbstract" xlink:to="lab_syn_ConsolidatedStatementsOfChangesInStockholdersEquityParentheticalAbstract"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuanceCost" xlink:label="loc_syn_StockIssuanceCost"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuanceCost" xml:lang="en-US">Stock Issuance Cost</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuanceCost" xml:lang="en-US">Stock Issuance Cost during the period.</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuanceCost" xml:lang="en-US">Stock Issuance Cost</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuanceCost" xlink:to="lab_syn_StockIssuanceCost"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfProperty" xlink:label="loc_us-gaap_GainLossOnDispositionOfProperty"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_GainLossOnDispositionOfProperty" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Gain (Loss) on Disposition of Property</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_GainLossOnDispositionOfProperty" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Gain (loss) on the sale of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfProperty" xlink:to="lab_us-gaap_GainLossOnDispositionOfProperty"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>syn-20120331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, August 08, 2012 09:40:52 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, August 08, 2012 09:45:41 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.3.6 on Thursday, August 09, 2012 08:36:41 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#DocumentAndEntityInformation" roleURI="http://www.adeonapharma.com/role/DocumentAndEntityInformation"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfFinancialPositionClassified" roleURI="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#Balancesheetparenthetical" roleURI="http://www.adeonapharma.com/role/Balancesheetparenthetical"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfIncomeAlternative" roleURI="http://www.adeonapharma.com/role/StatementOfIncomeAlternative"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfCashFlowsIndirect" roleURI="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#Organization" roleURI="http://www.adeonapharma.com/role/Organization"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#BasisOfPresentation" roleURI="http://www.adeonapharma.com/role/BasisOfPresentation"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.adeonapharma.com/role/SummaryOfSignificantAccountingPolicies"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable" roleURI="http://www.adeonapharma.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#SelectedBalanceSheetInformation" roleURI="http://www.adeonapharma.com/role/SelectedBalanceSheetInformation"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StockBasedCompensation" roleURI="http://www.adeonapharma.com/role/StockBasedCompensation"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StockPurchaseWarrants" roleURI="http://www.adeonapharma.com/role/StockPurchaseWarrants"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StockholdersEquity" roleURI="http://www.adeonapharma.com/role/StockholdersEquity"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#SubsequentEvent" roleURI="http://www.adeonapharma.com/role/SubsequentEvent"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.adeonapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.adeonapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#OrganizationAndNatureOfOperationsAndBasisOfPresentation" roleURI="http://www.adeonapharma.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#IncomeTaxes" roleURI="http://www.adeonapharma.com/role/IncomeTaxes"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#LicenseCollaborativeAndEmploymentAgreementsAndCommitments" roleURI="http://www.adeonapharma.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitments"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/DocumentAndEntityInformation">
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_DocumentAndEntityInformationAbstract" xlink:label="loc_syn_DocumentAndEntityInformationAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DocumentAndEntityInformationAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityRegistrantName_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCentralIndexKey_4" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityFilerCategory_5" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentType_6" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_AmendmentFlag_7" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentPeriodEndDate_8" order="50" use="optional"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AssetsAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Cash_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_OtherAssetsCurrent_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AssetsCurrent_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Assets_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_AccountsPayableCurrent_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesCurrent_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_Liabilities_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_StockholdersEquityAbstract_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_PreferredStockValue_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_23"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_CommonStockValue_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_24"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_25"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_StockholdersEquity_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_27"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/Balancesheetparenthetical">
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_BalanceSheetParentheticalAbstract" xlink:label="loc_syn_BalanceSheetParentheticalAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_BalanceSheetParentheticalAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesIssued_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_10" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_RevenuesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3" xlink:to="loc_us-gaap_LicensesRevenue_4" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3" xlink:to="loc_us-gaap_RevenueFromGrants_5" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3" xlink:to="loc_us-gaap_SalesRevenueNet_6" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_OperatingExpenses_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_syn_WarrantExpenses_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_us-gaap_InvestmentIncomeInterest_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_us-gaap_OtherNonoperatingIncome_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetIncomeLoss_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_23"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_23" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_24"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_23" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_25"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_23" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_26"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_26" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xlink:label="loc_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive_27"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive_27" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_syn_EquipmentImpairmentLoss" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_ShareBasedCompensation_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedAsCompensation" xlink:label="loc_syn_StockIssuedAsCompensation_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_StockIssuedAsCompensation_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForLicenseFee" xlink:label="loc_syn_StockIssuedForLicenseFee_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_StockIssuedForLicenseFee_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForConsultingFees" xlink:label="loc_syn_StockIssuedForConsultingFees_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_StockIssuedForConsultingFees_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_WarrantExpenses_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_Depreciation_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_AdjustmentForAmortization_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfProperty" xlink:label="loc_us-gaap_GainLossOnDispositionOfProperty_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_GainLossOnDispositionOfProperty_18" order="110" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_EquipmentImpairmentLoss_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_23"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_24"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_25"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation_26"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_27"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_28"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_29"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_29" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_32"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_33"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_34"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_35"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_38"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_38" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises_39"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises_39" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedForExclusiveChannelCollaborationAgreement_40"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_syn_StockIssuedForExclusiveChannelCollaborationAgreement_40" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises_41"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises_41" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_42"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_42" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_44"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_44" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_45"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_Cash_45" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_46"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_Cash_46" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_47"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_47" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_48"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_47" xlink:to="loc_us-gaap_InterestPaid_48" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_49"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_47" xlink:to="loc_us-gaap_IncomeTaxesPaid_49" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ExchangeOfEquipment" xlink:label="loc_syn_ExchangeOfEquipment_51"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_syn_ExchangeOfEquipment_51" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_52"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_52" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/Organization">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/BasisOfPresentation">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/SummaryOfSignificantAccountingPolicies">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/SelectedBalanceSheetInformation">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_0" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StockBasedCompensation">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StockPurchaseWarrants">
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockPurchaseWarrantsTextBlock" xlink:label="loc_syn_StockPurchaseWarrantsTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_0" xlink:to="loc_syn_StockPurchaseWarrantsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StockholdersEquity">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/SubsequentEvent">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_CommonStockMember_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_SubscriptionReceivableMember" xlink:label="loc_syn_SubscriptionReceivableMember_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_syn_SubscriptionReceivableMember_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockholdersEquity_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SharesOutstanding_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodValueLicenseFees" xlink:label="loc_syn_StockIssuedDuringPeriodValueLicenseFees_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_syn_StockIssuedDuringPeriodValueLicenseFees_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodSharesLicenseFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesLicenseFees_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_syn_StockIssuedDuringPeriodSharesLicenseFees_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodValueConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodValueConsultingFees_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_syn_StockIssuedDuringPeriodValueConsultingFees_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodSharesConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesConsultingFees_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_syn_StockIssuedDuringPeriodSharesConsultingFees_19" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_20" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_22" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_24"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_24" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_25"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_25" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xlink:label="loc_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified_26"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified_26" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_27"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_NetIncomeLoss_27" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_28"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockholdersEquity_28" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_29"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SharesOutstanding_29" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ConsolidatedStatementsOfChangesInStockholdersEquityParentheticalAbstract" xlink:label="loc_syn_ConsolidatedStatementsOfChangesInStockholdersEquityParentheticalAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_ConsolidatedStatementsOfChangesInStockholdersEquityParentheticalAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuanceCost" xlink:label="loc_syn_StockIssuanceCost_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_syn_StockIssuanceCost_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/IncomeTaxes">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitments">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>9
<FILENAME>0001144204-12-044299-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-12-044299-xbrl.zip
M4$L#!!0````(`.->"D&',[NJ9+8```;6!P`0`!P`<WEN+3(P,3(P,S,Q+GAM
M;%54"0`#VBXE4-HN)5!U>`L``00E#@``!#D!``#L77MSV[:6_[N=N=^!ZYUV
MTQG+XD-/.\D=Q8_$TR3VVDFWG=V=#$Q"$FXIDA<D;:L[<S_['H#4BZ1$@@(I
MV7&G;2(2P/F=!PX.@`/P]=\?)[9RCZE/7.?-@7:D'BC8,5V+.*,W!U^_7#1Z
M!W]_^[<?7_];HZ'\_N[FHV*Y9CC!3J"8%*,`6\H#"<;*^5\-_C9N26D?J4?0
MF/+?:K>IP[^JIBNJ<:RKQT9;N?[TOTJC,6OU'?*A%:C#&]"/M,4[_N1L1O`3
MH!J2)8J_$?R`J?);3!/H'1E''=;4EW%(?0M-#Y5!.`K]0%'[ATH$HG=L=(Z-
M/H"(Z3S>49L<L_\K(`O'/[:)\^>;@W$0>,?-YL/#PQ%[=^32$;"A&DWV^@XP
M'\3%V5N+S"LL%^XTHY?SHJFF'PQ>5NOW^TW^=E[4)UD%H5&M^?NGC[?F&$]0
M@SA^@!QS!0O9@#U9GOAN2]>ZFVI$)685'-=QPDEV>2N@S6#JX284:D`I3(DY
MKY=?:;6"A3V*369@:\'UFXB:U+5Q<XC,H($?/1LY*'#I]`)^SQJB>+BVA4X3
MWLXAXF`#*4X'BJQH/<C4>CO2^KRHZ89.0*>K97UL'HW<^V;\DO40K:%J#4.;
M5PLIA:ZXKE[\-J.BA4EV'7B141P_FN/L\NQ-1@7BW&,_R*X2O<NHY"!B^MEU
M^*N,*CXQLRO`BZSB@4?7E(<W&15"OS%"R)O7&2+_CNLP?K&^2@,%P?IJ\)*2
MNS#`_E(U9N-^9AW^)H/6H[VA6_[^<<E7^%-GI2BRL.L@;XSH!!V9[H2[7]6`
MIL'?_?":N9ECGSN0&SQ4N-LYCKO29N?4]*CK81H0`+SD!GD#C(TW!SZ9>/;\
MV9AW/H#7F"$X>O2M@R:'P7S_J>L$^#%0;K$9,!<>N>0?8I]LQF\)^("XY+>+
M/\Z_&5KC#)NL395S-"L/@P0)IOS)[!&QV$,8-:C".5YE<&8@IY>_'KQ5X9]>
MOZ6U>Z^;R<H1E6:*3$P%9$)<:X4P^%D:G('_@J<,*-.MJL%PTTR__V&)`VNY
MCJ:#/2SJ+-XNP"Q(SY[$4A.3X[?;`%IFP^SY/T/@[M2=>*X#/_W!(_&_P<^)
MZ]P&KOGG)SRYP[1.N<]%BD<,8/0L>F@!<7#[Q"1!A$NQ")2)@IFX/QYO9.W@
M[:Q8BL?7S4P2,:9F&M1W;"`#RR*L!R/[&A'KTCE%'@F0_6R-92._+X93W'!N
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M[&;&LU=&\!+Z?I=J?XE]GJ#ZV3F>KPY)'^)A+_[VX^6_M/^Y^.WZ`W[$9^U.
MM_?'#?XG>?O[U\M_L<=_/)![L]5JF>UVV_SR?^.WG=<?SE^WWK_7+CZ\/M9Z
M%YVV=G'QX40[?O.A_>;]Z\[[?N=R]910R&@SJ_MZ>W;P-GXXP<@/*7X;'U\\
MAG<S[+-7L]^L_IKFO@'GWV['B.)YPQ:Y!V-YNU3X,SNXR(X=EJ2=JL\>GF''
MG1`GJ]E8_0R5OZG=E2::J^AS6(\:3PFS*.6Y]L]MW@M2EF%A<GS.;?4&CX@?
M4+"XSVB"E=BN;MBQL;4[T+=3)QCC@)C*.^+:[HB8_J%RZ9A'KYOK&DY0/050
M%-F7CH4??\738F27O<;:IA*$+HB-Z2DX@Y%+"Y*YG2`;*BDWV'-I`&."PMP'
M<J;+5%?:G=.<G93^,O4*BO(*!$FCAI<KSUL<P!.+/;VPT:A8DT-D^SAJ<J5V
M"N4U]RKGT1Y[L;87&]*KF%>:XH3F837RQYEMI_/(%6:ZO`QS)(J%30*J\-\<
M-`R@W&GU0?^OF\L-EZ.D;:;4`1^Y+:6YQ#93ZJFZ')[4?H[TNEI;$D]YTE.9
M\#91&IC\R+6_&'0_X^"4GZ8.9%B*8:P:RB9Z<H'EB*:EMNL&5LP.6RVU'##N
MO0:^CP-?I@);Q@J<-!49('*4I76JQ%!,+STA.41OKH9GQ/=<']GOJ1MZ,"K;
M(;M+!)XR1,0)L77EL7@'X@&)2M.UUJH-E493)U,Y1J`;3XFG8D95%3\R'4"[
MU<X0O!S:.2KO:KHNGW8QU70-O2C?U]$]$--K&P+L@6.Q>:['(C'PU#)4T.JN
M(ME$3RZP'/T8B3Y9`[!BRC/4DL`^NP'VH<!'%SFK0^YGUS'E6?82MB(D)6,L
MV`/4U4BD,%"VHG,&$S:?!*S\TE`I*,2<?M'7.+XBY.3BRNL6M>,JIE!=$->J
MYY/BR31-RW"J9:GE#1^M;D<&M:(!8F)2G$4M#N:OT91U'9DA7Z>3.6U8I20+
M3%X'Z/7J`%-P+-#*2(9"H/61H#MB$W;!D]3@/#7!RR8F$5)>:)V:I%>'J)C2
M-+U;`E(U"FLGQL%J0.2M5VC=*D$479LP2H*0H@=#7T=]*[+E)5^.[-:R3H32
M>(A!]A;/EO@-V6'V\K&@L%>"YQ0%*0B*A\C2$0C/SO,0+"6L2%-!8G*5)+$]
M_6)A;`7T"P[<`OROR1M9JB-G(JXG%M3SZ58!,T=Q[5Y?U78)L^".B]IO=;:!
MF4P7@2`AG(0VNR;W#`]9JH`,I3=:1E=?74_-)UP%SARM-]I:KVOL$F<QM3?:
MAKH=3FX)8]>V,/6CG!(Y"YW=U3`X348&BKPYJ]JN%$7!I9^^VJE>%GD;I:FE
MYXI0""?<;AZV]1JL2/QLK$BHL1LY;\YUW3PPM]OM&EC8\H"B8&RQ&RVL23;-
M&2)!-OL@_W+@4^/[;B2_,=]S,PN)*>INA%\>?_6#KEQWF9@9[0;S%KXF/4'8
M#0NENFLZS-T-^#K,?6G19^!8U<2]J3V9/*+R$8KNX]2(L.3>CQ#"U<6E:T2O
M*#<]BZ]S7&/*DZ[+Z'HI97L),3/!(U75UBUOK4-0%6CM28'.MHC:0//W_B`,
MQBXE?V%+V"SB=/8EE.K!6[XGE4B9V$15-D!M;P%FJ+L>@)>^'\I2;PZJB)1,
M1+GZK`]1407*0705!NS($,O9JT5U2_2D8]M6B95@DZ3.==B69@*[&(@+D*\$
M;LDAN':XVPV^6\"M=MC-WN;:.&1LBZWPB%LG-M'!5@8VF>.L;K"5L%Y_`ZR,
M<60;2+EJ-#2CVU)5O09(1;5GZ+TVS.BVE9+TH58W#*/75;L;<!48-BH::PU-
M[^MM?9/%RP=77*/=;D?3RTCN/78P13;,D@?6A#C\F&I`[O'YHX<=/WLX2'[V
M,"??+K$ZFD-Q:W3)#]#D)+HETARJ1I?\K,MFV;43F9SURBXO2;#5*8_N!OL8
M47,,A<_P/;9=?AY`FM5I[<1NSD9Z6R(3LC@]L7I=)3`A8S.,UJY$EI>)U.N4
M!!:?U7)&\<OLU$`ARS(Z_55_EJ)1`H&8SVIU6M(1")E*NZ_W*I9!GN_IM45D
M<.F8[@1_='W_@KH31I$X(12>G^7SW^&A2W%4[@MZQ/[Y(W@OE\*`B>CT,L`3
M?CP#:E+7MJ'J):"&<34[)T?(HAJ:FCC=6B'<G8I%R,P;*3M_KF(1ZGN-5.=[
MKF(1<@B-E$>H6BSL'-=_(<IN=9$WNJC1^;!$NT+TA#I9-SZ=LRU1(1/66GU=
M"E4A"\FA=SI&S@B,X0(1RI>DKH9QT=EF8O9691GU%J"U-2XA,^BWYOJH`YO8
M)*BEUPJNC%$5Q36?*2'B,,]TY=PB&PJO')">GXZ6,(:N)G`6([L&:70S`L]Y
M6=2L$&(F/<`F7XC%SZ'L1(!EX.4*CQ\[AM'-G<7-T3"XO8M;3<180R9]84Q!
M*$*FU<ZXMT8B%C$OIM<HEQR+:0M#2;^6ME+3T+15T:REM04B,8_439P!J`*1
M6,RO=?J]FH4D9$/%X.1'Y%+,J=\6G`?(`"EF8;JNB\[XY4LRMQMT],[.)9D_
M[4ND_FT%,O.>)_\S#JZ&,$$<!`$E=V'`$DV_N/,[,:-;,"68;EO;).\ML-7(
ML5`_,+I/GE_!M9N-W?YI<"S4/Y,WE5;#,-18-"QC#.DF<K)7"&Q'6NY1B)U@
MW.+HPT[PECKGL$,;D'*T81NX@L&,EMB?DR>I/-(]+>%?)))^`AVUPC-*.\%;
MJJ-*M0'!X%-/9,&M)YT?EEYC^@[YQ&2[VL0.`VRM3\C<.)QEIV/J@%<]4CLB
MD?(:2!4RMM'S;&2LO]^,;?1KFQA;SNK:1\8V]IA=FN+FX+*>WJ:7BWQWR6R)
M'KB:[O]4&"W=(Y^^5HOVTFIYG8WRL]S_1`7)7;&W8"2'\-8@I0QB58,L/R#5
M"++\X-(2`\DS`S`9C>'!X!ZL>80_ARSXO!K&@7XRB_HLI/#_:_ZQEY46R;WH
M*)*=#:\;?:/=Z<59"]*PU<7N^DZ0S6Y;U]5.O_54V5W?G;+9[78UM:4_$^T6
M.*"@JH;6J4:[LWX^Z]S88M-*[/A\2-I^.;"5F.1ETRD+12Q=*Y%Q+Q>*T-I+
M/WD+2(52R=V++"P5_K5#MF83G7`:^))-I3M/55I+I20.03NI#(>8D;1JDD>Q
M-"TA#!<N!5I^:+--APLL([MS]F&@/$KEX8CEQ_0J1B.6%=IIURH<89/)1C)S
M.F?8H]"`)$=B)*YF76Y=C*R0120.396G*I@/W*J$V;SO<11D]IJZ]X1]4Q<,
MX,P-[X)A:,^^8B#AI)J1O+9D/;7M8(D=4]-J0B5D*:W$E]7J$E;>_5/E0"6S
M2=/?&I22<5Z<G`QT0E;621R^K06AD,7M!*&L].0<=)>.23&$R2`)_N>E4X4%
MMHS4<:5<JG)@BIVJ3&SWUP=3S`,FANA=23/O\QFI/*=M4?(TY?@S)QN^&B46
M91FI5-%<JG)@"F98=/*Z4%4XQ=(Q##V5T+<3>>8EI4E'R;_-MS#E3=_\$=+\
M1I391*M"*OBU0B&X;**5KI#]D3QIA_"*$I2#4*S#=Q8S\WIABO7WCKHCF()I
M.E)AEOA2L*19XCH62B"J@3^Q3/`GQY[8"L?2MU*?"H-B:RE5*#`_>HP_(BDC
MY;N?.GNQF:8$A&+SD_3U!I4#%+/Q=M&8ORH)YHT#75TVP,1',27L$*@%,":H
MRH$I>#=+?U<X!0].]@K,ZFN09XYI]@LLD62AS/:W2Z5J#E/:&T:!LJCJ8E2H
M`[0VA93[SJG@]1M/F-,R.WZ2N5PZ&G"*_#'?'+"P]6[ZU<?6I3._MVQ@!N1>
MTBC2T+3$I]N*4Y<)6G"5JY<Z<+4#S&+CB][K[I^@<^?#+4T*:"AO8FSQ=.",
M^U!@1KWY%A8AF^ZN+MH)T):*62QFWPO(8NY^+R"7W0`KBW=-![AT[K$OVSEW
M"O6]#-(R$6]AQKL!+'AUQ?[)N+@1"Z)E,<NRW;-D)>28>)Y0RS*8+ES*_[SB
MAXK/'S$UB90+"S6]/X\/RZ*HA@WAQ*=]9$)P!69/N1#;G:M9%_,+(:49DP#Z
M)/&JD>=>Z=[5A*1?'O_Y8SQU6E(@C,^%>!+S4+-/E<B$50^?XDL23Y-/(2_'
MQ_:GR6>9Y0BI',Y"C!MLNO>83MER!L5F<.KZ4G)9$_/*3#(E@8AEK_:37PR0
M!T3LIGRC7Y-$BL>7^1C61*`7Q`'KDSP=TM1$3F]QXC(Q"]Y;EKRS<B>8Q1)9
M^]W4-2D[EW->.)+L/B4Q\SK\`&%R<5?"6FMGU=6LI[4-)#'S;!EZ#9C$\E95
MO5^[G/+,2V^5@33["@"[4TE2>+J\];=H7(QJ^<3"LA2%#*`"'HL/>1LHSC_^
M($>=J8M0YFT+T]TB4W0KNN75*I-?$>6NI_L9!2&%>%GPSMFW/]O!B:?XP=3&
M;PXFB(Z(<ZRH7@#_/9XH0ZAVK&CL=T`F,-(Y^$&!^!PYA]&#0\4'/S(\.?AY
M%)RPMN[87[2CG]'$._EWK:.>9/WMBHZ00_[B.%FEYMVL>M-C?_O;CU)A+1"L
MH\!DTT`V&0&5?X1^0(;3$V5+LK=3)QCC@)C*.^+:[HB8\!Y4>*2\@N=*A*JG
MZ^H).Z"+G.G\B7:BN'2Y0$932X5_.01D=(*I/54&%G8=I%R/$9T@$X=0!RPI
MHGNH$%]!RAUQ`VR.'=80N_B4TX86S!!"#,5U%(;.6GQN3'&'BC\'</9YT+A#
MK"3+(44>)P'-.I9"',>]Y]_!4RR8B$&AQL2U0)00KR@3;!$(7$!H@)6+R0U]
MA=@V/())VQ$@Y(01#$.K%.\XR]-#_CH6%>.$0*<AR`:F8[",#%(\ZEJA&2@F
MNU3!0@%6`E<)H-5`\4(;YI*(3H$*N$FHK(RG;-,$.^P4F_+J>O#AER/ERQ(=
M$)X+E*"$Y;.&\*/'6&6*9W_B1\)7JD&,MHWNW%G7(Q$S*28X>YQ7%-]8>*AD
M*%<9(Q]DQ&Z-L!73!DY!BPT_0"/,^!M1-`$T8V")78-TAQF"8>A`H'C(+,<#
M]B+)S![>3941FR2#)9A@&H1?-0M%%]TP4J'I4H\Q@7D;#J8SQ3#+89IYX!I:
MDC@G.$;W\QJ1920,Z#"M%G^A%XIMY/G06(/B"0FX0"?L]+$'('W3QM3U`<"K
M3[=@ZJ8[8HIG1C;U@3^3YT2`P#_=0C\@=]`?I\@>$<090I.I&U#7&X-X;:#*
M!+K4XN#C[2]'M7J%]<XHTDE,^H%8P9BUJOYTHH!=69@VN(UY/CY69G\3(:Z8
MV+9]#['9`[NJA/_VF!E&OY>`T!D*,$#N0&9""%SO9+F@-2L8([QS@\"='"MW
M-C+_5#0`Y;LVL4Z494F:F,4H)TK,HF[\%+'1>."WI4!MUYY5@:$P[E/'BN,Z
M.#'.?&).!31ZZ;`_,T:3P,I"FX4FEL2<!0"_@/A3INZR&]^1**[C_G4ZZU]/
M6A)MM;PDV,VKH;^!_69`MS+V#-R\'(P>8J(N+LIUE6_7CLO3NJ%<4SP;J6J3
M^%:`GU_EJL1\DS$^?[JMF_$OE(UG`:J;[L"VP2<&A%W>K&"'?2$1LV"7!=D^
M5BXOYQ$:A#,0=M6GE]T9X2N7!5*@#0CC[5_JIFZY/H_U(;Z#>)X$+KLW36&A
M+GU`:<?W_,2_EY6K$O/IFH#_>_$_UY'OB5T/GU#-3'W9"]6FC_H]_VZ]S:IW
M?_$NS\N[7"RM&-3-[OEP2.AD!PYEME#S0(*Q`I-HI`S>?0>&'?F1H1UZA'U@
M"=?N2G9@WWO9F9^?F`<?:Q\5!^>?V84/M7N/.-YH7J9F/HI'L8?B4VK?43C^
M:H0@-G$I#N`A"U3_(HZI(!.S;P#MK9-I\@7GQ>\JM]N6$EM2^Y0KVYCO0I]M
M$OEG>/YAL('#;\/VV1$7[`.CO-H7X/Z=[9I_[G";4\_9YN2PV6;6,G`NE+W<
M[[Q#YI\CZD+'95L-+CU6'L8DP%MO>;#]-&3&&XW13!V%%HD_A<`7@U'`EU38
MIMQ$&49)3FRG9O81+3_:8KK#V(F=3+0$PYJE%LL4C6(9%-UKP(AX%#HAVT'R
ME1%VV,://67OL1?1XKM47QT.@W^LBVMJ,`$(9K1WQ`K0D#7`?E$\"NUXJPP*
MIFO?8C.D43X8*W_^:(Z1,^);B1/B\PU&MO69YI(X;/LV\IJL)N>$M4\<<"NA
M&=$,7.4"BH'4&__)BPV8O[0Q/&!X;N;PE-O&[X)[6E5I?A\M<8W<N5+/L,D_
MQ*88VJ'"4D+XECF,8^#4+64([49[U+'U9AJJ%_7UA8TE=O>U[HFO#!PGA&K1
MIS[9GOM,M;\V!]Q*6,4I1A1F_18TE0(6[5*7Z4C^V`UM"[H26#3B(*'N/V;+
M*G/;$T5]R%1DCKDW1H39:YZ@^#ZZRS>"QS`;"5S0F#O"[,<"QB?DH!&OL(*$
MG4(/HS[%NX*#["GXVL-BLML/8]RWSG$*`1AH;J5;@#2'KALP-;&<#M-V?1B]
MH2%6@CE4PN\%B(Q]77>HWELO!H>5?@#H7;9?P3(@O)"R(P4!SSK(<^RE73F=
M?;OW2!EP9N&O=I2Z,E4LE]G[3&0*L!A[^57W/Q,X4Y<)H1#+5V'4$,_5H7C,
MLE58OL524,&`+U#P>]YX;@D4">V`\^7.`RZ>LF$B?PQ38?>!97@$S,U-YEWM
M/Z""!X$]:V'L/K`\E,,XW00P3U"<.X,L9I.1FE\QP<>Y,$`LL@\@#W+DB_-+
M97]94M<$@2`BQ\'22I(,#Q&A66:UPGOD"F>Z^/_VWK6Y;219%/Q\'>'_@.UK
M[\H1$)M/47+/3(3\ZO%<N^UC=9^S9[],@&11JF,08.,A6?WK-S/K@0((@`2?
M((68F#9%`E5965E9^4ZU8L4(YA3F*ED!R(,PD^0#75O,"5NBYN5$T2*6`$"$
MA62'F\:``60N1\Y$MG"1JA`I%:OD66$\"OF$`Q[Q\:]\SG[@WN@H,17^9D2V
M+3Z4#FQ[/YVR,6U&;DA;:JSW7S^F7[X!3-\[/W(>E;^D'W_[KH\A6.&8,V!1
M>3/`$QGPYASTU)6`$T^F7_\G<]SH;@8:3\X;R8_F2\0BOL:1!PSE71#?PC8$
M\PQ.Z5?S)>!&Q`.R]`\8,X$PQ\:C\7#G(QOV'SPX._1;SI9J)"/ZB%M*G.`(
M,^=_?&"DC^<T1BM/(:RN\:5;[0!=\RE@W8NN]77R%:X`V,6P7$G,AO^2DCCA
M]X:R;89DB2-S#FM[7?'(R-.F(V'P[:W%8UEYYSO7<")C:]JM`??2K[EL&BWJ
MMFE%=;D1(C6Y'N@FGLV0HP/Y&7ME)9MEJ=TJF;#4</%S:L]2?V@F6'6O)&<4
M_S40!K<#PY'.Q9=+>/`.(2O9=XUZ_,#)9I=(5[`-;[6,I,P17",]US!QH&74
M#*T8!T)2QKF*F8X"QPN=<1(^ZZA&&XF$PUP.K%6J989XBH)+/=95-SPODN][
M$/-O*<99:>#OC.CB&PR+;LAX57A$ET$1GLZ`'B?6GS&%PR-KP+2?=*`]0]R;
MQ@\SL)LBTI<80:_--V0,.UFK0>4+&2H>OH?BNU0#YJ[CH;BA%4)#<1''"@5V
M.($S%-)(Q^-3BZ..DWE./V,+`P,)JG0F/=\*C:LH0.$USE^'F0R0LD"$$8;)
MWU(F`JB4<(.!6L9RP]Q1<2*()FSF>^+%":IS4N%V$3^(?>U-85,$;?Q(3$6B
M#Q<QPZD<@78QKM)/4+M.+8I6'Y#:E,I-R%WE%P]$PT?KPLXC`,HH(Z,2SGT3
MC]1:KV\#)M2Q;$*+<"FKGU/BJW8Y&Q3RAH2#!P97:TJ031XS9-^`"NN30&K%
M\W.@2]0'G4>5JO*BVQI8,^ZZ6C5D/T`-55HR&952X"&J1MQ3[G!)#:&@>)E/
M\U;MS">!2!\$F@>D*<?3"F,ROJ(\!9*D97C=5,*EB3E@H%NRG$.B;0G6@X,6
M%\OUO5LXI@'[,^9!2IIN^%O9]?%'2*K\>W@(;1=A<U>L"@^>'M.GBSS*-+#E
M6OR$F(,V+5#\UC3TM6Y:URU%Z:9I"AG@S/G.,!I,[*80O,(PGLVEHX0,560W
M$)8^.D?(,&9".--?R-F6+TG)=MJ#1?:Y%C!#N+&*(>'P_#BR<6(TB^%A#P5S
MG0)+]A]@I-?"3DZ0H77-'Q,4L,I;WY\\`!L3+ZA))E8<LFGLPH5S+W/IYK+P
MGTA(4U7_;&$\NW?<F*C_051)$4"&6$`%F)$`DS+#<.DB,>\>V'M()D*C;RB9
M$N?"%(,&S631DN<!%"-1/%8`,O?)&>Z@O1#C-]'B*<@'R0!WTDV*S6IF2/!*
M4RABB&S%"->$35E`N67.#\0Q]LN8Q)3;)\O1JHA@]@/!Q.7$Z&E6+!=^=7W*
M-*S'T:K;4?_L?$<<)?M:</B8++.3$C;^)Y[<X@/*E`P'T&5.B.*)$\+].8(S
M/@?L<S2GT/DT:5J1$!-G%OY"4[>G\B-#(![MC8"-)S+BP3B>8>/LL9*P*!43
M3[D8?&(,O/2`*^>5L52R9T^DY$/YM>0D`!2AK*E!'Y,S3;H')#_QT/<$0M-,
M42@*N`#[#.]Y297((3EP2$3Y/8*0<1@`WXC)@"[$.S'-A`.&`B6*^Z'!!1NJ
M7E$8T+TPC29PY$),L1O5S5*9J1J9874SB4)PD""81.7D'B:^X/*_Z#>ZH6R8
M5YQ\M0WB;INH?5"6%752:<3D4I2*`28<ZFM=>GZ$".#28U*V)X%:/9[.]\X.
M><_9@\QH1C4*^).ZY'RA=2:K!.72D1GTCN7%Y')&MQP<91_O?:Y*J&>@DYJ$
M'T?(SR;D//PG\#(_((U#3JN\@Z#ID`[`9Z,X"`6OPBLO(*<%K8QT$M!-,=@5
MD[(U?Q5KPY'F6&LM##5B4+5;@GF\=7WL&JP4I6+5*)/@;FJ3PMF*E0KP$@]E
MOJ)@Q0JE(U3>4&!*%'J.S!^X,0+*T0(+Y`8731@S31%"V"K<*_@V9*G=\A&-
M*.^8;!38@FAI&RI'\5*\)%>F)'-)AF(G$L<G#CAR4)\?B2T#';IEL"$,-(']
M!`G/4WNNSPXF[:,5QKG%V(HH#5@^7#0TEC_C0D@SESY'PO;C$+;A(4`'N7?N
M3Z?DL3'!'\/MAQN2Q43!A/7@/W7CAXM7T#?)A7!_*+6IL<)74TD39H*T&B9L
M_8Z1WJ`8GM:RA/G-'V,T`IN\MLXZKY`!A[%#D10,:ZPA7>,%!".@IG2K6"MP
M8H#RK/M*FDQ)/T(A%]4CEREV".P;9+N`HI?\$0`NU::SGGS1$0</7Y;G:0SK
M\F?P/`PVY3^$,7/"4'+D*#,SH1:=]5]E^1D/3<D:54ZR!^58]K+H`GK["V5Z
M#M!$*)=*RQFQPWB>LJ:9IDO/3U2W,<7%9-"N+'!<78D%`'U8(4`K=66DK*Z^
M!^L-L6K(3/"TY#YW$\N<,NA:AJV[9+YV\7QBJC`U%_)C90*57]HYL]/>D6I=
M:F!./GU:&()JKLBX']@K84R<&`U8S"O2C'P+BS!+0.&26]8-8\^?6=BKU.II
MVVVG\XME=GBQC')2&&]5?.47AI^</DO2C/V3I`K)X+-*P^$!K1GBBGPKXG21
M04<9Z=$,\:B"2Y/B0,Q5"GR(ICBRDWOG`<.Z1Z1=:`_!E"&`FK,9@B^)-N,[
M#INF#?980&F,@FK"*66PH/_HN&BR:ED?&%L4BC$$"J1XBEA"/8>'W_&FH0@_
MN&%DB0YS4"ES$6.>F&PUGE.O)[ID#.<"A2=%:'D1$BP%+R+3(#N"A48Z^#%1
M@S0*6]9_(:,VI7$*W3(@-DQI!M#&?1:*M)[,+6EKF`7W5XM!Z5,I.WHPJ?C(
MU:2&%EM.Q"01A;9-=((`UW%3HSAS^`EVK67]00#A6,9[,P8W\F0I7,8:4@28
M:($YD&LMCW0JJL,TH;E%+;4@H:K(CT3><N%@+<4K4C006;@Y<Y_C?>J)L3D>
MBQDW:588C2G:TCLW#*L&D4M7&<H5>!_F$@!Z0[=!`SPR)0Q]"X8I#1R/H35B
M6,>00*H'(ZH;8_R6\D%JGB.(C@>3<V10CU*F!`*0X@B0ABKLQR5K27PL!H'E
MA&)+,VD4..@U`0DT%&(=[9V>?PQ[3HD#:+NGPGM"6)7F$JVVEDFIUN\^&6?M
M'$*,3._NHYPX$8<::LF%9V7O?8[O6TF-9E2'V$H5/B#K`Y('5>2K6PMYU#2,
M67O/$'4Q]%09T\5(:LY0AQ)D;42K>_C%+;G$PX\F/B!&-81I_4/^E!'F\7@(
M$?EK)F>@6%8QKED9X3#^Q`#\?_KAG,,ED%[@'`O#=@8O%;2I!2DHSU[TA@.[
MW6Z_DK'W%`7`HBAC!M*Z@D8;,0V9U9^V;J)K!@M:H@`1N=+N)^UTZ*G+T0H!
MW1ED3[DKH_QA@;^]NTX8"+IMK0_O1`93AD862(3([$6GG1X<:/X[(S<+W?#W
MCBM6D"%;6L5<%$</$X^2L4YSB1(S9&,VF.G4&M(6X->:E6;!%F!([RA=ZEBR
M4I%B:D%D;8,G1](TB<;:B'Q)KL-GH>G<IL7_RP%@6VE=/;/.]!+EGEKH%A:.
M9I%%(GU*YAD>4S,%!7/N:5ZV08OT+^X%2;1YAZ'*(<#`+R%3B$T"DH-;P)U*
M+X!:5+)?.2PBS#<QB#=SJ)D0-TH;.9=9,:0$$S"9+9)@&UWP`1E4A:&&TWMI
M!:2YLI;`8R7:<V+_:!3HZL;0>0!:!F4P&9*>(NY4:$>`QB%D5`4:9B2Z[RDG
M4<MZ(QTRF5&D"XH8GBF6DHLJY?`2=5H#81,3?W#0SA;\)>HN*W0'D@.<LG/@
M&$</&,RIHGK0:R3ET'3`#!WD>22%:;(3"`B;L[F4J&8@9Z#%A>)5Q1V9>($H
M]D:&"+%$DM1[A!>>Z<^;HW)!M".JA8,^0..,-5,WG)JB\+12,(05EQNSIR\3
MU_>_"\U95<W6;E=\;`:W82I@!0.BA-=0)BKC2[<IX!5]&:JV]L))&I-?IT^"
ML2Y0CSG0F6$'`9T_L#I=+%L8W6$B)MXL#QA.\]WS'SRE+:,-%U4F"97A0Q13
M"IG(V`GG.T#ZX*06,UDZC-JS4$$FC!)B?Z2-C:OSK4P6Z0M?A*G<!GX82OH`
MJM!JH;2MT3-9ZL&YF8.'45A"ZD'\=3Z,0I<7+,UT_R-?2^".[D`&2Q%[0I%2
MG`Q"J>,8_H!]+G=]3(N$/$+4WW\216]^RJ2W#6M5,5VD_.7GXQ75MT[7]+&6
ME-'^"=<&4`)"NB*/7[H5"97Y67NY);X7P5F]%E'.4O+FV&C`;>`&:;[!2RY>
MR@J);0DO*U;^DF<F)V?^?X_'T^EX7)K>VGE9F-NZ"H+E*+WL,*G*:\O?WPX4
MG2KE]G>[_@#W68PS+".5I5"\7/KR\V>'7'B[>.$7@^TN?./S(&I(+*V25Q$3
M162_6")TH^G6@F>#I1@;V:\\6Q[5'G`!I;?8WLBOE!WO@`#?G@P!=JZ.G@*W
M<88.5=;AD+I>.F3H5PH0.ZR]LY:*[Q?/^LV_%]%K_3S/)D6Z/SAD.HP>?-G?
M3,1<H+GH1?_R"MUG,EH!7_V/&'X2[>B,&C8BX`W[1%M?`_]_,`7I[#]^?_?U
M%?Z)K=;0I!'&<RIZ5^3YT*G;JCV;,-'@.-:O`C(U&@)NEDW#(>^H!L]8!`-A
MS`4<FUL>NDE5,.P\,')Y>$>F.-]CYQ06,O=]"G=]T1%F-NE>U<BP0JS3EMOS
MCU/$N>Z<Y_F8A1Z93?V$B2R\\Q^,=+[(?VV=.:\2>A$Y2K@2W'0Q`-=969PB
M8D6?-^P@1_ZCV)NQ2+0$A!$]IOK6D?TWLLF`A(F3OGIS?!?XGHAX<L9QI!L,
MJJYU,EDL_,4Z&Z5`F\1C1HG3YY20)?!L$:*%B\QPRE'7Q;.Q\;YA14$[VN1>
M6-O@^5O?$2G[(L)TC#^(LH64B=]KGU/`J;)MY=5%<%T9'LJIK:=V2R=!&DCT
M29IXQO]D!N1DH]"$34\006-8*RN#H5$L2F.)Z&,\,<JMH%B,YB(:L=:=,Q'U
M)'3`,P;5BI#:*XS,<P*=[A,Y/XQDE%18\-/>H?1U^"WE`#JCP^G'(6Q0^.K8
M+L>\?HZ7@RT9)U5),92NL*37D*I1[<QBZ?D/P-7__I/X=_OVKVU.L)D]["(7
M%A5(G\#4Z]A;,)A57'<UC>VI;F$W%Y8MF7X;/&['5+Q3RE_3='S1+S3>?4K'
M"*YD!]RB!?/%"B\/B@V7YYO,?3B#]8:K[MJ#TO8HFZQ\KZ;;8I^1(DL,JZ]X
M*%??IRI]?"N2396A5Z3G7`:T`8BGAKNSWK#,C5$!?8N=;0YA4?Z43<4$S:%>
MIM(R:CTNLW77[G3+B.=8V>BOIC[^A'A!PT?7QUW_LLR'LQWL[9F?+AR0;FN@
M=NEWRF5,!>A66+XQT/I[0H-0W1&7K2,R5AQTS7,BEKK-DW+DR.O:%Z7.PLQR
MGS];&X4'<R?6S:A:J1H-#[\+-\H?GJQ('/&F2.I:(;K_3ZH*]5@UV@KC$;D5
MHTS=:8WYV,2\D3>A:Q7:R;C8>"?I6D350O0X%*6M/754?,"?6B/980,K@KIQ
MP(1K\M;U1YB=/O8]?\;'UA@>YR$EXHZ=."0WH\P>!L3`:684A:]JIE)I*)FN
M!SAS_0<6B$K6,B/YSYC#$X^4!A((7YU\-U!U0R=LZJ#K$$$?.=[W()Y'XT=;
MEO&,`C9CUKV/3E"13^S):6TJ<RH+C8K*.=*')N&A%8;,<`Q2^0A,,*8*,I1)
M;_EQ0)5G0W*4CAV9I#:*97XAU9F%YS`I`*M!B'AY?$M5[L$(?O@3[L2)'\BM
MI,$<+#4$RW2IDQ$;8RU,JM[F.IYRX.EMP:R(>ZJ#^J0]0568UEOL7H4(I0_O
M@1KN'9<U=1HKP*-12)W`6()"W:!LK)ZX@^-/IP;/-,8#!)%PIW/OGJD.8.1X
M]N'>YY1*C&U>N<JS%3D)(ND%G>PNII7E.L6CDII%V1K$Z?H!$ZI1E5E+<Z!6
M/5"N$X9T,:E,P,_$2LF':;;#"ZU_,I<2=C^++8:-^#UP\+H2C/OZ'FX9>@VY
MY0WL0W,FU\GVT4E4,JD+\]#G`:>BPPN;Q>G8)H>1>Z+,I"H)CL5"C$V,=+T<
MJG84!V-JZBWD"B9J<+-0Y$KJ@G0RU"0265L@.U`P3'C'6$0%/5IP=$=1:IX@
M@54D>-Y)VI'LX3$I,F(6`A%B#/8PO!>-_611"A5!`0/<^:ZL')I,9XR["`L2
MHXAG,F>;^$S4':$B=]&=G@X#C;*S&6`OKLQ)D3TFN[7T2=&O97!CIK[*0"F#
MN2*?U(%+LMQ0"NMV4HI(E6Z)$];[*$I@$]X"66%5U!::846EOZAI;!BUS(-N
M(O-.!&Q9(S\&X4_<`[@>W<Q"R#9BL^)@[HLN"R$3R9X1=BM9*(B]B+=(\(X4
M:B3(9L'@I)B]+6Z:V!,UA.%G*H9!;XD*[YDH*I@<)==0T@3E-B9+7CP=U%^F
MG&J1.C3H]DK48.MEB;309%4"F-3B$&DE"]3IT1'VW<O&$J8.K*BY;[8-E9*R
M..M)(X3P#F!#.@>IUHALE/AI69O>S+,\*FNNYV4MFE8NDRF(-','Y")=5I-A
MRYFSC*T,16%]HB0XYZC7`%?P9)XP:J[B+E)*';%N$A5$`=8PJ?%0%-%EO:X'
MYK<6Z'5Q-%FHJ^+B>!,<RP*Z]&&J:LNO:?;C\/)E"7E_59(>7M2Y:EP)&@X6
MXG%5'.)QUK=[FZ4C[L")O:)/,MTU00AE^LZ&"WO&8Y+[RG=GY:W8OC=X,-SF
M=/OS=:6/!!:Y81-5'6;50W%`M/?M[E6O5IBO2/`EX4Q81@1('@7FM7C4J3F9
MNY5#+8_@W)6YF3]H/:_"PH_<0;H/[_)3S+2LUB';:*+W7C71:RR7J\+S-;<)
MH:J[+8Q<HBJE[&D+`H[,6$-CBC9)B1K@HB50X.`9.7>QD)0HZ)U4TM+EW9X_
M2SHB3G7'-^H0:$GK%*5NN93VB5WI1!U+,LS0GV3<XS,J\VEV@\-"8K@`NH18
M('O)+O9AA%E'CW+&"0O'`:>^BJ(6I-%F,NE&$NV],N2FRBUM>5'%I:TE-6U%
MUXW\>:F&U+]ZN51]U#=4(/2[=NLR7^<K+A&#Y)`@_%U"%\N5%<Q"R`>@:+8J
MNEA_N(_UJV:[DP2T/^C`&/U.X.2L*XT4;G(NX/3D%W3B,X,W4?!`'&!OTF`5
M:6.+6U%MR$&>IY3:O.P1?49U5I:Z'FN*M.%YIVWM&TF?'2_&PI/"?GL4>-HS
MEO)L<9]R;V$5W(.G<Q65;_ERU\ZLVVR*3]CFD%I!+@@/*()(J85$D49L+_>+
M**F14\U_ZJ`HZH"@<_P'X=9]M%YT^GVJ_$$5YGO]"_JC6G^LM$=+=DZ1?:?1
MB3?A(7H\T2MBRQ+K4K3%T"_J%<P,,9>J>)!+<^;K$OVB.&K2K7$.NJ^LO>J0
M&UITNC':/U+_9;%L442$^MDU7K1E%1ZR_25D5]?\SNE$*=A-E`=:3C`:G9#W
M3(9K6CQB,Z,0A'@+-UXV?AZ!/`6B'Q84;F$C#$=V=!9Z"FE'",M"_PNI,7DF
M'"X9QZ8+Q-[M('VWK)4[ZP6RB9V7#D<5?:BI\3NULR8/8KK1MFR]:M0$5C`+
MGR(%O')O0M[`I"T#>KQ)_=+=Z!UYF$13"]'WQ9?5]!MR7M%F\0FC0SY1CP)2
M-YK@QS6[B.(1#"F&B@)N7-GV@9A]AAE@O!(9!E8Y+<4'(>G=I4^""E"6[2G4
M8;`^3F5O.T]V>--3+LY('4[%%9*$@1O0\P0HY%@4YYUS0N%Z_(%.D4PA?1FW
M''O4@A+@9S)X=$I.?M/TDBG5A6TW9B#@X.L49)7A:JIPN<#*Z-&(U%KD'8E]
M1T`I=BX)$&KXQXK\XU??G^#6-&QC57@4QO2UI0V7(KR+*O`SBI;)"A&J61.U
M,P1RCCT>B7P)>-.+*9Q.M$6@$,2`SW0U?C[5\H;B.GC.U5$6!M/"J_;6A%D)
M*"",9&&1G>-EG@E%Y-UJ<4B<1SSW`<->#RHO!6"@#H$DX#ZD`M\4/I*.[UKN
M&F%C"<^YU<VYTM%BV+(G#9Q=TGG61D%+P)=:*D8VW7J-=%P4<'#SUOK-;UF]
M01N0#;)O@)&76$GQ'.AWKAML4N\G(.D$N1G*UGT<TELFMG4*&DUDT8`XR,)U
MBH;S^5S8YA,.+IMXBC<PFR9W[!!3ER8TN(UG9(*MIR:`&<SH<9`PY)439N^<
MU6:5G53'6NW#^$LNHH(QC$X6^UL\UG"X8'0C.EL4#)3H,^`04TGLP_9,;F4G
M39T`I@3N9*ST5-AYBNA<-20K@!45Q\4]RKZL82Q\W%"%4JM+L$AVCB)R6'C7
M>`\I([O120H=2B`!%UQR.@6]7+`10_82I?F4M"*CB+%'&EG=FU#3`C:0$]9K
MDV#I>QZ:/Y"OJY!DQ:1EV"B=GV+&C%)=0;-RFTI]<C\.74/=3;%OU3*238Q+
M2Y=7W$7'\H8@\L7$-Z#Q``?"V_ZM[X%>$B)1?&".]ILTLN,*\*!Y9HSX\V06
M+_T!O`Z%)4K6>2#3C,J0%?'6&M\<.YZ!GI5)%UBT&^$M_M,HV3-CC*G8LY^L
MLS=O/[R2*0#*4CF*GC^SE&;7'(Y<>!;Z9R<H!XS:2:=K3+1(WXGX$SPC;629
M'I2.(`"%_51_UZDS-GM]BRF4:5J\A\\&<2),ZW'T9$F`!5SMI%^@2*=LR3JJ
MP@RAP)$;,EB11[Z#`>[%MG]*Q*Z&.:[,').S(CTB*%MHO63$IW&0R,`HKDPF
MQ+4TVI,S(/,6A0R187VA%&W2C!<U&)$&9HPBI%VI0B@)&0X&`)J56A.(92(<
M-2],<)SN8IC.Y303VTS.$H=2;WF#L1GG-^,[GSH4B]@B>!EC9*R9/V%N>C+4
M`$(=1;6PUM0*$RW<3#?ET_Q7[]#%E;R/5U+YA28C+"BQ40P*]QLV<;1*[R>Y
M[[2^!/UD"149FB8$E*V7R(JE`.58)97<2#9$F?DJ$$R]3^6>AVGZ0L$VH3S3
M&**?J1_GK-F)_X*^S<2M9IL8-357ZAI+C2M5+^^IB[54C#.H4I(3W5%8SM`)
M)A,JJ>&TK$."QWW"Y&<5FY>,-F*"]<C;F7O292>Z@R?*A3"7&3TU`;CTE9^L
M*,,/5,MU.T=WG@8,6SUXI/XOX6\/3D"5Z$4&*M4LH7',,,H5V$<]"*)N!)IW
MR0-/^XB=W8&'A-+*0E^^DP)7<^&OUV28>D;+^XGP2[TY;*FAX$E,"\AAGH4B
M<#A1/;9>QZLSP,1U<6.$V,9^;*A4R9V06X9$50\*9;1'(CX7BLIY@C5>6<:I
M-Z\Z^:81FBPD$7+@P<(I-@$GA8LL8B([.WDI@4>UJ4#/W@P;JHBH``E`8_Q>
M]6Q_485KQ/EN#O1:Y@WII5H4.A&ID[3X1:=>]"-.#I$H0*#N[*2<D.`*B74B
M3ZPQ3V_1F[K)CF@;Y6?T;NH7I&[.',4;X_F%ERZ4<D*C6._V7/[&(NN]+.!A
MG6%^X"N4[JP;9(C-Z5P5'D0CTVAT-1K%O4**W&P>2Z<*`,5)_/1RWL+276B]
MG[*``MWP6887KJX%(V1O&1\FL@7PHI)-Z+V8?`VB+,G,EX5'0#*-(R7VMH#]
MN@3,>B#+"B?+`-X`0L-#1R$RY)'*OI&N0Z8)XH:K'F*)$5'5N2'P*2*F:K2J
M0[HL39Y,JR!/S("@[)Y/$+F@4OR"*@2I$EHQQXA`-G?(_"S0*[1AA&8B]X3`
MTQLA#(X)RH2"$4KOOU!/S#)!NOR`PE3DC[_;1DD2]D-6L]$AL@8@I(-I'"$0
M*81/5XB`%+-T[:OAE:UZ?_7L[N#*[EQ>9.O8D`%C^:!M,6C'OKIJV_U^G][K
MV.TA_#7L9D*)Z\$0ZL:@%CG_-Q#!J2>;T+*H3R'IV:1[-:Q_'4U+RB4H`AG(
MG1C(E3J/$5QN?2MZ5H\F:P2A60&@XNZCJ`";M"8A2Z.1&2/5N]!QX7%:$[(!
M&8"!YQW>3%I?*A\5G/<0=3Y7O8]#@^;(2?A"(&(W<E3J"+)KE"T!7?>8^"5E
MS4"P(S=Q4QM+LK'M)A;%-?`$8Y)6B>P(!3P7S4^QZ/0IHL?A`U97TO#Z9/`T
MQG!ED)8OY3^,N;#3\V(H",F3&(GNW:&V:MB<<UN.PK0@K4;8>W+"L=9;#8V.
M]8!G@;>0N^$_E<GM@S;@?DR,;`V#J<)@IKG^&Q*7'/2/3M@4L[C-QU(AOT;Z
M@'"-4C]-BL)BV(S32S*ZU7F/0+8(0:@#J4G9BZE$-*F-9%41CSC"1#1BT0.F
M:$CW.0@Y$<<RAI1[<RT$(=L$D(=FUH=@3?'<]\R@(@&W&/+YL]2@<C6QL#$K
M@ZNY$`UURS+<7X;'0Q:)%$GRV%66RNB>1QP6?0?_0:;\:)19.[4::IUVK8JH
M+4LL[ZU1&*M7E.JM&1>N,54;;>K,X(9];86/LY'OIJ:\[(DI\3G-KTKGOUHM
MUSRUOY\H:+D#9`UB>?C:^H^8JAP@B<,6G,6><M<8C90I[)-B&3$(2P8I&F=`
ME+T7E=!U%??Z5#$1_VUAC]5<O(@ON8<K?&V=MUM=:L?:G(:G<AJZ^C1\I']M
M*03"_>!9?Z8.B%FN51TE76S7'Z&X*@K3BH+`$PZW(78?]T7`O_CK%Q04F^/1
M'(_C.!X]?3S^\`P2%U^F2W,+0Q1<"9%+GGI=.AC+63NR-(^.F4\'W^/](@IV
M2]V*HCK\!V\Q$+P.Q^:(9/R/*#ACY+=#Y:<=*XF4B=CXSN-_@NA*36.P?K#,
M]#.%:<'T0KWEJ$W/4+6>PS8G;6,R\1")E"L**XW02#KR[Z79$9O.A"J+"LL%
M&MG,-%&VB/[<==)Z-5),&E(SX$L&AV@H&OVZ4`',9+:&988+HZIC;NR4F0"C
MZB-(G1#/IKI;R3Z%P;(D3=K)HW/G46>@P9<!!L08@J9M9M";6R^3]LT@7KAW
M"5KEU3"K8TO#<#HVK"&1%4TP-V3Q>T-J]5?GD<[;-?H+1#QB8W]9/2E5-.DB
M?X5(SYO1\3-MJG.!X=31HM]51-BM#"1+0LK0D0T2*TJNXDGQ")TJ\04>(UW=
MA.0!8;&0+'0BDU[3`;.RD87S@'8AL]$`#2]Z5D2/<Y2EW$<9Q^9DHMA2X6M&
M%XQTNGKBE!*3)5(VWCNS)%!F+$,+L<!LR[HI-$6+440L`S[O^=XYF\U=_Y')
M!B/2UHS<RA/QJ.DV'Y&2ZA?C_D0OD^SK?N&CBYN;*5LX\VEJ9X+V>)UX1R4%
MJ)"A#%'(6+CSB":]"!$06>H10+!5ZSABPA,,?L:"CJ3>JZ=4*SD0RK#JG"-(
M#?Y1-[29,#9A\!+1K=QH3\0*9U$GS?Q-Y-.JC/BC\);_[OQH$A;6\ZIIP8.L
M7`*=$:)3F+3PW%#TH8AJ2LSCMS$7/WC^`YR"B6[$\>'ZYHV%"=J_^\`(K6&_
M;>M\QRY`M63O+%L_W/DEK3"%2:4`,X6)FN6@D5[$2`#PZ1AL3Y=#2?%:;(P(
M;(I*CRC[.K$K+=4EQWE!0%3]*G&R$;6'+$Q?MN4]P#Q'\&IX1321Q)(((OA"
M,A,1+Y$%CJ(Q#$Z/;8R#D#I6R24GVR9S$R+K3/*I5SH`/`E)T/57/"KZ:N`M
ML6T6H1-K+R3JDX.F>Z("LU8NM<7BD>;C+O^.MQ69DS#C@78Q1(@Q_P1N_3P8
M*,%!EY01O80:MIB?!KW6J3SOXL%4A]$XH>:Y3&4J?\0V75*7@%^M:]A]D==D
MGEGC*(_10S[E4G\UF`?RFFS;V#3S27?!RO*AW-5@3!3(=*1JIW"A@F#DF")Y
M8<+.C;\7TJ5@TAQ&0,?<.&VBSQOYTISO2/2>F1L^Y:XZ[PRN>X\.5OHU\UR/
M6#**\5)*H<3<#TXQV'#(A##FTSS"VA3I/Q%ITJ6'!4R`8`(>3CBY$UL%^$NS
M662OB6\2,TY491AL[J5WQV`Z%,B-X:@N%A<4DIJ3+B:1/S%&TU("B*B.L"IG
M55PX8-BFED:1O`W#>0G@XFN!NJ"%JMUNDE=%CL_D6M%1L526"GBX2V^KJ`Y`
M=PDV3)I.PNK7;D8VX1-=;BZ8I#9(-0G4ARI-9PWC7#EN:TRZO&95SY]97P/?
M\V,9T])(F57,KI_A2";-WNCP2PU4,V?2R&Y!.<VDH*62)RE,$^#1;RFAAMB<
MZO)&B:#`M7E.@1;1#8["+26;$_P<#TTF39;T0L'%4$=S1GX<I7/LA+#XZ_7U
M5WKX(_((3_4W3P)ROFG;_HV.)3G[^.';S2M<$?#*!`FAE`0I)9,$<5%%BX17
MJK"E"VJ-&&"?LG&=*3R4\)+.0/`2R7@GTCBBBG6:DR$7,:\>:B#JZ#HU5+0$
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M-V+V?,I),R-)%:+`G^!+Q07!)"Q25)P"'X57A6*[E'/)?&=&!?<T`YLC@421
MEB@;QE8'QE8L0*7Z>Q]<7JHE[_^=(K[IS,[A%`::%4CS$D:$2P<A96YD<)KM
M44SJLMD-5_@44T8HM!IYL52:='@W/.K+3D::BZO^=27%T9!QYQ='HS-*EOD,
MS*J5\O(3F*JN)I.+DE.)91.E"I]?V@!U/UW7M_"(_NWG.#R_=9SYZYO$[YZ(
M_5]]T%H!;[_##KYQ_?'W?SQ_]K_^5NT5*L\!?WQCT[__]%9\_G?O\_M_]SKG
MGYT`%-].]Z=_I"@M13_S'U7B?E+'L;<DR?0FGL%4=.T;:S'4'DNMIOC0;@WH
MPK.I9\@-R]H6KC3K^BIZP[O"Y/!6.W94VZ,E3&RWT!X&2==XP^.5?SY6I?*3
MJ/10Q2@(GD57+3428"ZG,IG"=C<V$;EP'D\1:XND]8=(&U1]I5:Z%$\1,RB_
M`7NG)$TIPJ4<J+DF5T%#I$Y$CPM^J'ER:F]5+`'^CJJ5[E[W1^NF==U*#)Q&
MZ2@*BOE>4GM56D,3RV22\3I3T3WRBSR?<.Z2U,&A,T69OSYF0%DWF-!:#(FX
M.VV<&%W)J"9)64"WYWMM)J8XPD#/4FJCG8DTT*T`[Z4-,;^QB)WQX^O\V"2D
M0J7/4C"$5`"T:YL*2"8!"5D[9[)HJ>T`%"-E?$ZW!)@Y:+2/)ZHB"I(!%>-/
M14E)!UV>KVJ:]6])\[(,H9)BC4YH4^J$[""0U!C'/-Z<O+53/+B?G>^D\NM=
M*CA*[`<+QARXG1G-J&I#MZR/Y!1T(FH8A89L)_0QK.,1E:V02FYH%Z^:2T<[
MZCQUQQ0"04>3&TS4)A+94WTE:$3V@U,1+CGXQ!AXZ7%5<;O&4LT"OY1A3DV3
MR$:!I=@4Z*("=.)PI=`/%.@I?E#UV?'(84&N4DECR.^X,)^(HODMDLT"M+M0
MJ)1(XE0"L)A&^(R5G]<WZTD_"1I=O':OE6SR3<=?TI&^3K&"=WX\BI`%JL>?
MZNU\O1BN*FH#)#=>)'WQ])LL_.B)0Z?YJ[A%)@JK2D!4IT@42M#73U(E*[E`
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M!F<NQ"%SZ89QY"%`JZAW[D^GF4C-$+W?$QXM8J)@P@/SZ0R_.RCKS;%H"L[S
M+8D6.3R4AU/?LL7#-6.F'I/"BY+22(1A@&H#`E&^MLXZ5`HIC)V0XFFIHM%8
M-]9+HNB%S`80G'5?F6&RJGR2RQ1#(P>M=!OY(UBS5#'.>J^T15,$7NL<B3&@
MQ)^)8.,I_R&BE<U`8Z%"G/5?93D21;IIN175,^IB65#*;2%0$21F#M!$*/7I
M&&6,W)B#X(9N&?4=B:V$.\]/U)PQQ;UDT"[?D4%X5'T@%R#59)%2\4'@]*([
M59[I,X5$RW"4K@I'Z:2N@)25UO<PO20"5,P$CTKN9Z,\B?S:@.;3PH^R2B7M
M*6!%..$+S,LZEFOU);22(#?=@:._>0<.&I\&2^Z!5H8QG#@[T'C])*OE2%:9
M%:!/'`V_%YP044.(S`BW`9.6'PI2@^$Q1$NG$#)7*9JJ.#)F9P0,B\&2I!W/
MSP5W$/6(-(\PA$`187G'V;T.9#'"_S3/$?::P'\4@6PMZP/+<0.AFQB+$9$3
M&61^'GY7CEV4(F2*A3EHP"PC#,Y@4%1U1+)KHW9L"(Q,-(<2TAS*EJ(_.[6)
ME.VK$I5`HU!V,\XZP$R(#0..`;1Q,X2B=&WFOM$^,A7,+!>CZV":@TDE0*XF
M-;3,^D%"4;DH23E<-S6*ZE/6LOX@@(BS)>_-&-QMDZ5P&6M($6"B$>5`GLX[
MHC3S"<U-F^4$"55%?H15I4H&:ZF3GZ(!$4(Z][E,1L6Q*3MZQDV:U35*D>8-
M<YY!Y+*@#M[0<)?D$P!6_]L&#?#(O*L5YF7!'W7>J';7B%%LYR2G:><ILCG%
MW(6!27,004(\F)PCNWF4LE920FTB<JQ]U[]5%?$3.WUYE+<TSD4!.HQ1,@N%
MN$,[H>>G2!S:&DX2F5'W2`0Y286L3'JS?O?))&@_?Y9#6%%"@B3*T=2)^/(D
M=O^+".:\L*W%EN2,8J0I.$B<Z<]LXEC7BF-KF<U,ME/QF&@N)H.2NAS>3]'R
MZ5AG/AI!IFX\YQ@YQ5[)>*(1@`CXO^6.(51B#2QEDDV*?M(]$X\D(2ZTFU([
MFMRN2HX&,%YT6P.\X%P<C.XP]D.5R9-,/[U*&=*IADB5:G9"75!0LW*/$-FR
MOL:H"@D;0Y&LK5[6EZ`X'Y_'GQB`_T\_G'-@T>D%4J6QSN"E@C:U(`7EV8O>
M<(`-V%^I*J9(\"R*,@8++:EKM!$3$!AXD[;#H8$?8_DI4,Z5%BII44+O38[V
M`^C.('O*A1V)=,+?WETG#`%=>=8'^`9W.$,C"R1"9/:BTTX/+DIRT"V-]^^]
MXXH59,B65B$S,G-2SS!,SEBBQ`Q90PWF.+6&+U7=5\T:LV`+,%A2KA75JDB1
M8FI!9!=B5#98!HG.'8I\'KL.GX6FPY,6_R\'@&VE==+,.M-+E'LJ\J_(^<A$
M9K;P3"R6VU0PYY[F91NT2/^"SY<48*AR"&"/Y(TO-@D;-=PY[E3:J]6BDOW*
M81%AOBHMWLRA9D)<ID7:,FU=RA>H!@>D[VMLHUN6>JE+GR:7?8-,]>!)7$")
MLIFHX$]>WS2*UAJBE**V_*3^`H5,Q5A+_T++>B-M^9E1I/="UDA/Y#[R;J1\
M)<!)^)A,.T"WX@^.+8VRIG9UN11ZDG(2=57H!3H<I*"7CFJ@DS57::^D5@L(
MG\1A,4EDABF6CI"'Y164N`,HW$%&922)D@G&*8?-<.S,418G2A#1X"`^TSAC
MS3,-[Q8UCK+2_>.X,7N:5[N^_UVHC2$F...]H?QO^-@,LQ;,J`*,01'N(YE>
M*BO@&\";:=U2S]3N&$DQ\NLT71OK`MV08]GEQ`A`\;J=KK0]RGH^#QCS\-T3
MU;IT+C=J&!(JPYDDII3![,E.4.KG@Y-:S&3I,$8A'S.26.R/-#!QICL:B%_3
M]ZF();@-L"J]H(]47H8P+-$S6>K1W=.E&:!N1VN+ITCHK(*SF"1._"4!I9<I
MXZ7H**G?S;UB6WM)-=PC1V5VW+PBB)>7=:J!./*CR)_EET&40(I'X%&L[V-U
MYEC4P.63=-S_F+1C`?VY:->!@[L3,?1;Z8<B!.47,%1%"]5T':Q96##<2A49
MMP0^;@T@V?O[3UV:&XEYG\LX(KQT=K^,5!W(A*Q'L`9@[:`IX)GR@]?6_QZ/
MI]/Q^!>K"L7G+5T5]E350*]+%JGJG%8I'&K.Z;)II&=<>Q0J\Y4`WI?C7%QN
M`L7+8UNVVJ^+J^TN>V4*!+$M8AO3'SWW)F<)ZV-Z$_32NX/*L^51SP$7T*ET
M%#8EA&VQ(G&3U@N3E0Y7'4EA&[1<6IQX5[+E'A/3MA]LQL/O0G?[PRR/E#%P
M/<6`L_\G-,.`QJK;2AB/_H<2<_R4YA5H/&;+3"GKE`[TMY-Q99*[$8V0C$/:
ML\Y!H8@(?VJ-T-N/X;A3A[NQZBAWZ_HC=)F/?<^?\;$UAL=Y2-[$L4.%IAU=
M8C*B!GZ>Z,LG#.D4NZGZ2-A4*#HPRDR[_,^8PQ./MNX*KNW^@4JAF;"I`]H_
M@3YRO.]!/(_&LBD<;!16.['N?<Q94*UGQ+0V9?S(G!L1&"=K&$EX5(*O3L$0
M,2WH):60,'+O6WX<4!)6*'*9'6F;'\72K4(I5SPB8PV&J`@[!KZE`O/0L@)_
MWC-OX@=R*VDP!R,)1?U3+/LT=E1Q)M?QE-U<;POUY!"%ZY[">5ED*&\Q%1K1
M0Q_>)TT=5V(ISY^=()(T2BA-W.ASJ0J]BQ_PB3LXG$33>.+,TM_<PWJ[RN$3
MW24M>V6%;:XRV8PP16P9@Z;U/'_2=51L%BJN""9SZK,+:>*Y2X#[5>9!'AZT
MPY"_6K_P]?M1T@7:EHU/0W(&27>T4>#%,?-?=3$;T<!`U(AQ'Z5?0!>*4>9H
M/M4-MD5&FX@(IZXP8]EA4'G8=;55G6QZ:\(L(,*HG>LL+#*')DG1#-FM#D$1
MW@(,+`Y8Q%+5^RD^C+QA-,(]7.8Z64Q$<JC<%YU7-'HT\@'3$1!X*M$EG`;.
M+@DFMO%B$_"EEHH5-&Z]G,*GITB86!;R-[]E]09&*4K'BA[\<RJ%I((E*5(`
MJU%I5&7H5+LETAL@-FG*`W0DX8"B8%'F9=A7K%E)])=D/,N`3/$&"B&Y8X<H
M\4UH<!LI7F8%Z9I5MBHU%V8+.JTVJXR*'1?5P\2;2`F"&?"NTW4X\9'B&DZJ
M08U*W#6]NC*'RQ@K4R_+EE2KR^GEPXK)PHM[E'U9PUCX.!5QEVD;YNK2V>J%
MY+#PKO$>U;[*LABM>:B:4LCS*#59,`61[*L$\K"DL,#3.-0YQ4YM6=+!D\F1
M.K9+,5!9.HA.0UD&1EB4)F*GBPC)6(,4:S4SN/6%HH6$76>*),+'DZ""12GL
M-Q99[YT`]=[0.OM$S>ZQ)?H-]D)_JJ(9(H5II+@:*:)!O$Q[BR6CF7!9A]'+
M>0OU##P#LL@%/0N:M-'-7F8!B+``X6E"NX2,,TB2H,T>]6$ZU?D==PF8]4"6
M9H5E`&\`829O.RD@8;Z1UIN2"EG<D^4RDW!`E01/X"/8:V2CB38W$H!D:@6]
M[B*,:0SG$T0PJ'V_6([H\2N#!+E(=Q!U=)A$<1+W/)'[0B#JS9"5'C7:5+46
M(>/*8BZ:/&*`W@F9B2VL\:+"A"F'_X?L!9ET%D@`"570JP8BA?35$4=3]>S+
M?L_N7PP$'NU^IV]?=;M9U9AL5BN.W!$C=^WNL&>WAW*'[,&@;U\,,F6XGRB/
M_F9VRGEG!/Z^Q<#?I\JD4S4G5!W%PJ9"(D;:(=L2)4!CKE1Y`Z)0%;0VHCN3
M?!J9`@C`Q1@?%P?(WF@6&^.SG(#*'X6%?:#(ONVJ1*X0I3!7O4]I3:I%.0(1
MNY&N\82,%7BRSL).0IKPR!DYO\:2;.#KMV@)-_!D-FQ"*P&EYU"!:U5W"CZ$
M*M>"9J;$;F,,66I'1HQ/&&H,=GI>%<Y*]F[OSO'2K1/SZT[ZDWB,S5[@]I@<
MM&Q.73C`-OK<G2(/:+K6-5WKFJYU2[O6-6Z'#0MC'WF-W:;,]<[+7#]_5E#H
M>@>DDT-$&Y71?L?#N0_;\&O@Q_/PH[HE32-;8F-[ISNRE!?8_O#?5&#['1MC
M@>V.*+"=JNN>BCT7V#F/_/GKBMB1AT/'[>+;6XD\!UA*2L<7A)BV6P/NI5\S
MPL#<I"YXFM<L#^_*;YBTEB&T9.Y#=;$7_S5PQSWT;[RVSL672[CG8;H'?%$I
M))?"1I+FDW"Q3\QV)KJ#&=S]91[(3Y_>6F<XD-$*$'XW.ON]0H;X3R>(0-FC
MYU,-4;!0@T_9>-)D9[PL.FM@6Q`0#A]`2J',L#P7@.+*<@!;BRM):K].FD4S
M_AE_)7UI,S9!#I]Q(.4!8IH(<UJT6_$<K4=^?"M`4K5BD?W`*[8U=V.<&&9^
M,6RW,7U>=VV?%V4S"S\FW7(B>1>F#2AIRY^!>(NW#=:`1A=B+/.[C6)JJB^G
M7L]>6X_4\A!\7*P7DO05[+8'V%?0H&0MAWU%2=J+DHZ$^LJ]T05_-;5TBQB=
M(;P9W6K/$`(Q]ZM,Z[ZD*(D.<\B0.H872>-O2L@Q5W''7%E6&]XU9W9RW&RB
MEF<61V]O%'9RB_6-`TYN36L6A]1[=<94&R-UTD6KRLHP+J2T'5&WG+QTM4Z[
M7:=\-90:R@2$BY>K(Z4TF04'4CE+@4A0:K<NYX:H@0LW-_!\ZLQ`(WYMA8^S
MD>^FIKSLB2GQN252B9DFF`M`\?H^ZT@=&TLJ*H^0$T=W?B!I6A;A4/FN)'JC
MSX*KB`\*,,4H#(;Q"(HKM\IEF34V;+-=.LC65-R.WQ7RJ%B,CK82D3CJ'B?V
M*-//YX)I)UJ1CONFF&,*",*+-C$WA:ICF8@GQF8WBB<)2YTHM$<-8)L=K+R#
MUYX(K28!YC9P9K@'HMD$G)11_$B5U93I7O6+D7%%$U5V`"NX"G=C[M$R6LI0
M4T_4WYO-6N^XF<*&/GJBQX:J=4NM?:;"?)MZS#384GO!J3A,J?[9H:S@2GM*
ML\EH-(R$1+FWV;D-&>6("85%^*1E/@9+9"VJN*BJ'",C-&O=R1ZBKI![L18[
M]HV0QK?$UKUDD_:HF=>NX6'Y+A4)^HYD:%JN1OL@L304K"G'`(/1$F%::0/%
MP6VR#E28;QBT\SI8ZFP'LA72#:FB1U+F1]D(505MRVM7=][,C^24[*(0VH`E
M`YG3QKKDZ=B1L2B&&G&M5=Z"@5/J#X!DFBW2T!4%"9HCI`-)5-%9LT736]-G
M\L9Q2:>ZN6.$DMPH1Q$VD?ZZ;<O2A\+#OZ!_:3WUC&#PXQ`>-]3-Y(%7KS,>
MA/V<@]U9S')K@@RVI&,I:RT:19'O#@G6714*6?D26JSS8.75@UC]5LL9,*]V
MPY)2%T8-BPN:VR3C%:ZWW=2RJ)(E3I/2Y]<6YA[R\69(K-FN[+.RR%'BI5TW
M*K6*RQ\L%6X33\[26_%USKI7WH[M%Q'8U;0GMZ2-B4D452FU`/9?YC@(]0D6
M-^.5.K]?"[I`>BQ:;J.K5*HF>:?`??EBA9<'F;>-#>OV-IF\XA+JL^S>Q8Z6
MO5N^E\N<"V@TE<J[.J]??8^J5`2K2#(5AG[^S-S7\ZHWVP9`G@+V4N6-AF7U
MC;:#O5UR\F+NK6#NM@8E!^9W:N4A]/@*B!"#;K@[-`CUGG/9.BROXJ"K7@`%
M"-SBH3EV['7Z>T#?;BZ5IR='GN"2]LI0Z:G5[(>-JG6<2]JSWIYK(BFZH-]*
MCXQL%T9A9Z)X%K5,9S63U2K?.,M%M%,7;W>`LFZ5"_I4A5K#(_5T9+,JAZ41
M;#<Y-EN1:Y^R^SR)1(EGF-3\5W'F&49<.^2,+LG-47G^&%JB$OP7?+#Y+EC1
M;UCW6BCPN1[(O]HX4!L':DT=J-O';,VV:B6OZCZ645>\E'E5M[2,W6IGI:XP
MH?L;5PR33<E*5EU'ST_'[I3V=CA=G]=@4'9R#^KTRE&`GI[IY027=(@HD"^Z
MONU;45X(I-SW,M>]L4H>YY(.8V').M0+*XC4:PL&O>KM5>I*3H.KK:[E4-;M
MK"';I^CF!%"S0IBJ'%.OC;@:5F]Y4U>BZE?K:59/YK2*P^1C4KN:*DWZWO-G
MNM!O146[B6Q9%<A3P][NG4YU=CH*!TK2-&&LA4I50.D)D4+'OKBJW,:T.4H&
M_MH7P_H?IT8=/\TE'9K/&C[13U0A'"L\%F4PKGY*CMS5>C;87@SFJZ>$MDY9
M$/^&:#N8:WI%#V=26W#30H&[KSK8^TQ5!S\[`58=[(JJ@ZO4UERG\J#`GRM+
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MF<E=UO_JZ/7:K6M6A].D+M*ZZ.[7LD$NT`FA7:>P;$/Q/T6\[*&0Y+YEN:SB
MM(?4GHV$\Q6$[TZG4HSJ6@I('=?=JR@V[4#!J*#S/SW+R0DNZ1"6Q9HG]J0+
M$3:4=*QFQ7:KVU>EVH\EY:=;%E1Z7%36VVJ>R:$M9$OH:]U$H).-CRX-Z5L-
MW4\WNKQ;FN"]'>S5FETWN1KF6>IO[HMXPF?I<O><Z!!"]$=O[,^8=8;Y@*^J
M!N`?4"PXZU;/V<P+AC^D9+-5(:U1S8]>U#TAU9PZ60K>4@-5O*&;FC"4#26[
M3E<KX@XURTSE!13[+I^0G'(QK'2K-%+>%H,U#B?C/3WN=()+.BS#-6)E?L,6
MND(O:#)RB:GV*U4=:J*X-E%TMAO%M;N\6/G[ERFF9C$OI!>_8=-H-B&'U,V=
M$[`W3L@F7YU'R@<K3XO]\-^4%ON.C3$MMB/28HMK%J^?$JNR:16"\>VM1"-A
M\_'B4MK9G9=N9[,][B*[=&7B[D`D'H[4ERM04[J.MQKH)@+\G].V6.;.E0Q_
MJ-SOW74/WE)6NL(I?N`:N:CW8>;O/;.^NHY`;!)>EZ"X]B7"=UA6_EU,J;S=
M=KN3RN],)2._\9U@@IK-.QZP,2@RPG8=(I+O?!>X,7PQ\>>13.W$T:R\+5A(
MWC:>I"TR$KE;UG62ABG3F_'SC`6W+"!@`V8]X'\Z=O_RRNX->B`4B#A2'H8H
M(R"49B9UDIU)$\]A2I'U&9&!WHLI+PHF"I%ETO2T2)&/*[N-8]XT2#[C._F;
MFE.CQ'+F<\`3EZG@>/^$L"&/UHA9MX%#*:,P!F;1^AZSV&SN^H],+U!EV&*>
MJA7&HY!/N!,\6A.Q5?(UD:<MDEBSZTH0B@MQ7<RPMMB/,8.)NP/*!@?LPO?.
M`VQLN)`1GC^(R/?%G8CG4N-57\G48_Q*+)"EZ$>LD,)]*?O6PW1<)_0!^=<"
M`DZW(%.XM!'74<#'E%U+>V$7X]9&-&#F/J7#RJU3V<#G(^*P<J59^A/3I\GN
M]QP,X#4)FGX(EU&`'V#XB)]/N!L3'//`O^>AH#R!&78O@YL="7<X=WFD%@&G
MFP,'G>`>^V2B4OV"G`D>3Y$:A-G1;$HIUG+4A&"S`!($$Q8*!",-S7@4)40E
MCC#L+^V/0@<B";[3N=P"]!\L&'/*^^=C9H-X'Y+3"I^QT6'%99$#.I4J;U\L
M0]02D`G&$ZYK5E`F,\UIR[V6A0V8JTHFR*?4;(@Z3[R#J<U(,\CA%%?(26M.
M,81>MPT,H5^1(20(72@O\)2Z?A3#H\MZ`'H19<-JE\8<R32Y)(8K7Q+#@DM"
M)P/@_M+QAPFQ-H9O=>V!+'R1,'-0)6=`:N(0PC,F0Y;5-+B&)<7=;2R)\6<,
M.*$"!IG?2EB3/NJ8\W?ON,@6U&\FD\,1%K\!`N724RP.&'V;YFFP#G\ZA:,:
MP)#B*76ET/SFE8UI_[$+U)^4.%#7C2JXH&\<SD+D-3PDMD.53/0&CA[3MS\L
M^#?X@4YD5U"&X%-I9I)<J.I<I@Z@N<NPHV:-"5FO96P(RK2;.4S.)#E1[$#>
MO0SWC]`5P+8SX%XXLR-8Z]3A`1Z#[RRR8)OB['6<HNT4'<F[D+@A?A!+0_@E
M;9VBB#$O%RZ^2(!'C*PWD@I(:P0R"0##,&@<ZB(<9-XQ)3U:A-B]6Q'KYCZ*
MNP>E#D\V$'*FD01*7&OX]M(;PJ$+`KZQ.X.+2A?$L+D@5K@@THR@T[8+SN8R
M':+3+K@>4E>#?JK"U=!#(FVNAHVOAFKL/;53)\7>JW&[O3.[_F"(LE`55I?:
MJX;5Y<+S,:OI>?IPI:C)4)+3);2PV#DHE'!@D6JQW-JMQ__*G`(9("BY&6A"
M:@XZ@`&R-^`_J"BR`"NNI5[&,0-,C"6-G0/#P(I9"?F@,A9&S)G8R2%)G0Z3
MI\R%\1@GU+!.+-#>@-`?!:&+5Z@ZE=+C!,TW))0+S^\&-=P)^=K%.\38"%G\
M#U&I*I?1I66E-T4R_!#O*+JHZ*P+)IW>5N:`6"F9&`P([Q$YJ,L.=A=W;D:;
M:/(^Q:>L."1K`#)D=+V<WXSA_L9+="YM(1Q-]];,GS!7`)!^S@'V,U/W0Y@8
M-Y;WA,QI`_FZ'ANY%F$UG1_KV#9/I'K_-Q!C,C\19?*GHL[DFY/)":___FPS
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ME)MI$IOZP93Q*`ZVU^IT:Z@NE5#J1QG[66MU@JIAWZ3#&9Z%DR!,V?I37@3Q
ME0[Z,PS\:(!>"'T+1.BYY=P&3+0?L55P`WD-5+27\FQH)X4>/W#0Q@"\WB,S
M-P\3[P(Z4Y1S8F$B86W6GH<$,ND*ALD2H*P[YYYIUYP,7#M9NW*GW:Y3N5`,
MT"^/Q1\6!9:7:F<R2%V9KP)AJVJW+N=&'#\N-65>FSHS[CZ^ML+'V<AW4[->
M]L2L^)QZ?XG-;''2I/&3I,U%8_&*]]T"WE9&4,U0<N>X4WU2-7Y<$6L@#O?,
MX>21EF<?B_V2F-$@[\_8"8!A)5[7!C=Z4NP_1O$3#6JRDV)(7W3'@XFUP)#H
MV(DC)_Y*(?'!;U"H46@1ZUK$H!1Q%`IU'#MBT$-)1E0J;W"(.)0<K`B-R06@
M46B<Y`:#:V&PUY,D^`N>]B>/1,)%SCW1JHWJ2/_MY"5==@^<=;E"/F$GG4^H
MXXL&@Z'=;G=U,&+D)R&I"W&HH**)ZTAD'OR@L*1,/-.+B_85Q?)FU-05@I,2
MY%D)W.U\N(?]GMWK;1/NP=5P7;CWN-4GK8;F5JJHW+YOW7Y_>8:O9<W[=@/)
M-KL8KAAEL]E"]P+W7G'P_%G>;/]%8[#%V_HD<7!`N#>(K6L8QE,BE%KCX!KH
MU;G-<\$_$00TW*+A%BLMM+E8ORGKP--%P?7M;<!N\V.6&F;1,(OLM:JG5+'G
M3_?H8*VXP!E'L>,^721\!!QP+^3CT^$?Q0C*30/:\0Y42FO)@T5F9I<`LFJF
MRY-'Y=>"-)L&D141^8E/&SQN`8__B9;T_2-RM^'/TD[>1S-Y2?W9-XY+)4W^
M;U5HH/-+-F>Z758JV$AFV;3&[]*A-BF?;G04765TLT^./;CHH,?FT*`?$,5E
M5937QVRGU2UK072$2%V[3'5E&EZ_=O6PU;E8&F;_E'"_*G%O4"Z\W4<'[7[Q
MO8O$!_S\J_!CYRQF+1O!=OH72*?Z=N?<<#W5>E[3*^W691F5-#TE3G))NQ$$
M\;,R+]7LM)YU!P/[:M"O/.D.^MVM=4K[U4%_6B1]@DO:92)A866<#R*%L-2]
M=`HMJ]*MY<\&[2O[HE.F=RZMCU/.-`Z)N\HM:99W^6JW+K:$K$H!N-MKL;9M
M:(H051L`ZP5-#="U6VO89A:P2A6NMM,::YL[O-2^U;NRVU=5JJ#M"L8=8:V,
MXU8U694JF?7#TVXM4ALTH&M=+2]O<4+HW$T?NH[=[EXN,2TU]J0U5`B97%(K
ME6@-376)A;U1ZTYR24_0GH36WU[E.>MB3AILM<#E"5+T"2ZI,2?MJ0/ZV57/
M'@XJURA^PK:D06-+JIEQI$%7#02@+=F2.JE?C;XY=51;=VP%Z-I7PRM['?M:
M8P0P;5)E[L@3PM_.;5+M3F.3VA2+YWM`WCZ%YXW8N]'!K8X4L'/VWA_T[8MV
MF7K;G*>E[+U?9L,[(?SMF!H'K8MNP]Z?!'LO-&`>I8WI^;/&<-8LZ;B6M->R
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MN5IM^>]+DF`WZ4F6(^OIAFM/J=_A/D$O:W=Z6,#+@-6#EO0U;@C@*1/`'OG0
M-\<S6X#ZTT-OZ1%3XS;/\ZZ)L;1/<K/?3VB_=\-LE@MN.4#J!L1ZY>NTYUQ?
M)MU,`-UFK];UUU!_C!QZEVN`H26MI_6\:S15K==>-]3?4/]VJ7\OC6H[_9>Y
MY@AZYT6[U;ZRSI\_LU[TRZLE)XT45\>HT7QQ`Q.MV2JRP"[;M2\OL=QA62S7
M=H'9*AI6;919F(;;7;$%YH$6GJ7`5&G`SO+2@#6GO=X%UF*[K/46[)#V5NQB
M73_:&[2&177+]A4-I>Z9W)N,M@?8\J5U;KVX:K4'5:_"E9%5O^+BP,ZOKHZG
M7'9MBHP/6E=E[1KJA;7%-2P5N(CCMH;+&VTW!Z(Y$,V!V&,T6-%59L1X2&VC
M\F5V*I%*357V;43N'EM5]E4/=6KU4CE:NV[Z*1R6IL;U%@[+D=6X7O^PE%2A
M;B+IJD?2M9M(NB:2;@7PFDBZ)I*N7J"?:"!50P!/G`":2+JCI,;3B*QJ]OMI
M[7<32=?$$NT,(\^?U7&?:X"C)I;N=/>VB:5[&K%TQQY)U^]?V>VK[MZ`J5<T
M4Z?,7'[XA9=$,PV1^HXZDJYC7[7;0']EKN'#;\$.(^GJ'4)8&L79'S:1=$W@
M4!,X=%R!0[TFDJ[V6]L<B'H<B":2KE;!08,>JBG5BS<WP4%F)%V9FE<__&T2
M27=5)*#68'MW?%A`K[I"O>JXPB9K=UCZ9>I9_?"WR6'I#9I(NL5(.A$)A_%S
M/+0<*XQG\.`C=F2,X->W_FSN>(\"QLMN9_@+S.![Y_<LQ#JG8>0#LE4P7E[I
MNB..L+L<;"G`3D)YCF<%0&T-!]S;8=3=]L+4=AWRMJ''?"]P'QP'E8*IMK:,
M35SEM8YDP!%&^.$/3S`Q&G^4F?-X(S7T^JC3[JX7MU<R.=IXW?R=NL'+TPA6
M7LM[;.V88QTE9M\YD>%R_N#P(/GK/[%IZ?Z1G#DH21N<[?IR+_K2"?*;%M*R
M!Y^JT2=?*HDM^09$M^2/)57K#^]Z&Y240NA?VA?]U;S61^EX*UD[2)F[6O@N
MG%_ZPLH-<%[KPJRXB44T-,"NXF46I37F/.!Z.JUVF9=@_\20R]7P\W\2]_I9
MA1#5C"[.!MU+N]TI.V/YD[ZJUSJ`'JJO8<_,8:GSY(,?3!E':GGK>*A&YZ=)
MG*CK[VS0L[NE!8LJ>+'RR/-4$=<N#VG;CN]OMQZV$GMJ(@&FVA`M6.@J8.!4
M?`>#;M_NMZOX?0]O^:Z9YZ#=NMR'FVV?UXFQ(\KF9CG"U&8%*J?$FK.`^Q/0
M"`,+3U=Y:O&I'J!.ZV)=SV/3:6E/0![,JY4"]7]B."/3QT.ZNDK@<:6M%#]P
M_$`V.>N_G`!UT9!*2KR#,>^=B-\SZQ-W1MSEV-J/@.;JW9_U*#585,V0_,6S
M_A6[CU975."P3;^B108_X+/<BWS+P:]GOF>)7?@:!^,[)V36]6W`V`P>M1YX
M=(=.2C@?+H.7D`/[0<NZ#JGEHO!:HA]3O9&>C8=A#),]J.V%.>=JDHNV?=&^
ML,([)X!5PT!C`8MP<<*3.-`<6*2`!"X%'!UN`0X#P:4PXQ%=&&$(*`A;%OI6
M]41W<(\`,:GR)#`0IL'@+"\P7H7HS+%</J7OI)\Z,X:4Y0"D?SE>C#Y:W1V,
M"I_,><`6I+M!R[KAH!(A]*$QV`-@W;H5!A>LAZ*PAS#^&?/HT0H<@#.-/L"3
M%06,.ES"]S-\T;$F,.\87YX"7<`%.?;#2(`.B(S=2+F2(Y@M=,9HY*:1/-AP
M>`=>!>2*26DCX?$%&=6V>FV[U^[)L<R5B)L9$9,4^VC5@_+K>!(EZ70O%6(W
M/8W1'?P);\`\48R;Z[CZ8(9;.9D=NP_@#H;=@L/9LMX[XSOU+OP;FF6`DDU`
MD0U@""+&/`O>CNZ,6BE.9+WHMMIM/,IB'CI683P*@38!7N!@[`<`Y-TR(?WA
M=B3G"5&!#P,%1MQQX6E<7NC,#```N;,0#PW^Y(-<P!%9>@P8GN%FWSD1/4%'
MVJ'S,H$S)Q<6,6\B(8@>?+D.<=X6A[QS)GBD$:;S"7=I?R3OF0=^Q,1IG,*1
MC@.0]OAT<5-"H+)Q'-"EAQ$>CGI?XXD`AJUU68A+@_DRF!1;K?;GSG=!ZD24
MN:XU`B[A1.,[ACQEXC]XBM.Z/K"HA*G0G"WKG_`M2.19MC31](?<S)JZ/F#'
M9+%]<U^Y!^3C>7+QDHC9`EH:)E+$1*X!5:YUL9R#>#[\%BSE(X+B@7AOZ5T<
M3Q(%;L<]#W&?\#0&[#QDD;%;B]<!3)O9[Y;U+F:*K-0(XB^#4-(TZDI![Y$.
M':#F.YN<1_XY?8HD+&,7+_LI1Y!AL2"U2_8W=_CD'*G,F?,(_@[I!N:1-6:P
M<'H:"#"":TLN1:Z1.!M<J(G`J>$HN1F!V337XB;PI*0L$HQ`TY=,''89E622
MD=Q$^K<$B^:!A2:`&4E$4P?^O$?O,LIHN+%X2?&(2!P9N(W&"+JH0NO%L'-A
MMX%)ZHM#W#*6N&%"9%*Y0YL`.9I>X:I@GIEF+4DK+WP/J"$2YPZHQH=CXNCH
M/8;WJ`%,P.9^$"56CY:5?_K-I4]+#A*<S($U`[X/$RILP!QPIS,AB'JP[G&`
MIP01D![VQ?!B@"@3=YWQ&QU1>"=&YA&C;D`@O$%SQOG-&.X;P"<^*N[2F3]A
MKA@$SF\\D\&+,9[,T6.*F^%M(0(B^5_$U,1J=<0D*=5[C7`TJ?CYLRV<JR<=
M^-@4_UD)]&],'B_D&IL#<[*AA6\UOS^Z+::(J8/N;)F/\9CK?ZR)^">*#A(N
MDMDOTI%H57R5ZZQM+^56AFT9)_;6]4E8$1;&^9+"./6L[M"K=Y^D72V\V]I9
M9ZQ]E99(@'D/RL.8["_\GD\8ZK;Y3&DMSK"=,*6R&-3\V5Z>W@+VEZR=0QP&
ME[+N?1=T*53KZH7D3F?8*KLCCH)2.NU^JZQ>T]ZHI3(C^<;#[]94N`/0#!A&
M=>0DY16)CH)$VN7]"8^"GY"S\XP<G?4+B:U.(76-]VZW+LM*:1Q/5$DM3<=H
M#HUOX1L+`QN6ND,2[R?YO*4[T328ALH36N"DROIOK2GW'`\M:95\DE8%5Z2T
M>J:&+G!/)MNC_91H44W<E/78M3I2T:HNM15#9+P"CWQ5AWSB8C`]\I?]OMV[
MZA3ZXPV/"EGG$W_*VH[Y87=@NO3,&2HZN8FHR>>&]+E-EW<*1L-R`1.8)R,;
M`F0<_^2Q-;SC1BJI"KE*17FD`R3,4`;'/-UY?"/D,^XZ@60;Y=S!.N.OZ+LE
M&T)@N#"PASXN&UZ3[V4PA,_1>H7G]`5<SVUZ6C^^)$P":4,[9\U=04E5D!L.
MK!BYB%/K&ON'[MXS?O]J<:>D2TW2=P*Y!D1A&<;7K!L&-WS20$6)%T\\WOBB
MG^Q58/(U;G#!?(^T8Q"'8S`/#$E<VS$]/`+'M.&.SF%T*[NCNX,>KC77%0VD
M7^B)'G1[N9YH_C0=T8T;.J5:U=K1U[BAM^"LS&_U41],-8[HQA'=.*(W0@>*
M%8;O^?)$'='B&N>@*^%=>MYN=?%NU%5_U(U)WYZ(TWJ'OMMZ+[S=NBPKEGHT
M3NO*--LXN(]D`7MV2*U/2,?A#.^>@C-\<'S.\,IT=2R.\VTXG0^]AFT<B:/A
M4XV3?5^+*9.LCL?)7C=#N;:)9TR=B3%4^J)SC=WYME]TZB%P5+SAC$RI?APZ
MWB1\)2RH256'IFSY3LVF:S'&"FSPC>-B.;B\NO1YTNJ&#*1,.RO@&^<[8QI;
M%G%,TMK\>OJOK#=FWXITI5%*>SOV=]93M.XRQEL1N[3@'%MPM=7KJN[VMUK+
M=;]Z17%%PBK*A@X6&`L_9&G`0`FR3JT<Y%G''O:JM!.J5$;S$'4@*]-&R8U9
MRSJ1NZEM6'8M-]79]@;/M=F,2%TK6$#J'@,X1-!@$B*A_D9EUQ+!7PM"'P5+
MK?!@AWHAA5+K")L>1DT,Q>XA:5H/K753;D@WQ0BK?>>3_"B4W^)T-P]_FGQ6
M=2VKRCA-CYE%6%1?@@2FKTN<X?OI++.[6($E$F)I7XF:J_'M8=ON#W>ERM<[
M+*#7ZC:=8K9@61`%9+<[Y0&7LZ2/<DWL628GKAD];-6X>SHK.6R#F(K7\S&;
MLZI8,=9K;=+@KFYM85(26K@/K]=&5XS=Z:'L=3J!`+U6OU[=U8Y)@.K:W6'7
MOKHHZ\MS7.30:75W5WSA*<A09YV!?=&ICL/Z!3MME:@;&6IO+L'NE=WME\4V
M-[WUULFRJ+,0M8)7LT3&JJ6?=!>CFV*/W1U<V9W+,NM'_;J!U<SKW&E=E5UT
M1^]X/G08:<J=3(4JDFH4LH62KDV3U*YP\DM=-`[B`SN(B]VWV_/LP$RCP/H9
MOUO'MW/*Z;&F)U'AZ$MRGAI,E6+JO5$%J\'42M$&"G7?5"-6\\NWP*0"9QS%
M9GVG3WS:8->HK'Y[&[!;K$ME8NXC((Y[(1\G</TG1O+N>*E[\5EOYC&]+"M[
MWB[3"&OL*JXTRK`8`[(`8,V1\/Q9@X;=TT*[==%9V@NZQGA8A1F4++_;N<):
M8#M:^_Z+>*^1QK3M4('#NG"HT6RSG'HNIX^-19<QF^-:4KVB*]8HZ;X6QRBU
MJ1_7!NK^Q,V*:KNB=JO7:_C&D<L9W5;W="ART!G:W4%9Y&VSGL-*&E?+U9KC
M6E*].,9^)(U>JW<ZDL9%Q^ZV3^>(G=AR>JU^PS&.7<;HM89;#=D[[)W<7F*:
M:I9S4`FCT^@D!Y,PU@N9JQSZLSQ2[J+5JQ(WU:1J9!AV=VCW!PT&&PP>#H/M
MUN7%4D[>(/'H<ZY*!-"G&4RZ;,0-B:8);6ZPV6"SY)"OX-0X(73NAE4N#^!8
MCL+GSYK@^_*I8:21^D`%EK_(=G?^U+J)1R&?<"?@3%!R4H%9OU/_Z/I=5L(K
MZK?Y]EW?>L/]<,R9-\:!/WKCEFTY,/+_^`&/'L_]!VR\&2H,4_+#S:,7W3&0
M>?!=U[_E8WCSCOHV1CXV"85GNF1KL42C"U_M57'&A-%]-OGT._4!38]QY]QC
M:]ALEU=LJ]AN=46)/D>V#,5YQDELKRAG#T^V6[VA8'Q-&]%J!/-^SB-_SM8G
MD<$J=)%+/":Q6)4IH]WNK$0:%ZU!>PEI_.WG.#R_=9SYZW<\'+L^MA3\,L4Z
MDLP+J23N-^9B,?FW?AB%-]C,^0WVROWJ/&)+O?!WP/H;%R#_Q_-G_^MO6QJ+
M%@-_?&/3O__T5GS^=^_S^W_W.N>?G>`<NP;_](\4V>3MOLK"@4U&*OGQR^H)
M/&D^?9%[H)-/U'_\G-9BF<LMYMJKP"TINSK<[V)JA-T%,K&MKWS.?B")!<Z<
MQ4#$LI$N]9D%]<X))D@J$QZP<>0'(1$6T>*=[X(4`5],@"BQ._(=HS%ENW7@
MKK!IV`SYJPN$>H8_JZ&[V!A./XF_ZU\ZO[Q"BN>A-<?7L/4L-7P5?5X%M+*E
MZQ<`"$\L#'5AS5AP"Y^I$^_-'9M..7,GJOLR/DUMIN5G\3`UP`V8A>VRK8[=
MO[RR>X.>/F*JJ[N7ZL5L@8K+@F2Q"*7H2RNN`X]*"N)$2<-W<70)-/@&VXU@
M'6G11S=]K#5R+6<^!XQS476:)##L9_V(;<YO14$*JD7M`0?RF,5F<]=_9'J!
MJM`K]2LWN-5$;+U\[9S*NHK^P'GKPB6XL"2?VFTSF+(K6!K@%;YW'H`X0NQT
M'\:RZWV&!KXF@V`W=.I>;L5SV5E9?84KE'"+I3&#!$.Y-NIU+#J48U]G)_0!
M[=<"`NZ-W7C"%!9MQ'($_)"Z3]$NV,58M1$!,/",DI3EIN$^C)WP[GQ$AU:N
M-$O#8OHLZ2YB0#8-#ZTQ"ZA[>+;;N^XC+BF;W<O.SHZ$.YR[/%*+T)W9`!L^
MDK!N6.Y,D$<@JFS,N)RP*;425_W*-:EF`20()BR4#>Y%2]0H(:<WQ`9@?V]%
M76&!#D02?#=A8B-93D-ZV[K'=B/8B@2>L1?ZS],MA>FEM`Q\1N+>]T21=7U\
MQ9RVW&LBXO&8N;+QM7I*S8:H\\0[6'T1:0;YH.('<$G`T9,W?3?#!]H7V-1[
M6)$/)-A<N$MWRLR+I:F=3OO%DT@$\041,+0+6Y7GW2%SI#AY9^2]@R.N?(\,
M"^X17;T:=Y!.-P`1SY%FN_:@+>4NS:6QT3M0DCAC\(S):>\"/[Z]0^*3L*38
MM@TLTOL3)"L.M\XD^UL)Y]$GF?T9\WO'Q5.O?C-Y&(ZP^`V0(#:O)\*D\T/?
MIED6K,.'NQ`8#PPIGE)W!<UOWNIPZ,+8C2B5.W./X,\X5VAHGPO7M-I4N*=3
M`@(L^#?X@>[%KJ`6P886A=?T;9@Z8N8N8T:Y9CNZ`?S8$*UH-W-X&$KZ:M$V
M+4M>J@SWC]`5P+8S8$XXLR.;QV/7#C@QWUF4[I>41[LI.I)7'3$[_""6AO!+
MVGJ"LH.R9HP8H(JE2@D`F6![%!@T#N7@<"D!%TJ)<+0(L7NWS(,KP'4?Q=6"
M0H4G5!K+F482*'%KX=OE%X`C^#]\W;OJ5^+_PY7X_]&R^O3Q[;0%LZ^N''3:
M!4P]Q=#U4Q48>@])JV'H&S/T:DPYM5,GQ91WRJ-"E.])7=J860W[(*Q>5&)6
MJ4T[-6;U,:M`>?IXI.C!T#U3DBO<M'!KC4&_Q$L93NC8O_7X7QDZAGV$STSR
M(U`PU!QTA`)D4,!!4/]B0<`FZ9=QS``[J9`BS.'(<R#R9-M1QPDCYDSLA,Q3
M]&URA;FPC>&$&E9JV0VD^BA(5;Q"#1^5>B2H]M3V_G=C&^^$0.KR=)M+T!G]
MV",<D*H+>YV'3<EK0[P>Z(Z@TR7X8WH_F`-'4_(/&%!UWE'W#&Q+TF[39#N*
M0UAQ2-HQ\D)TPYW?C.'JQ/N+QCQ')HP/S/P)<P4`Z>?(.*98<Y@H^\#MHKM0
M]NQ)<Q!I=NYTB(>45&;:`3T44D9NO:7++=5;VEEII8T"D/+Z6>PD<$B51<GK
MGZ$KH5S(,Q0PHTW'9Z*BY._W2$[&STA7R9]`8+M'P08=;TYHM[K"'0^GN636
MO%&WOK2]3+([_%4I0;E=BBV.P;;6;=_T/B6[YZULJZV_=CW8BTZKT]?&OD[G
M%^M%M]5?-0EJ;V#6=S!`8+>316#%O.#M5*LJB@]=C=07@5-!1)84%2[Z+_-!
M??\#;68@`RG5?+7*.]NM1[;K<0<%`[=?;AG0>BV[MNA,D>;*R-S1/5'I9.OC
M<N^[H*X6-1P_*B[8:5^^3#'!SK!?\6`<&=_?+OHN!QGT@5YV`E=("7#?>/C=
MFH(F!-HTX`54>#2IL-RKXZCV$H,!,YO9NEIY-X^3?K<Z6+=UV4DCL-<:U.0X
M[.-:$*&#PMYT]*>A4ZT\VG%2[%8'&TAWA7D`AFOD91_=C:`/P%1T=HF#4[@-
MML+X:[:HPV"HA*Q+B3F;UW)"+ACAYPI3#I:4(TQ\I<-!#1\5NF(6@B(#$1QN
M.;<@F%%`N*WB8LCQI>(`E7-.^]GT^(&#5CNXPSR&D_,P<9"A/U#YUQ8F$GX7
M[3Q+()/Q"#!9`I0(S5?^81G2N%<?2V:&/,]*I]VNDVLE\N?YS%F"VU-%C.%'
MA,Q,!CD/^5],@)J+"7QF"9]:?Y:KB^%5U6FN^E7FX;,9FW!T&4KZL\NG6]$]
MLH#Q':!W%[A<>4P,4;MSW*D^MAJ1KHA^$2<=TV,P-$(R`E3Y$FEF-23OGX4W
M)_J83S1YYI/@#$URS<%>:<P_8R>`6[5!X+IC.IX74S1:@[^U;Y;HC@<3:^%N
MIHLER;G,8/K!;_!<$<_D9K_+0;04_!6F==Y/@^@-1*5J:/90C1)A9K\@X3?(
M7A'9EKS"BO"=2*8)22=<NE5KT70?B<NDKQ-"2H(<TU&]*AZS8_=DFH`*F([\
M)'Y^(6@>5'GBXYF@3\IT^D%1G<#<7_2L&7?='(M&7D2GE8[H3#!I&:L+G1E3
MN3547P++$>2MI]?MVX-V-W\UJT'?[U'NQ#JP%^W][JEKPQE2[4W-](;GSRQG
M'/%['G&F^IEFZ0J)1"6B4!*4(+^<`A+E?4\;/?&IA&E^*?:7[6HE^RMXJ,WG
MF47K#I5NTD$QIT?EUAK(GAYJEK;O-+Y>IX'G$6%,-^0TUYSTXS2^7*LCYY*U
M[-8#+QGSH"N-2&\<EW(;31]K]G)9K87>>OZPA>"UM4811>/4,%=RF*X]Z%W9
M[=(VD-N!92=8J%8C/[OXJJW_ZK/N+>W^'H%YTFC81;@$?OY5:!U%ZN]:R]H$
ML2(D93`$_>5T>EUU6MVRBJ_'M9A=37MR2]J-B&$*V#4[MF?=GMWK56^V^JI>
MRVBW3JB-6W-:MWU:MQ&/F)M-2:]^$+&(C"K!B=H2>:=\_VK<?IH@G%WU[.&@
M4H^C8ESF\95311PPK:OM8&T/YH-M0Y,CG]<+P'I!4U-T[4Y>6L7\DF>^..`E
MU[6OAE=VN57HN*[M3JO7/YG%-&+5`<4J_%Q+NX5V19\,471;O=-I!]H<VL9R
M462YP$+Q_1,P772KK^%IT?8)+JDQ7=1!`S_K]"_L;C6O11:9SY\]5>O%Y99L
M/HTZWJ#KA*P715M@]!S,,VYDBH.:/QDEA"ML^:FTC.S9E_V>W;^HI-0LT$-5
M;)Q8Q\A.:[B9K?EH\+=C:L1QS.P">HSJ>F,^^SE]^UH-0F\,6YW+5;)93W(W
M=M3_U.[V*AMMUD3BKJQA3TO?:9;4+*G>BO:!93RCM44=^?B.;]6NW<-`I.X^
M&'H-L+DK&>]B(TO&\>"O=C+>("7:M8;+>]R?T&[LB)KMRT[_$#+>`;-UMU#V
M:X6^YT4)E2MV(3&1OOOVF4>:/+F.<76E5,9.C^91N8P:;U_6LA'5+U6ST\Y?
MW_NUY*/]-S?).R4JG6XWTG=1LMYF,VT5%#/3LAZ`Z`&-A,^#0M;LUDYW:X<G
M^IOCW1J]FOSI$R*5NIR>5(YV<XY/9G.V<&S7R7O'<71%!`W=;NLA;",_?[T*
M%_OR*F]CA?O>E<.OV*PTH><\\3H3E>G8#,(YDC4VE+PK2MY?IXYLQZH+5:"B
MW6I?6>?6BWYY7FH=RR-TU#B8U8=Q%Y72X.M3)6*](B%Z]9W61;6`B=HL?%VY
M;0$%PU;W:@T[]O$BHH`4,-H`G5-/JEJ.<1#ZE7+`ZK/PK1V$0>OR8J<'85_1
MX&6-@06MP(5UB1?75:M=%F]W:L',EU?VU=7Q)&/7#X&#UE6E+)8&?6EK0[<U
MZ&S!9_P$L=B<XN84/\%3O'\EMR2T0NN[%<6&4PD8:E(4MA*^UJ0HK#]Z*L;`
M;7(4ZL,<FMC6)K;UJ)G#(!W/ND?F4)>XS%V$/&X0K-EI@C6;8,TF6'-[,2)-
ML.:)A_\UNW5,NW7,P9K/G]686.IR?IIPS=/<G"9<LPG7;(+<FG#-DUMA0\=-
ML&8]8I0*8]2&W8Y]]61CU+I/I:5;48S:16LX:((U\2!T+GMV>U@MCJ$V:-CX
M(#R9WH;%!Z$[;((U3R[,I@GSVAX"FS"OS6P-O298LSG%!T=@<XJ/YA0WP9J'
MCH!)Q6-==E!5KI;7>+3Q1+N*Q^I5:KAZO/BK7SS61>MBT`1K[HHY=(=H/G@B
MP8:[8@X;MH,]&OS5D3ET+DXY6!/&&JD//`<BKE>K'S,C%"?\?F>0?%'1G%/K
M)AZ%?,*=X+$0*(!D)V"ET9&:9>M1H<^?F5._BP,,8.VVVWV*8H4/0]MZ^ZYO
MW8K.CY8HVJ_"7EO6%\^ZCF\!`&N`@:WM*QNF$X],K>B.A4F(K&Q.U;*N\XN7
M6I$?.2[^U$U-8CVP@)4&V#[PZ`Z^5-\Q:XZN/1P)).5NFYYWK$!%15CCQ#-F
MN7Q*3[9;G:XX=:TLQ1UYF'(^NM_/>>3/F77GA-8@C>\LJC/;L3+FV^W.2JB_
M:'4'"O4)BO2GWU-41,2@J'&BZ?72!H4+J-#Q/!C:?;1\T+\L.:Q-8-PY]PQ@
MF3H\L.X=-Q9@PMK1S`NX>0!,3!@P[ADPYHD5AS@TD+#U!MG]^<WXSG<!US-_
MPERQ</Q1Q&\3JL(PG@DH7R.QLS&!R._YA,'TCYRY$Z*TE[\D/]_[KA-QET>/
M@O#;+VVXA\/OUC1@S.)XC^"R`B<B<+NM_O"E0*J7#*(0V6DO4/#??H[#\UO'
MF;]^Q\.QZX=QP+Y,W_JS.?-"!X']Q@`"-GGKAU%X<^<$[(T3LLE7YW$&MUCX
M.Q#D&]<??__'\V?_ZV_AH_?Z)H*_OL9`3?#<?SD!;D7R&&TP_/&-3?_^TUOQ
M^=\?_OO]OWN=\W=L?(ZQ[S_]0S),XRXSP\X%O9\#>;ZN2._RJ.AK#]_>2LPY
MP)*^XM7AS%7GI2>BW1IPKU#N4)?/92MSK2R_XU.3ZX%H8ZQO;"[WQOH:^'!0
M9B7#EU[X"_=;#K^JNC.2B8G_&NCA(!#A2.?BRR7L<H>0E>PR7G7`WERKIVXZ
M//]XE!SO40![V>T,?PFM-[X3T%%_!Q?>./*#T'+F\P!8$C+#HGVRG#BZ\P/^
ME^([<F@@/F"@ZFD;.(,_HR7`"3G'?XD?1'>!']_>93NL(YCQ'(=XT;%FW'7A
MQ"-D/`KAJ,YF\%>(\*BG'$#'#SZ+9_C0U(\#_5*(O`$6$@D>3Y>*''E@S6%"
M>D#=[@N-WE/8`EX\,=8TL2X[=O^RJ^:8^H%`&$`"O`FX^0MY19W!M7+12:9[
M95LC&B">`X@XPY^QCRP161WA,7#H'B.82ZZ7*&`.\,9'O4RX93P_`@X\=N,)
M#,C%\("S>1P1X\1E`K?%:RVTSF"^\%4"F.#1\.^$L1F\#F@:P=O83\1%*O!P
M_1')0T74_;>?E[/;3;AR[S-Q91`,D"MW!5=>11+9A#,C`X1W]1E7S&N8NS?)
M)W%HU`(MM<)B-6&G(A6P`B%/=09*GC*IF]0_HADZ48#\,'8CDA%N`Z0'4`>)
MQJTI]X`D.`A#>!AC#^X<(>;,!4^PY7-`5]PGEA(],!?D&#BXT5T(L\)Y'+%;
MD`:`(#^P41"#QH(2&X%%IW%L7/8T7!@#Y'H"0=4$(6#4XC"WPY%/T11P]J9,
M4/,#,`(D8@YR#C$R``J&FU&/G`>Q(2GA$.?JRH,KCY50"G*9ILF-Y*&&/YWQ
M'6?W`F7P\ACN99`DD2F!6.1[#%20/_#H@W09<7TL<0Z]P(&IC^0!'9+HB)K)
M[_D/(%*R"TOOB2\$+\F;890)"FSX(=EQE"]AE'&,_(F&6)";V9\H%P/1B`5(
M47HEC$GV-Y&"HI@(T"$6E19Z\4&U-(//3JP7%QW"%6TW@#LCIE@B#..0`NLD
M%HO)#$$87H2W1X^IXX%L$9Z`,\C_2CAK(DB3'%*<$+D]+:Q2%N3EX)!)D%MR
M-!EK247%"F(K$3_K%"K558%BK8H9^?6+$$KT@?=9A3'/I[D^ZC>)T*-W*V&:
MWGBY/E8W=J+FX#71M.N%V$[[<I^HW1K!?LNW4M0+N>V*3LXZ$JZR[L@;NUX(
M[E:/OZ@Q[P6I;,IX!"+/J7/?0N_.?LM-[%I+TV8(J1%UUE/4$C7-F=SST$<[
M`0ONT0RR1$,KT<"2$596P5(ZGM(\45#7.EF1'M9IKZ.'"7F^0`LBDPM.3*I2
M%@M3#CC(4XK0^(30HB5IEQH035)-^^E*)#T1]:=1>HY0Z>FT.KLJYMTH/8W2
MLR^E9UB)B!NEIYK2,ZR41%I'PJVUTK-&FF:->6^C].Q:Z3F8^B/\U1<KJ#YO
MA22=<;-=)\X+&>C#/0`N(L\"R.G<0\^)'Y"6,W>"2,C7H"AH_2D]ZX*>`I-K
M/_AEOV_WKCJ&CE*HBX0RFB<W\JC3:JN8+\5&IGP:,>9II2PUE/#^6'PV8Q,N
M_,TBP@SCU51X6\=TJ>7$4_4D\#KL30\O@I_0G97$517'F)V6_OTOQQ/*ZN6V
M:#"Z$[=O'AF&5>E0[Y%)AAV[#^`.AMTM$&)_BX3XV7FT.N5$..Q?`/!7M2'"
M='3I`<DP=I7!I+T%-FBA.<!E:[._7+*[:-L7[8L"FM,6$=<9"TB<6QK=#RB4
M9XY1BQ$2CQ.&@+TL9942::^;(5(5C9E+G7YRJF5HCTFDV;B?0<NZX6@?RM!C
M*HS32;"',/X98SADX'",=DI'#844J(/OP/<S?-$!W1&#K.#E*0M$B&D8"=`!
MD;$;*9M/!+.%SIC,-3B2!QL.[XSI$A*3%IVKSJ7=N>S6YEA5/%2;Q@]+:]6C
M(8];B,=['G$,E<H/Y_9$D`-B'JD)3AJ&4>7$A?%PI3K(3\CNM9)P[_D/@3/_
M^T_BW_4S;8IJ]JX]P=9K%'=S84F%@!UHJ;F9Q/M$W'(L&<5E1X'U,QUH6:92
MP[2EVF@5%[Y;^X(\R,.VM'N^<5SR4VC_0>>7!694IG#6HV1.D5'8[L`2VL-*
MD03UJ1RTH4F\U^KOJM'K+LPR^/E7(?G4R]Z"F;-=^^JB4DV*Y;,>TLS<ZE9J
MZ'08EB6L<8(%UXPDSCH#^Z)3'8>OZK6,3JN]5:+>I;6VL#K)>Y$_6?56WHGX
ML9_Z.&>=[I7=[6^6B:Z1D$>3IXJY;JM:5&&-:N*L*JSEN;@.R&)Z=G=P97<N
M*]6DJ?GE>768R_,49*F>R#HY)6+8ZF*>H"1E=Z[Z=O>B>N!#[82I;O4U-,+4
MH46"\YW+`PWNZB9+%>V'40XH3]1*V_*M<].[46'7=US#R=B?G9<4ZW?Z]E7%
M"O5'6Q)K-R7%NJW>/NHU[DK*K*M@MJMI3VY)=>:PYD]LK<Z;)\1KNWODM1B@
M<JK<=A_574^]O;,.]$C51,L/>#B:?LY'$-RP0X^X=G:[B4=\'^[NHXH:,&(K
M%([6[WC]U#"U?N_LD\9467=AA;I4YU+UY=8:V9TP=J]O;P-V*U.1%.(^`MZX
M%_)Q`M9_8A;LCE>ZY\2A+4637.H$RVIF^_J$T6P:3314\30BE:%!PI-'0KO5
MNSCFEH1KL@*U_'Z_5]6)5^MTZVKHD-RP6KIYK0U+L@A&LYZ:KJ??NNQO/[7V
MP%MTL>TM.D1>]EJ<HUHCTWIO(R4`-<NIYW)Z:W5.KO62.H=C&X<5-ZI%>]9Z
M#V4V[NFLI]LYJ?6T6^W+$V,;@^'PB8H;58L!UWH;NR<6/7IBR^FTKM8PB]1Z
M294BW$Y"U`"&<3H2\*`SM+N#ZJ6.F_7L9SW]UD7#,8Y?R.BU>BO>8L^?'<$6
M7G3L;OMT#MF)+0>)K>$91RYEH&GJ9+;OQ,3X$UM.KW5Y:N:,8Y8QBM.`*GJE
M"\>YV#2CXFDG=?6Z0[L_:##88/!P&,1!XA2R)FSL!]13XK7E^1Y3INJ+CL';
M8_5N@_9CS^?<AG"Z<:KA"K?.)D,>>3[D+D9_NMFE.\?F/O/'#H3-_:7CX3B8
M#Y1"';`O%KC<8^?T[6LU2*4KK=.ZS+_2<+J-[[>:;^"NT_\Z=J??K1R[NM4<
MP)7;E\?A^:WCS,6C=[X+2P[?4SGFW_R(O>,A]G*/`Z;?RNUF_N&_J9OY.S;&
M;N8=T<U<=E*7*S=3X3;O9*Z0A&]O)1$.8$GOI\H.S!4"9)QQNS7@7B&K=65W
M]0M1DWI4X5BE)M<#F7LD2((ZL5EBOTHF*4T4_3FU3ZD_=-IDU?V1N93BOP:2
M./`N'.E<?)E'W/.]0%:RUS@\QP__C86SW^<6SA8GFVMD'Q[HFB&QM.P_J`<3
MJP.B0M?N=#M5N]-CYT(+N1)F`R>5]-NMR^Z`BIZ#B!^&V(%^S-@D%&7VL6>]
MBPW9#43I3[\;L%'OQ[RB]G*@S@`9>^XP-XQ9R#2M@8798`&E*^L<9E5N7_;1
MX*$>?J%D?4-".,&[.%!]'TM*V+=S>SQT!P/[:M`OZ.=@8]M'N,8\)OH1R"UA
M28,&>$&VM12M)$6?T31)]<B`+7H=Z.Z2;NAK&(97]K!;!`,-:+0\3?J1WCGW
ME.>>:9SY`B5K[(]Y!J0^O,"F$V+H5[9UV;';O4'93"Z,[<'"IJQLBF%;SW`Y
M3,V`#04NVO:@6]0@B&9AL[GK/U*'#+F>XKGZPV0UYEP%34,!=M7M5/:O&#G8
MWI/ZH.+>_1G[>+P48X@"9Z(91-@<L;6ONDYSU6V#3W7R^=2EW>OUBHY452XE
M6^?*"V>18PUT?UU@FQ>=0H81,%=T>:&VS$YXY[(P3$VK)DES/[FH8<\>7)9R
MHRI\XDIQO4ZK>V4Y(FO=X!=B/<../;PJ[-]3F==V+@::.\&PB[/:DOVLQ'P*
MKX@>R#^`K,%E$>!.2'!SD/B3_M5$1W<.$(:;;8Z$.>?LA^^5K*PU5+(0K0XN
MR8U6UW#60OFWM/L:R<!=^W(PM#O]0B$A=:`S7<63)2_KF98\B>3SHJ^%8>M=
MKJ!+UZO1G!OD^!?=JPLA^-8"O37<[I)NCU+?N;B\M(>719LDNX`5M9`O;\^8
MV>%>:[#6'HN,Z\(]_MO/E:U%6[0Q]3Z3C>FS$Z"-J2ML3*L4=MK$SH3F''A7
MVRJ4*>8R5P,T=,$JIIIYBF#WNR)#>A'-'45O1"G%9,MLY8HP5W:O7R3#;$/5
MRE#IQ66YWJ5+/6\@5BF>NQ28CG'2MGI4XE'(_HSA8G]_STRC[>KFUQWK#42^
M'=B'!%2+8"TF[H-<"+OE^EK,[[97Z+%JR*"Z1R51V)1[H-ERQ[6<R3T/?1`;
M$B$5'W!0.N/^A+3A!^;>,]W$])KL8W-0[Q,1,8SAV"8C($AR;H=$1=>U1DS8
MNAPQ$!#SE$D1L:WUA`<00!>Z!F>O)ED(H:(=+]7?$ML0FL.25J_T_04$3/F]
MT+5`R8$-I.DF<"#Q-X*6;(0+_3:!2`'!JI>G,ARN9'.4@G!J$K$`,9_Z(4HO
MZ0,;!4(&E)UC3_U$Y)INDK:5">^<@+313M/9C#G(#R=6'*H;Z0WZW,YOQL`^
M`3H<4Y#XS)\P5^#?`?S/I/H;H\XR>DR=0"P,*3IH\K_H(-*OHDXD38/T5EPO
M<ET49;>@<#/R2D0.VC4L$6D5AVJ6N<B&`UF+YWWJ,);XP3:K7[2&HU>^W.V^
M+/;HEA?B63I]]5BEU7=!Q#!5"*1__V,.L@]#-\<]GX"@EQ>RO#+JMQ]W7#TH
M_.7VL5I*VTOP>N^[P*=<)>C7!K&=8?5J4CM`;66"_<;#[W#34^=YE*?"R`ID
ML<7Z(+?=&E:J5U='PE4MR.6%72\$[Z#(S`%Y+\BT4\8C$'A.G?L6%B;?J<Q[
M('WPL_-HY5I+2)/R8-=G0D9]PP*82?0>P/^K!VWK:^NZ99TI7:3;_J7H4?U(
MYY=7=J$>@R$W<T9Q-QB6P$.AD3KC,1`RJ:)3'LSP?5":)L(:Y."3L>L$UM=X
MY/*Q7L5U\M87."4ADHWUQG>"20KBKV^OO[PQP0,HPKDTN`!_*5X\KH+>3M1.
M5,00>`(0?W?B"8\L?\X]'(Y[8S>>)*)]'@ZN/0]5OV]L[@<1*G,?8!]@Z\__
MCW:HE+GN3#48M@Y442>(/'@``"I:"K`&G][S?%!\XNC.%PH(16\:RPQB5&TB
M:;VB']3*4.L=1U3P/@XLST'*8=ZM<ROL!@H(,F`!&T'\*NTV69]`UAE9L;@?
MB/6HG_]#7*A\!N_?<_80OK*<:23A`X"!Z@%M.7,&?D1*G#\5&IZD)F-U-VP,
MM!1Q)KR2[W^,[QSOEK9G!DN%]150*6CE`B>(\PBU_L@!ZL&5I68G!];-^?]K
M?8.GK>YYNV.=6_\!V\RGP+N%0@BD)BD6C7FOMJ]^'U;35J0V8BYG]TA&ZHC,
M<3_].$2K#G?QNM$&IA!W#C<S7(WVJ;/"&#837FM9'ST+M4=$;YJ_W4E2'S'F
MK<3H+-\X!O;.0*?C)\''*7UX*WA`/91[]X#8"1G0',![A(0/%`,`C.'`<FGS
MP9W*.0%E1Q]Q$0)?`J7]C+^R(N<[X&0:NRX=4_3GCD@[T*L0A]0)Z0^7.;GG
M7,)#S]HP,(P,AT,BVK$F#,X)XDL<9;)5PXQB:+)@3U#8,)W[J5,N'A3&PRD<
M(0Y'\9'.+DP%<P5,<L`%%BP,,7+:!"1IB$'\22#D0B9\0ML"T,1NA'P;D2;X
M0ZC@RF/CN90``,-@R8MKDXLM:`,I46):$KHR8QEW.^&%_F[++R;:H!^*FX@#
M#226<8:6<0*T#,X#V0</*2NUE;#T+S8%%>_1^E?+^C^!\Q#2Y>G,YSZGL$EY
M.`QIQL9TAG/V`RZ:"`W";^\<3@=2;A>))2V\ZRS:#&$-IVNEXB"V]3G04$G;
MN3P,*O)F.S9Q80OEQ"C&#.%QA.22,O"+6!XC^C`O6$X!IN"M;%U-:,'P915Y
MI3;P7=7*K7NUS*V;\76%*SB[2I:P=LNA1M-H-(U&TSA&36,7W&"%"WP7TYHJ
MB+RO0%J'C3'<LGE!%=8HECYHI%CIL,4P*7%7BITE#6$*^Y+N_B;XB@R&-*5`
M>=)NSGL6L@U7N,`1:+F]$L+0NHWY1+B5%9`W[]_"(6)2^M,^72'1P9K@>X92
MZG0*A!\6GGU'2O5`/WC1<2]FR7$+$RK%>1BM,A,^"R<$D0?O!"R*`X\$>"DZ
M"+S*0Z<<JC*L)#T,:1]^C/PR?ZF`-CA,28H*R:I2_\$39,"!&AAY_@%S<!KP
MZ@OUT0>2PI/*4>D#UDGD,F9AZ`2/3X+^CUJ$75G`O)9:$-#B8VH4)\EI4L(F
M<DZ9;;JN!$QW3$GL!EY0.E`9=_`[BU0P1U&01E8<OD<B!I48O4B.;<'0`="^
M"PP'J=RQH@=?W-(RY$2'B('\`F\FS^L(%9@."&``RU43X1QXN#B(%!-.T6+I
M8ZH%\B@W9B(3V!\M!)Y=4#RN%.>=<F'^%ZD4:`Y,T9](0S\22T#>UO@/*EJG
M\&0=Y]G]?4'_60@DP3!!QQW'Z,N5&M/2;5JQ"^E>&XX>-IID2P6^5#3)<!_1
M)(NY^5OI;-5MZR9WP]-I:_6$HTEV6B#W"*))=ACOL$."/8IHDDZK>WGLA*NB
M2>3M6"\$#_<63;(/WOL4HTFJFJ4_<:&@@PK^9?J.AW,_=-Q?86/F'\FP!T(,
M9F5(S7WR92YS+M_&08!Z;I[Q^CK\]Y>ID7H!,E'L<?','S?O?K(F;`PBNQO^
M_:?SWD__Z/9!9$_@WA"BO:^N4[ZZ':U,VM7"K\XC;OVU-X%O`GC+F.0WWQMO
M;YMZW=0V50-@U["OO@D;P/U)E(L(OZ'?,F8K)!TMH_Q.=Y"A_=0,&\Y>A3*+
MYY7??0#EYU>A)V^\[O[E56K9"U-L#,#J2R^?^\9Q-59^8_FT6&W++SII=I>9
M8</95U]WV;P?/334H`T9&),_8Q^52+CQ\@T`BB;9%B1+4)'9AE)H=-6XC^2$
M^N`'\L!\8%O@`L,V05(VR3:@6$X:*T%`OWV9TG/PQ/L?<'.%_)[)V@MOT8(R
MDK45DSH,VR"<M6??.>S+2.WBLJ^W>/T5Z!ML@O8^_!K>OY[Y("__)<R:VSR>
MA;-L#98E6!L,T_+&2O#\D[D34!><"-U*CXD3],9W)_*OQV\,Q.N_V.17AWN?
M_#"D+4#AZPOZH'Z'??B=S>:P!<'CQ]D<W09L*[>>L9C=@5D?;"S9WFX[M;U[
MP@A(??3E[_[U^,^8!^PS^4I0$C0\YMO<ZI5FW`F,2S:@WQNFMV`-2&4)`!2>
M4)[X++</A&KD8R+@!'2=Y'+=,FZKS[\'^)?AO7O52^-]TU5D]PT&Q+"-QZ\N
MR+,P"A98F&_G&NYTRTFF<.K=0;RZR%L1VD5Q:,_"SCJ3[QKR)=@^[Q7(LA6A
M5_%*7Z9;)-Z+1`K+&7_#N5<3K\OF_<;&KA.&.G[JR_0="_B]@_$+RCCQ"+2K
M0P^^.GSRT7OKS'E$P0K;H;K-P-C?:I8)W<->LMU;6)/6FRERXXL1?;6"?:I]
M]>\;%98ERMU@7('O(3>Z_L'#?[^E:`\Z,I\I^-%8G(@5,=?71M-1OW_5&W0-
MA3X+V.9@=]I;![O7ZUT.V\/=@MW9-MB]3O>J.^BVEX&=X7NBC-17BI?Y3PR0
M2/3I+0A"^7:#LCEW`>,&J%[IYJO9>@I8Q"IK.XK]^H8)4QZ;O'<"#^8)3V+3
MT!4V#CAY7+]1B!\J-?M?FF`:^SM@N;SLLM/N#4J7M0#F8KW"`ES0FV^P2NI;
M,W1R<X=!VA94'80]K&#KC/"85[L!FSR!O5Z3B1[SDC=BL75>^!(UXZI?>VK=
M1!H^POW:'6<Z@;T^0<ZT;,DUYDQ"T#J(R)$K&EZT!]W.TD670;V'56]=N1_V
M!I>#S5>]3$]XJ\O<;D?][W9R;:U+YMT1J'NW`M1A51M<)<>T>3LR"=1A:3LU
M#.QC@4LC3P:U(;/MBZ''L*H->,0Q;=X1\XB=RH_;7:"00?9Z.^=[<897PVY_
M!1OB7I:W=8&P,^P,KR[66]Y*"@/^]D7D_ZB4S<D68C-Z[=7UTSP0=K^`PU@B
M:KG632Z&3N_(-WJ79HA:+GC]2Z13P1R^[M*E;GN`4YU_O0P&5X/^JAKY1OO]
M&WN@7[:@CU]>#E;>*3WM;@#=+IOM',FR-N"HEY>KFW8/N\@=<L[#+FSG9MK=
M+F^)(GYQ=5&78[1E/;PN3&^'BOC%U>#B2%9YM.SAX%Z<2LL3HL>^[N1\);5+
M_UM12MKQZK:N@O<'_<%5]V*MU2VSN>PW\V^XD@UOH_C^W:YPN]?%:FZ/XT7'
M1O9>(TWT-+&S(S/Q\2)DI\;EK:%%<-FZ<)6B"/W>8'"Y@M%VN\1BFA^NO<E_
MR5J25>PGR^Z0U;Q`RP#9VVKV[N8[EI5O<C6<%@WLZ!HXEN7OE.EOBH1%J^H!
M&$$^B[^\ZJ_"X%?"P&)9B;`P_R\_Z,N<YAN#%88\8C>B&+4`!_;6O_7XEE(@
MVFGOWIX`KRNR=N9);/"ZJ[R.AH#W9^=OD+MS8^+31O&RM)AAKSGL>\C`:?"Z
MJUR?AH#WYW9JD'M2MU5*0\-.,&_];=0.[>190=3P&TV\K!)A[VJ%B5?!L-)%
M=<V9I##-5DR%9LV;C>'9[\IV8C8\+1QL8D`\7<K8P)AX6HC8V*RX'72H&^=+
M<.MXLD8K!LK[+I\(!XLW^1JP$*:1M;@^J*;/>GWA.]TX^G=6UB<WRQ[_L=#O
M:?.VN*(#A7A[K6Y/V986`$M)#^B"7DWMUH![Z=>,9A2J56^GE>F]N[S)1+K_
MM1K(W#WJ?_@;5J6DSB6Z+X%H+0H"`Z=.=N:FED!1T+AB.[VUQ7\-5''J!OC:
M.A=?KMI=;0>=Q15F\0/'#^^8/J[4E!>;UK%0M"KA&G7E;91WV@%]?Y/>/'K1
M'8-#8KWAONO?\C&,\=$;MZPS["=GM#9^N]![&?OT&@_D#)5NU$P]H+%/X?6$
M`7NSOH+4.W/&+*8S*N>U+:!IQQIQ/V+C.P\'>J1VD-BD<.J/J1>>:JW([IGK
MBSJ1L(^A!N#=;]?G(Q2GJ;FI,Z<I0ME-U/-%^4'LJ,K@H?.9/P%\`!NQL#?B
M&&F!NB,C*OTXM+CK(GFPL`40BJZ_`7/2,XYHR8_IUM<<&V,"+\=>E0I83NT1
MYX$_B<<@(6,).^H0B5T/8=3(^GK]SW1G1D"-;S9!93_FN!#<>OR7P0U$'0''
MIB\]5%VA%T`DX&DECKQH;"MGZT3?5H`YP)J0+JP#^6@8.;?8Y,Z_#9Q9*#I3
M8Y?!$4,(L"DLF]A(%]BQ6*Q;?3EZ%/TY89_'L/%<W!6^P>W$!HW]`"M)`TID
MUV.%=AX*O#\0_@U\TH1WSKU^0W:Q3).'O8CT,,%ZP+#](`QV'K`9CPBAGV\`
M5*%?(;4\AK`4T<D;<(L_3OD(#M^CX]YRAV"__G13W)ERGQPCK_%BIWW0SHMY
M=W'9M=OM)]`J06"$+3*M#@!(0LTOEISSG%H\X55].8_$0LX?F/ANY+N3-`['
M0!`L@%5X_@,PA[__)/XE8#XC!P"*_^A-9,72Y<T<NR^+`%EUUI5:6AT4+U_E
MV7FKSD[=T-*_/`1:4&Z.%WN<%;1>6_D(;(8VN$%*\+6'+=ELBIO":SROX^31
M+`N$='6-UHQ>]K#X9HK-IS@LD7S+%9".&=6_!RC31,XQK^':=>%2BSA:;BSF
M!=BU@EJ%?Z6F]Q\_:M$=Y%R0Q^M&5:=V:,^`H$!I=%\=\W(F?DA:*B@T,Q^T
M'Q_C_"Q4XX('9_$.;BBHF:+FE]?;`BW^F)%]"M?75W%UR9N+##6*S9B76,VH
MZ;C%GA.[K-+R3<THY>39^FE,<5@B^6!8D8\9P>^G4Q[,CGH)7[7_X(%'=]9G
M-G&LZS<UHY<MX^'YLP,A^\Q'U]+4C><<\.:QH[Z&:LM=3IYYG\84AR62ZT]'
M+=)>O__MO--N'_,2WJ;$6&L>L+DC//F-X66GE]"M`TJ0'[`('D(#P5_<&UO.
MF&%`W).XD;8="';`8*8OGO6.C2GLTNIV;`L#$_.#6QS/\V-O3)Y%)Z)HD3>^
M$TPPJ.<=#]@X\@,,@8'?G>_,TX$PCF@)C7$C<U"=L3/W7\SB42A"DS`PR8\#
M"[8E0`L&AI?`T&S&<`&WUI0S=Y(;.)03\I.!D4=F$%#(V'?$RW=&GA@5*D-Q
M2P@.DK'TG<JPE]!"[%-X6\"<_T\:O^AO%<75O^S^0F9?_>0#<]W"1^L1ZK+7
MR,'<D$M"V5L=MG03!8#N.&`)UNC3DX@GO";LZ%/8TZ?0C(O#<T7A%G2>@.F&
M\2CD$^X$'*?\RN?L!YZ'0$7NJ9!$(]IP\:%TL*&,,=3WZB<1&N?#N3S3@8C_
MA&.#O]C6IT]OX25089F`*#<V,07`^Z\?TS/>P$&^=W[D/"I_23_^]ET?&5(X
MY@P.>=X,\$3ZE?=S#I?Y2L"))].O_Y,Y;G0W`U4KYXWD1_,E(NVO,?"61^M=
M$-\2F6<V@GXU7VI9A50`2"O;&A-&<VJ,]WNX\S&<T'_P@*?1;SEDHO<`L8L/
M*93A"#/G?Y!C/Y[3&"?/O3[`53!5`?X6")1^(.Z*&#A5B`/BF?13'9XQU0<@
MPJ!_V,!,+"M=0_!U<<PPNJ-#G4J`S_HZ9-T6X\(N@CBK#VMG^(O%**="!'\Z
MX9TU=?T'<9,Q9WRG`$'Y+`+^0%LY%^P7*8&J),H<!]A5`8/!3ZP'!B_0D9\(
M69J&<YV'4`U-V0^"8N%K'!^P\"_'BQW@%I=(NVV@7?9CS`#E"!>1\<,=!^@>
M'`RUU4&KY'PWA]&'H-.E@=K),5YA`)[``>#!ZS"(/!.KO?V;?R^F%Z]?I$Y8
M,H1$3^9E#;MX>2AB7(L9:S%('UUXW,<(7@SN=OF,XP^N2F71`=Z`L.OX%JA8
MHGUPH%-Z(.GULQ,``FGI2"[F^0,*!V('VH:]0`$/94$X!"@4EC)4N-@60OGA
M]Q23!WD2;T)77H0V[+,X;H^4^B.C2D:/!)#Q,AQ>23H!\>7`1FCP./*)//9T
M7,[X*WJ5SS#`'L\:YBW=>BIP/V]8DR\YXS%(PK#H0"=76?$<7@O\^/9.Q'K+
M$XRY2Q02/G=!'#_C,/.+(1PZ.'@@)#_2J\``,8LTLJ1X#HB<$2]PK.C!/W]D
M3@`*E7<.LX$P'U*\^XR'(9*XY\,\(1O'@<`([@AE!(0ABT)C,<"(`.H`X7<I
M+0"(?R0332BV?L1`KTCXF`S7-WF9P;T-I@JO3GB(^\*]&',A-(=%'0+9=.!X
MH2-=W/`P);N,Q!0SGR+G(X>[@CO`:GJ:-#J=7ZQWYMA&PA&LK)C,C%.:)#YO
M.PTM74`WGL]=>M1QWS@NY@3?W#$6)>^%3?Y:E?RU_K;RUVZ8"S(TP_0TVA:+
M]@7D`V0438I:(?)(4;S.X71GQ!K\.`1N&+[**)6'EE_S$DV&@RWEF:ASA.2J
MZ/@G.;(^0AL>*7%&\P_0JOC(/RHY:07*HJ<80V<>;39@CC%P61+$3[@3@#3O
M[S]=T-RFFK:"-=*$/2=U8DN.CJ>\+5V:&V^EW6_'4>)E%4_/7LG4&@'0MR"-
M>A/D>'[PVOK?X_%T.AZ7WLP7F,I5;$I;O`M*UJV2_%Y6V*'DG0+IX,4*+P\R
M;Y.W0KQ^<=7=9/:*:ZC/NOO#7:U[8[($%3UBR]DJ`5-\_M\X$]`B1A&J/_X#
M27GGUAB(UP=5L.+A7'W;EF7W;4!%588V-OJL>SFLRHORH5S%U7@R6.OT>KO"
MVF[Y=AZO7C@EW=9`;=#O?I03DUJ\5./5]3>`!K$F?@P7QCH,KN*@)M]K#RHO
M=A/Z.S'T]7I7>T#??IW_!]6FD]F_8`(QW%!!@"9'::QK%&NE6`^K:M:6U2AQ
MC6Y]A-O2Z-:-;@TO_8J5B(Y7L3Y_DFIUKUM&G">@5G_%J%^.);VP!C!;K"MS
MNCIAYV([&N%:>L.Q(Z^[)77Z8#R[T:M+%<-*AZ-1J[/71K_*\:BG6EU)V3V,
M)JO@^!I@1(J,Y\/0/E&`,:-LKP?L4>O,C6K6:,Q'N"V-QMQHS/#2)RR5C,';
M%I_-`XPJQC"](],@GZ;>?'E1)@`=@]Z<HL3/CA=/'<RPPMA@+6'D+''E'=A@
MPPM=865L88WY#KB67JF[]@A427H0`^ECX/$DE_K3*1^SNA)/9U#F"#PNXH&W
M:D4\%3E.L=1AY+V4D=&IVIPZO<9BMX'%KM/?.?8.Q&?KRH@NKLJ"4XZ,J=J#
MX5&RU24.D$^8'.6,Q_$L=BD#:L+F`1OS98T83HT]G/5*(TB;N,*"N$*[77K(
MF\C"S;;@@#;\2BZNQ@6R$)"^C\#,I^$"24]Y/1X'F"FK7/;;\7-LM>!2XQ4I
M)OWZFYD;KT@MMZ7QBC1>$8/]WS-O0ET/'X_1+5)&PZ?K%NF49JO4S2V"G]_X
M7DZSN8-:(LH\:D=F4]FNQV:WS*F0ZZ.7`P31IV8PZ5YN1^U_DL;H+9E,:F!>
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M;"H7+:U<=%6-P@L1\*0B#,KK/6V$M7TS[1)-+8=_VR";50EO/'*]K]^O9`PL
M0^935)O+"T%M"WVKQ1ML3^.I4M5H%\I7*K/RO<ZLK*)EVM74S$3+M%[O2G%N
M5,H34X"(XA*`,&)!_]$HF=M5,E-H?J+:YNKY8'76O"HFC)V,QKF[=>]5X]3.
MUR;%[-C7<FA%K,DPD]M:T0:WV?H;[%5?_RXYK()'!!9?+?/>'Y#]G%)BV9;7
M4A]6VB26"0-FKZ*!OS'[WBY-Q]N/V7<;4NKS9V6FMOS*74_,\MMK5RIVT5A^
MO0J)>L=J^75W8_I\9UQ"*H.,&F925\J[@#%K!@/>A1;S)G!IY40,D?46.ZZ^
MZ(HFE_CEBTOZ;%L!"^>BH;7[6-Q)=5,\N:I+>AIA(_6C.>F$W^<\*K_=0L`;
MJ.`S'E$2QK4W>4N=+&^9-^8LKZ7DZITA)80YANFGU29RN*TVD9_X&,G=MMZB
M[9X47>R[3JZ-V=SU*9'&NKZ%0R#[GL(OQNZ6@%'*'7Y.[63JCP/WE]PA9*LD
MS\H-,5!.0.7&&!X(U)JA[G>C/3-V]"5S/O79C7SKW@FX'X>6/R?NCM3K2@P[
M"5$K9A^'U+UX#KJ)HG7XF@?`H`)DXKYLA`Q<$0ZZ[O;+TJ/=.7""J*]P"I0'
M'MUI>-@D%@,XV`$85A/%HL$OSGGGAW,.+#=O<&25#O=4CIL5CN]@+!<0Z2,C
M(JW*F8FX@4DL[K$SYU4>`J8,L7TV>J4OO8#QV0A[+=-<PDMY-GX%*ML=9Z+6
M(.(GC,=CU.1F'.:-?(^%HM^[SKX.F%#O1&?G(NQ@8^=@(IK'8R-BNE9QR@G,
MY?HD]BY<EPW-I]C%-X4WS2\:=E$.ST?/NF'S*..W`ZK&/O?I9N^IX^L(45#T
M)4_(5:%='&]\^P\/;M`@Q+;M,.IG#F?GUO%:UM=4OW,G2M[-M)B?8Y=NG%?/
M@DW1Y_/`_\%G<*[<1^M%_T(V4V>!A1#E!NGK5O8@E.+R+M,38<-U[HF#>F><
MT25C]6FLJU)4*>XT!YEQ&680'_`\/6&VFQ_)?`)X]$7G:HC+S87,Y/^TAHD:
M\<5`XX@$>-L"MLA%IW@U.@\M:O8`+'4:NRXPLF@Q,,/.OI+9C5Y7"_T\3/$U
MQPKO_"`Z1URCY4LP9@!.1^,>_$#4[8!JWI8K@#;LK1P>.*<?V"B(G>#1NB#J
M;6=.Z@\VCDE*,!D:2W"=86G_<A"NFY;U?V+?MCZWWK5`6;AS>$!`O@7!8&J]
MIS%1<?A"[E;A>OT*_(M/BAC*[R;+L;"6,<<S@_**@W**%X-H-')`>`CAW`6/
MD@]<"95Z`EIDP$B`@I_@A%.V$9Y.$MH"QPN=L92O1IBOK8L""*FFWQ;\$\07
MT#^%<!2*!3MH!&#!F,/4\T`ZCV$8(<S@1GQGD?S%]^B["?`!A.\6^QGEL\^I
ME(12$]JP]0*.>T:A8WPV8Q,NN$H,]X`840FBP%EF#FHS`4`*\A:^A)BS0&MS
M;`3&$8P.W@;,<1C?!X:;B4:+[G@0/9Z'_(<T:Y"4:4UA2T$\=6.F`M@45B)T
M]@!PP.8N-9]#8\>$B2L$?HM#,32SWJ"5ZOQF?.>C4#KS)\Q-;@`C)BX,XYF8
MX#4)CI1#!J<$*69B/7+F4B1=^Z6=_'SO@US)77F!=-O]%A86"'CXW9JBF8;3
M+01(">2&]%J#JY<$K^,EP[A\2K]VVG1WAHV0F0O/^^E46*T2CM)3\8OO`F((
M**+`BWAN82KK#F]3'RYXH<J$"0L0=H-\9M&R0"8#O<9C=&(%M=S118J#DYJ4
MS)B1-#P@OW.B8XK`C-V(J&M1+%/\[PS_$*B^[';;O[Q-WDID:/5SYY=76<$-
M1UI\(X&/3N:((9P\<H4PXIBP@=HE>-DP+9T0BH"G.5PP%3+GXMN:&^&W:89U
MAZ=D!'HOGPF9DK0KR4S.>B"K75U=O<*=D&>:Z3U5/*MH18(3(WC<I\):G`*[
M3(Y',\(^@09(!TD00;5IFK-7^>S]"[`;L$?K&ZC?C\2(01SUD?<1L<%,:,$+
M3:I7!-T9_A*N>&<7'4HYER#ZST#T`HQB7:E8M"@[EF+4/!&P_'`6OV="FWM(
M"Z6.7M^X]]2;L&D<[<]X3-:71D#?F$RX^,E]3($(.TBW/T:4ZYO8FL>@A"%\
MPX&48.Z<@(7)$5O<[[$_`P8C.<<J(@ZR)!JV5-CA<(,S9:%*)*A*<DFN)*)(
M8L8<=!,(T6=1/$ES0M2GTTI9IS5$"Y6+U"O$$R<CG.!PPNM#8LHO4D1[<`+$
M.RP&*-I">>N'MF7E(MA_D-AMF-FJS.Q",;.W+>O]/=#C&Z!_0/JCQ[(<K92+
M?>`>G#,.M+M,F%C@6\:,VV9>QM#5.=B2EQ>`K\;+NE=[Y669;2UC:/WN(,/0
M_#BHQKSPA1-A7@WKVB,\SY^5NY?2N#=45_08D>UP[+ACC&E36O#2'0](1!/Z
M<+B0U;7+Q:Z13U<"3EYVV$6[3MEAY(9?K^KD`*M.JMB80"3GM%N7*C3F?8H-
ME?CAY7#EHU7)'>E=%0V5E]HD`HVZK5[;.H<;H-4ORYY6,ZP+ZXI%Q@IVI:3"
M6-D^9,Q'J[1L7G,#JB&]_7+;D&R&WI6J&98@.#'`U07#G6&_9CA>BX2_Y=LP
M:X/EUE7O)3`/^'=8,W1O2M+*&"QOYMI@7-JFZX7LS=@S:!)3QB,,&ZP+FJLS
MZ,*AU@V4W:>L5P\97SEXOX!<'"Q$$S;.W4)XKDDMS@E/R$9\Y<2XI36.=4I-
M'-$>"*V$AOO[3^*0_E1K)67-`M1+&@<DD</_#7=)@LGW%&&3_)U;QR"',:[,
MA+>?$K>;:7=9$5D52+C*JUVO=2N16-D9MGKJEEM2G.-@-?POBVOX]U90*`]3
MPG_E;E\K[$I>2LT!3\0^4D1WW'DP%\UY+3D;-.^`GO-6UB!Z6YTTRW%?M6OO
M,>?M'D%C@TI=/F1]^?3^7K8N2JK./[%N!X,R>6`O?0Y/5*G.Z,]S%@B7TR?F
MA.PPVG,M%>5WH@I9M]T>EN8I>+YW/D;GMDL*HZ\1ZB)"2946!:1LRTW*`*$C
M?![XDUB$&*#JAW9;Z]J#_P?PF)VD?9@!SSR4XU(T';K!C6#M[J50YBF`0:5M
MJ-2#`O#)\7P>^3(`D@:WR9ML3?AT"H]ZD>7Z8QE"N13$NFUCW>"19(4[0L99
MF1"^6,A3YH2W4YN'>2&W'O^+,GM@8U36'89E7/23M/%NI[]"WGBS(RE>^-:A
ME,E#<L+CP1IPF'_%'D/^>)%F,,[XSYA8TXL+$8T#Q*EKD%@QY1XLL,VQQ#WQ
MGW083)*0=0M<#H-_9!P1AHX+9DC!$<QUF1$_+/Y.1:H`:PXIZ"@92$96B*P(
M,V5,Y4L(LRA%'LU!>B'&^?R9Q<)QX#\49J4DP<L+^00XJ(`:Q[QL#3HOC6&L
M;S+O5<4+J<@H2BH&UC'F<U@`I8FID2E0YT7'[B.N[YD1<HV)MOQ']*C"BXQY
MS!Q&(['/96$(-Q;LNN!+5+\"$\_P'@N82LH;P3U"L>5B8%N&55E3CNB=.5C"
M$Z95H5+_<CQQ0;4[W4*<+>X!80MNO!1QX-V4Y99M63B#F![=?L:,=/\MC$(;
M:F3MZ0V?`H7*X"=)7C(S06XYH(U9O_FPL)Z.U^MT?K&P*`45J<`NHE*LPC`=
M6,3UA`'966]=6-X8&8R6`XZ&)2<%/:K5Y4B5]/CHC?T9^]WYT13PV$(!CZMM
M%?`0VV+!OK"F&,?V*DH$@LEX/K`80G#D_%BH#;2B#(A.N9(03(^AC!Z&K,E#
M6UK@(X4X<TN$NA,F$H01C:WR_HRPZPVVT[;.QJ+`,&5>82V01Z44?&`@'\$=
M\=8/YC[)##B/3D;LOT0ZP+VV1@QFI9^9J/DQ:`U>$B0Z+?X&BWFDAT+D42:Z
M*Z"D[RD$%8FU-VQ=]%Z^LE=P\Y8TKCLBFLOM3##8DEM7W2K"O-=N#8E=[:I=
MP<J6OB/J/;^-(OBGB)<JO4S7Q,MN#>)&Z?\".>>MXI`KL.$1\]B41]:Y8I\E
MZ#F8\[M;[/P^Z]H7G;+&UTL!*"OB6LL5#P9E-+S&>O?JKMN`0NE.SEGZRENS
M?;?I6;]?1GRK4]PAUW"5Y_2ONH0].]?IJ=]\4%F='R2(3*7T1TEN]4+P^79G
M.R2I="YK02N5&<YGYK@@7)+8@#4>9JHJAH]1L/5"\NE4TJ]74$DN@U%L9,+(
MH2A4&G_\_7Q$YDM4-D%-+2J1?T#<]BXJ];:H-9UT2B6:>H<?T5/_)3)_E5&C
M7M@=G`ZA;/4F/83$\O;.\6XI7"&=H_Q09P*Z*K,E-`2T1S[S#<08"F$@,Z;O
MB3;>(1NCTY#G)G8=$-F5VD0W9+/K,.0%2US"C)*"%KHE?,F*3RU$MFNW>[L/
MDSU=_%T,R_J=U"3(>(7DV:9]S5)FMZWPX09YQQA[?5Q>:Q%))HKSL1GZ<8-'
M'9D[9J&HH'F+-3L#*O#I/W]F8<U3/@66@F61_4`'(DT8O$85I9P?6(.(16%>
M.)41>+!:RF_C"ZZ9+[C8`WF2[M#&37RB;N(JN'XGF5L"+'"YY`_![E[7;V,7
M-FYM\?L8R?J@J]]'[GYQA,,-E?.C,I*B:0&67>;CTLHVM?3E][IE#/CT8A>Z
MI:TQ#Q&[L(81]XTS$88W,XA]K(TI92:4`]JPSKKMZOZXNH4J]*^VL(3#IZ>+
MZ`46F3F/:-$=.T'P>`X,[<$))D_(@G36:=O][I9L<$^J*_>E?=$O"\G8"&^'
M8*Z4K&_!,&&8IW37C!\!W5X-JKO'ZL96+^VKTJ(81\99/V%_S*?MTUA*F(U3
MHQR!RXY$3=P:&_H"#6L[BB.K,=S&=-_X/9Z4WZ.6+H[B5JEF/VZ',AS+U(R<
M_K;=H=&]Q[EWN*@T@#T^IE-@"M8TQCK"EHJ]EEF:NDU9=`<\ZA9+J/0Z+>L/
MK%G^E[B*?=6)<1$J[%?H/&)'%)?/.!64%ZF;<Q\;@F.7&?_!8T%XQ^=2VPYE
M380;V6ZF=]E5=0(^HHD,,^J_L7OFQ8B4"6M2/`N=93G24G&Y@`RY7+:N%+6(
M^A.XN>.RX!+8VE0ME\*\3YK-0P(+J/9`#JTF4W_TZ,X*=3?,@,*EG)%N6IES
MO]F`)L^Y%;V%L%$@GV`JZ\,=H_K(G'KLS3!=U.7?<<8(%F9Y?B3<AR$2OG04
M8A-X6*(B03V9D<0L/8?4ZP;'&"D@V42@#COTX=(4[.K4E`S&45&:,TKM%GU+
M<?9;YLE""OAZ_H$U=D&4O0AQOT`&'V.')1]]HKF.TQ$3K^N8Z9;U.0^)5$QD
M?`>/N51V!_M/.V[1<EPN=HHC"<,>_X^L6YX'NN@CBV]ADVLJ?1%&F)!["V_C
M(F;.=]EN-91$0?T.K3<4UNU[&LH,7P+&,X/IC>7<I7NMTJXSC_A;#-B@=(((
M._OR,,*NF=BCX5[GG&>VL90N5/4.ZLRD(D*IDLI\[O*Q'L0193=RCVQ^C>J&
M\>7"HPN59=LT!X!`V,2)[``<R#L$:T7U+Z\*FZ'_0;>1*ORBVP+2(+*4BAJ*
MAX*'"*HNW)^D>$A9!1`J%?)_G9];'WP_\K#`BKH1S\_I-Y=[WU]/Y8^?X`_K
M!WT5/<X!L4R6K/E)?AOXB.Z[*)J__OGGAX>'UH]1X+;\X/;G;KO=^QE__AD?
M_(G&_GEA</HZ?/1>OU>UBSX"6GF`GSZ1_+%"P1(X7%P\\<?-NY_@T(R!+[KA
MWW\Z[_WTC_;??BX9?POSM\OG[W0[0`/+@5";]ROP"/SRBW?CN.S+]&N`LD_T
M^!7;L^D!MH*7:E,60`DTICH))V]N#M[Y!6%MQ?D`MNTC<,G&'AJ!2\#K5<7?
MSWAT^6O\+_SY_P-02P,$%`````@`XUX*09Y1'ZN1"0``-7P``!0`'`!S>6XM
M,C`Q,C`S,S%?8V%L+GAM;%54"0`#VBXE4-HN)5!U>`L``00E#@``!#D!``#=
M75M3X[@2?MY3=?Z#-_NZ(01F9H%BSE8FP)Q4P80*S.R^30F[0W3&D;*2#<G\
M^B,I=B"Q+<N.X\@\`4FWU/U]NK1:%\[_G$]]YPD8QY1\;'4/#EL.$)=ZF#Q^
M;'V]OVJ?M/[\S[__=?YKN_WWI]&U<T'=<`HD<&Z$S!B#YSSC8.)<_FQ_P_`,
MS/FV+,L111V\/SAQQ*]_@4>`>VCQN],+'T,>.(<GOSM'A]TCY_#T[-WAV?LC
MY_;&:;=W7-'[LW?=+2LZ/O@@*[J?A&R]GM.XGI.SXP_"IY=Z?$Q^/"`.CD":
M\(^M21#,SCJ=Y^?G@_D#\P\H>^P<'1X>=V+!UE+R;,[QFO3S<2S;[?Q]<WWG
M3F"*VICP`!'W14L6DZ;7/3T][:AOA2C'9USI7U,7!8K[7+N<3`GY5SL6:\N/
MVMVC]G'W8,Z]EL#@EW-&?1C!V%'UGP6+&7QL<3R=^=)N]=F$P5A\MB!MB>/A
M\5+[M[L`!2#I&8ZO,!&.8N3?4HZES7T?<:XH:SFR@J^CP9H;R`-*T&R"V!0=
MN'3:D4(=PQ([RFX7^6[H*X2NA95K]L,\`.+)RI>?RM*KJU]6_\NY3]VU.GU)
M%V7KH$55*D[&B#\H8D+>?D1H)@CJ=CO@!SS^1.+;;1]V(WY^BS[^WN,<`MX/
M&1.VQ17XZ`%\5>WW=+E.[7;V$9]HS%-?1U:]8J_'U@U$S(T+$;\FJ%MOWY%$
MAX?3J2JMC06%L?Z8T:D.HKA>FF*H0YD'3`R\8MP-N;"!SF3YR&\YSX`?)X'X
M:@\8]UR7AB3@(W`!/Z$''[Y`8-`T=&I-X$3O=\35D5U<#8,),-/.FR+<!%[2
M?(S8.+:+C:61P_$%YC/*D?^9T7`V(*X?RI!*?.I2$F`2@C><`5,`F0ZYI0IM
M`KO;8!:U@G<VMH)<1H5E>V9&3\DFRCFS5)T(WS(JVD*PN/41"7K$N_PGQ#,9
M58D!6X.[5LU:-O3.FDU+=9+SA0;`A9W7%)'UN?0+)6[N<&>D;BU99LZ;S5YF
MI"463>*#[Q<PDXL*:<FKV5.+OY&:=;B;.6LV3]392:XQ>L"^6/:!0=R6(ERO
MM7%D?(L6LC6;KP4V%/;8?+(!SUH&;#IKWS0H+&4B+BK4EK)UFD).ELOVS82O
MK*QX3;!MR8W@>FOXJIQF*V\19NQ:PI0!17:/DZ]'=!$G)(<1H]BT8$%V<U<4
M%?O&U[N`NC\FU!=V<;DJ"A8:[E*$ZUZTPA@$EIZRY!OR0]"8FR:]Q_:4#75R
MN9KBIGUC0I].IY0849$0;00/20?MZ\`]S\-+&VX1]@:DCV8X0/XKTW6#<;YR
M(X@R`<&^2&8$`<($O$O$B`C$N)@[PJD$&KP+&&,7Z^91`^5&4&<"@M6Y!S'I
M%YI$<U7M"'FT;FEB6..)JFD^IDD:3@>=C5,0E9WH$(LX.H6>'P`CHO0G*'F.
M(UE.':<WDK76OL]TAWS@(W@"L?K5;WQL2M:_)W:-72!\981VB%F7W/,>9@;(
MR4%DPS\[CW9$YET)-S\S1+2[E$G99E"1XJ.E9S>6"2OR>#F?J<:C.[J1D*TW
M9O@,1!C@RR2!-\4$\X"I42\R1V-YGN8>9]-,`C:;5*[W]JUO1\!!X#$1-E^(
M#N%3M66<3Y=>KPEDY7ANWRIX&4I<4\[EF-5?YK.%HZN$-O\$8\I@*7>/YL`O
MYZ(%"D\P06PQ$+BI3)W0%)`*^QX'1,0EP'4QP2YKW6,SJ0',1'"].2]9OHC8
M`T0IG3>_'[;MZXA;]2>[.<^B;J>MQ;YY4UA*X\:Z="E_SLS6:23C&@CLFSS%
M@/OBJ8ZC-;D]\I)J</%.9V/?6;<Z=6^>"_>'8S%*](*`X8<PD%N/]W0$,\K4
M_"`4M!G(ZNIH5AO8"LU]I_KD;9<KGS[S`?$P`S<HF>I+EE-'JB]9:^VI`GD1
M15AQR^@3%KY\6GSEX`W(*JSJN6(YFG>LI$`A]2=#=A][[35W59S`W4T)^Z76
M_FGA3364&N:-VO<]Q%`-GY#`I4^G,C!5/NFV/](5&L]T%A!57XY+O6*@MA0'
MG(MVU>,Y1.CE&\M##@Q5WT[+H^&*LF@;Z@K2EJM:\;="P@8($0?O=\J!JGDX
M5E:(^B_GKA]R_`3]"2($_#[U!0MT.?3V'AFHN#*#H')E-9J]DO!%U'ZHL7N)
MJ(N'OO1(-*ZT@#17I=%$Z<&(^/ACIWS\A9C<T]7LF*9)-1KUA,L1T"<[!5IV
MOD<8D"N$F3H_.AQ'AL1GD-+"<5/-1A-B!$U$TJE=H?,%S!BX."]@7A-K+%?I
M3J_6R'8QH_R3+TV)D?6"A@_!./3C&QH:IK1JC6=.#TK,I&7ICI[WOY`',D81
M5O>F<D7],Z_#9>LTGD,-'#&!EN47_@N^%U`!3\C$4'X'KOPI/+RCOA?]M1@!
M\O%/\#XC3&2J106M\D:BNH%^+V:(>YC.1-#*%H/I3$P4$@!=1]YAI8UO0KLD
M)&Z#EKTD%+LQ),N+K^J&R'`<OP6B.V^7H]GXUI`+34RI)O'2KB!"7KW#\M*>
M,O:@==*-I4,+04Q!97F7JGN5/+,U'"=??#/J6)G*C26S"$`QMYK$2\'N5=DV
M$P/$X0*6/P>D$+U&ZHTGV`RDF&)-+L<2BM7L'CT]D/ONFI'Z&Z0X#:288DT6
MR1**U9-:+ZTS_W$4XR+>(-598,5T:_)15<1$28/2'^?*VOPP56\L<\5`6NV_
MU\U:B4<YC2DM4_8;X[L4O'%CL"S=E1U11`_+E(JY8MW&$E\`GIA8R])@J99O
MO`]4E-M-];=);P*DF.'=GLA)VE+V!37CL;QT!8TEOFJ@XZ917;)JIR>.!^0)
M^+8GCM,*J?DM+K10^=][VG/_"3&#&\1^@#H&^9)>UFV[&>GO]X9!0?H2>V]F
M$.4?.:[]&I]PV@7PU/%7F<:ZB38.1'0MSQ*!JX[`RB<\)!AY&S-E2FLV\67@
ML^]B6*+]9KZC7J2?9Q?2;,X+@)5_NGCO/?YE-Z@0V05*:3;;1>"R[_VR#`"B
M_Z>U76B25LA6+_&_QEH>G93_K6TX?O6XWQ5EZN=0X7HY!^;B[).-I8NSK\%J
M^'H=;)<'L,H+LJ6Y79W>W)[71%%OFM,D<%7&&`:'O;<ZQE^JJ,;R60ZX2@.)
M<AUT=4KHU0@BIK^J.JUI\8TEOCJ`[0LS1N#2)V`+F="1M[[[E.>\EY<FWTAJ
M<R#(OU15^PI`.0H,4V\S.:=A3*.T1]KR74D\V%(@FVGYVU25.9^Z'#*,(!KO
M?&H7-WQ#/.41D//5?X$6?_P?4$L#!!0````(`.->"D'IDW[6AA(``/(:`0`4
M`!P`<WEN+3(P,3(P,S,Q7V1E9BYX;6Q55`D``]HN)5#:+B50=7@+``$$)0X`
M``0Y`0``[5U9<^,V$G[.5NU_T#JOD65)]F3LFMF4QL>L:CV6RW:.-Q9,0A(V
M%*D`I(_\^@5(4:)$$`1)4`"G]))X;`#LKQM'=Z.[\>F7MX7;>8&8(-_[?-0_
M/CGJ0,_V'>3-/A_]^G33_7CTR[__^8]/_^IV__CR<-NY\NUP`;V@\XVVF2+H
M=%Y1,.]<_]W]#<%7B#N_Q6-UZ%#'9\<?._3'WZ'C0>*`]Y\ZHW`6DJ!S\O&G
MSN"D/^B<G%^<GER<#3KWWSK=;L,?.KLX[=?\T/#X`_O0TSS$V]\Y3[[S\6+X
M@6+:?,=%WI_/@,`.Y;1'/A_-@V!YT>N]OKX>OSUC]]C'L][@Y&382QH>Q2TO
MW@C::OTZ3-KV>W]\NWVTYW`!NL@C`?#L32\V#*]?__S\O!?]E38EZ()$_6]]
M&P21[`OIZN2V8/_J)LVZ[%?=_J`[[!^_$6=-%VWC!.O/I`<XZ\5_/*+L^N$3
MP#;V7?@`IYW5C[\^C+/]D!?T'+3HK=KT@.O23S$B+H+W)?Q\1-!BZ<+D=W,,
MI[D8$P(8Z6>,Z!_9:+TZY-"?H<>F3=>!4Q"Z@4+BLF.K(M5?`.0U0VD\=#U"
MHS&Z"[AXAE@EE5OCUB)Q3JG!=O@,NVOH"@GEC5Z+7,\/1DK7S6K`F*B$HJ+1
MR;O799OGR3#>,GY,MN21YUQ[`0K>Q][4QXMHHSKJ[*)C5`$'^AY8S@%M=6S[
MBUX$3SA.31H?`Q!`-OAD>H,\N@,CX-[[!+&Q+UU`2'26E*%6<L2:='\!+CLN
MR!S"8`DP_=P<!L@&;AE2\P=1Q]4Q54,6<.0&$'M48B^P(B^SXZBC\1*0^8WK
MOY*QYR`,[:`BC=EQ:M)XZ7O$=Y%#O^"LOT/HA^;`FT'ZF<?`M_^<^ZY#E9OK
MOT*Z-LJ07F7X_2.ZKSJ]:W\KQDI/9^1%R_>6`MN"#-\"Z#EL?XA_RSY;=T-C
MW_SAD^O;6U]RF8+G8^Y^'NWE4T">HPT])-T9`$NZL??[/>@&)/D-$T2_>])?
M:70_KGYMK5E#X<$Q_9$D7W'!,W2C;UOYC:V3F$]Z:'X"SYLY)Z(W:FCU$UHW
M0AWA;:KIH9J,MSI?2VFM4^PO)%B6?-(O(+?C8SH[/Q_1'B&AE/A+1C-;!_&9
M?6'[7D"GX;4;=:,K#L[8#YN_NSZ!SN>C`(>PLJ`(M(]G_DO/@2B6$?UA5S3T
M5U8\FQ_@#)$``R^X`PN></*:6H-FQ,/5.*L)2D!Z(JI^1E;[8?LEI1P#EYX]
M\.V_\%W(]YVVUK!%C,_2GG!^H(GS-\B%^))BF/E8S/>MEM9IB[B^2WG"\^'>
M>9Z<GD]TV!QFIYM89ZW@\@[)"7M/]\[>$:7"893<N&"6P]^M-M:'5C!XE^:$
MPV?:)O`]Q,BG&J!S11$4S.2MMM;/K>!X'NT)YS_P.?^IMZUQ-Z2$2]KI!W7\
MH(Z;IHY7%]2($!B0T3-37.U`(*CMABU0S',)5Z^65V<_<Q`)F,[^K%D5S[*/
MS^85J;GK0</4MFT_]`+R`&V(7MAZO8/!98AQO/QR)[J@FV8%7586!1!,6@"3
M8`YQC*M8--G&FG5Y68%P"5=OI-8]!B;3*T26/@'N5^R'R[%GNR&+&*"_9<<8
M\D+H3)801WY)B954>5#-%H3T.JL#4+V]7%?\LA)-,.@U.LH):4.S>D.Z.M_O
ML4\G1O!^[X+8^?]7B)9,KZ'[M4`,HF[6QU9(I0"">EN\NI#N_``22N*M#[SM
M(_7.]^S"-2/3W3IOA=`DH128\Y+"R]P4TE]85W#)+')&1.I,%<I!IIO5/S%:
M`+(8$L[_;,"RB>DK/$RL?D,V?R/'"*,V8?)'`YA\B\`S<BG/HG69O;Z6,.QE
MA[#Z[;'YRV`R2@U?&6[WX)UMK/+&ZG8'JZ_79U"*_6(3-@O,+`\#ILI]"JZ4
MQ/A]K+Y>YX(:H>5C,\GKD*)0L<U;<V2KK]>AH6`2*."`25MRJ<7-F_EZ71EJ
M!9H"99+[(D7A1A\NI_ID^UE]O?X-M9+CXS/)%[)SXE/,V>-$RN`N-Y#5U^LP
M*9:1E((D@=(@Q2E%H]SRM/IZ/21J%R-#8Y*'JY+=*&#"0*\W18&PQ.#4.+A4
MN9#A%-(U'N/\#;BA*-R"T]H:Z'7`%+`ZSWW,Q6'0%G?I+Q:^)R64W:;60+>G
MI8)$>"!,,OE&CH/BC]\#Y(R]2[!$`7!39(M4BL+.UD!WQ'0%F<G!,LD:>X`!
MY09TK@'VJ"%)J,X3+D*7)?1<4;;;2'1B%7>V!KHCL"M(40Z62?8:+TFMA)YA
M#71'<%>0$A^&2098D=I4XP[!&GQ/7I!<B`77;WN*8\Y/XCV$+A]"E[^?T.5M
M&^`>X`F.,#J1_GD/\2-=&/+&4-X`+0IUE@9DDF*^371$(1F%P=S'Z._-WE<H
MOMV.+<A@E`9BD@;.(W9,2%A:5'&G%J0\2H$P2;WF$3H)`U9/BMV^E913JF<+
M,B?ED9BD>J<L[@KGF$3O%J1DED-CDOL\17&)XTO0JP7IG'(H3'*49R@M/+5R
M>FB.L*XEG34"DR)%,U3*'5:B;IH#JFO):!M&0;3I_G.CLW6W#FZ%@UOA^W$K
M/,`7Z(50)B=ZMVF+7`4<TDUR"MPB&WH$DA690M?S5LL6F?U9RDVR\U=4W5"(
M7UE-*]$6FVG;(JN>1[M)QOPC<-=31)P5N-.R1<9ZEG*3C/-5A+(WNWY;1@M6
MXF3([=,B0UR$P23S^ROT**$NBX!T%I2EC$BFEZ[(%DBIH*=F,US(?[[(B@$9
M%"'U``FD+)E3:J_HVG?]*/^W6&K"?IJ-\PHR*X)CDEJ6@5=F"]1LDU<0#0^"
M23I:;(K?^H0P]>4R3JFAY*YS:L@7./4QC-L]@3=(KM\H9@H!>0"_1P<`"Q*G
M/2DK*7VS,;7-,"2BLZW!K^K.PRYS/#;,!I-<IY1*/UD*,9S5@I#0A`K[ZDX`
M+R-S*3!J7*O<\@>_`\QL%,'NRVFE.W%;CFG;#,^!H>8LY+(VK@$_]FX`PM%E
MTV2Z(B")_.(%P$GVU)V0754$DM!,.A._4GZP37GB,:MR,MTJ-+.N,B,R"J0&
MT)VM746BY1&:9(:/O1=Z-#+*8KQ2F@J_B^ZDW#K"$V$RR2J/:M1D@8H,!GX/
MW7FX=80E@-0*_:Z*7J<[H;:.O(2@3+HR+S8^:AEPNM-MU=IAZ71;$XHV;5/,
M+89![F`PF5*C<10$&#V'`;M<??(?X-+'D4,B>H)!6L8UOJ$[F;?Z5*@).IDQ
MYP;,&$KT!IMH4TZWTY_86\*PWB5\8^D9P/XDLRZ)/_P""+*9OQ:Y80`="2^(
MY`CZ,W_E158"TEJ8)OBPB\\+BF@'3%$$;N4Q=:<-EQ%BU>-7`-V@VZ@R9T?=
M"5)I=-VYR:JG2F4FF'0A5L"4ZB>"_AQG92=!.L^Y7\]%R'>*0S2;LQGX0B?1
M#-Z%#-EDNHJKW0VIO0HQ_6_\`M$6H=%+M'Q_NK(/Z,Z#EI&J>L1KX=>+I^(*
M?^VN'"^6`.$(&U]'%K5NF[]"B%P<O+;_@/'L(\B'@/%#P/CW$S#.WM:A4_P>
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MR;<J=]3D4DHL46ICD-!ED.BLRW,`BKKH3C[0M5:S7%`3]JDR@EWS&W%[DPP'
MN)J@3ATQ[WH=4_L3FB0S3(KXO()+#&U49".DF^G.8=BO:;"+W*3@SP@@H5^G
MF_>5'SX'T]!-GH,1"%/437<ZPWZ%6\0)DX)%-YRAQ(X6S.7U=]&RS>VC^WFY
M_8I9R`:3PCO_`UTGH!P,0DS/BD=HL_]3B(^^ZZS^]?X`@<NJZB7).Y$"SF[?
MHQR#)WH$/<'%DBK@^'US(2S:#IK[J.[TFOW.LF;Y:%0<["9Q+'[7,1+L)G],
M,-D*>NK.\=GOC)%@AJ*(V>9"9G1G^>Q/NQ<P0%%46S.)KXE"0YD#T4M!#$EQ
M9]TI0;J6J(@?B@+;E-U@8P@(O(+Q_U/(5^\Z2=PCR@^B.R]HO_.A'%_6\\*,
MO.E=TDOM##+==6<:E92.K(CY0,T*6MG%S?3)U2O-(T*@T`*0Z:X[(ZDAT?*!
MFA1`DJ7YS@]@:BX6OT8N.X3N)*2&9)P/MLD+R0P95S!2\=FK8=&LRUV69;KK
M3@:J);*R0!N\0N1L^M%G)]/8-`/N5^R'2]HLMM>Y`6K2LJPPMNX\H`8$79$+
M9M6BR=,55L^Q5U*H5GUU)PDUK$VE4)I4KX9+,*:34.ZM>IGNUD"OEZLYP7*`
MJKGME-RT4]]N9N>N^@%KH-=-UL#V78<5)MVBRL<7"Y:]_"#60*__3&4X=3G4
M)E73SZ$\+JJF*%=+,)@U;$\QG6KH3`J)IYK&RC\XLO\*$8;?`/X31NDCFVLZ
M4<"$3']KJ-?W55%,.8$1LH@-<H)1Y#:$3I0_Q)SUWU8WL=2.9$&IT(YRB-B[
M54GAQ((@F;*C64/-]765SH!J^$WRG&4F\59]4PI$I@JL_"#6T,BL344;@!"V
M49O]SL3=*6LK*W;Y4:RAD5F8:I9]`>YVJG1*5#EK:&1:9#6QEX-MD@<NA_(;
MY`'/5J3("P:SAN87\JF'KD&G>WJS85DHE`RX+BZTRB^*_C^)/GG]!K&-\I-%
MJ@YG#347EJXFEZR/I@X#FLMTE:%JG>Y27\*[0UE#S66H]RE='OB]Y<;62KJL
M,I0U--*55EZT5<$W>']=.-O6H<NI'86JAZI6LN3PUJE>1]K^5G<)AIBDE;.(
MO!>(W]D5`:OY=NF3@B=D.>VM4R-]:^6D7(BPG6JU$G7:.C72=59-P.5@FW3W
M'9$=E>_<O>X32#F_DW7:GD>XQ2A,6IJ,T@)Q6*?M>7<[H=>D=?`8+I=QD4G@
M)E5+Q][4QXM8!ROV)$B.8)VVI[IS"4@F9;@G[V+=`R0JPYUN9IUJ=NJ4X#1?
M5KMH#+JF2SV#6BB2K9;6J5XWC0JI9`"9=%^6@&)OT=(?-\Y?S^'H+BRVQ_5)
MB&4>?ZT[M'6JUXE3]D"KB[7!IV.I'1F5*9E,1?=@.2VM4_/?`Q.0KJ:>`Y>M
MU*IS`2%HBFP0I_%>46WR!;#:]^OJ+T_^R'%0_$FV`XR]5?!=C@3J#6J=F1]D
MI`9E00V'/96Z9_6S?!<Y@#U2DF`GDVE<%HB,8S_.W'<IK83-R^#]4`'_4`'_
M.ZJ`OP84SVY6I-/WV"(8O2&I><;KUU1=^SGMB>WP&7;I;Z%'4F'@`K&N154@
MTAPD!BGB.Q1>19NZ0$C<]HU5JD]$TG6VZ!)()H_C?$'EH?G^!&1=P2D(W:!Q
M0:T^LR=)K6$9)+'4=<VW+>6(9Q+MMM5<S#]W0>18.1SR#9)$CK)8*!5A/\V%
M\$M*J`B*2:Z'!QA0+-!)7I`KE!._@^:B]24%E(NAP6O]Q_"9V!A%XVU2XG/9
M7=1%<_%Y289+H##IRIQC)HI4Y]W&FBO-ES.`.,2;M"]EGC@426*WK>:2\*4$
MP:'=I*#^K2)/.0<;_Q&/5+0,>8!TCA$4P$>(7Y`-X_M>%H\QBZ4C5`SV0H'N
MVO-E)LT>66+<]AP'ZZ4?/(T*?I=_?*?T8+IKX)?>WTNC,RG8(@=!O%^JDK9H
M--W5\Q6(NPA>@P\;B";@YFD:B4="1+UU%\27O6<I`:?!HAW"25)9)IGNN@O9
MUQ0*%T^#M\*BN:$PM+_ZV+HKUJM89*7`-GA7+9QS#4F[Y."Z2\<K6;ZET*IY
MAZ#TXB[[6E;!`+H+N*M8IEE$BHKOEU^,=:3#&T%WM78ERRH+25&5_#W8ARG#
M-TG9$85`EAY+=W5V9=9A'CBC2NV+#1XULA8,IKOTNCK;,`^=487U1?/U#KY&
M?Q%'N4CTUUU"7=4"W@)D5!U\X4RL(<>=`7073%>V.+<0K26Y9V=->H?89+T*
M]]6Z0^JNAJY"E97!N!;IOIT]:F4J-Z;N>NE*%&`9D&NI-N`LDKGX28A:!W!O
MHKQS)5M[7-U%TF6EJP3H6L(FO$ZY]=Z.X.S<:J>[P'G)XDG;A*_9W[JD@WO`
MWK^8PP#9E-A#!L(A`^&0@7#(0&AO@/LA`\%P`1TR$&K;3ZP<%"L45&03)>TT
M)Q.4-G-2=!?$?W+TJD\]-O`S()#^X_]02P,$%`````@`XUX*02G9DN'&*P``
M084"`!0`'`!S>6XM,C`Q,C`S,S%?;&%B+GAM;%54"0`#VBXE4-HN)5!U>`L`
M`00E#@``!#D!``#=76UOW#B2_GP'W'_@Y0[8!&@G=C)OR<WLP;&3.>,\:</Q
MS"XP6`QDB6US1RWU2&K'/;_^^*)WBA0I421]'Q:;<;/(*JKJ(5E5+'[_WX_;
M&#S`+$=I\L.SDY?'SP!,PC1"R=T/SWZ^^7CTW;/__NN__>OW_WYT]/?WUY?@
M/`WW6Y@4X"?<9H-@!+Z@XAY\^//H%P2_P`S\POH"N*N77[_\#N!__@U&"<RC
MX+`"I_N[?5Z`X^]6X/7QR6MP_/;=5\?OOGX-KGX"1T<+#_3UNZ].9@[TYN4W
M9*";^WW6'>=M-<YW[]Y\@V5JQHE1\OMMD$.`9SK)?WAV7Q2[=Z]>??GRY>7C
M;1:_3+.[5Z^/C]^\JAH^8RW?/>:HT_K+FZKMR:N__W3Y.;R'V^`()7D1)&%#
M1;H9HCMY^_;M*_HK;IJC=SFEOTS#H*#??I0O(&Q!_NNH:G9$_G1T\OKHS<G+
MQSQZAN?@7[[/TAA>PPV@X[\K#COXP[,<;7<QX9O^[3Z#FV$FXBQ[1>A?)?`N
M*&!$!OCN"(_!!OB/\L_/`&GT\_5%W0OM89^_VN='=T&P8YW$P2V,JZZ>O5J$
MN[=$_)-OVMQ=DF%Y%OMS^;;3%R.RQN,5S%`:?4BF,=NCMLSUYR+(BAE\M^BM
M<7Z3%D$\B><6I35N/\%I\UO3V9M7#-APVKPVE$:Y+7A.M2>S,XL4Q2[Q^!W.
MX&,!DXA`(?LKH90`.\-#LB"0/G&G:=CI+B9K0YIU)<T/R1%9Z8[?E/"+__!;
MM8:>)A@`"E0<+I)-FFWIRG)ZFQ=9$!95-Y1UVOEORJ2O2@8):8?%#.;I/@NA
MEL1LXKO<!+?JW)"5%A.2'1),CG[^_.RO]1XB2"+`"$&+$OQ:T?[C>S:\27GP
M[NTVK17^_XU843DX'<JJ7+PPIUG7,H(LK#C"_QR1IFSQ*DSQ-FU7''7T;Y.E
M6TUCJ#A)->?AE8:5MW=0FR"_I=)4^RAL_B>O8%S4.RL"""='QR?5CJS\\V]X
M42T@X>LFN&T0LP4`@H96S%W(9%];Z@;@5]K$@0V;Y-6&+LL5H-+<D:_O0$_Q
MB@HO\#]S%5UM&KO1US:S$CT@S0!MYX/BFF#:B09SJB'48EXO=#4YA^'+N_3A
M50014V+\C[[NXC_]QK#^&MXA`O%)\2G8#J&LL*D5O94PVE>`<BENV@'2T+[6
M+L"R#9T=4XE*8T?U85E]/<,VD@7Q!3ZI//XO/$@5MM_6LL;RK`J^?]D0T)8`
M-W6IM":YMJNW`M7@%5>D%\MJ[D<4P^P,P_Q=FLGUMMO2LM;VV11\?=H,5.U<
M*JPAANWJZJ`R\)HZK`E+Z6EU$+S!W0H4M-/$FF;V&!.>R,GO;E1Q'H>V=&_H
M`[>5;O#K+J5MIWBDB(SV,0[N!.K6;6--W_JL]3]G_3L@#=QHW%P>;>G<X&=N
M*]WP-UX:X^J`TSE&UQ&PZ[:UCGI]5H7@PAH"W!*0IFZ1T!S7MM%Q4#6&8')8
M+QQXGM:;CR@)DA`%\56:HY'`B1:Y&^^47""QZV>]`34AJ"B=!E",B99JB^;$
MTZ6@BD+?EXH>VK.NTSR'1:Y@1[V&5BV&8Y+;!M`&7IB`(J]N%7GXJ_=55O#)
M[2GG69#?2U22_FQ5$4N&^I^4_-F=QMEE:L?E$DUA#`0%*.XAN(5W*$E0<D>0
MGW6]&,]-UM8<CO$V7L:K32MNFT??=CNV87$Y"<-TGQ3Y-0PA>B"QRD^P.-MG
M&5[X9(N+C,SN4B,7@`/SLCEHVJ\`IEB!DL;A0C11DJQN#Q*X!/]%*Z?/VG=8
M`9H0Z'C95;`.;A%6,0U[!K[&&)BQC<&X60\TMFK,@\SV58<V`JR5!V:KSK,K
MTYS#H4UK$ZMJW\8D>FK[)+;>G*-\E^9!_&.6[G<721COR4T3_%<L=H&2/8S6
M>/-!\]84%M;IG3HXX4T47G`:7&]`FQ#4E`.'+[NG0[-RXMUHU)8SE<AI_Y`Y
M1Z&'#Z2SM-FV/:N:J$.K&U,P#Q;%,4;IWJYB$X@\+)9VKD9XM6^H2K;GSIRN
M,H)KQ>$*3R9-XOYCCW;$GXJWPQ+KDI)9-;81`?IJ4C5?`4K`\O`K$GJV<6>.
M$T6A,L!&!H?'2^,?0WB^M.EP6T"J][6#[GT0DTNT+MUS"\B'1Y4*9Q.'52"N
M#\M*^&8/I3^E!<PQ&Y=ID'1=%I_P'(SNA93(K:*VHD!]U:-D*T"IJ-Z5,3^L
M:IR'JNG(':)/%/,R3>Z."IAM08([:+D.W1J2CA;V#4I+!:??!H4[$OLE`[6<
M#U(;42*S=PMT7``N%Z8DH?;0]KHYM0`3PJ14F,#)L>,)\*]T355?A+,@RPX$
M41^">`^)&R38LB``N:Z1;R`FC$"1@N(>91'8X0T4@CG8I!G((>Z6Y$OO]AD>
M%_^UN`_P!B&#`#[N8%@PPEL":<4^2XA7!4_0;A<C^LN7((MRW..!79'=8`@$
M:0+!`089:7D+#RF>5Q(O++TQF,WP$!+,1QL08]@D$XZ;!'&>`D1=&)B+X.XN
MH]?L05@)QV1:X:]#)*0Q4[97`?D]A`6(<.L5^2FIYZK\D@23L:18;MPD/E`G
M48R%C?!X0QWA.<0R;W'C#`4QF1T,MSF**F_2RY:=5D,,SA@F_I/-&.D`?_JH
M/T7/\6^$@X3<P(TE<_3BI<.;QHH8W;EEK`K0MOU0HPXH%YXGC>P8NYXFH=O&
M!]>2-G/V?4ER)Y(#([A$P2W"F(;HWNYSD8:_WZ<QAK:<')B*@T("G'(75@U)
M0S!N\]Z0TJ6H30P8M1<9=0N)^)=21K?VHJN8?8O2UDK[N4!7P8&<H-2S@'H$
M3O)_.*:%&2=E2Q^B)-J\[UA+UTD^TR?;J[2>8447)?0(M-RJ?69[&+401,E$
M!32VK53(^H#ND+:@U=@/6]66(&X:.[18(Q/OB]W*#6#`=$>TW\F.UG#.T-R>
M7>U_#675M/>,+(6(]@EHIRM0=RM(+O(`6Y:=$U_3C0P9A&2#_402C[06=-<K
MN=)*XM?2K<1R-\OGTOW*;9IK1Z:M;JU>&&#C^=7S,`W0N3++01&D%MH*$WCF
M/U*3)<6+^PT):K<HWWEC`6*5DAB#1)^<.81.DXC?4"NEB6AVY-*!-"[DF*^#
M.BX'SU(^)(Z8$U?HBW+HRE%4T1$7CZI^.EFAU-8C9ZN/?*WQ8E$1[J/\VO5-
M8]/1(J>PI#DI13,A;NA+I%`K<#84"SPMB@S=[@NZ*-VD>'WR9HLW6;8J".AX
M>Z<?]_,JTG>%^Z+95I2K7T@ZEL0@AEI;OHDQQ"Z?/5ZV8E'C%:`-5^`BS_%*
M[O+RA1[W.>/^/X]?'A^?D"PXEB_W7^#D>'5\3/\'\GMLRSD(]L5]FI'DK15)
M)X,`45E9CN"^(*]H$7^7NTL;\[^;)_<T3`CBV=4,$R+Y=1M#"&K\)0PQHEFL
MEI1NMVFB!,%<4[M5E'A&N=Q>VL06\A:MU[`,<"U!7"GDOOYN=?+ZV]4W7WW5
M!E[\U]?';_$OW[0QF/WT9O75Z^/5R7=O.P1O5F_>?+?Z]OC;A4%;M3[5XA/W
MYF3UYMNO\*^OV_.`__KZ[>O5UZ^/?9LXI=5NGI5XL<[-%<&K%6ZN,#ZM;:*E
M@JLB)EHG+#J-HXC6R`SBJP!%%\E9L$-8L5N<R1S%X\1VG<,JPG`>TIH($"IP
MD8"2;@7:&N?0"3Q3K!VF.D()"!F=6]`R\HV0X!MYAFD+R^H3Y*GC".?-5P<1
M>[!X#8L`)3#Z$&1$F?+3,-QO]S%YH?4<;E"(9"Y)!6*KL*@D3%\-*R)048'G
M+3I0$KYPAXJ3I&J+$+%6KC:@'O.O`>=+ZI9G:+ZLJ#Z!N3KZ]<%<`_I<QI6T
MXDFNXTB*,19!`,FGJ)$P1JIV<<P.+OO'M@8<*S'O`9;.X]-M[%`]9NCA35RU
M?)1A4J]NWLHS5T0W;KW(:%&5A\L?T;AD:P<K+0OET\UAA10:N15-+FY4PN)G
M4E:$K?'WL$!A$$NR9=3HK)4W4A%!L!H`2@0Z5$Z39)Z</"KU@@P+Y*[*C+*Q
MM,O,J%N*JR0@S-4ZHV]>131R<`6SSR1PIYP7).S`8:J01*C13`=,"]898-0L
M-D0>!02T`U^RB28)6$9MZW`M>(X2$*5Q'.!=#=YPLXCM@"/.73;'F';*$SQ&
M5=.5T5$N\M,Z,JYL;!RA0R,;$&+4N!@-:(A\,2@M84I#XA(<?+(<D8K)+4:H
M7VXMA87F-:VD)')N(37SJM;A5^*JLA!=JT`"(5Q;1%>55*RAIT=N+6'=Y#MI
MFD.;TKE-=,50-8RU#UER<\3IFLBRN6N3TYP-?2'/8FX+R>A3L$T1+U0P;P@L
MG"1(3SB>JE"[2J/6.+=U,W0\/97.$NU)G$<U=%&2E.G12;3%E<8Q5$;ERI@4
MSFQ=(_+H]#E)##_/G0H*);$,#TZ<'#>CQTT1A5M+$)[1AJS`_?U(;?[5#IAV
MXI5F)M^+ZHHCZC]JN\[.QQPG:H=C*9E;"Y8?2(8UR8M#\31)/#T.F_XLGIV$
MS8OGTR%8!11&(<WM\?<B"=,MI*>%K5I!.A&%5303L]U7*=82U$V]*$VR$/LV
M=7]$<?IJ/Z8U-G,-0YCD,+^&#S"17HCOM[2<2=AGDT\<9"U`V<1EEJ`BKR!C
M+03/O-K-E!M4`SXQ;E@';%[JHB-_Q!+\F`6)]-4FOJWE*UL\J_S5$MH&D$:`
MM7)Y&VN<8?I#I;BN;[@(5(&_T"+2`XOW5X*X-AOY<]S]EG9OKG!L"C36\?/:
MXWRR'.6RB;/B@O/YM'I/8EA)N4L2`@VU9TWKZC7$#X\[NB`I[-3%-%8M3,9Z
M7S?JMJ!J[,5^?9H(9VE>OJ5:D3FN*#BJ1'V]']<@>Q;P(TPP,S&IFQMM48((
M(P5Z@"5K$CL8H[1J#>-B<!L01L%*/G=H*KUR9QCSI`DZ-*Y6K&5EL&G?BB;2
MMW)5^[!YYLDAEOT>LW2.5]TXW1&GP;BER^DLGX7D(O"[3-:>*E6+PKV-SY(D
M:BC<E:PP^R6\"*0I60A_+%0Q#X>;6IW-K.--K-+FU:,=J_`@)MNONC+9I;AW
MNME6WF0["P-=IGE.?$9G[.$RS%+]<EG^'F[2#+)V-\$CS#\\XFU"FD4H";+#
M10&W]/4*3(DG"?-W=Y$4$"O(>"AIF5$=A*.6FCY!3.@Y&>\%<Z0V0S:/#N:`
M#0K*]G38%>@,#.C([-689FQ0#>XZ0F9K1LDX8".<2%<PZ/DDV`\W+@I0PR'+
M9=')'L)C1M)JH6$<E\N-@B-QG-8JVJJ(TE?N-DT%B,]+LA=>^!BG2+4N[F'&
MB>/8RZBL:7V#4U>SR55(_A9D)!XF.6\,M;)6881GK__%RQ8.3QAZ?,+%O!<J
M!4'&^;RYAR#8DH?9R!O&L`HZ(/8.6P0PP(,OI2S1/B/H@6T.L`2XER;%>LO$
M2N`=N;FQ\.S;*F0BL+=VV1*1L4VV\;-[/!5X5?X8H(Q>@%EORC&J*D=#]<14
M*:UA@9H87`8EI2+EP`E=>7EKO0&51M2T;H!CEE`H`1LB%+O`A<VU,LQX0:%4
M8&::5`1Z,,YD,,CQXAU!]J\7/,P0P<E_A;C/`_FIGH`(__[`0D$HP6LDY30'
M&=RE&;F[%^3UW)":9<5]4(``GP@C3%ZDX!:25]MW^)M%=#I1<8^'(F\\'6"0
M@><8^\BX29IM@Q@T^Z?P$,9P!=`&Q"D6/'OA"`BM:Y,MV-2`L#:4ZN"7Q<!M
M@!)RBEHG)(UBO;G*B"85AZN8P/X?>T2]T++XK5H'=L.XJD)QL4-,6+ENU@D@
MU`2?*WI`.P!U#PY#NU,EI'Z$E$%63L0C&ZL%Y5$+\IKX7FGYO5+Q]UK@B1TU
M/#0D:%P)JOCUK(:WM8"$BW+KH8A-W_L#S`LR.#OT*CG.!226O=Y"QGF7==6T
M]%:LO/`Q:_#/?B(;-MS2M2]4KC"\(W-$6RQ&?(G#BO?SR.*^`@J[T5\AV\,>
MN0%OH\-0L";S(A6W%/J=Q"UX7KHZC#[MHK?RFIIGJT%JN3URH>H18_0@G#$E
MC.%)^$(W;.%AK$*<IS$8J1#<`[.#-`L+X47(13O4XF7NR:P4$M\R0>8D=%A[
M+$?I\>-)LGZ"!;"?;F$LZT0@$3DV^YLE8NHS^)7P,3UOPSG(G:,\9'S!J&$+
M?Y/UYB9X;%OY37I-G?DD/1`32)_",3>&0\B<-S4*R-H>H*7M]'HG\<3B459>
M`ZW9&2)2=V=I(YDE7Z#9KSEPAXL&@$0.GR90Q.*I$!8-^[*38*>=W=-?C\5Q
M7?0+BU3X7V@WI'HX=<>AVKE3@;]+P_SI>;*FSZ#50^^0L7,'W4%+MX=(U9.R
M51'>]T&.0G+_"L5[_"44DF]5>["*8NIB]76G?E&XKBB]`I2:7;=C]%XDY$Z7
MD<?P6EAPU)<6/4#'";N:.MHW,5T%]<FSA'GNL3M6\7UZGY[YH<2B3W5/K:B:
M\\;LN&Z\R:D8=LOY6$M^MN[KNU7&%-]/;\M<")C6N[<>EEFPH.1;>0(@86J*
M!//Q!`!CELW,<2GX`R(C^YKI6W:OMNI3M^C>[LMEP8ZK!5^Q43K[3^-=YRSA
M);8HFI+FR<+`=4"([N[)&06K7G`'/^VWMS!;;\H:W?WRW.?T8L85O9/1805/
M^P`:&![`WB5$DY/"W4PK.P=E[X!U3S8'5?%W[N4SP,8`;)`!G7=T"=+*/`7E
M/"5LGM(-",L'#;B7#-HWA^@%'@$Z,,HETH>D&.C]G)6WK82HNMR\*=UE77+J
MZ#58;M:JZ<K`/D%%]0P.G9CV%-;7RO;D(AF>J#"(PWW,DM9NZ[F,RIW^AZO/
M`_?%K-U(-0[YG<NLYO'>8L7FJCH_9CC([S_&Z1>5,K-2,KNUG.4"])6^>52!
MK#Z8`%`*+YS/DT5)E46Q6F=90;6XHLLJ>F4UMDS8N,K2!Q3!Z/WA9XQV%TE=
MO>LTQ&9+[]FJ5%31[\QVE%I?V*&C"]7%JAOP_@">DY[PB>9%JW1;TYL7MF=$
M^)814M?8D+2N"[5,UNB!*.M4=;9GP*?1/_?L&E1.<E7()*$8=@+$-ZDY$U]D
M.*L@L-"$]2VE-0Q);ZD'`KSK`__\%`'%P406*<CJB4S*?`WR5_+OD,QAM5EO
M[I<$O@#3DI;:AZY%S=3BWKWTC\$(GS7(38[!HV1[1S9,8'>_+F*:V]Z2AD>T
M)6@W=;@_5V:=O/1W=$M9#Y=E7>U]%KTYO^7FW(ORUW)UYTX2<EV?[#ZFWY8]
M27N:C]B=O+TUYZZ,Y4'5+5\/!J>Y8\N;QGWELLH!W.[B]`#ATE:HXLO3D>.&
M5F!*Z)I=7G(N/6YA2.K6Y;1&'?%?UI6,Z%NW>&%GP>:(/.A`$HCQ/.`-0#4/
M.9F4]EPX=,J-&E+;QS9N128,^F.:E6__?82BZ(ZPN0MS[C,LM6;<&%1O,N+F
MSJU9C?G2F(F^QR7SFT68U[3A,>Y+OFO+9(MJFK2EJ()<SJM++O95'(#)H!$+
ML&38@B=#">UTO:$#X*X_/(;Q/D</D-1H2V!\1B+TMRE+?CF]RR`4%$&;WI<U
M$)HJ*I=01OHAOGBF5P2CZKY`V1GH]`;J[MP@F"G).4."M=QA*7?8D3M84&X5
M\',ON#?5>-U/A3NHG05R;1R>AW"&]GMG>+>\CXE+!Z\`HMK@4A)'^SZ.\=&]
M7T-!MG^.JHA/$J)E(&$CQ&89(?3W@:-2D.-<M^XL*<66H9`<S\J#6]8[P=V1
M$J[L](9/@IT#W"XX4#0<F`\_SG-"NQ)OPP1&9<^9>@YW&0S1F`NUT\RJX[3'
M()=VWOK9G8O4+9-*SE`-%KUP>PXI9M_9.:B5]FR'ADER/#8VY/-T?UML]O%I
MZ:F2V)*4S*IMC0C0UY&Z.5U7*P)04;@SO\ER;&B^']EKPK!`I.A`[6G$B@71
M`RE$X.YR^BRY%+Z/37M6,9:^?2M9BHNL"LS/Z984`/ES;.$4TSC*;^!9YV+K
MK9]]2"30XYAL,_&JL$7[+7$[HKH@L,,B$S9D<9.T(#`$<>:!R`KL6?'_P#@J
MTFU0[#-4'#[#D/P_@OGG-([*_SI<PR!&?\*H*J1.#^DDC9F6Q;S!)_4;?#3!
MA_3L<+'=X2,._2@2&%AP4*LXLNCD]4V!#'9TDQ[]5`X'FO%6@(Q8_>&P`M6@
MH/6(P0K40Y?U3,G@H!X=M(9W!W16I[1ZL*)Z[B"_Q[9X5,!LVT(7=T#Y%.;"
M)M`NCU5]I+8`5)-=F/7+%4VO@N)GLM;6')=B=KE;R%7+%B(9KXNE[JQ49[S%
M;EQ:TY+/WZCX*,TP[TW(9:EO8<L].F*S;<_HF,&Z>\:K.G->USX!R59/@=CI
M\UV#PB@^W571@NM%O"/S7NU2%ZQZ\PD615Q?):L]/[O@X-;M8UTPER];B6UK
M[%4KB6%9+;]$W[(\+]^T;"7+GP4[5`2QPOT9C4YL%U-2%VZ@9E+YWN=Y_=[G
M1=*ZN5)VX<6UE5F2LK<H\]X-DQQ;84YO@[?>)75\VT1?6P?J&^FJJDMCU%JY
ME<@=&Z#26B`P/:]6[XFBG?H4GUE2!K>PH+XJ:QF-TW69."?.R%/W27%*P5EO
M1>;)7:_%0P*IKL+4'5H2`T;M$Q8HR<:$"$LA`N-"S`4#@T(XWB0(34=A>R"V
M&Y=H\"DM8`NA2@:U$$'0A6-4$`JFB`R4OK5#6%4HX1,\*`M)&GJZ53`G@UMP
MD%O2.$",F-'T6RG<2.=PE^:HR$^3B**2<!>@16[O[HFZ0$);KVB)I5?4](S*
MEB%7&X&9XG4D2:DDYG<#.E=&IHM"J]/=W64455@%"^I=:`<DLNKQH:J,'TK`
M-DW@(0=WZ`$F)%DZKR/C]"9%@<_H\8JD6V^#[(Z432T9>@E.XSPE#_3&^XC$
MU5M#$G\&G4S.JY&D!?OI"\*Z%,$-2EB%#<)>$3RF2;H]N+JD8D6/K%T[T42Q
MSDT370@SB+6LY_7F'.5XR"#^,4OWNXND#!0/UL56!N(I?3M$Z6E3H>K380:Y
MWH"J>T#[!_4`@DKUOH"\F=DIIR'=D!(`C;3IDJ_Y35L)S,A+E@E4:T14:\3(
M*A&,39/#BS1&,40.@W,`Q`=O]A4+Y$UR95>TGOBQ&U%TG=A7YL.TICS88J%.
M%PPR:SZD;.2#(/Z#>'%[2-EVU-W9?<-Q#`091J?+)K"HBP5]<O=PP`NDC@B$
M%K2(/0.%<=$J&>)%99@.#88D<`X!`JM10@&1R1@\-;6Z7^;H-'D`A^>G&9.B
MB""M$9[P2<K@/+4GY`F<J0Q*/O%@%2M-F#<>,0]4Q=VQ<B[(RL^6LQ'6QS+_
MDMVE1B>>EO4?"KGIE_-_"C7\99*6PMF23?7Y>.N2^?DJ@6BC.L'ZG./+!;U<
M9^@9$5EG/N"-7%A-W*D[\ZWJOQ'A^\^(#$GKYS,B"AJM:+@JZFRQP`VKN)7?
MI*?A'WN4P9^"['=8$#=8<S-48K-J]'9+WBB*Q-56*>G(NQPE)6A(04/KL`K.
M5-$P/_?DN".Z`^TPJ=*F3%:KX>A8%E<61\NLK-;#"B&,Z,O7Y(I65;?A-(G.
MRA)+^"BXWEPT7T$&'A-ZLUT]:X*X`T6;:"]LS2/]K$!=\(+DH31]$=_4Q3)6
MJ5UORZ3DQ#S\M-+I"CU0RFJR-CM<\#';^"A1'*[PERLPK_4=;9U57]R)VZ5?
M)IS*^E_1KP#M847-]<."]0^F;@2T!"U7SIP5GV*$5+)%*CO,W`XL+IG33<&H
M]8WN#,9-S]WV8+V9A"X:O3C=#LC%&]\&D-7>6X0Q(RM=^&G!@K($TY+%8Y0\
MC@X$<[FA43#!L8V,BOWYZ'(TXFKTU<5HQK7X%/R)WDHZ)\!A44X_O:?SO:;^
M8,]'E`1):"C<(>O,!RR2"ZNIP75G3R3<H2=\/]PQ)*V?X0X%C58T7!5UGIQ>
MU]ZID`<W\$AXMW*6;K=I4KV^0_]_3=\>^?`(LQ#EPM=P)G=G+75NAL#RXTC5
M&3F2L.Y:[Y:Q?[$N0=VGFZ2X)6:`[N51-0-X+Q^R&6#OUFQZ+]C0$]J7("//
MV`"XX&RH9,H9G`Z2%T??947)!F-6<\()H@@1XB#&O[."7B2YB;["2N:C2&DS
MS"EQ:'/354W14'U-6REB<X&BG1`V&R46A;N_,<4T`75<5U[!W("@,R"N[&U1
M="M@-A_;=,0>QS4;,&8(U)^>X*;P6T%R@]C-S8SGL"T"/%W(%J*=H?<89[V9
M.ZDK1^\WSGPSM/6NH^?OY1H26P.U?'](U[DB>%/4_4GIAIN'-*>_KSL+#9?;
M?=>/9+1V_Z=)9&I'KMJ]/[MT]0F9N'-O'O_IN"C(`=W&AM[$SM;`'-6;/1$^
M^+JWG2Z[H?TNK/5GU,$3*2TMWFR,-;%(:[.L"T3VXC/7,$RQ41[(M;P,AL59
MFDL34(?;6XVRB%CN:WS5CMU>)BT!;>HN1*+*.8V"[`(4D:)U$6,]W6P@M:;0
MM`QZV69+RF`SC"-5_'ZD1J[U/D93C411?8V>FHF:/H50J:JDEN2;D[^QN'1^
M!H'G!W\=X`SEC.[8^G?Y);@B(;**(U+F!Y<IUAIP!8'=(826#,1FALISH(3N
M^%WAP+(RV+3V<7/H6[>"+=BSYL_[W8Z]?!;$A#&27W.1;-)LRQP^XXE7JCU8
MM7-UL3AO:8L2U"E'H$7L14:5(0%)]9DXS?<9N^1!G0#4!8":OASG5&EJ:-_:
M=-739I7"`N)Y+Z[P04AB7YUFEJL.=ACD:X.QGP'YW64!02F7S5F3N/51V=A=
MK4`CS-HM"\BK*5_^;T!'K=;[3+?P)GB$^:@Q=5O:KN+98W.@W!YN`6@3YV8U
MQFQ760O2TF$)3A/,6JZV.:2S`X4U!Q5V^IOPC^RQBO5&=GE0U-+>6_"#;'+O
MP)>MB!O7X2V_"0PO?'=/Z>%W-8[K%]ZK]G[%;B3ZW'DK7:+,DVWI&H9QD.=H
M@T(ZT>O-.9Z.!_SO!UB5-3S<I*=U%(V8\$52OOLJ,+N9G5JST-G"#\1D.AW2
MV$S=95US]D`K"C2!2=(MJ597=NS&^I>?#`P851`UKF>B2-LA6K*\'5&GR%(S
MH0(K/DX%6_1]@"LSD-%&-D-X86^W7KX/@%>0JS1&H=KU/@F1U3V\E'G!XQ5D
MK:Q:+^L\DN;$/PT1%(\GBPIA\QPP;@W](X&"*5B,.I.R3'A759=EED:7^<9V
MH\A#S'+1!MJ(;#Z:9N#7&_A8@/=8F-]=7J/5X#_5X-]J=%2H,%P45*PM]O3[
M_3Y'"<SS<YB'&:J2L]X'.<I)(0^85[LA,L%T?B7Z/Z$SJ_8Q2=B^_E6=@%8O
M-`>0]L.*]#0]>6)9-B1/M22W:9/3E;QOLS,TW&+,$]TE=+N<%/Q:JF+'BAW8
MC7BJ"L7%`QM",+A1\L)`'8EG-="II99<G%-/)^U9V^#C'>1!W<Y;'RIG0-V>
MK-J?OIC<8\J#CR6QMY6[+RSY<03S1V*;5CI1G?OF.E67K=IMBQ'Y6SSY>9U'
MHK)^SN[:MF7/G8@!Q6\K]VKTR33<I.G9DR7YJ<V+990P8CP#L&'&<NRN_STN
MFIPLQ55_G-[Z6J\BTM!Z5ZIJHZF@(?5F6;<NG.T57%DAA]9M=6UTD\?[/HC)
M+<//]Q`6#;]J)UN=;IQE]"H(*,UZ+>D![:"U@'ASV/5`5E<IOJK**\OS5=9<
M%ZL@O?R[@TE.%^EK&).;E?32X.?[((.W00ZCJBR]UO(XJ6-'Z^;$29"L.:R8
M0=TE*/MDUWI7@'9[])[T"^JG*?Q:;LW/2:HR)[?J<^)FE9YC,.+E>Y:U>(@;
M[]L,*Q["9_7L)W((I\$T='BQ45AT6B:AAS=["D.&,QE`1JQF7AF\ZF6>LDB(
M;)\P3F.WL)V$]>'"9?7+A!6%TV7;EAQ6BXB-J1-7+6Q4E\RJMVPY4R!RJ^#2
MDYI(,YRN+D])%.4ZBCJRW)0UK?`BV%R0;97BWE52EFG(+HNZJAG,J`4[S<<@
M#-VG<02SG-S.*`Z?T@*J7#V7$]KU3XT),6@P)0%@%("0>'$JG27-7Y3%L>ID
M4M(RSJVDIF*NC44O_JK>AP<FI!8Y%%J3=V%34U+^99J8[DU.(]RIKZ@V(RZW
M.?QCC_<)'QX4?;5"$LN1%"'C?"2A:@I86S\6IZ4$L!OSD*L/']\8T1UWFJ\6
M6!31.-5]>1B-TQT_%I`%97!I`0HAOC$=LKD-"PH:;5QO^$5*Z>BB0F]Y^Z4F
M$K\I*>F((WUPA^+%HC%;NG2"='9W6QHJR>^T=/31@9TQ3HC+/4WH^O>(9%<-
MY71N[$H@@E#C5I6&-218V3"1#V:TI#!.K$:F8$)KD6J7/2OIL7&>;@/$>4-;
M0@^WMVH5(I:'ZL^TM0;\RIHZM($%6+>I\5)EZ6NZ7%,L5AUN'DSX"6YO82;1
M;KZMW1K#`ZQRY<C:[Z[\RIHY5@OA#'/U:X73:[&&R'`UDU'5D-/9K20R(@)7
MQ*);\NBH*7GDB0(I?1.NF(72!['YYDF!`0Y&'X(L0<E=/JI1`@++KYX(F.9+
M*;&&H&KIB>K(9YU_<4,ZY=-S#_:W]:WU:QA"]!#<QE"H`:,D]O(.Y(P/.87J
M^@1->XDNS.9>*4QO1@J?BA.J:%0G-*^B3A8/WR21+5_OB[P($G+/3';@YMK:
M/60/L,II#&VS`JU6#@_2"@R7]Q@68))9!C[&9H5!1L%SE("<MG^Q&-,?DM%W
MJ(RQ;-41(3(VSOD@M#2;^^]_[O."Y;:*2@LV:;#M1-G6*W?Y-2F!FZ,"?H;9
M`PHA>Q6#/*AUEZ"AE:*SV[3#@>4S@:UIY4\7]<CR^JK=?/@V"ZO.LZ$89VL^
M0,E(]9A.BQ6'%02=S36E+S/GPU:_KH]O5DV:/PC:M6?+&5OL?>5SNC=E3/T2
MQ'LX+)$TKJ'=F?T<+EUAI2^6LVY*Z%@!VI,,A,AK4>L->>A\`Q&I(.CP,3\C
MLW$A?:=\NXO3`X0>`<ET?1],_YJF[,[-F^W23-FWM#<?#'Q$7!T+KXYI3]K$
M->=#W\8].KA,-P!%@U?2_GE7C@0H<XGW$$D./\+!5W-UJ.U>0E(21]THV:H+
M2G)`Z!U>2YHDG-3"XE*PS3*"*5]2FB09^S98+"8/8M^/<X.2M[8#@-G?QS27
MB<H<4IE=7U]2-S[N'I.&Y9D&"(9*DQ&")W<-$4,":6`$(_<7)%3$4T:)A5V=
M,Q!#1<Q/>Q)1H)C!/MH$T'!^Z5'#(A5@0VR.BVPL\-[UPV,8[W/T`,_N@R2!
M\5D:8QY35KSO]"Z#4/(XFYF^72..]E1H;UEPYZ#N'93=@T[_H![`*[B:/3?R
M,T4])V$Y)V%G3H(%YV3N=FC.I*ANEK3TQC\DG(8QJKLK?8!99N^U$(CJ=NX:
M1?4G0W]7]W1Q=/[LF`%2WW>,<V9(?3_YQ'%U(NXH[S_=(RL%^+,T(3M^_,>)
MGJ]>!ZX1<E@H[<UDTX-_IULU$:50%C;B>>H(&Y5OHB^L*[E_L",Q2M4]F\`B
ME]F8S<&/P1Y<`XA`+/U]E,\0HBBD#H;XOND9%7:RI\QW2)$9JO)V90:H6,BM
M:>4%?7B$68AR&$U-K1GLRX?`NU34*8DU[1P^4'?F78!=2VXI9*6EK%`LJP?A
M]'&5ULJ>D>JS<_LM`_YF#%C6F0\6+!=V\!+#0%8,."6%'.^8J^']8:AJ-3C]
M$F38TNL$W6J<G.3W,F:\LW.]V=$S]*>20V/`ZE6,P+G94VCZ!+_07^35/53H
M?3!N3J0)2S(F9PW\2W,;%4]DD"N00+I/1E6#D)1.]](*A]529[GE==*YK3%`
MF&%L_0Y\L#9>J"F)IQ[;V[B`F@;W1);`J=8G4M)%O.;MU?4TB:K2VK*MZ^PN
M73O&5`77]K5WSZ'D1>"ZI+S#0^D",Z&T927R5\7F90=5YQ[Z"1/`OK>>PY[\
MPBCD,^2?WTT+*52=^\HPL8R[WRSP*?;I&OF41=</$CPY[)L\%S/`S_?0PH39
MZ`4;QB:@A9+A/LN(AZ>L>.(?[.D!A7(`8GG@4[F77`U[B8);%*/B<`W#.,AS
MM$%"\)O?KS4`-#$%D^L---!7=PW:?;O!P26FI&P/XEK.K$4`BI1!8UU^&-+2
MC(Z@;XD)N$C"#))GE3"P!XU"[(A"X#^%I4)$>+>()Z,&1+7Y*J?+J_)0QK"E
MC9?F@&4R9I*P<!JCB+R(6)?*S=<;DM%V!_,+5K*A4V+Z*B#KUSTL4!C$(\\9
M&NO>&H(:G!"^DFC3-6CZIH^:LMX)F'[N($=5N+PSQC^<OZOX]&?)%G"8-K`V
M?ABWKOEG3G)"("^KCITCZW;VSX8M%L7G/7K2(:U<GU?TN%5:,ZV>/N?.MO7#
M4%^#!P\XG/K:"Q*ML[L@07]2Y6D`@"2<)]$5_IJ58JTW'U&"^41!W&"#PG,G
M9OJW&F(R-25]!6WWNP*=GNE!O]TWK7)2]=Y>MWQX4<6+"4HG3)#-J)91P^H'
MO<Q:U1-!&[VG+HT/]70P2.U)22-PY-TCF[Y-G`BFO'RV<RGS-`I??CP">I&$
MZ1;>!(\-.PJ[(1F557R1LS_@G\.M`6[>T5L/MB)+RV'3^A14JF](*OKDU"94
M5FHIF6NKD"T$`G7R8AVT((ICVQA=993TRNY#5HBYY_$RAY<]<GL*XL4-YEIK
MB%X_UA_`TA%QZ'&LDI[NI#H]^+;T>"&L[7?"M!5XZ`TQ?>WUS$I55C7-CORS
M4]ERH:Z[7BR&OLCKG;6.KJ$3M=CFLVT/,-E#%5<TU]3R4VT<H_PC;:R)%\N;
M!K_O7+\A-ZP"_.MQ@N]O<74)\ON/<?KE$Y8,__,B>8`YL2AL6Z6G`_\[+-`#
M*K2WA7.[MKL"S9\(#J-Q/X#TN0)EKZ#NEH)VW3%H>O9N4VE^7C[O=[N8NLY(
M"E4C;KH!29H<T8E"G8G:U!,5U$,YMG%3AL.M;Z:LQAZ&_!B@Y#+-\W6"V=FE
M.6*>TJLLW<&L.$@@8HR2R**@[@-JJ\B3#G+TU9@,`9Z305Z`-`&M<8@F5R,U
M6NI.D+=,D`3>D4R:2ZD\<24/O=<2Q-0L2<+BKEM.T;[%*<Y$WZ"4=(R)=8GI
M_XK_C?^//(F%?_@_4$L#!!0````(`.->"D$?&'8=DA<``*]^`0`4`!P`<WEN
M+3(P,3(P,S,Q7W!R92YX;6Q55`D``]HN)5#:+B50=7@+``$$)0X```0Y`0``
M[5U;<]LXLG[>4[7_0<?[NHXMV<G&J>1L*;[,NM:Q7+9G=M]0-`5)V*%(!2!]
MF5^_`"E2I$2"``FQ21Z_S"0*T.SNKW%K=#>^_OUUZ0R>,67$<[\=##\<'PRP
M:WM3XLZ_'?SZ>'7X^>#O__?G__GZOX>'__Y^?S.X\.Q@B5U_\(.WF1$\';P0
M?S&X_./P-X)?,!W\%M$:<%(?/G[X/.!__!>>NIA-K;>_#L;!/&#^X/CS7P>C
MX^%H<'SVY?3XR\?1X.['X/!PSQ_Z^.5T6/-#)Q\^B0\]+@*:_<Y9_)W/7TX^
M9;[C$/?W)XOA`=>TR[X=+'Q_]>7HZ.7EY</K$W4^>'1^-#H^/CF*&QY$+;^\
M,I)I_7(2MQT>_?O'S8.]P$OKD+C,MUQ[TTN0R>LW/#L[.PK_E3=EY`L+^]]X
MMN6'V)?R-2AL(?YV&#<[%#\=#D>')\,/KVQZP'7PIZ_4<_`]G@W"[W_QWU;X
MVP$CRY4C^`Y_6U`\X[^]N8="C\<G4>^_Q.B,W>FEZQ/_[=J=>709\GPP$&1_
MO;_.,&]-L>=:JX7%6WVPO>61:'0DI7-4C\<'W_*Q(#Z971&7@T$LY\YC1-`^
M=RS&0K/2X5:18DV^OUN.L!RVP-A?691_;H%]8EN.#JO%1,QI]9K/2$L\=GQ,
M78[8,ZZHRUTZYG@\M]CBRO%>V+4[)13;?D4>=^G4Y'%"YY9+_M`>,9E^M2V-
M$3:9W5',N)#:K.1UKXM<L%Q:]&TR>R!SEX\FV^)S@VU[`9\<W/F=YQ";8*:%
MH1K%FGQ?$&9[@F*`IY,5IJ$RN&[&(4_GO*L8>S?6D\?_R:-O?+Z[]7S^+1N3
M9^O)T1HZ]3]6%R7L\!&`I^M)YD%,,A47@#)2M6<"S_Z=VRF>GGO+%7:9/H/Y
M%$SP=1=0>\$I_\NBE%NEGEGG$C#!U<)SIGQK=?DSX,NQ-DO9WK5G@R>&?P9\
M<KE\YO_1&_;9KC4Y.><#C$\54[X>3)-5@0^Y\X7ESC%?%.JIK@KYYB6ZJ[H9
MJ?TM@VNMF`PM/Z!X,MO,G?S'FFMAU4_4E"S:.CU:KWJ+8KI;30YNB,TG17SN
M.4ZTX/#]F]C-\Z[>6[BUGU,<`<Y_YG/HDOCAWW3XK?X1/>GRCE(.I1$3+IX+
M`Q8'J3-QD!I^"A6P_IDOM[A@4*1/96<96E&GQGB\PY1X_*!5C=FMW@USS><-
MZM?@.]6_,<X?/3_<A^GSG.K9&+>WN)I^DW[-Z94O$[B:7C<]C7+K[W*JK<R,
M%E>I1>*&LY%A$+_ZV)T*WT7TJR!0U]DBOOJGKXYG9[[D"#^41TO6`/X#DA$?
M/S&?6N+L'9%QA*`A<:3:%1U'BE%D<:V+4,\SBSV%R@[8X=RR5ESIP^$1=GP6
M_R*D&1X>#]>^L;^L?T;)7N4Q.J+M<)_?$`UC7M,HCFF6;XO:,47^QQT(LZZ\
M=8NCR)5S:"^(DZ`_H]Y26YDQ*UZ)(`./\DW9MP/>(V"<0V\E"(GM'Y=MABE=
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M04S\,_@1;U?W^1BMF>T),NNP%;8)Y+C%_GE`:7@W7CS&)-W`#XVJ2)8(47QF
M[Q;$$W^!::23<F!W&X.?357AS&6]V`70+1`CN2:S"\)6'K.<7Z@7K*Y=VPE$
M_'9N]);"**Y,%/PTK3S&ZXA8[-[HHO&HVD,L/_3A70_B#=?%#A--U/RM"_-&
M,;NC'C=(_^W.L:*+MY\!68EM)%^C)!#*NJ&SCB!:(D2Q5Z9;PU($T(K8HAO/
M<K.;D%O/M4M'JTIW-#SN".:JTL3@?P(#/S]4`:^$ET5(D-J'2'%4Z8:&T`ZE
M,OQ4I8AQ^UO'!VTD6^DBBH;0/B.]Y5/P&T/TN=,+YPVQGHA#?!).)[M1P`H>
M)%42:-@EYY*.5'TY^\9'_#OK3:PFZHZ-;`<TA/9.:8$G=W?LBM8?7Q;E![F4
MJI3PSN^#AM!N+#.0%TO7ES&>DLZP?Z0F932$=IT9,"$#.NB+#TYK8LD;<]!.
M,[/FD!++F*.L+3O'S=E%;[NXVP\-H?UH9E'/E]"8SPU^"Y'>(W%][2ZA2LX9
M/4)H".V:*T=8:5.I(&=/-ILI^=2F!C2"=L69G0B$/,8\L:#S?B4?@41](VB?
MG0&@Y>+!.V%-7;*LF0W%_<UR`EFH7TYK-()V\Y4`573!DBM)3Z9FD:OMN4J0
M;C=%(WB/7@4\\\3HR_%^/)V2B/$[BTROW7-K1?ABD1)9M@TK[8Q&T*Z]2HBK
M"=:7D_<]]BWBXNFE15WBSAG?8P;+P!'9UQ=X1FPB6ZG+.Z,1M*^OD@VH"=:7
M():\:C@:NS,T@G;&5<(X7Y!^A+B4;5-KW-"A4;]\;85"&KM6W[:$!G.;BNM*
MUHW*2%>`RU1_*JD>4=KO/2=)L72$BB8+I[[W9*3W9*1V8I@]0'/#GM!0W&EX
M_+K#]('/<>J^A"("G4I>4A:IES80"L?&@;_P*/ECLP:68K_=$3P1JCKF.:+T
MQ0N1)^@U8X$VT%$G\!RINB`G8O3%Q9`GY"3P1<5]$>.@B7*J)WC^5%VHL[+T
MQ9V0\I156+X5>H.G2.G@KB9/7V[Y4])J+-N27N"Y4A6QSI&C+\DU.U*6KM8%
M/<"SIFIAF\C0ERO;'0G5%FE9-_@DJ5H0;TFRQT0;F'I'NT^Y-&YT$0L)3PKA
M(04]WOV&&J.B6(?O'L-WCV'',+S'S]@-L$H!H^VFG?("YC#?%Q_0^L4(MA91
M>CV9:0GNTLL#I>C.<9OS!+UN@[<6Z(KKYI?URTAE`W#3%MQ=IPY@'N^)CZ[;
M$#Y83F*8\BH86RW!77#J\.URGCC<NASJL4X+<^>7KZMP?E%8!@O[=,JS)I.B
M+[[S7[#+A71$\L=T2=RPZKPXJ*U%EF!<TA/<KR9%+Q_P<I%ZLZ-EF&MSP26]
MX!.6XX4E>LHQE_8#][950+Q,H+[L?W=4HS-YPSO9*B";*X6Q61MT18Z<*S<>
M8V*K>![E;W-)-Z\+?L<SC^+4LWZ7KUQ=7'CB6O0M7/9$9A_OR:7A_,VO71]S
M:,O=8GOY*GRI))UMP9X5T8^$;"Z?%X_`2!'K<:BP>RSM"U^A2<=>E,2!OY_-
MC<)=/R4L635R6L'75E)3>1:N`D'J[P`*W_BL`TST5NZU>V41&M[U3V9KYN/0
M\[P8?,6>\#63J@*H*%S]?4!=4`V=WBSBBH5HX@KG@WA+.%5],RF]*3O$*1&`
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M[\DML<Y:6=>\*E&'+_YCVM`JJZ$O%]4E"JV^E+6AB)"Q)2Q=2&AXW+(K(TSF
M"V'[G*PUQ[?!\@G3R6R=^[*=]G(14/[?Z/'NC)`B6:3@MLG8!^!+#:G8A'F9
M$].!FRUR32=QQE\O5Q:AH5[RSR2RUMWS:DEEKQT.4'A5!9,3)A[AO7*\%W;-
M;95B?CR!2\I)<:/WXOU.M_?LL"JS7KXB"];$]Q2Q]Q2QMF(H7I_FEGQ'O6?"
M9\?O;[\R/+UVDR#$L<W7WJ@<H$+\DS:Q3J6951*O)W:R[RL=:,=+-6PKW_C\
MOW2UP-_X0'M=]F=E];32%R?,>/J?(`J;84),KA&;A._Y;I3UZ)E;[_;Q.?"\
M09,VNB<%]26'+?:0X>FYMQ1G[1!KV28ZMP-X;N*^8"[8CA<I`7Q)S?4-A55S
MHI)(8U:"L[0]>&)B,S"7Z0!^K2J#^<JCZY(&5[C(%US4'#P7$03D;17`3_"Y
M&(?,3F8AXYSERU?;"1AYQB)XW\7.N>=PE+UH[S6>4XP+@M@KTX)/:&S./"HK
M"+Y:J,($P4^%+'"$/KC%%UT4R+K`IQY"S12[>H!/?S"9@P;M%FT.UQS1X9,;
M(++6H+V@S4&NJ(Z^9#Y<8,ZN3<K.=>EF\#F,S1[GMF7O2Q)$J!S&.>=+UH47
M//FSP(E?+I:8@JP;?#ICLZ91I@MCP="M<5MR0<=+X9S]HVS**.R#AM`>Q&:-
M1*J(OH1)_P,[4]];6GY`^0KY@&WQ?ZZ>!\^9KO_V=H\M1Q14C].&PQ.3B*H*
M,PP?^<+[B)<K?F*B;YM0'=E4M+^/PB?G-FNC^]5D"P(J35<%N"!LY;'PM=E-
MWKO$5$MZPF<(-VMO"NHP$$JYE_H@1D(IX7.$FSM125208-SUB[+M2ACQ)I`K
M%I/GDAC"\L[P"<50TX-,(XGU["&"M^D8%8HMAB]P]/^4UM9/F*L]KJ!(!#ZO
MN%EKTM-,8E7=KU6S+;;6K*32'3Y761-;50/)%[7V_7UKIQNQ@S\/J-#XF#$L
M/76I=(=/:]Z38>2+"E_*;E^6<>OY.#4*UI)K64<^"?A4YCU92+&X\+7Q\H,&
M=D2XP.&1C(W=:6COA5."3G?XE.):@.N*NL?L,K-@1RQ/9M%!W')^H5ZPXLTB
MWTYNV*ZR)52@#9]-O`<SJ:@'^+"!?>]$[ZRWRMO0=5_X5.,][T%3<L(''^S1
M("@W__B.G4CKZ*MT1R-HC^K^S")'5/AX!,7E)L7W?M:<JA]`(VB7[!X6GCK*
MJ!_GT(Y#C7J^B&3*42>"3J!]M2839/3D[LD+"_DR1R6/#:4<2XBA$VCWK(&<
MXQ+YX',D#,5066]K+_;8_AD0BG]8]'<<IC%N+M%EP50J_=$)M)>U(L@%05.J
M,O?$W<JU9F,\#;-@Q776CW64Q=B=BAP!;(>9L.))[[BD>DGXG2XU=`+MC#5K
M/]4TT-LI)_/J`E>"RNL4ZD30";2?=K^3CU1P>(_M?J:@K:<Z5(U&G0HZ@7;V
M[G7**9$</L&KZ8VPD0TP.H%V_1HU&CW!C?EZVWATNB*NY=J&CDX28N@$VA=L
MX.A4(E]+4X_34Z3(A.0BX*2,YCI%-OS_)&3W\A53FQ0G'58EATZ@W;X54=WU
MYM5103LK3:A(E*1<UK>/;5+H!-K#VZAMY(EO[!!4\5T-A<3S6D4+JI!"IRUU
MV.J;157QX<\YU>:+)`4E-0_RS;BI.421/#J%=M@V-Z]HJ*0OIR`1G\Q9>!,7
M:**J\KG'I!ZZW/;HM*4^7#T;*96Q_C&F'1X3=6T9.<"@TY:Z:*N9AY[@QJ):
M0(^^H<#APP#;U_`2"RGNA$ZA_:XZ1UFY'/VX%A8RED")3J'=GKJ@"8Z-N9Y6
MH05P%JC?:I"@W8SZ('TR-TE&(%VZ8$OK0[!:.:'XEA,_4G#MSCRZC'!0>"Y"
MC0(Z[9(W4$,H^&`_4V&@T:/A=Q:1O3^5;H9.H?U[.CCE([TM#[BSSF2E]4?K
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MB]G@`8M$+<SW%XZ(,7I88%'\+_&XPHSU+5UOO,**([RT/\P2G')NI]6]X5AM
M(=8@TXKQJH*&PEV<@JS]&)$BH&_WK4?`@1@&'B:<W&-'!(2%D6;A"XM/@M<X
MGT]KA%8A#+4DJ['\/<VRXHI<AW*+!GA%,(O7YYIZZ<]D<!=0>\'%7`?W:IV`
MBP/]MZE*1FYI'\U!J<Z4;`B5=P(;'2H*R[F.*)6F/S:]\!PN"1/W<?Y;\XO;
M+@_BC*L2\B3M"+.OS&5)[V"H3`-\P2D%H&@KJ2%A/X99\,3PSX"3O7P680``
MYYT,`RI;PZ(N0.>U+#-JA[."/O#CIEBUA8>O8EEZ,4+$^[">0Z9B0YG$#S&^
MWPR#1=BUVXZ5:LW8^H7C##M*"Y9"?Z!U:\W98TGIV6Q#^)&DJ-'"A6A+&O`P
M),-P1HH0AS;/#6>:5R*+AI#V0]"!1[MHE:!:($5/0-Z2[L);6D3V^&1N>P2=
M8U<*5C[&1<+TI1IT*KWX!UX^82H!=J<M:DV:G!ZH>8(8BQAW@)`L"%@L157:
M#[4FITX/X3*AC!7R@4+['OM\(L+32XNZQ)VS4ICS.Z#6I./IX5LHC;%T5WU@
M\SV<_$`5AW1MPBD*T2KK@EJ35:>&EX(\QC)@H8;B;AJ*RLXW:8S`D^ITM[MI
MUON2:)5S[-?QG"+P++I<<%3=HLA@QEP+$M'#2T(V"7SF6ZX(\9%AN=T6#5N8
MUU:,91[[QG8W+<`R\UQIP;9N<RF<OC9.54EB]YC;.2,^?L#TF=@XJI<A*NG,
MW9"B=(/<"`=HV!HGEX+=-:B4OM2R2A6(NPBH"#<.I?W-<@*<KZJR)4B+&!JV
MQJ^FND9IR]>71]L*I(\F>U.V(J.&AJWQUU4WEC(!X7UX924Y=TS_AD^2+L-7
MN+"PHF)O-&R-[TX"L*9`\+59=`"-S+,RHCO=T;`USKIJD.9*U-*B"S*K-%A(
MMSIM-&R-:Z_&`-<2-S:5SYTPE<C:]V0KFL31L#5^Q3I3AY:\L;6<=<):PM$@
M@E<"1V0J5MP`9`F@86M<CS6FB%V9-JZL3D`;V6X=;/,HH&$77)(5A$K0[87+
MN>B(FW*2Q(6]957=M&FA4:>\G%7$2PP%[K66)KP!9BQ%0DP\>-QY4RF1+[&5
M/CL9;_%+^"_R^TF%_FC4%U=B1J3$"+I>VU4Z!FI8P18!-.J-DS`C4V(''?(Y
MI&>VS9L@TA6A+DDTZH,+447*Q"#@[A7T#Q1F+4*-)AKUP@6I(F9B$RV[/5"Y
MF(T%2LI=;FIB%MI%;;IHU!6'I!%1$_N`\T8:*G,IBL.(`MLW'BMY<&?3#HVZ
MX%`L9#T!#\XYV(ZPME$7/(1R_C?!4-U_O:-67-NH"PY!*?L)E(:"%+-0MCL+
M]2Y4\0+[HE)?[6H@=1DH*1QBBOQ[CJIBX1&#"B^<7-]36'42(5HRU;8DA14J
M-^,]=U62N]I54.LFW+3&;:6?<&,P3W5/KBA1KU%4:BMS+\7MVI-AFM&RQ&.4
MXKP7)5'2+X&(PL\[3SSDEZ)OOBQ*FM'-AB?B.LW99+9^'\9R-GLAA;(I1NB#
M;%EK<:Y7-<STI\!+NYA"O6`2WX.^>C'KI![M:WXF23ZN]6*>I!?(J,_A1V4$
MR[J!CT:YC@O&6(E$O1@OZ[#X5#SK,^93R.5RY7AA(=PDN%6LUZ+""8FN,)H?
M7:F/AZR$;VM@U]9^H5*'#L@(5.)094SJ$0(?I;K(%(Q;;:D;'LE?CP3;HHHU
M_\M_`5!+`P04````"`#C7@I!/]OGD,0)``"+4P``$``<`'-Y;BTR,#$R,#,S
M,2YX<V155`D``]HN)5#:+B50=7@+``$$)0X```0Y`0``[5S=;]NV%G_N@/L_
M<'ZY+[5E)TW6&$F'-!^#@;0VDJPM<'$QT-*QS3N9=$DJL??7WT-*LF3KPW+D
M8O'@EU46S^]\DSRD3G;^ZWSJDR>0B@E^T>BTV@T"W!4>X^.+QN^/M\WWC5\_
M_.NG\Y^;S6\?[^_(M7"#*7!-/B'-B(%'GIF>D)N_FE\8/(,D7T)>!%FU3EKO
M"3Y^!8^#\NCB+;D,QH'2I/W^+3EJ=XY(^ZS[KMT].2*#3Z39_,&"3KKO.C4%
M';=.C:#'22!7Y9S%<MYWCT_1ID2.<B<PI01\,%)NA9Q>PX@&OKYH?`^H;T4V
M"(:!JXO&1.M9UW&>GY];S\<M(<?.4;O=<;Y]NGNP;"+"KL_XGRO4\Z'T8_IC
MQPP/J8*8W(QZ>@E($Y\XX>"2U"_A^^T.&:>9LA)BQI6FW$V4R"@=F=@Y.SMS
M[&A,RF%,-7B%S,\<*7QP(K(8%:CFF-+9$C6B:F@1T0`B.YUFN],\[JQ!FE3K
M8A@.2C8,-*@8YHJ`:[E8=:@"MS463TXTF"/-#:3$V56$BT9S@!ZP?`P.Y)##
MW)WDTYN1'`#C3Z!T/B0<RP%QRER5C[%#.1#%W'P`#N1'1R]FH')#8T?R9.B9
M+!""(SD`":/"1#MU<#2)PDR"NR$QJ71M;HZHJYLPG_F44RWDXA9_+STG.`^F
M^4P\+1UCFH-$3:0"R=QD6NC-4R*1LEE$S%Y3.0;]F4Y!S:@+*S#J@>!T-J%R
M2ENNF!H/'K6/4PY?\(H`7`[?G%/.A:8:5]0/YW0V8WPDS/LW;\[-"M`U5CRB
M<L0\_'[?*V=M;8Y7\$ONW7#-]**'/)'"R&@0AM$JI0BE1^(]&#'.K':X\))F
MLCVD'BGW2,B'I!B=.^L<THP#!5Z??[#/F$8*^5B465$C9$12A$H85\>XU'<#
MOTQ0]"IV>\U0/*!1=I_KCVX9Q]6?47\@E-7ZRJ=*1=N="4I%VN+P'&%,EDSP
M^4IP)7SFF1E*/E+?;#[D80*@U2$VX$0>4<8A,XI;C9Z`9JA%&([BX>(('%>/
M`/G/(,WTOX>(K,R6'A;=4[CT-4C<+]@39.9(EJ(X+N_*XK(<4$2,2'\&TEI\
MF".K$;FB:G+KBV?5XQ[#?5]G(I*E*([(+]4C8M@2R_<0$7#Z<DPY^RNUF:^\
M*?;X>[-C,^7Z0@42\$<:=_"LV0\44_W1(&5@O!-D!XK]?+;N9PLWB9QF<'`X
M+B[!=$KEHC]Z8&..Q8U+L2)U[7&1\?$`EP.7F3.F76:JT1:&I=-9#TO$T00F
MQ9,D3$G,]1`K/%.@ZX1Q2X`2EEMD?W1IJ:^0K:EB[NA02'N\PY/%9Z'A'EQ@
M3W3H1_MW?3;%$3Y:CW!:6&I?-Q$/Y9%8($DDVL.,D4D2H8<$P,D*/N[HX$55
MK"UB,^?*343%P3O.3,^(U6K9?#A?KM=GPOT3-QCPKL1T!ERE@Y$_5AR#=YD8
M&`Y-RX*D>1P\'WE^$$AW@N[Y2J7$S4.E')\9*O;[2:[?2<R!Q"P.;H_</A&^
M!U+=?`^87J1\OOJ^V.&GN0Z/T/\F(?[@;5.A#15\#]"XFR?\3UR*K;XL]G.F
M%$Z@Q&(//@8G??)-#KYXFIY0/@8\2Q>E_$N`Q<>6DRT.Y*$`POAAXNPNJ(/L
M%61M+L7A/MU9N`\7F>67-.8(0S6N?_U1<@;!EX77#2\%%Z_#[;*KG_#`8X6L
MWG_:@</E14&(P^OG1SJ/;RC2+XI#D;F%"V'$X@Y^!>>.N7C,@"OA^^&9G#V!
M^4PYG?EB8;]9CB6$BQ.^QE/)E&G[*XS"R^'%,?ME/6:1D+=D14SX&70IB"22
M[$A*UC\NSN8_IK_F'D;$-JYTS??TBX9BZ`[3\&+?36QG@5KP9OP%_`^TKS6?
M^C&%X5W206,39-TED=R81=1O4-Y7@TP$KG.:@7)BW1O.3BQ"WV]KT6JX7ID]
MF-_;VH,0\%^A*9CBVYJR-BMV;-"Y$S=\X%/2!F*Z0M`6(37AN2TH17UE86O=
MG7`MGQ*(^=6,<4WSJMDY:AYW6G/EA;IMH\#2JBT5B'%;*I#?K5=1=`PP,D^J
M2"MMFBL0:@7F`AWPM8K?-!-6E>TNZ4(K4R8'%CW742*OLZ^*%FE<_*.6'GF=
M@I4420.7O^JHDFDHK*+&$F2?ZHC/-AI6D9^@PL<Z&JQW+E:1'V/,0RW9ZPV-
ME83'(/NTI?A-C;A55B5?RA6469K.S'+8.:VE0L5%,25>UQ9=WNU959TTEYN$
MR9;:E38&5\F,&&,>ZN1%MK^TBB/6475BD]]$NYT6@G\N4R3JY[>:E#>87@Z5
MEC3N'\(*[8]JU&&59[OLN_B.\7%/P]0<11J$1E07#2T#4P-:*BR[F/`>+<X+
M9'3'PIDYM)FR+:15`8*9#LSH;U($LU@(0_;YUL',]&6:$V1?3T!>*@5:?18\
MW$'2EFVD3%LU%3@'J5SDV36BOLHU+"SC=#PT##^7HL$P9'H7UJ8_YJY<]64#
M68'T]40Q^JR&"XPYS*O$BLQ`[1@E:O^H((67M#U^2YG\0OT`^J/(C#M&A\Q?
M?C4P!E8BW@.COP(;3W#'O'P"2<>`Z],09']D;EH$?YA@`JI^H,WT,'^_=1V8
M;!M8#<VUIHN3\IKY0=)=:H._0YXKN6ZA+W1@?5?9F_N>4@%:IK*]`L;R$I(]
MR(64]K="1C=TMP"Y]JU1_#CS7`G>;NRSBO='U@A4_V;N^H'"+#-SF8.?NHG$
M/3.^>4R,?R%\'SRS&E?S(2OP3?\>AE8517^=:@\2W'QMFYG?O>D,UVWS="=4
MRL)"@CTPKL<Q'ZB":PC_[?'\RBF5T)41^Y##66M"[?NC:Z;0+.I;/DCF!W;?
MR>NC+'/.B]CM9>+$)0R#W7GOY3SW(?D&4K@`GKJ58FI62,-_6?%$&X;]MS\S
M3&_F(%VV4C&_G,,>I%@5XY9'AA>Y)HO>`[>L;JC;UB,O0_\C9I,UUBP9J1F!
M>U:-%*K,<0_2"FVQI]/^:%G/I$J<O,%]2(I[<*._X`TOVW`7006>;-_`\LS]
M*"X]SWX'IOZ`,J_'K^B,Z;@;S#B@+I]]\%5N^W3VKFD#V>NY9\I5]!'F^J./
M`QL,2M&%%H7_KX2NCM__?3<*B'`ELXM-\J<RG\#<EZ2,*J5:,<D34\KXWQJE
M<$-*7^K8Z['DKB#_0%D.V)LYES4FO._:QOP<Q.N\!<O$K%X14X?=WB?([ERW
M-;\]2:X*MU(;,7N?)ELZ(1^T)P%/5>(J*<557(M[U5)@,Y>]3XK:CJK*YA4E
MSJ7WOT"%K<"%M7ILP;*J3TK_M%-VP&H?4JCN7\)DCP^[X_C*3AKQ#<&54'G[
M;3+T&N-^[H1-*?CX?U!+`0(>`Q0````(`.->"D&',[NJ9+8```;6!P`0`!@`
M``````$```"D@0````!S>6XM,C`Q,C`S,S$N>&UL550%``/:+B50=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`XUX*09Y1'ZN1"0``-7P``!0`&```````
M`0```*2!KK8``'-Y;BTR,#$R,#,S,5]C86PN>&UL550%``/:+B50=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`XUX*0>F3?M:&$@``\AH!`!0`&```````
M`0```*2!C<```'-Y;BTR,#$R,#,S,5]D968N>&UL550%``/:+B50=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`XUX*02G9DN'&*P``084"`!0`&```````
M`0```*2!8=,``'-Y;BTR,#$R,#,S,5]L86(N>&UL550%``/:+B50=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`XUX*01\8=AV2%P``KWX!`!0`&```````
M`0```*2!=?\``'-Y;BTR,#$R,#,S,5]P<F4N>&UL550%``/:+B50=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`XUX*03_;YY#$"0``BU,``!``&```````
M`0```*2!51<!`'-Y;BTR,#$R,#,S,2YX<V155`4``]HN)5!U>`L``00E#@``
;!#D!``!02P4&``````8`!@`4`@``8R$!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>2.&#160;&#160;&#160;Basis of Presentation</b></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The accompanying unaudited consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.</p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The financial information as of December 31, 2011, is derived from the audited financial statements presented in the Company&#8217;s Annual Report on Form 10-K/A for the year ended December 31, 2011. The unaudited consolidated interim financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K/A, which contains the audited financial statements and notes thereto, together with the Management&#8217;s Discussion and Analysis, for the year ended December 31, 2011.</p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been consolidated or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the period ended March 31, 2012, are not necessarily indicative of results for the full year.</p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has seven subsidiaries, Pipex Therapeutics, Inc. (&#8220;Pipex Therapeutics&#8221;), Effective Pharmaceuticals, Inc. (&#8220;EPI&#8221;), Solovax, Inc. (&#8220;Solovax&#8221;), CD4 Biosciences, Inc. (&#8220;CD4&#8221;), Epitope Pharmaceuticals, Inc. (&#8220;Epitope&#8221;), Healthmine, Inc. (&#8220;Healthmine&#8221;) and Putney Drug Corp. (&#8220;Putney&#8221;). As of March 31, 2012, EPI, Healthmine and Putney are wholly owned and Pipex Therapeutics, Solovax, CD4 and Epitope are majority-owned.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?0VAA/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?0VAA,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]R9V%N
M:7IA=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D)A<VES7V]F7U!R97-E;G1A=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D]R9V%N:7IA=&EO;E]A;F1?3F%T=7)E7V]F7T]P
M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA
M<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D1I<V-O;G1I;G5E9%]/<&5R871I;VYS7V]F
M7T%D93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-E
M;&5C=&5D7T)A;&%N8V5?4VAE971?26YF;W)M83PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K0F%S961?0V]M<&5N<V%T:6]N
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM?
M4'5R8VAA<V5?5V%R<F%N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$V
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^3&EC96YS95]#;VQL86)O<F%T:79E
M7V%N9%]%;7!L/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^26YC;VUE7U1A>&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$X+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N=#PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q.2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS
M:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E
M<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E
M=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R
M=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T
M5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF
M72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U
M;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R
M+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S,U,C1F-C=F7S(S,3A?-#8S.5]A83<W7S0Y.30Y-#8T86%B,@T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S-3(T9C8W9E\R,S$X7S0V,SE?86$W
M-U\T.3DT.30V-&%A8C(O5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%1T-!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@
M16YT:71Y($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/E-Y;G1H971I8R!":6]L;V=I8W,L($EN
M8RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^,#`P,#@Y-#$U.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G
M;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y3;6%L;&5R(%)E
M<&]R=&EN9R!#;VUP86YY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y/=&AE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/F9A;'-E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I
M;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DUA
M<B`S,2P-"@D),C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,S4R-&8V-V9?,C,Q.%\T-C,Y7V%A-S=?-#DY-#DT-C1A86(R
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,U,C1F-C=F7S(S,3A?
M-#8S.5]A83<W7S0Y.30Y-#8T86%B,B]7;W)K<VAE971S+U-H965T,#(N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4Q3D%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O
M;&ED871E9"!"86QA;F-E(%-H965T<R`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!<W-E
M=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+#@P,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-BPV-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(L-C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE(&YE=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-S971S(&]F
M(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!#=7)R96YT($%S<V5T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPS,C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#$R,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-30U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]N9RUT97)M(&YO=&4@<F5C96EV
M86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P
M;W-I=',@86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@07-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX+#,T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-#<V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ,3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EA
M8FEL:71I97,@86YD(%-T;V-K:&]L9&5R<R<@17%U:71Y/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B
M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET:65S(&]F(&1I<V-O;G1I;G5E9"!O
M<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!#=7)R96YT($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&]N9R!497)M($QI
M86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!,:6%B:6QI=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#0S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K
M:&]L9&5R<R<@17%U:71Y.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL("0P+C`P,2!P87(@=F%L
M=64[(#$P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960L(&YO;F4@:7-S=65D
M(&%N9"!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("0P+C`P,2!P87(@=F%L=64[(#$P,"PP
M,#`L,#`P('-H87)E<R!A=71H;W)I>F5D+"`S,2PS-S0L,#`R(&ES<W5E9"!A
M;F0@,S$L,CDR+#4R,"!O=71S=&%N9&EN9R!A;F0@,C,L-#(P+#$X.2!I<W-U
M960@86YD(#(S+#,S."PW,#<@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN(&-A
M<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P+#DT-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X
M+#DP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0W+#(X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-3,L,#<S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4Q+#@W,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,RPW,C0I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@4W1O8VMH;VQD97)S)R!%<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<L.3`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-RPP-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#4W.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($QI86)I;&ET:65S
M(&%N9"!3=&]C:VAO;&1E<G,G($5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`X+#,T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-RPT-S8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L,3$Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P149#044^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S(%M0
M87)E;G1H971I8V%L72`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL
M('!A<B!V86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M969E<G)E9"!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@
M<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E("AI;B!D;VQL87)S
M('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T
M:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H
M87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R
M+#@U-RPV,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,2PS-S0L,#`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C,L-#(P+#$X.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S
M:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,R+#<W-BPQ,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,2PR.3(L-3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L,S,X+#<P-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S4R-&8V-V9?,C,Q.%\T
M-C,Y7V%A-S=?-#DY-#DT-C1A86(R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S,U,C1F-C=F7S(S,3A?-#8S.5]A83<W7S0Y.30Y-#8T86%B,B]7
M;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4Q-$%'/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($]P
M97)A=&EO;G,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R
M92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4F5V96YU97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQI8V5N<V4@<F5V96YU92P@;F5T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,3(U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N="!R979E;G5E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M4F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8Q
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY/<&5R871I;F<@0V]S=',@86YD($5X<&5N<V5S.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L
M(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PT-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#(S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ,3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E
M;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPS-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#4X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L($]P97)A=&EN9R!#;W-T<R!A;F0@17AP96YS
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#4T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT-C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#DR.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3&]S<R!F<F]M($-O;G1I;G5I;F<@3W!E<F%T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PX-30I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PT-C0I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PY
M,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2PP.#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R($EN8V]M92`H17AP96YS92DZ/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A
M;G0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<Q
M-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q+#0Y,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W87)R86YT(&QI
M86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DT*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(T
M,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);7!A:7)M96YT(&QO<W,@;VX@97%U:7!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3(Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O;B!T:&4@<V%L92!O
M9B!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);G1E<F5S="!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W1H97(@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($]T:&5R($EN8V]M92`H17AP96YS
M92DL(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<U.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M+#8Y."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q,3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T($QO<W,@9G)O;2!#;VYT:6YU:6YG($]P97)A=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.#0Y*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,C(S
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#<L-C(V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L,3DU*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T($EN8V]M92`H3&]S<RD@9G)O;2!$:7-C;VYT
M:6YU960@3W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-3$V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!,;W-S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#$L,C`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BPQ.#8I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X+#$T.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$L-S$Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY.970@26YC;VUE("A,;W-S*2!097(@4VAA<F4@+2!"87-I
M8R!A;F0@1&EL=71I=F4Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;G1I;G5I;F<@3W!E<F%T:6]N<R`H:6X@9&]L;&%R
M<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#`N,#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@P+C`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,"XR-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7-C;VYT:6YU960@3W!E
M<F%T:6]N<R`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`R*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M($QO<W,@4&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#`N,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@P+C`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,"XR.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R
M86=E(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG(&1U<FEN
M9R!T:&4@>65A<B!"87-I8R!A;F0@1&EL=71I=F4@*&EN('-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R+#`P,RPQ-C0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PR,C`L
M-CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C<L-S$P+#0R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(R+#,Y,RPU-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S,U,C1F-C=F7S(S,3A?-#8S.5]A83<W7S0Y
M.30Y-#8T86%B,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S-3(T
M9C8W9E\R,S$X7S0V,SE?86$W-U\T.3DT.30V-&%A8C(O5V]R:W-H965T<R]3
M:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%4%="23X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T
M<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#:&%N9V5S(&EN(%-T
M;V-K:&]L9&5R<R<@17%U:71Y("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E
M>&-E<'0@4VAA<F4@9&%T83PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y!9&1I=&EO;F%L(%!A:60M26X@0V%P:71A
M;"!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y2
M971A:6YE9"!%87)N:6YG<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y3=6)S8W)I<'1I;VX@4F5C96EV86)L92!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y4;W1A;#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$
M96,N(#,Q+"`R,#`Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`T-2PU-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#0R+#`Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#$W*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPU-#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@*&EN
M('-H87)E<RD@870@1&5C+B`S,2P@,C`P.3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C$L-#0Y+#,U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@96UP;&]Y964@8V]M<&5N
M<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R(&5M<&QO>65E(&-O;7!E
M;G-A=&EO;B`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C`L-3(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R(&QI
M8V5N<V4@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!L:6-E;G-E(&9E
M97,@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@Q+#`S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!C;VYS=6QT
M:6YG(&9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!C;VYS=6QT:6YG
M(&9E97,@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(W.2PW,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@;W!T
M:6]N<R!E>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@;W!T
M:6]N<R!E>&5R8VES960@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(U-2PY-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C
M:RP@;F5T(&]F(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C
M:RP@;F5T(&]F(&ES<W5A;F-E(&-O<W1S("AI;B!S:&%R97,I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(Q,BPQ,C$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S$Q*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#<Q,2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)A;&%N8V4@870@1&5C+B`S,2P@,C`Q,#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT-RPR.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@T,RPW,C0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3<Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E("AI
M;B!S:&%R97,I(&%T($1E8RX@,S$L(#(P,3`\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(S+#,S."PW,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDW,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3<S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R(&5M<&QO>65E(&-O;7!E
M;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDT/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!E;7!L;WEE92!C;VUP
M96YS871I;VX@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<S+#4X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!E
M>&-L=7-I=F4@8VAA;FYE;"!C;VQL86)O<F%T:6]N(&%G<F5E;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C@T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8X-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!E>&-L=7-I=F4@8VAA;FYE;"!C
M;VQL86)O<F%T:6]N(&%G<F5E;65N="`H:6X@<VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,C,L-34X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C
M;VUM;VX@<W1O8VL@9F]R(&-O;G-U;'1I;F<@9F5E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM
M;VX@<W1O8VL@9F]R(&-O;G-U;'1I;F<@9F5E<R`H:6X@<VAA<F5S*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<Q+#<Y-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@
M;V8@8V]M;6]N('-T;V-K(&9O<B!O<'1I;VYS(&%N9"!W87)R86YT<R!E>&5R
M8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@;W!T:6]N<R!A;F0@=V%R
M<F%N=',@97AE<F-I<V5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS."PY-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C
M:RP@;F5T(&]F(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-BPY-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8L.38Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VLL(&YE="!O9B!I<W-U86YC92!C;W-T<R`H:6X@<VAA<F5S*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PU-#4L.3(V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M(&QI86)I;&ET>2!R96-L87-S:69I960@=&\@<W1O8VMH;VQD97)S)R!E<75I
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<S-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW
M,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#@L,30Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#@L,30Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q+"`R,#$Q/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U."PY,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4Q+#@W
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#<L,#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y"86QA;F-E("AI;B!S:&%R97,I(&%T($1E8RX@,S$L
M(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#(Y,BPU
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,U
M,C1F-C=F7S(S,3A?-#8S.5]A83<W7S0Y.30Y-#8T86%B,@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\S-3(T9C8W9E\R,S$X7S0V,SE?86$W-U\T
M.3DT.30V-&%A8C(O5V]R:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M2D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E
M;65N=',@;V8@0VAA;F=E<R!I;B!3=&]C:VAO;&1E<G,G($5Q=6ET>2!;4&%R
M96YT:&5T:6-A;%T@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O
M=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W1O8VL@27-S=6%N8V4@0V]S=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`U,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S4R-&8V-V9?,C,Q.%\T-C,Y7V%A
M-S=?-#DY-#DT-C1A86(R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S,U,C1F-C=F7S(S,3A?-#8S.5]A83<W7S0Y.30Y-#8T86%B,B]7;W)K<VAE
M971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V1T))/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($-A<V@@1FQO
M=W,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@
M<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H($9L;W=S($9R;VT@3W!E
M<F%T:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#$L.#0Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,BPR,C,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@W+#8R-BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$L,3DU*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T($EN8V]M92`H3&]S<RD@9G)O;2!$:7-C;VYT:6YU960@3W!E<F%T:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C0Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,C,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3$V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R96-O;F-I;&4@;F5T(&QO<W,@
M=&\@;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM
M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!A<R!E;7!L;WEE92!C
M;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K(&ES<W5E9"!F;W(@;&EC96YS92!F964\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@:7-S=65D(&9O<B!E
M>&-L=7-I=F4@8VAA;FYE;"!C;VQL86)O<F%T:6]N(&%G<F5E;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV.#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!I<W-U
M960@9F]R(&-O;G-U;'1I;F<@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,38U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(&5X<&5N<V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,38\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0Y,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F
M86ER('9A;'5E(&]F('=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W9I<VEO
M;B!F;W(@=6YC;VQL96-T:6)L92!A8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA
M=&EO;B!O9B!P<F5M:75M(&]N(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@;VX@<V%L92!O9B!S:&]R="UT
M97)M(&EN=F5S=&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1V%I;B`H;&]S<RD@;VX@=&AE('-A;&4@;V8@97%U:7!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26UP86ER;65N
M="!L;W-S(&]N(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1V%I;B!O;B!T:&4@<V5T=&QE;65N="!O9B!A8V-O=6YT
M<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A=&EN9R!A<W-E=',@86YD
M(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@T,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#@P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0S."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&-U<G)E
M;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V-RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@S,S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.;W1E(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#<P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97!O<VET<R!A;F0@;W1H97(@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E
M=',@;V8@9&ES8V]N=&EN=65D(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W,BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.38I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-R=65D(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$Y,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q.#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,:6%B:6QI=&EE<R!O9B!D:7-C;VYT:6YU
M960@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#0P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T($-A<V@@57-E9"!);B!/<&5R871I;F<@06-T:79I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PT,34I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(L.#<U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L,30U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H($9L;W=S($9R;VT@26YV97-T
M:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!U<F-H87-E(&]F('-H;W)T+71E<FT@:6YV97-T;65N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L,S<P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;V-E961S(&9R;VT@<VAO<G0M=&5R;2!I;G9E<W1M96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-"PR.3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@;V8@<')O
M<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!T:&4@<V%L92!O9B!E<75I<&UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M($-A<V@@4')O=FED960@0GD@*%5S960@26XI($EN=F5S=&EN9R!!8W1I=FET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<U*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-A<V@@1FQO=W,@1G)O;2!&:6YA;F-I;F<@06-T:79I=&EE<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R('-T;V-K
M(&]P=&EO;B!A;F0@=V%R<F%N="!E>&5R8VES97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A
M;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@=V%R<F%N="!E>&5R8VES97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#<Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@
M9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R(&5X8VQU<VEV92!C
M:&%N;F5L(&-O;&QA8F]R871I;VX@86=R965M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!T:&4@:7-S=6%N
M8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A:60@87,@9&ER96-T(&]F
M9F5R:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,CDV*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#4S.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T($-A<V@@4')O=FED960@0GD@1FEN86YC:6YG
M($%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-3,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPW,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV+#DW.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8W)E87-E("AD96-R96%S92D@
M:6X@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT
M,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#`R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#8V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%S:"!A="!T:&4@8F5G:6YN:6YG(&]F('!E<FEO9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPV-S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8T.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C0Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPW,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-A<V@@870@=&AE(&5N9"!O9B!P97)I;V0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8L.#`R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPP.#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#8W.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C0Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E<R!O9B!C87-H(&9L;W<@:6YF
M;W)M871I;VXZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-A<V@@<&%I9"!F;W(@:6YT97)E<W0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9F]R('1A>&5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U
M<'!L96UE;G1A;"!D:7-C;&]S=7)E(&]F(&YO;BUC87-H(&EN=F5S=&EN9R!A
M;F0@9FEN86YC:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X8VAA;F=E(&]F(&5Q=6EP;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-L87-S:69I
M8V%T:6]N(&]F('=A<G)A;G0@;&EA8FEL:71Y('1O(&%D9&ET:6]N86P@<&%I
M9"UI;B!C87!I=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$L-S,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D]R9V%N:7IA=&EO
M;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.871U<F4@;V8@3W!E
M<F%T:6]N<R!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/C$N)B,Q-C`[
M)B,Q-C`[)B,Q-C`[3W)G86YI>F%T:6]N/"]B/CPO<#X-"CQP('-T>6QE/3-$
M)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/E-Y;G1H971I8R!":6]L
M;V=I8W,L($EN8RX@*'1H92`F(S@R,C`[0V]M<&%N>28C.#(R,3L@;W(@)B,X
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M=&4@=&\@=')E870@<'5L;6]N87)Y(&%R=&5R:6%L(&AY<&5R=&5N<VEO;B`H
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M:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC
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M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('=I9'1H.B`R)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97([('=I9'1H.B`U,"4[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+61E8V]R
M871I;VXZ(&YO;F4[)SX\8CY3=&%T=7,\+V(^/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CLG/E!!2#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<^4F5L87!S:6YG+7)E;6ET=&EN9R!-4SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SY4<FEM97-T
M83PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SY!
M;&P@<&%T:65N=',@96YR;VQL960@:6X@4&AA<V4@24D@8VQI;FEC86P@=')I
M86P[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M('1O<#LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M)SXH;W)A;"!E<W1R:6]L*3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([)SYD;W-I;F<@86YD(&UO;FET;W)I;F<@=6YD97)W87D\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
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M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([)SY-4SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([)SXH;W)A;"!E<W1R:6]L*3PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SYC;&EN:6-A;"!T<FEA
M;#PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CLG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([)SY&:6)R;VUY86QG:6$\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R<^169F:7)M83PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([)SY087)T;F5R960@=VET:"!-961A($%"/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXH;W)A
M;"!F;'5P:7)T:6YE*3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R<^04Q3/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CLG/D%%3BTQ,#`\+W1D/@T*/'1D('-T>6QE
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M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXH9V%S=')O<F5T96YT:79E
M('II;F,@86-E=&%T92D\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S4R-&8V-V9?,C,Q.%\T
M-C,Y7V%A-S=?-#DY-#DT-C1A86(R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S,U,C1F-C=F7S(S,3A?-#8S.5]A83<W7S0Y.30Y-#8T86%B,B]7
M;W)K<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY"87-I<R!O9B!0<F5S96YT871I;VX\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT
M:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0G5S:6YE<W,@1&5S8W)I<'1I;VX@86YD
M($)A<VES(&]F(%!R97-E;G1A=&EO;B!;5&5X="!";&]C:UT\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/CQB/C(N)B,Q-C`[)B,Q-C`[)B,Q-C`[0F%S:7,@;V8@4')E<V5N=&%T
M:6]N/"]B/CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
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M('1O($9O<FT@,3`M42!A;F0@07)T:6-L92`Q,"!O9B!296=U;&%T:6]N(%,M
M6"X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@8F%C:V=R;W5N
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M($9O<FT@,3`M2R]!(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q,2X@5&AE('5N875D:71E9"!C;VYS;VQI9&%T960@:6YT97)I;2!F:6YA
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M>7-I<RP@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q+CPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
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M($UA<F-H(#,Q+"`R,#$R+"!A<F4@;F]T(&YE8V5S<V%R:6QY(&EN9&EC871I
M=F4@;V8@<F5S=6QT<R!F;W(@=&AE(&9U;&P@>65A<BX\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET93L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5&AE($-O;7!A
M;GD@:&%S('-E=F5N('-U8G-I9&EA<FEE<RP@4&EP97@@5&AE<F%P975T:6-S
M+"!);F,N("@F(S@R,C`[4&EP97@@5&AE<F%P975T:6-S)B,X,C(Q.RDL($5F
M9F5C=&EV92!0:&%R;6%C975T:6-A;',L($EN8RX@*"8C.#(R,#M%4$DF(S@R
M,C$[*2P@4V]L;W9A>"P@26YC+B`H)B,X,C(P.U-O;&]V87@F(S@R,C$[*2P@
M0T0T($)I;W-C:65N8V5S+"!);F,N("@F(S@R,C`[0T0T)B,X,C(Q.RDL($5P
M:71O<&4@4&AA<FUA8V5U=&EC86QS+"!);F,N("@F(S@R,C`[17!I=&]P928C
M.#(R,3LI+"!(96%L=&AM:6YE+"!);F,N("@F(S@R,C`[2&5A;'1H;6EN928C
M.#(R,3LI(&%N9"!0=71N97D@1')U9R!#;W)P+B`H)B,X,C(P.U!U=&YE>28C
M.#(R,3LI+B!!<R!O9B!-87)C:"`S,2P@,C`Q,BP@15!)+"!(96%L=&AM:6YE
M(&%N9"!0=71N97D@87)E('=H;VQL>2!O=VYE9"!A;F0@4&EP97@@5&AE<F%P
M975T:6-S+"!3;VQO=F%X+"!#1#0@86YD($5P:71O<&4@87)E(&UA:F]R:71Y
M+6]W;F5D+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G86YI>F%T
M:6]N(&%N9"!.871U<F4@;V8@3W!E<F%T:6]N<R!A;F0@0F%S:7,@;V8@4')E
M<V5N=&%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;BP@0V]N<V]L:61A=&EO;B!A;F0@
M4')E<V5N=&%T:6]N($]F($9I;F%N8VEA;"!3=&%T96UE;G1S(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W)G86YI>F%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0<F5S96YT871I;VX@
M;V8@1FEN86YC:6%L(%-T871E;65N=',@1&ES8VQO<W5R92!;5&5X="!";&]C
M:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQT86)L92!S='EL
M93TS1"=M87)G:6XM=&]P.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUB;W1T;VTZ(#!P>#LG(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#LG/CQB
M/C$N/"]B/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3LG/CQB/D]R9V%N:7IA=&EO;B!A;F0@3F%T=7)E(&]F($]P97)A=&EO;G,@
M86YD($)A<VES(&]F(%!R97-E;G1A=&EO;CPO8CX\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P(#!P="`P+C5I;CL@=&5X
M="UI;F1E;G0Z("TP+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\8CX\:3Y$97-C<FEP
M=&EO;B!O9B!"=7-I;F5S<SPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY3
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M+"!F:6)R;VUY86QG:6$@86YD($%,4RX\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/'1A
M8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#(T)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P
M861D:6YG+7)I9VAT.B`P+CAP=#L@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M
M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#Y-961I8V%L($EN9&EC
M871I;VX\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@<&%D9&EN9RUR
M:6=H=#H@,"XX<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO
M=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R-"4[(&)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@
M,"XX<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([
M)R!N;W=R87`],T1N;W=R87`^4')O9'5C="!#86YD:61A=&4\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`R)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E
M>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`T."4[(&)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R
M87`^4W1A='5S/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^4$%(
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI
M9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#Y3>6YT:&5T:6,@1$Y!+6)A
M<V5D('1H97)A<'D\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP
M=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/E!R96-L
M:6YI8V%L/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T
M.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI
M9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!C
M96YT97([)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W
M<F%P/3-$;F]W<F%P/E)E;&%P<VEN9RUR96UI='1I;F<@35,\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!C
M96YT97([)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R<@;F]W<F%P/3-$;F]W<F%P/E1R:6UE<W1A/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@
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M:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P
M+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[
M('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#LH
M97-T<FEO;"D\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/F1O<VEN9R!A
M;F0@;6]N:71O<FEN9R!U;F1E<G=A>3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P
M/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@,"XX<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO
M=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP
M=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E
M>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI
M9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#Y#;V=N:71I=F4@9'ES9G5N
M8W1I;VX@:6X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/E1R:6UE<W1A
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI
M9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#Y0871I96YT(&5N<F]L;&UE
M;G0@=6YD97)W87D@:6X@4&AA<V4@24D\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A
M<#TS1&YO=W)A<#Y-4SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H
M=#H@,"XX<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A
M<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[*&5S=')I;VPI/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX
M<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#YC;&EN
M:6-A;"!T<FEA;#PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P
M+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[
M('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT
M+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG
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M/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT97([
M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W
M<F%P/3-$;F]W<F%P/D5F9FER;6$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W
M<F%P/E!A<G1N97)E9"!W:71H($UE9&$@04(\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO
M=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT97([)PT*(&YO=W)A
M<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N
M;W=R87`^*&]R86P@9FQU<&ER=&EN92D\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$
M;F]W<F%P/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX
M<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T
M97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA
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M9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$
M;F]W<F%P/D%%3BTQ,#`\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P
M+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/D-L
M:6YI8V%L('1R:6%L('!R97!A<F%T:6]N('5N9&5R=V%Y/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT
M97([)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@
M;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A
M<#TS1&YO=W)A<#XH9V%S=')O<F5T96YT:79E('II;F,@86-E=&%T92D\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L
M:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\+W1R/@T*
M/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
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M>FEN8RUB87-E9"!P<F]D=6-T<R`\:3YR96%::6X\+VD^("8C.#0X,CL@86YD
M(#QI/G=E;&Q::6X\+VD^("8C.#0X,CLN/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\
M8CX\:3Y"87-I<R!O9B!0<F5S96YT871I;VX@86YD($-O<G!O<F%T92!3=')U
M8W1U<F4\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^07,@;V8@1&5C96UB
M97(@,S$L(#(P,3$L('1H92!#;VUP86YY(&AA9"!E:6=H="!A8W1I=F4@<W5B
M<VED:6%R:65S+"!0:7!E>"!4:&5R87!E=71I8W,L($EN8RX@*"8C.#(R,#M0
M:7!E>"!4:&5R87!E=71I8W,F(S@R,C$[*2P@061E;VYA($-L:6YI8V%L($QA
M8F]R871O<GD@*&9O<FUE<FQY($AA<G0@3&%B+"!,3$,I+"!%9F9E8W1I=F4@
M4&AA<FUA8V5U=&EC86QS+"!);F,N("@F(S@R,C`[15!))B,X,C(Q.RDL(%-O
M;&]V87@L($EN8RX@*"8C.#(R,#M3;VQO=F%X)B,X,C(Q.RDL($-$-"!":6]S
M8VEE;F-E<RP@26YC+B`H)B,X,C(P.T-$-"8C.#(R,3LI+"!%<&ET;W!E(%!H
M87)M86-E=71I8V%L<RP@26YC+B`H)B,X,C(P.T5P:71O<&4F(S@R,C$[*2P@
M2&5A;'1H;6EN92P@26YC+B`H)B,X,C(P.TAE86QT:&UI;F4F(S@R,C$[*2!A
M;F0@4'5T;F5Y($1R=6<@0V]R<"X@*"8C.#(R,#M0=71N97DF(S@R,C$[*2X@
M07,@;V8@1&5C96UB97(@,S$L(#(P,3$L($5022P@061E;VYA($-L:6YI8V%L
M($QA8F]R871O<GDL($AE86QT:&UI;F4@86YD(%!U=&YE>2!A<F4@=VAO;&QY
M(&]W;F5D(&%N9"!0:7!E>"!4:&5R87!E=71I8W,L(%-O;&]V87@L($-$-"!A
M;F0@17!I=&]P92!A<F4@;6%J;W)I='DM;W=N960N/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I
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M87,@:6YC;W)P;W)A=&5D(&EN($1E;&%W87)E(&]N($1E8V5M8F5R(#$R+"`R
M,#`P+"!%<&ET;W!E('=H:6-H('=A<R!I;F-O<G!O<F%T960@:6X@1&5L87=A
M<F4@:6X@2F%N=6%R>2!O9B`R,#`R+"!0=71N97D@=VAI8V@@=V%S(&EN8V]R
M<&]R871E9"!I;B!$96QA=V%R92!I;B!.;W9E;6)E<B!O9B`R,#`V+"!(96%L
M=&AM:6YE('=H:6-H('=A<R!F;W)M960@:6X@1&5L87=A<F4@:6X@1&5C96UB
M97(@;V8@,C`P-R!A;F0@061E;VYA($-L:6YI8V%L($QA8F]R871O<GD@=VAI
M8V@@=V%S(&EN8V]R<&]R871E9"!I;B!);&QI;F]I<R!A<R!A(&QI;6ET960@
M;&EA8FEL:71Y(&-O;7!A;GD@;VX@075G=7-T(#@L(#(P,#4N/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C
M,38P.R8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[)SY/;B!-87)C:"`X+"`R,#$R+"!T:&4@0V]M<&%N
M>2!S;VQD(&%L;"!O9B!I=',@:6YT97)E<W0@:6X@061E;VYA($-L:6YI8V%L
M($QA8F]R871O<GDL($Q,0R`H=&AE("8C.#(R,#M,86(F(S@R,C$[*2!T;R!(
M87)T;&%B+"!,3$,L(&%N(&5N=&ET>2!C;VYT<F]L;&5D(&)Y('1H92!,86(F
M(S@R,3<[<R!F;W)M97(@;W=N97(L(&EN(&-O;G-I9&5R871I;VX@9F]R("AI
M*2!T:&4@:6UM961I871E(&%S<VEG;FUE;G0@;V8@=&AE($QA8B8C.#(Q-SMS
M(&]U='-T86YD:6YG(&%C8V]U;G1S(')E8V5I=F%B;&4@=7`@=&AR;W5G:"!T
M:&4@9&%T92!O9B!C;&]S:6YG+"!P;'5S("AI:2D@)#<P,"PP,#`@<&%Y86)L
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M=&4@,R`F(S@R,3$[($1I<V-O;G1I;G5E9"!/<&5R871I;VYS(&]F($%D96]N
M82!#;&EN:6-A;"!,86)O<F%T;W)Y+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S,U,C1F-C=F7S(S,3A?-#8S.5]A83<W
M7S0Y.30Y-#8T86%B,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S
M-3(T9C8W9E\R,S$X7S0V,SE?86$W-U\T.3DT.30V-&%A8C(O5V]R:W-H965T
M<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%4T<^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC
M:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;5&5X="!";&]C
M:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$
M)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/CQB/C,N)B,Q-C`[)B,Q-C`[)B,Q-C`[4W5M;6%R
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M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
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M97,N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
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M:&4@86QL;W=A;F-E(&9O<B!D;W5B=&9U;"!A8V-O=6YT<RX\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
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M9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"`R,#$Q+"!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&]N;'D@<W1R96%M(&]F(')E=F5N=64@=V%S(&QA8F]R871O<GD@<F5V
M96YU92XF(S$V,#M,86)O<F%T;W)Y(')E=F5N=65S(&%R92!A(&-O;7!O;F5N
M="!O9B!D:7-C;VYT:6YU960@;W!E<F%T:6]N<R!F;W(@=&AE('1H<F5E(&UO
M;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,B!A;F0@,C`Q,2X@/&D^4V5E($YO
M=&4@-"`F(S@R,3$[($1I<V-O;G1I;G5E9"!/<&5R871I;VYS(&]F($%D96]N
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M+VD^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
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M8F5C;VUE(&1U92X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
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M<RX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/;B!-87D@-BP@,C`Q,"P@=&AE
M($-O;7!A;GD@96YT97)E9"!I;G1O('1H92!-961A($%G<F5E;65N="!F;W(@
M=&AE(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!O9B!%9F9I
M<FUA("AO<F%L(&9L=7!I<G1I;F4I(&9O<B!F:6)R;VUY86QG:6$N)B,Q-C`[
M($%S(&-O;G-I9&5R871I;VX@9F]R('1H92!S=6)L:6-E;G-E+"!T:&4@0V]M
M<&%N>2!R96-E:79E9"!A;B!U<"UF<F]N="!P87EM96YT(&]F("0R+C4@;6EL
M;&EO;B!U<&]N(&5X96-U=&EO;B!O9B!T:&4@365D82!!9W)E96UE;G0N(%1H
M:7,@<&%Y;65N="!W87,@<F5C;W)D960@87,@;&EC96YS92!R979E;G5E(&EN
M(#(P,3`N(%!U<G-U86YT('1O('1H92!#;VUP86YY)B,X,C$W.W,@;&EC96YS
M92!A9W)E96UE;G0@=VET:"!-8TQE86X@2&]S<&ET86PL('1H92!#;VUP86YY
M('!A:60@,34E(&]F('1H92`D,BXU(&UI;&QI;VX@<&%Y;65N="`H)#,W-2PP
M,#`I+"!T:&%T('=A<R!N971T960@86=A:6YS="!T:&4@<F5V96YU97,@<F5C
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M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
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M;6%T960@<F5C96EP=',@9G)O;2!S=6-H('!A>65R<RX\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
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M('!E<FEO9"X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SY4:&4@0V]M<&%N>2!G96YE<F%T960@<F5I;6)U<G-E;65N
M=',@9G)O;28C,38P.S,@<VEG;FEF:6-A;G0@:6YS=7)A;F-E('!R;W9I9&5R
M<R!I;B!-87)C:"`S,2P@,C`Q,B!A;F0@,C`Q,2P@87,@9F]L;&]W<SH\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#@X)3L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
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M97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(^,C`Q,CPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
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M:6=N.B!C96YT97([('=I9'1H.B`S,R4[)SY!/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`S-"4[)SXV.#PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^
M)3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W
M:61T:#H@,S,E.R<^-CD\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3LG/B4\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/D(\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXU/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
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M/CQB/CQI/E)I<VMS(&%N9"!5;F-E<G1A:6YT:65S/"]I/CPO8CX\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
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M8G5S:6YE<W,@86-T:79I=&EE<RX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\
M8CX\:3Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]I/CPO8CX\+W`^#0H\
M<`T*('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T
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M;G1H<R!O<B!L97-S+B8C,38P.R8C,38P.T%T($UA<F-H(#,Q+"`R,#$R(&%N
M9"`R,#$Q+"!R97-P96-T:79E;'DL('1H92!#;VUP86YY(&AA9"!N;R!C87-H
M(&5Q=6EV86QE;G1S+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/CQB/CQI/B8C,38P.SPO:3X\+V(^/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^/&(^/&D^1V]O9'=I;&P\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/D=O;V1W:6QL('=A<R!N;W0@86UO<G1I>F5D+"!A;F0@=V%S('1E
M<W1E9"!F;W(@:6UP86ER;65N="!A="!T:&4@<F5P;W)T:6YG('5N:70@;&5V
M96P@86YN=6%L;'D@86YD(&EN(&EN=&5R:6T@<&5R:6]D<R!I9B!C97)T86EN
M(&5V96YT<R!O8V-U<B!I;F1I8V%T:6YG('1H870@=&AE(&-A<G)Y:6YG('9A
M;'5E(&]F(&=O;V1W:6QL('=A<R!I;7!A:7)E9"X@02!R97!O<G1I;F<@=6YI
M="!W87,@86X@;W!E<F%T:6YG('-E9VUE;G0@9F]R('=H:6-H(&1I<V-R971E
M(&9I;F%N8VEA;"!I;F9O<FUA=&EO;B!W87,@879A:6QA8FQE(&%N9"!W87,@
M<F5G=6QA<FQY(')E=FEE=V5D(&)Y(&UA;F%G96UE;G0N(%1H92!#;VUP86YY
M(&AA9"!O;F4@<F5P;W)T:6YG('5N:70L($%D96]N82!#;&EN:6-A;"!,86)O
M<F%T;W)Y+"!T;R!W:&EC:"!G;V]D=VEL;"!W87,@87-S:6=N960N/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^05-#($YO+B`S-3`@<F5Q=6ER97,@82!T=V\M
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M=&EO;G,N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^070@1&5C96UB97(@,S$L
M(#(P,3$L(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@0V]M<&%N>2!C;&%S<VEF
M>6EN9R!!9&5O;F$@0VQI;FEC86P@3&%B;W)A=&]R>2!A<R!D:7-C;VYT:6YU
M960@;W!E<F%T:6]N<RP@<')E=FEO=7-L>2!R96-O<F1E9"!G;V]D=VEL;"!W
M87,@8V]N<VED97)E9"!I;7!A:7)E9"X@/&D^4V5E($YO=&4@-"`F(S@R,3$[
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M;65S+"!S97)I9CLG/CQB/CQI/DYE="!%87)N:6YG<R`H3&]S<RD@<&5R(%-H
M87)E/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
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M<R`H;&]S<RD@<&5R('-H87)E(&ES(&-O;7!U=&5D(&)Y(&1I=FED:6YG(&YE
M="!I;F-O;64@*&QO<W,I(&QE<W,@<')E9F5R<F5D(&1I=FED96YD<R!B>2!T
M:&4@=V5I9VAT960@879E<F%G92!N=6UB97(@;V8@8V]M;6]N('-H87)E<R!O
M=71S=&%N9&EN9R!I;F-L=61I;F<@=&AE(&5F9F5C="!O9B!C;VUM;VX@<VAA
M<F4@97%U:79A;&5N=',N)B,Q-C`[4VEN8V4@=&AE($-O;7!A;GD@<F5P;W)T
M960@82!N970@;&]S<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C
M:"`S,2P@,C`Q,B!A;F0@,C`Q,2P@86QL(&-O;6UO;B!E<75I=F%L96YT('-H
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M,S$L(#(P,3(@=V5R92`S+#@T,RPT-C4@86YD(#(L-#$T+#DR,BP@<F5S<&5C
M=&EV96QY+"!A;F0@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@
M,S$L(#(P,3$@=V5R92`R+#(W,RPP-S(@86YD(#(L-34T+#8U,"P@<F5S<&5C
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M(&%N9"!$979E;&]P;65N="!#;W-T<SPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
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M<RX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#LF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y3=&]C:RU"
M87-E9"!087EM96YT($%R<F%N9V5M96YT<SPO:3X\+V(^/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^1V5N97)A;&QY+"!A;&P@9F]R;7,@;V8@<W1O8VLM8F%S
M960@<&%Y;65N=',L(&EN8VQU9&EN9R!S=&]C:R!O<'1I;VX@9W)A;G1S+"!W
M87)R86YT<RP@<F5S=')I8W1E9"!S=&]C:R!G<F%N=',@86YD('-T;V-K(&%P
M<')E8VEA=&EO;B!R:6=H=',@87)E(&UE87-U<F5D(&%T('1H96ER(&9A:7(@
M=F%L=64@;VX@=&AE(&%W87)D<R8C.#(Q-SL@9W)A;G0@9&%T92!T>7!I8V%L
M;'D@=7-I;F<@82!";&%C:RU38VAO;&5S('!R:6-I;F<@;6]D96PL(&)A<V5D
M(&]N('1H92!E<W1I;6%T960@;G5M8F5R(&]F(&%W87)D<R!T:&%T(&%R92!U
M;'1I;6%T96QY(&5X<&5C=&5D('1O('9E<W0N(%-T;V-K+6)A<V5D(&-O;7!E
M;G-A=&EO;B!A=V%R9',@:7-S=65D('1O(&YO;BUE;7!L;WEE97,@9F]R('-E
M<G9I8V5S(')E;F1E<F5D(&%R92!R96-O<F1E9"!A="!E:71H97(@=&AE(&9A
M:7(@=F%L=64@;V8@=&AE('-E<G9I8V5S(')E;F1E<F5D(&]R('1H92!F86ER
M('9A;'5E(&]F('1H92!S=&]C:RUB87-E9"!P87EM96YT+"!W:&EC:&5V97(@
M:7,@;6]R92!R96%D:6QY(&1E=&5R;6EN86)L92X@5&AE(&5X<&5N<V4@<F5S
M=6QT:6YG(&9R;VT@<W1O8VLM8F%S960@<&%Y;65N=',@87)E(')E8V]R9&5D
M(&EN(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E(&]R(&=E;F5R
M86P@86YD(&%D;6EN:7-T<F%T:79E(&5X<&5N<V4@:6X@=&AE(&-O;G-O;&ED
M871E9"!S=&%T96UE;G0@;V8@;W!E<F%T:6]N<RP@9&5P96YD:6YG(&]N('1H
M92!N871U<F4@;V8@=&AE('-E<G9I8V5S('!R;W9I9&5D+CPO<#X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB
M/CQI/B8C,38P.SPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
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M;W(@8V%S:`T*(&9L;W=S+CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.R8C,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'1A8FQE('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CL@;6%R9VEN+6)O='1O;3H@,'!X.R<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R<^/&(^,BX\+V(^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&(^
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]B
M/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=CX-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!T(#`@,'!T(#`N-6EN.R!T97AT+6EN9&5N=#H@+3`N
M-6EN.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQB/CQI/E!R:6YC
M:7!L97,@;V8@0V]N<V]L:61A=&EO;CPO:3X\+V(^/"]P/@T*/"]D:78^#0H\
M9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY!;&P@:6YT97(M
M8V]M<&%N>2!T<F%N<V%C=&EO;G,@86YD(&%C8V]U;G1S(&AA=F4@8F5E;B!E
M;&EM:6YA=&5D(&EN(&-O;G-O;&ED871I;VXN/"]P/@T*/"]D:78^#0H\9&EV
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\8CX\:3Y%;65R9VEN
M9R!F<F]M('1H92!$979E;&]P;65N="!3=&%G93PO:3X\+V(^/"]P/@T*/"]D
M:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY$=7)I
M;F<@=&AE('-E8V]N9"!Q=6%R=&5R(&]F(#(P,3`L('1H92!#;VUP86YY(&5M
M97)G960@9G)O;2!T:&4@9&5V96QO<&UE;G0@<W1A9V4N)B,Q-C`[)B,Q-C`[
M)B,Q-C`[02!D979E;&]P;65N="US=&%G92!E;G1E<G!R:7-E(&ES(&]N92!I
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M.T]N($UA>2`V+"`R,#$P+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!3
M=6)L:6-E;G-E($%G<F5E;65N="`H=&AE("8C.#(R,#M-961A($%G<F5E;65N
M="8C.#(R,3LI('=I=&@@365D828C,38P.T%"(&]F(%-W961E;B`H)B,X,C(P
M.TUE9&$F(S@R,C$[*2!A;F0@<F5C96EV960@86X@=7`M9G)O;G0@<&%Y;65N
M="!O9B`D,BXU(&UI;&QI;VXN(%1H92!E>&5C=71I;VX@;V8@=&AE($UE9&$@
M06=R965M96YT(&-O;6)I;F5D('=I=&@@<F5V96YU97,@9G)O;2!!9&5O;F$@
M0VQI;FEC86P@3&%B;W)A=&]R>2!W97)E(&%N(&EN9&EC871I;VX@;V8@=&AE
M(&-O;6UE;F-E;65N="!O9B!P<FEN8VEP86P@;W!E<F%T:6]N<RP@86YD('1H
M97)E9F]R92!D979E;&]P;65N="US=&%G92!R97!O<G1I;F<@=V%S(&YO(&QO
M;F=E<B!R97%U:7)E9"X\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P
M/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3LG/CQB/CQI/E5S92!O9B!%<W1I;6%T97,\+VD^
M/"]B/CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-
M"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J
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M<F%T:6YG(&QO<W-E<RX\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P
M/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
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M('1H;W-E(&5S=&EM871E<RX\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[
M/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQB/CQI/D%C8V]U;G1S(%)E8V5I=F%B
M;&4@86YD($%L;&]W86YC92!F;W(@1&]U8G1F=6P@06-C;W5N=',\+VD^/"]B
M/CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
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M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&(^/&D^
M4F5V96YU92!296-O9VYI=&EO;CPO:3X\+V(^/"]P/@T*/"]D:78^#0H\9&EV
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY4:&4@0V]M<&%N>2!R
M96-O<F1S(')E=F5N=64@=VAE;B!A;&P@;V8@=&AE(&9O;&QO=VEN9R!H879E
M(&]C8W5R<F5D.B`H,2D@<&5R<W5A<VEV92!E=FED96YC92!O9B!A;B!A<G)A
M;F=E;65N="!E>&ES=',L("@R*2!T:&4@<V5R=FEC92!I<R!C;VUP;&5T960@
M=VET:&]U="!F=7)T:&5R(&]B;&EG871I;VXL("@S*2!T:&4@<V%L97,@<')I
M8V4@=&\@=&AE(&-U<W1O;65R(&ES(&9I>&5D(&]R(&1E=&5R;6EN86)L92P@
M86YD("@T*2!C;VQL96-T86)I;&ET>2!I<R!R96%S;VYA8FQY(&%S<W5R960N
M)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!M:6QE<W1O;F4@
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M96YD960@1&5C96UB97(@,S$L(#(P,3`L('1H92!#;VUP86YY)B,X,C$W.W,@
M<W1R96%M<R!O9B!R979E;G5E('=E<F4@;&EC96YS92!R979E;G5E+"!L86)O
M<F%T;W)Y(')E=F5N=64@86YD(&=R86YT(')E=F5N=64N)B,Q-C`[)B,Q-C`[
M)B,Q-C`[3&%B;W)A=&]R>2!R979E;G5E<R!A<F4@82!C;VUP;VYE;G0@;V8@
M9&ES8V]N=&EN=65D(&]P97)A=&EO;G,@9F]R('1H92!Y96%R<R!E;F1E9"!$
M96-E;6)E<B`S,2P@,C`Q,2!A;F0@,C`Q,"X@4V5E#0H@3F]T92`S("8C.#(Q
M,3L@1&ES8V]N=&EN=65D($]P97)A=&EO;G,@;V8@061E;VYA($-L:6YI8V%L
M($QA8F]R871O<GDN/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M)SX\:3Y,:6-E;G-E(%)E=F5N=65S/"]I/CPO<#X-"CPO9&EV/@T*/&1I=CX-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^5&AE($-O;7!A;GDF(S@R
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M97,@8F5C;VUE(&1U92X\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P
M/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
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M96-E:79E9"!A;GD@<F]Y86QT>2!R979E;G5E<RX\+W`^#0H\+V1I=CX-"CQD
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D]N($UA>2`V+"`R
M,#$P+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@=&AE($UE9&$@06=R965M
M96YT(&9O<B!T:&4@9&5V96QO<&UE;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N
M(&]F($5F9FER;6$@*&]R86P@9FQU<&ER=&EN92D@9F]R(&9I8G)O;7EA;&=I
M82XF(S$V,#L@07,@8V]N<VED97)A=&EO;B!F;W(@=&AE('-U8FQI8V5N<V4L
M('1H92!#;VUP86YY(')E8V5I=F5D(&%N('5P+69R;VYT('!A>6UE;G0@;V8@
M)#(N-2!M:6QL:6]N('5P;VX@97AE8W5T:6]N(&]F('1H92!-961A($%G<F5E
M;65N="X@5&AI<R!P87EM96YT('=A<R!R96-O<F1E9"!A<R!L:6-E;G-E(')E
M=F5N=64@:6X@,C`Q,"X@4'5R<W5A;G0@=&\@=&AE($-O;7!A;GDF(S@R,3<[
M<R!L:6-E;G-E(&%G<F5E;65N="!W:71H($UC3&5A;B!(;W-P:71A;"P@=&AE
M($-O;7!A;GD@<&%I9"`Q-24@;V8@=&AE("0R+C4@;6EL;&EO;B!P87EM96YT
M("@D,S<U+#`P,"DL('1H870@=V%S(&YE='1E9"!A9V%I;G-T('1H92!R979E
M;G5E<R!R96-E:79E9"!F<F]M($UE9&$@04(N(%1H92!#;VUP86YY(&ES(&%L
M<V\@96YT:71L960@=&\@861D:71I;VYA;"!M:6QE<W1O;F4@<&%Y;65N=',@
M;V8@)#4@;6EL;&EO;B!U<&]N(&9I;&EN9R!O9B!A;B!.1$$@=VET:"!T:&4@
M52Y3+B!&1$$@9F]R(&]R86P@9FQU<&ER=&EN92!F;W(@9FEB<F]M>6%L9VEA
M(&%N9"`D,3`@;6EL;&EO;B!U<&]N(&UA<FME=&EN9R!A<'!R;W9A;"X@5&AE
M($UE9&$@06=R965M96YT(&%L<V\@<')O=FED97,@=&AA="!T:&4@0V]M<&%N
M>2!I<R!E;G1I=&QE9"!T;R!R96-E:79E(&YE="!R;WEA;'1I97,@;V8@-R4@
M;V8@;F5T('-A;&5S(&]F(&]R86P@9FQU<&ER=&EN92!A<'!R;W9E9"!F;W(@
M=&AE('1R96%T;65N="!O9B!F:6)R;VUY86QG:6$@8V]V97)E9"!B>2!I<W-U
M960@<&%T96YT(&-L86EM<R!I;B!T:&4@52Y3+B!A;F0@2F%P86XN)B,Q-C`[
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M,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I
M=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R<^)B,Q-C`[(#QI/DQA8F]R871O<GD@4F5V96YU97,\+VD^
M/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I
M=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[)SY4:&4@0V]M<&%N>2!P<FEM87)I;'D@<F5C;V=N:7IE9"!R979E;G5E
M(&9O<B!S97)V:6-E<R!R96YD97)E9"!U<&]N(&-O;7!L971I;VX@;V8@=&AE
M('1E<W1I;F<@<')O8V5S<RX@0FEL;&EN9R!F;W(@<V5R=FEC97,@<F5I;6)U
M<G-E9"!B>2!T:&ER9"UP87)T>2!P87EE<G,L(&EN8VQU9&EN9R!-961I8V%R
M92!A;F0@365D:6-A:60L('=E<F4@<F5C;W)D960@87,@<F5V96YU97,L(&YE
M="!O9B!A;&QO=V%N8V5S(&9O<B!D:69F97)E;F-E<R!B971W965N(&%M;W5N
M=',@8FEL;&5D(&%N9"!T:&4@97-T:6UA=&5D(')E8V5I<'1S(&9R;VT@<W5C
M:"!P87EE<G,N/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO
M9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
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M86-H('!E<FEO9"X\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*
M/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3LG/E1H92!#;VUP86YY(&=E;F5R871E9"!R96EM8G5R
M<V5M96YT(&9R;VTF(S$V,#MT:')E92!S:6=N:69I8V%N="!I;G-U<F%N8V4@
M<')O=FED97)S(&EN(#(P,3$@86YD(#(P,3`N/"]P/@T*/"]D:78^#0H\9&EV
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV
M/@T*/&1I=CX-"CQT86)L92!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=W:61T
M:#H@-S`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
M9#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R<@8V]L<W!A;CTS1#(^
M,C`Q,3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
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M/'1D('-T>6QE/3-$)W=I9'1H.B`S,24[('1E>'0M86QI9VXZ(&-E;G1E<CLG
M/D$\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`S
M,24[('1E>'0M86QI9VXZ(')I9VAT.R<^-S`\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B4\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.@T*(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`S,"4[('1E>'0M86QI9VXZ(')I9VAT.R<^
M-C4\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@
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M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C$Q/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SY#/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
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M)SXE/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I
M=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[)SX\:3Y'<F%N="!2979E;G5E
M<SPO:3X\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M="`P.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D]N($YO=F5M8F5R
M(#0L(#(P,3`L('1H92!#;VUP86YY('=A<R!A=V%R9&5D('1W;R!G<F%N=',@
M=&]T86QI;F<@)#0X.2PP,#`@=6YD97(@=&AE(%%U86QI9GEI;F<@5&AE<F%P
M975T:6,@1&ES8V]V97)Y(%!R;VIE8W0@*%%41%`I(%!R;V=R86T@=&\@<W5P
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M=&AE<F%P975T:6-S('=H:6-H('-H;W<@<&]T96YT:6%L('1O.B`H82DF(S$V
M,#MR97-U;'0@:6X@;F5W('1H97)A<&EE<R!T:&%T(&5I=&AE<B!T<F5A="!A
M<F5A<R!O9B!U;FUE="!M961I8V%L(&YE960L(&]R('!R979E;G0L(&1E=&5C
M="P@;W(@=')E870@8VAR;VYI8R!O<B!A8W5T92!D:7-E87-E<R!A;F0@8V]N
M9&ET:6]N<SL@*&(I)B,Q-C`[<F5D=6-E(&QO;F<M=&5R;2!H96%L=&@@8V%R
M92!C;W-T<R!I;B!T:&4@52Y3+CL@;W(@*&,I)B,Q-C`[<VEG;FEF:6-A;G1L
M>2!A9'9A;F-E('1H92!G;V%L(&]F(&-U<FEN9R!C86YC97(@=VET:&EN(&$@
M,S`M>65A<B!P97)I;V0N)B,Q-C`[)B,Q-C`[06QL(&=R86YT(&EN8V]M92!W
M87,@<F5C;V=N:7IE9"!I;B`R,#$P(&%N9"!T:&5R92!A<F4@;F\@9G5T=7)E
M(&]B;&EG871I;VYS(&%S<V]C:6%T960@=VET:"!T:&5S92!G<F%N=',N/"]P
M/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M)SY$=7)I;F<@,C`Q,"!A;F0@36%R8V@@,C`Q,2P@86QL(&%M;W5N=',@87=A
M<F1E9"!U;F1E<B!T:&5S92!G<F%N=',@:&%D(&)E96X@<F5C96EV960N(%-E
M92!.;W1E(#D@<F5G87)D:6YG('1H92!T87AA8FEL:71Y(&]F(&=R86YT(')E
M=F5N=65S+CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I
M=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R<^/&D^4F5V96YU
M97,L(&YE="`H:6X@=&AO=7-A;F1S*3PO:3X\+W`^#0H\+V1I=CX-"CQD:78^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R<^)B,Q-C`[/"]P/@T*/"]D:78^
M#0H\9&EV/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`X-24[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`P+C<U:6X[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@<&%D
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M96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO
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M<F%P/C(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^,C`Q,#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`V-"4[('1E>'0M86QI
M9VXZ(&QE9G0[)SY,:6-E;G-E(')E=F5N=64\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$U)3L@=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S
M='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$U)3L@=&5X="UA;&EG;CH@<FEG
M:'0[)SXR+#4P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,7!T.R<^3&EC96YS92!F965S/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[
M)SXM/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
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M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
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M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SY'<F%N
M="!R979E;G5E/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0[)SXT.#D\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M5&]T86P@<F5V96YU97,L(&YE=#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXR+#8Q-#PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ#0H@,BXU<'0[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG
M/CQB/CQI/E)I<VMS(&%N9"!5;F-E<G1A:6YT:65S/"]I/CPO8CX\+W`^#0H\
M+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/E1H
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M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^/&(^/&D^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<SPO:3X\+V(^
M/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I
M=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[)SY#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S(&EN8VQU9&4@8V%S:"!A
M;F0@:&EG:&QY(&QI<75I9"!S:&]R="UT97)M(&EN=F5S=&UE;G1S('=I=&@@
M;W)I9VEN86P@;6%T=7)I=&EE<R!O9B!T:')E92!M;VYT:',@;W(@;&5S<RXF
M(S$V,#LF(S$V,#M!="!$96-E;6)E<B`S,2P@,C`Q,2!A;F0@,C`Q,"P@<F5S
M<&5C=&EV96QY+"!T:&4@0V]M<&%N>2!H860@;F\@8V%S:"!E<75I=F%L96YT
M<RX\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\
M9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3LG/CQB/CQI/D-L87-S:69I8V%T:6]N(&]F($UA<FME=&%B;&4@4V5C
M=7)I=&EE<R!A<R!(96QD('1O($UA='5R:71Y+"!4<F%D:6YG+"!A;F0@079A
M:6QA8FQE(&9O<B!386QE/"]I/CPO8CX\+W`^#0H\+V1I=CX-"CQD:78^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
M)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
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M,S$L(#(P,3$@86YD(#(P,3`L(')E<W!E8W1I=F5L>2P@=&AE($-O;7!A;GD@
M:&%D(&YO(&UA<FME=&%B;&4@<V5C=7)I=&EE<RX\+W`^#0H\+V1I=CX-"CQD
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D1U<FEN9R!T:&4@
M>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2P@=&AE($-O;7!A;GD@:&5L
M9"!I;G9E<W1M96YT<R!I;B!M87)K971A8FQE('-E8W5R:71I97,@=&AA="!W
M97)E(&-L87-S:69I960@87,@:&5L9"!T;R!M871U<FET>2!A;F0@8V]N<VES
M=&5D(&]F(&-O<G!O<F%T92!B;VYD<R!A;F0@8V5R=&EF:6-A=&5S(&]F(&1E
M<&]S:71S(&%S(&9O;&QO=W,@/&D^*&EN('1H;W5S86YD<RD\+VD^(#H\+W`^
M#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*
M/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`V,"4[(&)O<F1E<BUC;VQL87!S93H@
M8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O
M;&0[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/D1E8V5M
M8F5R(#,Q+"`R,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M
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M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG
M/E!R;V-E961S(&9R;VT@<VAO<G0M=&5R;2!I;G9E<W1M96YT<SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C0L,CDS/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O
M;3H@,7!T.R<^3&]S<R!O;B!S86QE(&]F('-H;W)T+71E<FT@:6YV97-T;65N
M=',\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/C(P/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/D9A:7(@=F%L=64\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^
M)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I
M=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[)SXF(S$V,#L\+W`^#0H\+V1I
M=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R<^/&(^/&D^4')O<&5R='D@86YD($5Q=6EP;65N=#PO:3X\
M+V(^/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*
M/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU
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M/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#LG
M/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQT86)L92!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=W:61T:#H@.#4E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#0Y)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P
M861D:6YG+7)I9VAT.B`P+CAP=#L@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M
M86QI9VXZ(&-E;G1E<CLG/D%S<V5T)B,Q-C`[1&5S8W)I<'1I;VX\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`T)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[
M('1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#0W)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@9F]N="UW96EG:'0Z(&)O;&0[('1E
M>'0M86QI9VXZ(&-E;G1E<CLG/D5S=&EM871E9"8C,38P.U5S969U;"8C,38P
M.TQI9F4\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[
M)SY/9F9I8V4@97%U:7!M96YT(&%N9"!F=7)N:71U<F4\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT
M97([)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R!T97AT+6%L:6=N.B!C96YT97([)SXU)B,Q-C`[)B,Q-C`[>65A
M<G,\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SY,
M86)O<F%T;W)Y(&5Q=6EP;65N=#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M
M86QI9VXZ(&-E;G1E<CLG/C<M,3`@>65A<G,\+W1D/@T*/"]T<CX-"CQT<B!S
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M9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T
M.R<@;F]W<F%P/3-$;F]W<F%P/DQE87-E:&]L9"!I;7!R;W9E;65N=',@86YD
M(&9I>'1U<F5S/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P
M+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[
M('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#Y,97-S97(@
M;V8@97-T:6UA=&5D('5S969U;"!O<B!L:69E(&]F(&QE87-E/"]T9#X-"CPO
M='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY$97!R96-I
M871I;VX@97AP96YS92!W87,@87!P<F]X:6UA=&5L>2`D,30T+#`P,"!A;F0@
M)#,T-BPP,#`@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q
M,2!A;F0@,C`Q,"P@<F5S<&5C=&EV96QY+B!7:&5N(&%S<V5T<R!A<F4@9&ES
M<&]S960@;V8L('1H92!C;W-T(&%N9"!A8V-U;75L871E9"!D97!R96-I871I
M;VX@87)E(')E;6]V960@9G)O;2!T:&4@86-C;W5N=',N(%)E<&%I<G,@86YD
M(&UA:6YT96YA;F-E(&%R92!C:&%R9V5D('1O(&5X<&5N<V4@87,@:6YC=7)R
M960N/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*
M/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SY$=7)I;F<@,C`Q,"P@=&AE($-O;7!A;GD@<F5V:65W960@<')O
M<&5R='D@86YD(&5Q=6EP;65N="!F;W(@:6UP86ER;65N="!A;F0@9&5T97)M
M:6YE9"!T:&%T(&-E<G1A:6X@:71E;7,@:&%D(&)E96X@:6UP86ER960@9'5E
M('1O(&]B<V]L97-C96YC92X@07,@82!R97-U;'0@;V8@=&AI<R!R979I97<L
M('1H92!#;VUP86YY(')E8V]R9&5D(&%N(&EM<&%I<FUE;G0@;&]S<R!O9B!A
M<'!R;WAI;6%T96QY("0Q,C$L,#`P+B!&;W(@=&AE('EE87(@96YD960@1&5C
M96UB97(@,S$L(#(P,3$L('1H97)E('=E<F4@;F\@<VEG;FEF:6-A;G0@979E
M;G1S(&]R(&-H86YG97,@:6X@8VER8W5M<W1A;F-E<R!I9&5N=&EF:65D(&)Y
M('1H92!#;VUP86YY('1H870@=V]U;&0@:6YD:6-A=&4@=&AA="!T:&4@8V%R
M<GEI;F<@=F%L=64@;V8@86X@87-S970@=V%S(&YO="!R96-O=F5R86)L92X\
M+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3LG/CQB/CQI/DQO;F<M3&EV960@07-S971S/"]I/CPO8CX\+W`^#0H\+V1I
M=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/E1H92!#
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M<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF
M(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&(^/&D^1V]O9'=I;&P\+VD^
M/"]B/CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-
M"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J
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M8F]R871O<GDL('1O('=H:6-H(&=O;V1W:6QL('=A<R!A<W-I9VYE9"X\+W`^
M#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG
M/D%30R!.;RX@,S4P(')E<75I<F5S(&$@='=O+7-T97`@87!P<F]A8V@@=&\@
M=&5S="!G;V]D=VEL;"!F;W(@:6UP86ER;65N="!F;W(@96%C:"!R97!O<G1I
M;F<@=6YI="X@5&AE(&9I<G-T('-T97`@=&5S=',@9F]R(&EM<&%I<FUE;G0@
M8GD@87!P;'EI;F<@9F%I<B!V86QU92UB87-E9"!T97-T<R!T;R!A(')E<&]R
M=&EN9R!U;FET+B!4:&4@<V5C;VYD('-T97`L(&EF(&1E96UE9"!N96-E<W-A
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M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^070@1&5C
M96UB97(@,S$L(#(P,3$L(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@0V]M<&%N
M>2!C;&%S<VEF>6EN9R!!9&5O;F$@0VQI;FEC86P@3&%B;W)A=&]R>2!A<R!D
M:7-C;VYT:6YU960@;W!E<F%T:6]N<RP@<')E=FEO=7-L>2!R96-O<F1E9"!G
M;V]D=VEL;"!W87,@8V]N<VED97)E9"!I;7!A:7)E9"X@4V5E($YO=&4@,R`F
M(S@R,3$[($1I<V-O;G1I;G5E9"!/<&5R871I;VYS(&]F($%D96]N82!#;&EN
M:6-A;"!,86)O<F%T;W)Y+CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\
M+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R<^/&(^/&D^0F5N969I8VEA;"!#;VYV97)S
M:6]N($9E871U<F4\+VD^/"]B/CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V
M,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^1F]R(&-O;G9E;G1I;VYA;"!C;VYV
M97)T:6)L92!D96)T('=H97)E('1H92!R871E(&]F(&-O;G9E<G-I;VX@:7,@
M8F5L;W<@;6%R:V5T('9A;'5E+"!T:&4@0V]M<&%N>2!R96-O<F1S(&$@(F)E
M;F5F:6-I86P@8V]N=F5R<VEO;B!F96%T=7)E(B`H0D-&*2!A;F0@<F5L871E
M9"!D96)T#0H@9&ES8V]U;G0N/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P
M.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[
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M/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\
M8CX\:3Y$97)I=F%T:79E($QI86)I;&ET:65S/"]I/CPO8CX\+W`^#0H\+V1I
M=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D9A:7(@
M=F%L=64@86-C;W5N=&EN9R!R97%U:7)E<R!B:69U<F-A=&EO;B!O9B!E;6)E
M9&1E9"!D97)I=F%T:79E(&EN<W1R=6UE;G1S('-U8V@@87,@8V]N=F5R<VEO
M;B!F96%T=7)E<R!I;B!C;VYV97)T:6)L92!D96)T(&]R(&5Q=6ET>2!I;G-T
M<G5M96YT<RP@86YD(&UE87-U<F5M96YT(&]F('1H96ER(&9A:7(@=F%L=64@
M9F]R(&%C8V]U;G1I;F<@<'5R<&]S97,N($EN)B,Q-C`[9&5T97)M:6YI;F<@
M=&AE(&%P<')O<')I871E(&9A:7(@=F%L=64L('1H92!#;VUP86YY('5S97,@
M=&AE($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@;6]D96PN($EN)B,Q
M-C`[87-S97-S:6YG('1H92!C;VYV97)T:6)L92!D96)T(&EN<W1R=6UE;G1S
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M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[)SXF(S$V,#LF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
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M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&(^/&D^1&5B
M="!)<W-U92!#;W-T<R!A;F0@1&5B="!$:7-C;W5N=#PO:3X\+V(^/"]P/@T*
M/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY4
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M86UO=6YT<R!I<R!I;6UE9&EA=&5L>2!E>'!E;G-E9"X\+W`^#0H\+V1I=CX-
M"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQB/CQI/D]R
M:6=I;F%L($ES<W5E($1I<V-O=6YT/"]I/CPO8CX\+W`^#0H\+V1I=CX-"CQD
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D9O<B!C97)T86EN
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M;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\
M+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R<^/&(^/&D^3F5T($5A<FYI;F=S("A,;W-S*2!P97(@
M4VAA<F4\+VD^/"]B/CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^
M#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT
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M('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2!A;F0@,C`Q,"P@
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M96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q('=E<F4@,BPY-SDL,#$P(&%N
M9"`S+#(U.2PQ.#8L(')E<W!E8W1I=F5L>2P@86YD(&9O<B!T:&4@>65A<B!E
M;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"!W97)E(#$L.3DP+#0T-"!A;F0@,2PP
M-S`L-#<R+"!R97-P96-T:79E;'DN/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C
M,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\8CX\:3Y297-E87)C:"!A;F0@
M1&5V96QO<&UE;G0@0V]S=',\+VD^/"]B/CPO<#X-"CPO9&EV/@T*/&1I=CX-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^5&AE($-O;7!A;GD@97AP
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M-SMS('!R;V1U8W0@8V%N9&ED871E<RX\+W`^#0H\+V1I=CX-"CQD:78^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
M)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQB/CQI/D9A:7(@5F%L=64@
M;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S/"]I/CPO8CX\+W`^#0H\+V1I=CX-
M"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/E1H92!F86ER
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M=&EE<B!H:65R87)C:'D@87,@9F]L;&]W<SH\+W`^#0H\+V1I=CX-"CQD:78^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'1A8FQE('-T>6QE/3-$
M)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#,E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,R4[('!A9&1I;F<M
M<FEG:'0Z(#`N.'!T.R<^/&9O;G0^)B,Q.#,[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#DT)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[)SY,979E;"`Q(&EN<'5T<SH@475O=&5D('!R
M:6-E<R`H=6YA9&IU<W1E9"DF(S$V,#MF;W(@:61E;G1I8V%L(&%S<V5T<R!O
M<B!L:6%B:6QI=&EE<R!I;B!A8W1I=F4@;6%R:V5T<SL\+W1D/@T*/"]T<CX-
M"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M="`P(#!P="`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z("TP+C(U:6X[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\=&%B
M;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L
M;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W
M:61T:#H@,R4[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`S
M)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SX\9F]N=#XF(S$X,SL\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@.30E.R!P861D:6YG+7)I9VAT
M.B`P+CAP=#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/DQE=F5L(#(@:6YP=71S
M.B!);G!U=',L(&]T:&5R('1H86X@<75O=&5D('!R:6-E<R!I;F-L=61E9"!I
M;B!,979E;"`Q('1H870@87)E(&]B<V5R=F%B;&4@96ET:&5R(&1I<F5C=&QY
M(&]R(&EN9&ER96-T;'D[(&%N9#PO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO
M9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T(#`N-6EN
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3`N,C5I;CLG
M/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQT86)L92!S='EL93TS1"=W
M:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`S)3LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#,E.R!P861D:6YG+7)I
M9VAT.B`P+CAP=#LG/CQF;VYT/B8C,3@S.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Y-"4[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R<^3&5V96P@,R!I;G!U=',Z(%5N;V)S97)V86)L
M92!I;G!U=',@9F]R('=H:6-H('1H97)E(&ES(&QI='1L92!O<B!N;R!M87)K
M970@9&%T82P@=VAI8V@@<F5Q=6ER92!T:&4@<F5P;W)T:6YG(&5N=&ET>2!T
M;R!D979E;&]P(&ET<R!O=VX@87-S=6UP=&EO;G,N/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*
M/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU
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M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
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M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^/&(^/&D^4W1O8VLM0F%S960@4&%Y;65N="!!<G)A;F=E;65N=',\
M+VD^/"]B/CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I
M=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
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M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&(^/&D^
M26YC;VUE(%1A>&5S/"]I/CPO8CX\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q
M-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/E1H92!#;VUP86YY(&%C8V]U;G1S
M(&9O<B!I;F-O;64@=&%X97,@:6X@86-C;W)D86YC92!W:71H(&%C8V]U;G1I
M;F<@9W5I9&%N8V4@;F]W(&-O9&EF:65D(&%S($9!4T(@05-#(%1O<&EC(#<T
M,"P@)B,X,C(P.R`\:3Y);F-O;64@5&%X97,\+VD^("PF(S@R,C$[('=H:6-H
M(')E<75I<F5S('1H870@=&AE($-O;7!A;GD@<F5C;V=N:7IE(&1E9F5R<F5D
M('1A>"!L:6%B:6QI=&EE<R!A;F0@87-S971S(&)A<V5D(&]N('1H92!D:69F
M97)E;F-E<R!B971W965N('1H92!F:6YA;F-I86P@<W1A=&5M96YT(&-A<G)Y
M:6YG(&%M;W5N=',@86YD('1H92!T87@@8F%S97,@;V8@87-S971S(&%N9"!L
M:6%B:6QI=&EE<RP@=7-I;F<@96YA8W1E9"!T87@@<F%T97,@:6X@969F96-T
M(&EN('1H92!Y96%R<R!T:&4@9&EF9F5R96YC97,@87)E(&5X<&5C=&5D('1O
M(')E=F5R<V4N($1E9F5R<F5D(&EN8V]M92!T87@@8F5N969I="`H97AP96YS
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M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY!8V-O=6YT:6YG(&=U
M:61A;F-E(&YO=R!C;V1I9FEE9"!A<R!&05-"($%30R!4;W!I8R`W-#`M,C`L
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M96YS92X@070@1&5C96UB97(@,S$L(#(P,3$@86YD(#(P,3`L(')E<W!E8W1I
M=F5L>2P@=&AE($-O;7!A;GD@9&ED(&YO="!R96-O<F0@86YY(&QI86)I;&ET
M:65S(&9O<B!U;F-E<G1A:6X@=&%X('!O<VET:6]N<RX\+W`^#0H\+V1I=CX-
M"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQB/CQI/E)E
M8V5N="!!8V-O=6YT:6YG#0H@4')O;F]U;F-E;65N=',\+VD^/"]B/CPO<#X-
M"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
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M96-E;6)E<B`Q-2P@,C`Q,2X@5&AE(&%D;W!T:6]N(&]F('1H:7,@9W5I9&%N
M8V4@:7,@;F]T(&5X<&5C=&5D('1O(&AA=F4@82!M871E<FEA;"!I;7!A8W0@
M;VX@=&AE($-O;7!A;GDF(S@R,3<[<R!F:6YA;F-I86P@<&]S:71I;VX@;W(@
M<F5S=6QT<R!O9B!O<&5R871I;VYS+CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF
M(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^26X@4V5P=&5M8F5R(#(P,3$L
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M;W(@9FES8V%L('EE87)S(&)E9VEN;FEN9R!A9G1E<B!$96-E;6)E<B`Q-2P@
M,C`Q,2P@=VET:"!E87)L>2!A9&]P=&EO;B!P97)M:71T960N(%1H92!A9&]P
M=&EO;B!O9B!T:&ES(&=U:61A;F-E(&ES(&YO="!E>'!E8W1E9"!T;R!H879E
M(&$@;6%T97)I86P@:6UP86-T(&]N('1H92!#;VUP86YY)B,X,C$W.W,@9FEN
M86YC:6%L('!O<VET:6]N(&]R(')E<W5L=',@;V8@;W!E<F%T:6]N<RX\+W`^
M#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'0@,#LG/CQB/CQI/E)E8VQA<W-I9FEC871I
M;VYS/"]I/CPO8CX\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P="`P.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/E1O(&-O
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M+"!R97-U;'1S(&]F(&]P97)A=&EO;G,@;W(@8V%S:"!F;&]W<RX\+W`^#0H\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%4T<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&ES8V]N=&EN=65D($]P
M97)A=&EO;G,@;V8@061E;VYA($-L:6YI8V%L($QA8F]R871O<GD@86YD($YO
M=&4@4F5C96EV86)L93QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&ES8V]N=&EN=65D($]P
M97)A=&EO;G,@86YD($1I<W!O<V%L($=R;W5P<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I<W!O<V%L
M($=R;W5P<RP@26YC;'5D:6YG($1I<V-O;G1I;G5E9"!/<&5R871I;VYS+"!$
M:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN+71O<#H@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
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M:6]N(')E8V5I=F5D('=A<R`H:2D@=&AE(&EM;65D:6%T92!A<W-I9VYM96YT
M(&]F('1H92!,86(F(S@R,3<[<R!O=71S=&%N9&EN9R!A8V-O=6YT<R!R96-E
M:79A8FQE('5P('1H<F]U9V@@=&AE(&1A=&4@;V8@8VQO<VEN9RP@<&QU<R`H
M:6DI("0W,#`L,#`P('!A>6%B;&4@<'5R<W5A;G0@=&\@=&AE('1E<FUS(&]F
M(&$@='=O+7EE87(@;F]N+7)E8V]U<G-E('!R;VUI<W-O<GD@;F]T92!B96%R
M:6YG(&EN=&5R97-T(&%T(#4N-R4@<&5R(&%N;G5M('-E8W5R960@8GD@86QL
M(&]F('1H92!A<W-E=',@;V8@=&AE($QA8BX@5&AE(&YO=&4@86YD(&%L;"!U
M;G!A:60@:6YT97)E<W0@87)E(&1U92!O;B!-87)C:"`Q+"`R,#$T+CPO<#X-
M"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/DEN
M(&%C8V]R9&%N8V4@=VET:"!!4T,@5&]P:6,@,C`U+3(P("8C.#(R,#L@/&D^
M4')E<V5N=&%T:6]N(&]F($9I;F%N8VEA;"!3=&%T96UE;G1S)B,X,C$R.T1I
M<V-O;G1I;G5E9"!/<&5R871I;VYS/"]I/B`F(S@R,C$[("A!4T,@,C`U+3(P
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M=',@870@36%R8V@@,S$L(#(P,3(L(&%N9"!$96-E;6)E<B`S,2P@,C`Q,2P@
M86YD(&-O;G-I<W0@;V8@=&AE(&9O;&QO=VEN9R`\:3XH:6X@=&AO=7-A;F1S
M*3H\+VD^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TP+C5I;CL@
M;6%R9VEN.B`P<'0@,'!X(#!P="`P+C5I;CL@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.R8C,38P.SPO<#X-"CQT
M86)L92!S='EL93TS1"=W:61T:#H@.#@E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US='EL93H@:71A;&EC.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^36%R8V@@,S$L(#(P,3(\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W
M<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^07-S
M971S(&]F(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS.CPO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@<&%D9&EN9RUL969T.B`Y<'0[('=I9'1H.B`W
M,"4[)SY0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('=I9'1H.B`Q)3LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3(E.R<^+3PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
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M=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R!P861D:6YG+6QE9G0Z(#EP=#LG/E1O=&%L(&%S<V5T<SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
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M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^5&AE('-U;6UA<FEZ960@<W1A=&5M96YT(&]F
M(&]P97)A=&EO;G,@9&%T82!F;W(@061E;VYA($-L:6YI8V%L($QA8F]R871O
M<GD@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P,3(@
M86YD($UA<F-H(#,Q+"`R,#$Q(&%R92!A<R!F;VQL;W=S(#QI/BAI;B!T:&]U
M<V%N9',I.CPO:3X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\
M:3XF(S$V,#L\+VD^/"]P/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`X."4[
M(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C
M;VQS<&%N/3-$-CY-87)C:"`S,2P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T
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M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I
M9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(^,C`Q,3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF
M(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#<P)3LG/DQA8F]R
M871O<GD@9F5E<RP@;F5T/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!W:61T:#H@,3(E.R<^,3$U/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,B4[)SXS,C,\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY/<&5R871I;F<@0V]S=',@86YD($5X
M<&5N<V5S.CPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.@T*(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R!P861D
M:6YG+6QE9G0Z(#`N,C1I;CLG/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E
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M969T.R!P861D:6YG+6)O='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z(#`N,C1I
M;CLG/D-O<W0@;V8F(S$V,#L@;&%B;W)A=&]R>2!S97)V:6-E<SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT.R<^,3$V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[)SXR-3$\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@,"XR-&EN
M.R<^5&]T86P@;W!E<F%T:6YG(&-O<W1S(&%N9"!E>'!E;G-E<SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT.R<^,30S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[)SXR.#8\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/DEN8V]M92`H;&]S<RD@9G)O;2!D:7-C;VYT:6YU960@;W!E<F%T
M:6]N<SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
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M;&EG;CH@8F]T=&]M.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY/=&AE
M<B!);F-O;64Z/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R!P861D
M:6YG+6QE9G0Z(#`N,3)I;CLG/D=A:6X@;VX@=&AE('-A;&4@;V8@061E;VYA
M($-L:6YI8V%L($QA8F]R871O<GD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/C8W-SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/DYE="!I;F-O;64@9G)O;2!D:7-C;VYT:6YU960@;W!E<F%T:6]N<SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R<^-C0Y/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
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M/@T*/"]T<CX-"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQT86)L92!S='EL93TS1"=M87)G
M:6XM=&]P.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;BUB;W1T;VTZ(#!P>#LG(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#LG/CQB/C,N/"]B/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQB/D1I
M<V-O;G1I;G5E9"!/<&5R871I;VYS(&]F($%D96]N82!#;&EN:6-A;"!,86)O
M<F%T;W)Y/"]B/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I
M=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T(#`N-6EN.R!T97AT+6EN
M9&5N=#H@+3`N-6EN.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D]N
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M92!C;VYS:61E<F%T:6]N(')E8V5I=F5D('=A<R`H:2D@=&AE(&EM;65D:6%T
M92!A<W-I9VYM96YT(&]F('1H92!,86(F(S@R,3<[<R!O=71S=&%N9&EN9R!A
M8V-O=6YT<R!R96-E:79A8FQE('5P('1H<F]U9V@@=&AE(&1A=&4@;V8@8VQO
M<VEN9RP@<&QU<R`H:6DI("0W,#`L,#`P('!A>6%B;&4@<'5R<W5A;G0@=&\@
M=&AE('1E<FUS(&]F(&$@='=O+7EE87(@;F]N+7)E8V]U<G-E('!R;VUI<W-O
M<GD@;F]T92!S96-U<F5D(&)Y(&%L;"!O9B!T:&4@87-S971S(&]F('1H92!,
M86(N/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@
M,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY);B!A8V-O<F1A;F-E
M('=I=&@@05-#(%1O<&EC(#(P-2TR,"`F(S@R,C`[/&D^4')E<V5N=&%T:6]N
M(&]F($9I;F%N8VEA;"!3=&%T96UE;G1S)B,X,C$R.T1I<V-O;G1I;G5E9"!/
M<&5R871I;VYS/"]I/B8C.#(R,3L@*$%30R`R,#4M,C`I+"!T:&4@0V]M<&%N
M>2!D971E<FUI;F5D('1H870@=&AE('-A;&4@;V8@=&AE($QA8B!S:&]U;&0@
M8F4@8VQA<W-I9FEE9"!A<R`F(S@R,C`[:&5L9"!F;W(@<V%L928C.#(R,3L@
M870@1&5C96UB97(@,S$L(#(P,3$N($EN(&%C8V]R9&%N8V4@=VET:"!!0U,@
M,C`U+3(P(&%L;"!O9B!T:&4@9F]L;&]W:6YG(&-R:71E<FEA(&UU<W0@8F4@
M;65T(&9O<B!A;B!E;G1I='D@=&\@8F4@8VQA<W-I9FEE9"!A<R`F(S@R,C`[
M:&5L9"!F;W(@<V%L928C.#(R,3LZ/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C
M,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQT86)L92!S='EL93TS1"=W:61T
M:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`V)3L@=&5X="UA
M;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#8E.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG/CQF;VYT/B8C,3@S.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`X."4[('!A9&1I;F<M
M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^36%N86=E;65N
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M.B`P+CAP=#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/E1H92!A<W-E="!I<R!A
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M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^/&9O;G0^
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M)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`P+CAP=#LG/CQF;VYT/B8C,3@S.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N
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M:'0Z(#`N.'!T.R<^/&9O;G0^)B,Q.#,[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[)SY4:&4@87-S970@:7,@8F5I;F<@86-T:79E;'D@;6%R:V5T960@9F]R
M('-A;&4@870@82!P<FEC92!T:&%T(&ES(')E87-O;F%B;&4@:6X@<F5L871I
M;VX@=&\@:71S(&-U<G)E;G0@9F%I<B!V86QU92X\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\
M9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S
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M=&EN=65D(&]P97)A=&EO;G,F(S@R,C$[(&%N9"`F(S@R,C`[3&EA8FEL:71I
M97,@;V8@9&ES8V]N=&EN=65D(&]P97)A=&EO;G,L)B,X,C(Q.R!R97-P96-T
M:79E;'DL(&EN('1H92!A8V-O;7!A;GEI;F<@0V]N<V]L:61A=&5D($)A;&%N
M8V4@4VAE971S(&%T($1E8V5M8F5R(#,Q+"`R,#$Q+"!A;F0@1&5C96UB97(@
M,S$L(#(P,3`L(&%N9"!C;VYS:7-T(&]F('1H92!F;VQL;W=I;F<@/&D^*&EN
M('1H;W5S86YD<SPO:3X@/&D^*3H\+VD^/"]P/@T*/"]D:78^#0H\9&EV/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,"XU:6X[('1E>'0M:6YD96YT
M.B`M,"XU:6X[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\=&%B;&4@
M<W1Y;&4],T0G=VED=&@Z(#@U)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S
M93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN+6QE9G0Z(#`N-S5I;CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG
M:'0Z(&)O;&0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C
M96YT97([(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#LG(&-O;'-P
M86X],T0V/D1E8V5M8F5R(#,Q+#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@<&%D9&EN
M9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,3PO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I
M9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!C;VQS
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M.CPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#8T)3L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Y<'0[)SY0
M<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$U)3L@=&5X="UA;&EG;CH@<FEG:'0[)SXR,SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ(')I
M9VAT.R<^,S8\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V9F8V,[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!P
M861D:6YG+6QE9G0Z(#EP=#LG/D=O;V1W:6QL/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH-"B!R:6=H=#LG
M/BT\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
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M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,C,\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,C$T/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
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M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('!A9&1I;F<M;&5F=#H@.7!T.R<^0W5R<F5N="!P;W)T:6]N(&]F(&-A<&ET
M86P@;&5A<V4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT.R<^,C0\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@<&%D9&EN9RUL969T.B`Y
M<'0[)SY4;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXR-#PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*
M/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!T(#`[)SY4:&4@<W5M;6%R:7IE9"!S=&%T96UE
M;G0@;V8@;W!E<F%T:6]N<R!D871A(&9O<B!!9&5O;F$@0VQI;FEC86P@3&%B
M;W)A=&]R>2!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q
M(&%N9"!$96-E;6)E<B`S,2P@,C`Q,"!A<F4@87,@9F]L;&]W<R`\:3XH:6X@
M=&AO=7-A;F1S*3H\+VD^/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQT
M86)L92!S='EL93TS1"=W:61T:#H@.#4E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R!M87)G:6XM;&5F=#H@,"XW-6EN.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
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M9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[)R!C;VQS<&%N/3-$,CXR,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7=E:6=H=#H@8F]L9#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#LG(&-O;'-P86X],T0R/C(P,3`\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O
M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C
M8SLG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`V-"4[('1E>'0M86QI9VXZ(&QE
M9G0[)SY,86)O<F%T;W)Y(&9E97,L(&YE=#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W
M:61T:#H@,34E.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$L,38Y/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^
M)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$U)3L@=&5X="UA;&EG;CH@
M<FEG:'0[)SXU-3$\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY/<&5R871I;F<@
M0V]S=',@86YD($5X<&5N<V5S.CPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Y
M<'0[)SY'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C4S
M.3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
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M<SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/CDW-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C0V.#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@<&%D9&EN9RUL969T.B`Y<'0[
M)SY);7!A:7)M96YT(&QO<W,@;VX-"B!G;V]D=VEL;#PO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R<^,3<X/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXM
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@.7!T.R<^5&]T86P@
M;W!E<F%T:6YG(&-O<W1S(&%N9"!E>'!E;G-E<SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^
M,2PV.3(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$L
M,#8W/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
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M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C
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M9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S4R-&8V-V9?,C,Q.%\T
M-C,Y7V%A-S=?-#DY-#DT-C1A86(R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S,U,C1F-C=F7S(S,3A?-#8S.5]A83<W7S0Y.30Y-#8T86%B,B]7
M;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$531SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY396QE8W1E9"!"86QA;F-E(%-H965T($EN9F]R;6%T
M:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY$:7-C;&]S=7)E(%1E>'0@0FQO8VL@4W5P
M<&QE;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-U<'!L96UE;G1A;"!"86QA;F-E(%-H965T($1I
M<V-L;W-U<F5S(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN+71O<#H@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
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M($1E8V5M8F5R(#,Q+"`R,#$Q(#QI/BAI;B!T:&]U<V%N9',I.CPO:3X\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#@X)3L@
M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/DUA<F-H(#,Q+"`R,#$R/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO
M=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$
M;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/D1E
M8V5M8F5R(#,Q+"`R,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A
M<#XF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#<P)3LG/D%C
M8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[('=I9'1H.B`Q,B4[)SXW,S8\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$R)3LG/C8Y
M,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,7!T.R<^0F%D(&1E8G0@86QL;W=A;F-E("T@8W5S=&]M97(\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/B@R.38\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
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M970\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0[)SXT,#4\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
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M36%R8V@@,S$L(#(P,3(L(&%N9"!$96-E;6)E<B`S,2P@,C`Q,2`\:3XH:6X@
M=&AO=7-A;F1S*3PO:3X@.CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@.#@E.R!B
M;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^36%R8V@F(S$V,#LS,2PF(S$V,#LR,#$R/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W
M:61T:#H@-S`E.R<^36%N=69A8W1U<FEN9R!E<75I<&UE;G0\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,B4[)SXT,#`\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T
M:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@=VED=&@Z(#$R)3LG/C0P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^0V]M<'5T97(@86YD(&]F9FEC92!E<75I<&UE;G0\+W1D/@T*/'1D
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXQ-3D\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXQ-3D\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG/DQA8F]R871O<GD@97%U:7!M96YT/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0[)SXQ,S8\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
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M.B`Y<'0[)SY4;W1A;#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C8Y-3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
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M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/B@S
M.3(\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/C,P,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
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M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^
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M<F-H(#,Q+"`R,#$R(&%N9"`R,#$Q('=A<R`D,C`L,#`P(&%N9"`D.#`L,#`P
M+"!R97-P96-T:79E;'DN/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/&(^)B,Q-C`[/"]B/CPO<#X-"CQD:78^)B,Q-C`[/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6)O='1O;3H@,'!X.R<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N-6EN.R!T97AT+6%L:6=N.B!L969T
M.R<^/&(^-"X\+V(^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R<^/&(^4V5L96-T960@0F%L86YC92!3:&5E="!);F9O<FUA=&EO
M;CPO8CX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P="`P(#!P="`P+C5I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SX\:3Y!8V-O=6YT<R!R96-E:79A8FQE("AI;B!T:&]U<V%N9',I
M/"]I/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z
M(#<U)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z(#`N
M-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T
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M97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7=E:6=H=#H@8F]L9#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$P/"]T9#X-
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M,T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,34E.R!T97AT+6%L:6=N.B!R:6=H=#LG/C8Y,CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG
M/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ
M(')I9VAT.R<^-#<R/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SY"860@9&5B="!A;&QO=V%N8V4@+2!C=7-T
M;VUE<CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(')I9VAT.R<^*#(X-SPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/B@Q,S,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/E1O=&%L/"]T
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M;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^,S,Y/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P
M.R<^)B,Q-C`[)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQI/B8C,38P.T]T:&5R(&-U<G)E;G0@
M87-S971S("AI;B!T:&]U<V%N9',I/"]I/CPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\
M=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#<U)3L@8F]R9&5R+6-O;&QA<'-E.B!C
M;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN+6QE9G0Z(#`N-S5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"`@/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R<@8V]L<W!A;CTS1#(^,C`Q
M,3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
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M86)L93PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,34E.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,34E.R!T97AT+6%L:6=N.B!R:6=H=#LG/C,R,#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
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M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^,38\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/C(S/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P
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M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXS-#,\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\:3XF(S$V,#L\
M+VD^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3LG/CQI/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@*&EN('1H;W5S
M86YD<RDF(S$V,#L\+VD^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="<^
M)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`W-24[(&)O<F1E
M<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`P+C<U:6X[)R!B;W)D
M97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
M9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[)R!C;VQS<&%N/3-$-CY$96-E;6)E<B`S,2P\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I
M9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!C;VQS
M<&%N/3-$,CXR,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B
M;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#LG(&-O;'-P86X],T0R/C(P,3`\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`V-"4[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY,
M96%S96AO;&0@:6UP<F]V96UE;G1S/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q-24[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ(')I9VAT.R<^
M.#8S/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SY-86YU9F%C
M='5R:6YG(&5Q=6EP;65N=#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C0P,#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C,S
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M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ-C`\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SY,86)O
M<F%T;W)Y(&5Q=6EP;65N=#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^,3,V/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXR,30\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C8Y-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$L-3<P/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6)O='1O;3H@,7!T.R<^3&5S<R!A8V-U;75L871E9"!D97!R
M96-I871I;VX\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/B@S-S(\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXI
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@<FEG:'0[)SXH,2PP.34\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/E1O
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M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^-#<U/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&D^)B,Q-C`[/"]I/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[)SX\:3Y!8V-R=65D(&5X<&5N
M<V5S("AI;B!T:&]U<V%N9',I)B,Q-C`[/"]I/CPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!T(#`[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED
M=&@Z(#<U)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z
M(#`N-S5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#LG(&-O;'-P86X],T0V/D1E8V5M8F5R
M(#,Q+#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD
M.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#LG(&-O;'-P86X],T0R/C(P,3$\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,#PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#8T)3L@=&5X="UA;&EG
M;CH@:G5S=&EF>3LG/D%C8W)U960@=F5N9&]R('!A>6UE;G1S/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ(')I9VAT.R<^,3PO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@
M;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-24[('1E>'0M
M86QI9VXZ(')I9VAT.R<^,3`U/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
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M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
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M('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
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M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
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M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/C(Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?,S4R-&8V-V9?,C,Q.%\T-C,Y7V%A-S=?-#DY
M-#DT-C1A86(R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,U,C1F
M-C=F7S(S,3A?-#8S.5]A83<W7S0Y.30Y-#8T86%B,B]7;W)K<VAE971S+U-H
M965T,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$531SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I
M<V-L;W-U<F4@3V8@0V]M<&5N<V%T:6]N(%)E;&%T960@0V]S=',L(%-H87)E
M+4)A<V5D(%!A>6UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&ES8VQO<W5R92!O9B!#;VUP96YS
M871I;VX@4F5L871E9"!#;W-T<RP@4VAA<F4M8F%S960@4&%Y;65N=',@6U1E
M>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XM=&]P.B`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\
M8CXV+B8C,38P.R8C,38P.R8C,38P.U-T;V-K+4)A<V5D($-O;7!E;G-A=&EO
M;CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SY$=7)I;F<@,C`P,2P@4&EP97@@5&AE<F%P975T:6-S
M)B,X,C$W.R!B;V%R9"!O9B!D:7)E8W1O<G,@86YD('-T;V-K:&]L9&5R<R!A
M9&]P=&5D('1H92`R,#`Q(%-T;V-K($EN8V5N=&EV92!0;&%N("AT:&4@)B,X
M,C(P.S(P,#$@4W1O8VL@4&QA;B8C.#(R,3LI+B!4:&ES('!L86X@=V%S(&%S
M<W5M960@8GD@4&EP97@@:6X@=&AE($]C=&]B97(@,C`P-B!M97)G97(@=VET
M:"!3:&5F9FEE;&0N($%S(&]F('1H92!D871E(&]F('1H92!M97)G97(L('1H
M97)E('=E<F4@,2PT.#DL,S4S(&]P=&EO;G,@:7-S=65D(&%N9"!O=71S=&%N
M9&EN9R!U;F1E<B!T:&4@,C`P,2!P;&%N+B!4:&4@=&]T86P@;G5M8F5R(&]F
M('-H87)E<R!O9B!S=&]C:R!W:71H(')E<W!E8W0@=&\@=VAI8V@@<W1O8VL@
M;W!T:6]N<R!A;F0@<W1O8VL@87!P<F5C:6%T:6]N(')I9VAT<R!M87D@8F4@
M9W)A;G1E9"!T;R!A;GD@;VYE(&5M<&QO>65E(&]F('1H92!#;VUP86YY(&]R
M(&$@<W5B<VED:6%R>2!D=7)I;F<@86YY(&]N92UY96%R('!E<FEO9"!U;F1E
M<B!T:&4@,C`P,2!P;&%N('-H86QL(&YO="!E>&-E960@,C4P+#`P,"X@06QL
M(&%W87)D<R!P=7)S=6%N="!T;R!T:&4@,C`P,2!3=&]C:R!0;&%N('-H86QL
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M,C`P,2!3=&]C:R!0;&%N(&-O;G1A:6YS(&-E<G1A:6X@86YT:2UD:6QU=&EO
M;B!P<F]V:7-I;VYS(&EN('1H92!E=F5N="!O9B!A('-T;V-K('-P;&ET+"!S
M=&]C:R!D:79I9&5N9"!O<B!O=&AE<B!C87!I=&%L(&%D:G5S=&UE;G0L(&%S
M(&1E9FEN960@:6X@=&AE('!L86XN(%1H92`R,#`Q(%-T;V-K(%!L86X@<')O
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M,#`W(&]P=&EO;G,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!U;F1E<B!T:&4@
M,C`P,2!3=&]C:R!0;&%N+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D]N($UA
M<F-H(#(P+"`R,#`W+"!T:&4@0V]M<&%N>28C.#(Q-SMS(&)O87)D(&]F(&1I
M<F5C=&]R<R!A<'!R;W9E9"!T:&4@0V]M<&%N>28C.#(Q-SMS(#(P,#<@4W1O
M8VL@26YC96YT:79E(%!L86X@*'1H92`F(S@R,C`[,C`P-R!3=&]C:R!0;&%N
M)B,X,C(Q.RD@9F]R('1H92!I<W-U86YC92!O9B!U<"!T;R`R+#4P,"PP,#`@
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M<'1I;VYS('5N9&5R('1H92`R,#`W(%-T;V-K(%!L86X@:7,@9&5T97)M:6YE
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M;F<@86YY(&]N92UY96%R('!E<FEO9"!U;F1E<B!T:&4@,C`P,2!P;&%N('-H
M86QL(&YO="!E>&-E960@,C4P+#`P,"X@3W!T:6]N<R!B96-O;64@97AE<F-I
M<V%B;&4@;W9E<B!V87)I;W5S('!E<FEO9',@9G)O;2!T:&4@9&%T92!O9B!G
M<F%N="P@86YD(&=E;F5R86QL>2!E>'!I<F4@=&5N('EE87)S(&%F=&5R('1H
M92!G<F%N="!D871E+B!!<R!O9B!-87)C:"`S,2P@,C`Q,BP@=&AE<F4@87)E
M(#$L,#,Q+#,Y-"!O<'1I;VYS(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@=6YD
M97(@=&AE(#(P,#<@4W1O8VL@4&QA;BX\+W`^#0H\<"!S='EL93TS1"=M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/;B!.;W9E;6)E<B`R+"`R,#$P
M+"!T:&4@8F]A<F0@;V8@9&ER96-T;W)S(&%N9"!S=&]C:VAO;&1E<G,@861O
M<'1E9"!T:&4@,C`Q,"!3=&]C:R!);F-E;G1I=F4@4&QA;B`H)B,X,C(P.S(P
M,3`@4W1O8VL@4&QA;B8C.#(R,3LI(&9O<B!T:&4@:7-S=6%N8V4@;V8@=7`@
M=&\@,RPP,#`L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=&\@8F4@9W)A
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M:6]N<R!U;F1E<B!T:&4@,C`Q,"!3=&]C:R!0;&%N(&ES(&1E=&5R;6EN960@
M8GD@=&AE(&-O;7!E;G-A=&EO;B!C;VUM:71T964@;V8@=&AE($)O87)D(&]F
M($1I<F5C=&]R<RP@86YD(&UA>2!B92!E<75A;"!T;R!O<B!G<F5A=&5R('1H
M86X@=&AE(&9A:7(@;6%R:V5T('9A;'5E(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,@8V]M;6]N('-T;V-K(&]N('1H92!D871E('1H92!O<'1I;VX@:7,@9W)A
M;G1E9"X@3W!T:6]N<R!B96-O;64@97AE<F-I<V%B;&4@;W9E<B!V87)I;W5S
M('!E<FEO9',@9G)O;2!T:&4@9&%T92!O9B!G<F%N="P@86YD(&=E;F5R86QL
M>2!E>'!I<F4@<V5V96X@=&\@=&5N('EE87)S(&%F=&5R('1H92!G<F%N="!D
M871E+B!!<R!O9B!-87)C:"`S,2P@,C`Q,BP@=&AE<F4@87)E(#$L-S0V+#`V
M-"!O<'1I;VYS(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@=6YD97(@=&AE(#(P
M,3`@4W1O8VL@4&QA;BX\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
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M+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
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M(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,B!A;F0@,C`Q,2!A<F4@87,@
M9F]L;&]W<SH\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#LF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#@X)3L@8F]R
M9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P
M86X],T0V/E1H<F5E)B,Q-C`[36]N=&AS)B,Q-C`[16YD960F(S$V,#M-87)C
M:"8C,38P.S,Q+#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(^,C`Q
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M<W!A;CTS1#(^,C`Q,3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M/D5X97)C:7-E('!R:6-E/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^)#$N,30@)B,X,C$Q
M.R`D,BXT-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
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M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.@T*(&QE9G0[('=I9'1H
M.B`V-"4[)R!N;W=R87`],T1N;W=R87`^17AP96-T960@9&EV:61E;F1S/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M('=I9'1H.B`Q)3LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#$U)3LG(&YO
M=W)A<#TS1&YO=W)A<#XP)3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!W:61T:#H@,24[)R!N;W=R87`],T1N;W=R87`^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('=I9'1H.B`Q)3LG
M(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#$E.R<@;F]W<F%P/3-$;F]W<F%P
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!W:61T:#H@,34E.R<@;F]W<F%P/3-$;F]W<F%P/C`E/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)R!N;W=R87`]
M,T1N;W=R87`^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R
M87`^17AP96-T960@=F]L871I;&ET>3PO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/C$P."4@
M)B,X,C$Q.R`Q-S0E/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^,3@U)2`F(S@R,3$[
M(#$X."4\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
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M/3-$;F]W<F%P/C`N,S<E("8C.#(Q,3L@,2XY."4\+W1D/@T*/'1D('-T>6QE
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M=W)A<#XR+C@Q)2`F(S@R,3$[(#,N-3@E/"]T9#X-"CQT9"!S='EL93TS1"=T
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M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R
M87`],T1N;W=R87`^-2!Y96%R<R`F(S@R,3$[(#<@>65A<G,\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<@;F]W<F%P/3-$;F]W<F%P/D5X
M<&5C=&5D(&9O<F9E:71U<F5S/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^,"4\+W1D/@T*
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M<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
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M9CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@
M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O
M<#LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`S)3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`S)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#LG/B8C.38W.3L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@.30E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^:6UM
M961I871E('9E<W1I;F<L/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(SDV-SD[/"]F;VYT
M/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^
M;VYE+6AA;&8@=F5S=&EN9R!I;6UE9&EA=&5L>2!A;F0@=&AE(')E;6%I;F1E
M<B!O=F5R('1H<F5E('EE87)S/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT
M86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C
M;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`S)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`S)3LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C.38W.3L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@.30E.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^;6]N=&AL>2!O=F5R('1H<F5E('EE
M87)S+#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R<^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Y-C<Y.SPO9F]N=#X\+W1D/@T*/'1D
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/G%U87)T97)L>2!O
M=F5R('1H<F5E('EE87)S+#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Y-C<Y.SPO9F]N
M=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG
M/F%N;G5A;&QY(&]V97(@=&AR964@>65A<G,L/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF
M(SDV-SD[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R<^;VYE+71H:7)D(&EM;65D:6%T92!V97-T:6YG(&%N9"!R
M96UA:6YI;F<@86YN=6%L;'D@;W9E<B!T=V\@>65A<G,L/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-
M"CQT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[)SXF(SDV-SD[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R<^;VYE+65I9VAT:"!I;6UE9&EA=&4@=F5S=&EN
M9R!W:71H(')E;6%I;FEN9R!V97-T:6YG(&]V97(@='=O('EE87)S+#PO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R<^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R<^)B,Y-C<Y.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/F]N92UH86QF(&EM;65D:6%T92!V
M97-T:6YG('=I=&@@<F5M86EN:6YG('9E<W1I;F<@;W9E<B!N:6YE(&UO;G1H
M<SL@86YD/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[)SX-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(SDV-SD[/"]F;VYT/CPO=&0^#0H\
M=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^;VYE('%U87)T
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M9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R+"!T:&4@
M0V]M<&%N>2!G<F%N=&5D(#$L,S`P+#`P,"!O<'1I;VYS('1O(&5M<&QO>65E
M<R!A;F0@8V]N<W5L=&%N=',@:&%V:6YG(&$@9F%I<B!V86QU92!O9B!A<'!R
M;WAI;6%T96QY("0S(&UI;&QI;VX@8F%S960@=7!O;B!T:&4@0FQA8VLM4V-H
M;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"XF(S$V,#L@1'5R:6YG('1H92!S
M86UE('!E<FEO9"!O9B`R,#$Q+"!T:&4@0V]M<&%N>2!G<F%N=&5D(#,R-"PU
M,#(@;W!T:6]N<R!T;R!E;7!L;WEE97,@:&%V:6YG(&$@9F%I<B!V86QU92!O
M9B!A<'!R;WAI;6%T96QY("0T,S,L,#`P(&)A<V5D('5P;VX@=&AE($)L86-K
M+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@;6]D96PN/"]P/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^02!S=6UM87)Y(&]F('-T;V-K(&]P=&EO;@T*(&%C=&EV
M:71I97,@87,@;V8@36%R8V@@,S$L(#(P,3(L(&%N9"!F;W(@=&AE('EE87(@
M96YD960@1&5C96UB97(@,S$L(#(P,3$L(&ES(&%S(&9O;&QO=W,Z/"]P/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE
M('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA
M<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^)B,Q-C`[/"]T
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M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
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M97([)R!C;VQS<&%N/3-$,CY796EG:'1E9#QB<B`O/D%V97)A9V4\8G(@+SY2
M96UA:6YI;F<\8G(@+SY#;VYT<F%C='5A;#QB<B`O/DQI9F4\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^06=G<F5G871E
M/&)R("\^26YT<FEN<VEC/&)R("\^5F%L=64\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#4R)3LG
M/D)A;&%N8V4@)B,X,C$Q.R!$96-E;6)E<B`S,2P@,C`Q,#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[)SXR
M+#4S.2PP.3$\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R<^,2XS,CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y
M)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#Y'<F%N
M=&5D/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^-34W+#`P,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
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M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
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M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T.R<^1F]R9F5I=&5D(&]R(&5X<&ER960\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/B@Y
M,RPW-3`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXP+C4Y/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T
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M;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^#0H\=&0^0F%L86YC92`F(S@R,3$[($1E8V5M8F5R(#,Q+"`R,#$Q
M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^,BPY-SDL,#$P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2XS-#PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^#0H\=&0^1W)A;G1E9#PO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$L,S`P
M+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
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M=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
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M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
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M,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
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M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
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M,T0G=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/D)A;&%N8V4@)B,X,C$Q
M.R!-87)C:"`S,2P@,C`Q,B`F(S@R,3$[(&]U='-T86YD:6YG/"]T9#X-"CQT
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
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M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G
M=&5X="UU;F1E<FQI;F4M<W1Y;&4Z(&1O=6)L93LG/C<N,3@@>65A<G,\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/C(L,C,P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^0F%L
M86YC92`F(S@R,3$[($UA<F-H(#,Q+"`R,#$R("8C.#(Q,3L@97AE<F-I<V%B
M;&4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,BPS,C,L,S(P/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
M.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N-C(\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N
M="!S='EL93TS1"=T97AT+75N9&5R;&EN92US='EL93H@9&]U8FQE.R<^-3PO
M9F]N=#XN-S,@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(')I9VAT.R<^,2PX,30L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[
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M.SPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O
M;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P
M86X],T0Q,SY/<'1I;VYS)B,Q-C`[3W5T<W1A;F1I;F<\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG
M:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,3`^3W!T:6]N<R8C,38P.T5X97)C:7-A
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M<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@
M8V]L<W!A;CTS1#(^5V5I9VAT960\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([)R!C;VQS<&%N/3-$,CY796EG:'1E9"8C,38P.T%V97)A9V4\+W1D/@T*
M/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D
M/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CY796EG:'1E
M9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/E=E
M:6=H=&5D)B,Q-C`[079E<F%G93PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/E)A;F=E)B,Q-C`[
M;V8\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^079E<F%G93PO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/E)E;6%I;FEN9SPO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/D%V
M97)A9V4\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$
M,CY296UA:6YI;F<\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CLG/D5X97)C:7-E)B,Q-C`[4')I8V4\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
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M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG
M(&-O;'-P86X],T0R/D-O;G1R86-T=6%L)B,Q-C`[3&EF93PO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CY/<'1I;VYS/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H-"B`Q<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
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M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
M8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!W:61T:#H@,38E.R<^)#`N,#D@+2`D
M-"XU-SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!W:61T:#H@,3$E.R<^,RPW-3,L-#8V/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,24[)SXQ+C8Y
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@
M,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([('=I9'1H.B`Q,24[)SXW+C(Y('EE87)S/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED
M=&@Z(#$Q)3LG/C(L,C,S+#,R,3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3$E.R<^,2XT-#PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!W:61T:#H@,3$E.R<^-2XX-B!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXD-"XU."`M
M("0Y+C`U/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXX.2PY.3D\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/C4N.3,\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXX.2PY.3D\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/C4N.3,\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
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M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^)#`N,#D@+2`D.2XP-3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[
M)SXS+#@T,RPT-C4\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R<^,2XW.3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!C96YT97([)SX\9F]N="!S='EL93TS1"=T97AT+75N9&5R;&EN
M92US='EL93H@9&]U8FQE.R<^-RXQ."!Y96%R<SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXR+#,R,RPS
M,C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^
M,2XV,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
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M:6YG(&%N9"!E>&5R8VES86)L92!A<R!O9B!-87)C:"`S,2P@,C`Q,2P@87)E
M(&%S(&9O;&QO=W,Z/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE
M/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L
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M,T0Q,#Y/<'1I;VYS)B,Q-C`[17AE<F-I<V%B;&4\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CLG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D
M/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CY796EG:'1E
M9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/E=E
M:6=H=&5D)B,Q-C`[079E<F%G93PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
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M;&EG;CH@8V5N=&5R.R<^4F%N9V4F(S$V,#MO9CPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)PT*(&-O
M;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG
M(&-O;'-P86X],T0R/D%V97)A9V4\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([)R!C;VQS<&%N/3-$,CY296UA:6YI;F<\+W1D/@T*/'1D/B8C,38P.SPO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([)R!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
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M='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG
M(&-O;'-P86X],T0R/D]P=&EO;G,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
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M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R<@8V]L<W!A;CTS1#(^3W!T:6]N<SPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CY%>&5R8VES928C,38P.U!R:6-E
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R
M/D-O;G1R86-T=6%L)B,Q-C`[3&EF93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([('=I9'1H.B`Q-B4[)SXD,"XP.2`M("0T+C4W/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,24[)SXR+#<R
M,2PY,C$\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@=VED=&@Z(#$Q)3LG/C$N,C(\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#$Q
M)3LG/C8N-S4@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3$E.R<^,BPQ.#,L,#<S
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@
M,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[('=I9'1H.B`Q,24[)SXQ+C,R/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('=I9'1H.B`Q,24[)SXV
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R<^-2XY,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG
M/C,N-3$@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R<^-2XY,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG
M/C,N-3$@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXD,"XP.2`M("0Y
M+C`U/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
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M(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
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M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&-E;G1E<CLG/CQF
M;VYT('-T>6QE/3-$)W1E>'0M=6YD97)L:6YE+7-T>6QE.B!D;W5B;&4[)SXV
M+C8U('EE87)S/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/C(L,C<S+#`W,CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
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M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&-E;G1E<CLG/CQF;VYT('-T>6QE
M/3-$)W1E>'0M=6YD97)L:6YE+7-T>6QE.B!D;W5B;&4[)SXV+C$V('EE87)S
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^)B,Q
M-C`[/"]I/CPO8CX\+W`^#0H\9&EV('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/CQB/CQI/D]P=&EO;G,@;V8@4W5B<VED:6%R>3PO:3X\+V(^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO9&EV/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L#0H@<V5R:68[
M)SY$=7)I;F<@,C`P-"!A;F0@,C`P-RP@0T0T(&=R86YT960@,S`L,#`P(&]P
M=&EO;G,N($]N($%U9W5S="`U+"`R,#`Y+"`Q,"PP,#`@;V8@=&AE<V4@;W!T
M:6]N<R!E>'!I<F5D+B!!<R!O9B!-87)C:"`S,2P@,C`Q,BP@82!T;W1A;"!O
M9B`R,"PP,#`@;W!T:6]N<R!W97)E(&]U='-T86YD:6YG(&%N9"!E>&5R8VES
M86)L92!W:71H(&%N(&5X97)C:7-E('!R:6-E(&]F("0P+C(P(&%N9"!A(')E
M;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E(&]F(#`N,3(@>65A<G,N/"]P/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^07,@
M;V8@36%R8V@@,S$L(#(P,3(L($5P:71O<&4@:&%S(#4P+#`P,"!O<'1I;VYS
M(&]U='-T86YD:6YG(&%N9"`R,"PP,#`@;W!T:6]N<R!E>&5R8VES86)L92!W
M:71H(&%N(&5X97)C:7-E('!R:6-E(&]F("0P+C`P,2!A;F0@82!R96UA:6YI
M;F<@8V]N=')A8W1U86P@;&EF92!O9B`V+C(U('EE87)S+B8C,38P.R8C,38P
M.U1H97-E(&]P=&EO;G,@=V5R92!G<F%N=&5D(&1U<FEN9R`R,#`X+"!V97-T
M(&%N;G5A;&QY(&]V97(@-2!Y96%R<RP@86YD(&AA=F4@82!F86ER('9A;'5E
M(&]F("0U,"P@=VAI8V@@=V%S(&1E=&5R;6EN960@=7-I;F<@=&AE($)L86-K
M+5-C:&]L97,@;6]D96P@=VET:"!T:&4@9F]L;&]W:6YG(&%S<W5M<'1I;VYS
M.B!E>'!E8W1E9"!D:79I9&5N9"!Y:65L9"!O9B`P)3L@97AP96-T960@=F]L
M871I;&ET>2!O9B`R,#`E+"!R:7-K(&9R964@:6YT97)E<W0@<F%T92!O9B`R
M+C0W)2!A;F0@86X@97AP96-T960@;&EF92!O9B`Q,"!Y96%R<RX\+W`^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=CX-"CQT86)L92!S='EL93TS1"=M87)G:6XM=&]P.B`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUB;W1T
M;VTZ(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P+C5I;CL@=&5X="UA
M;&EG;CH@;&5F=#LG/CQB/C4N/"]B/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3LG/CQB/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO
M;CPO8CX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P="`P(#!P="`P+C5I;CL@=&5X="UI;F1E;G0Z
M("TP+C5I;CLG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!T(#`[)SX\8CX\:3Y3=&]C:R!);F-E;G1I=F4@4&QA;CPO
M:3X\+V(^/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY$=7)I;F<@,C`P
M,2P@=&AE($-O;7!A;GDF(S@R,3<[<R!";V%R9"!O9B!$:7)E8W1O<G,@86YD
M('-T;V-K:&]L9&5R<R!A9&]P=&5D('1H92`R,#`Q(%-T;V-K($EN8V5N=&EV
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M8VL@4&QA;B!S:&%L;"!N;W0@97AC965D(#(U,"PP,#`N($%L;"!A=V%R9',@
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M87)D<R`H=&AE("8C.#(R,#M!=V%R9',F(S@R,C$[*2X@5&AE(#(P,#$@4W1O
M8VL@4&QA;B!C;VYT86EN<R!C97)T86EN(&%N=&DM9&EL=71I;VX@<')O=FES
M:6]N<R!I;B!T:&4@979E;G0@;V8@82!S=&]C:R!S<&QI="P@<W1O8VL@9&EV
M:61E;F0@;W(@;W1H97(@8V%P:71A;"!A9&IU<W1M96YT+"!A<R!D969I;F5D
M(&EN('1H92!P;&%N+B!4:&4@,C`P,2!3=&]C:R!0;&%N('!R;W9I9&5S(&9O
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M(&]F($1E8V5M8F5R(#,Q+"`R,#$Q+"!T:&5R92!W97)E(#$L,S(P+#,U-"!O
M<'1I;VYS(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@=6YD97(@=&AE(#(P,#$@
M4W1O8VL@4&QA;BX\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*
M/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3LG/D]N($UA<F-H(#(P+"`R,#`W+"!T:&4@0V]M<&%N
M>28C.#(Q-SMS($)O87)D(&]F($1I<F5C=&]R<R!A<'!R;W9E9"!T:&4@,C`P
M-R!3=&]C:R!);F-E;G1I=F4@4&QA;B`H=&AE("8C.#(R,#LR,#`W(%-T;V-K
M(%!L86XF(S@R,C$[*2!F;W(@=&AE(&ES<W5A;F-E(&]F('5P('1O(#(L-3`P
M+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K('1O(&)E(&=R86YT960@=&AR
M;W5G:"!I;F-E;G1I=F4@<W1O8VL@;W!T:6]N<RP@;F]N<75A;&EF:65D('-T
M;V-K(&]P=&EO;G,L('-T;V-K(&%P<')E8VEA=&EO;B!R:6=H=',L(&1I=FED
M96YD(&5Q=6EV86QE;G0@<FEG:'1S+"!R97-T<FEC=&5D('-T;V-K+"!R97-T
M<FEC=&5D('-T;V-K('5N:71S(&%N9"!O=&AE<B!S=&]C:RUB87-E9"!A=V%R
M9',@=&\@;V9F:6-E<G,L(&]T:&5R(&5M<&QO>65E<RP@9&ER96-T;W)S(&%N
M9"!C;VYS=6QT86YT<R!O9B!T:&4@0V]M<&%N>2!A;F0@:71S('-U8G-I9&EA
M<FEE<RX@5&AI<R!P;&%N('=A<R!A<'!R;W9E9"!B>2!S=&]C:VAO;&1E<G,@
M;VX@3F]V96UB97(@,BP@,C`P-RX@5&AE(&5X97)C:7-E('!R:6-E(&]F('-T
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M(&1U<FEN9R!A;GD@;VYE+7EE87(@<&5R:6]D('5N9&5R('1H92`R,#`Q('!L
M86X@<VAA;&P@;F]T(&5X8V5E9"`R-3`L,#`P+B!/<'1I;VYS(&)E8V]M92!E
M>&5R8VES86)L92!O=F5R('9A<FEO=7,@<&5R:6]D<R!F<F]M('1H92!D871E
M(&]F(&=R86YT+"!A;F0@9V5N97)A;&QY(&5X<&ER92!T96X@>65A<G,@869T
M97(@=&AE(&=R86YT(&1A=&4N($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q+"!T
M:&5R92!A<F4@,2PR,#$L,34V(&]P=&EO;G,@:7-S=65D(&%N9"!O=71S=&%N
M9&EN9R!U;F1E<B!T:&4@,C`P-R!3=&]C:R!0;&%N+CPO<#X-"CPO9&EV/@T*
M/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^3VX@3F]V96UB
M97(@,BP@,C`Q,"P@=&AE($)O87)D(&]F($1I<F5C=&]R<R!A;F0@<W1O8VMH
M;VQD97)S(&%D;W!T960@=&AE(#(P,3`@4W1O8VL@26YC96YT:79E(%!L86X@
M*"8C.#(R,#LR,#$P(%-T;V-K(%!L86XF(S@R,C$[*2!F;W(@=&AE(&ES<W5A
M;F-E(&]F('5P('1O(#,L,#`P+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K
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M('-T;V-K(&]P=&EO;G,@=6YD97(@=&AE(#(P,3`@4W1O8VL@4&QA;B!I<R!D
M971E<FUI;F5D(&)Y('1H92!C;VUP96YS871I;VX@8V]M;6ET=&5E(&]F('1H
M92!";V%R9"!O9B!$:7)E8W1O<G,L(&%N9"!M87D@8F4@97%U86P@=&\@;W(@
M9W)E871E<B!T:&%N('1H92!F86ER(&UA<FME="!V86QU92!O9B!T:&4@0V]M
M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!O;B!T:&4@9&%T92!T:&4@;W!T
M:6]N(&ES(&=R86YT960N($]P=&EO;G,@8F5C;VUE(&5X97)C:7-A8FQE(&]V
M97(@=F%R:6]U<R!P97)I;V0@9G)O;2!T:&4@9&%T92!O9B!G<F%N="P@86YD
M(&=E;F5R86QL>2!E>'!I<F4@=&5N('EE87)S(&%F=&5R('1H92!G<F%N="!D
M871E+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,2P@=&AE<F4@87)E(#0U-RPU
M,#`@;W!T:6]N<R!I<W-U960@86YD(&]U='-T86YD:6YG('5N9&5R('1H92`R
M,#$P(%-T;V-K(%!L86XN/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO
M<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E
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M9"X\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\
M9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S
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M;B!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,3$@86YD(#(P,3`@
M87)E(&%S(&9O;&QO=W,Z/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO
M<#X-"CPO9&EV/@T*/&1I=CX-"CQT86)L92!S='EL93TS1"=W:61T:#H@.#4E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM;&5F=#H@,"XW-6EN
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW
M96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R<@8V]L<W!A;CTS1#8^665A<B8C,38P.V5N
M9&5D)B,Q-C`[1&5C96UB97(F(S$V,#LS,2P\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UW96EG:'0Z(&)O;&0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L
M:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#LG
M(&-O;'-P86X],T0R/C(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C
M96YT97([)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT
M.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!C96YT
M97([)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B
M;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#LG(&-O;'-P86X],T0R/C(P,3`\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ#0H@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\
M=&0^17AE<F-I<V4@<')I8V4\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXD,"XT.2`M("0R+C(R
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M)SXD,"XU-B`M("0P+C@W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[
M)SX-"CQT9"!S='EL93TS1"=W:61T:#H@-C0E.R!T97AT+6%L:6=N.B!L969T
M.R<^17AP96-T960@9&EV:61E;F1S/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,34E.R!T97AT+6%L:6=N.B!C96YT97([)SXP)3PO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!C96YT97([)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG
M;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[('1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$U)3L@=&5X="UA;&EG;CH@8V5N=&5R.R<^,"4\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[)SX-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^17AP96-T960@=F]L871I
M;&ET>3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CLG/C$W-24@+2`Q.#@E/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXQ.#<E("T@,C`W)3PO
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M8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([)SXQ+C,P)2`M(#,N-3@E/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXR+C4T)2`M(#,N-C,E/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SY%>'!E8W1E9"!L:69E(&]F(&]P=&EO;CPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CLG/C4@+2`W('EE87)S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG
M/C`E/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I
M=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I
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M<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\=&%B;&4@<W1Y;&4],T0G
M=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,"XW-6EN
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,"XU:6X[('!A
M9&1I;F<M<FEG:'0Z(#`N.'!T.R<^/&9O;G0^)B,Q.#,[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SYI;6UE9&EA
M=&4@=F5S=&EN9RP\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+7)I9VAT.B`P+CAP=#LG/CQF;VYT/B8C,3@S.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^:&%L
M9B!V97-T:6YG(&EM;65D:6%T96QY(&%N9"!T:&4@<F5M86EN9&5R(&]V97(@
M=&AR964@>65A<G,L/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#LG/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SX\9F]N=#XF(S$X,SL\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#LG/G%U
M87)T97)L>2!O=F5R('1H<F5E('EE87)S+#PO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^/&9O;G0^
M)B,Q.#,[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H
M=#H@,"XX<'0[)SYA;FYU86QL>2!O=F5R('1H<F5E('EE87)S+#PO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R<^/&9O;G0^)B,Q.#,[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SYO;F4M=&AI<F0@:6UM961I871E('9E
M<W1I;F<@86YD(')E;6%I;FEN9R!A;FYU86QL>2!O=F5R('1W;R!Y96%R<RP\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P
M.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`P+CAP=#LG/CQF;VYT/B8C,3@S.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^;VYE(&AA;&8@:6UM961I
M871E('9E<W1I;F<@=VET:"!R96UA:6YI;F<@=F5S=&EN9R!O=F5R(&YI;F4@
M;6]N=&AS+#PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!T;W`[)SX-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M<FEG:'0Z(#`N.'!T.R<^/&9O;G0^)B,Q.#,[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SYO;F4@<75A
M<G1E<B!I;6UE9&EA=&4@=F5S=&EN9R!W:71H('1H92!R96UA:6YI;F<@;W9E
M<B!T:')E92!Y96%R<SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[)SX-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^/&9O;G0^)B,Q.#,[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SYO
M;F4@<75A<G1E<B!I;6UE9&EA=&4@=F5S=&EN9R!W:71H('1H92!R96UA:6YI
M;F<@;W9E<B`S,R!M;VYT:',[(&%N9#PO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^/&9O;G0^)B,Q
M.#,[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@
M,"XX<'0[)SYM;VYT:&QY(&]V97(@=&AR964@>65A<G,N/"]T9#X-"CPO='(^
M#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'0@,"`P<'0@,6EN.R!T97AT+6EN9&5N=#H@+3`N,C5I;CLG/B8C,38P.SPO
M<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[)SY$=7)I;F<@,C`Q,2P@=&AE($-O;7!A;GD@
M9W)A;G1E9"`U-3<L,#`R(&]P=&EO;G,@=&\@96UP;&]Y965S(&%N9"!C;VYS
M=6QT86YT<R!H879I;F<@86X@87!P<F]X:6UA=&4@9F%I<B!V86QU92!O9B`D
M-C`Y+#`P,"!B87-E9"!U<&]N('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P
M<FEC:6YG(&UO9&5L+B8C,38P.R!$=7)I;F<@,C`Q,"P@=&AE($-O;7!A;GD@
M9W)A;G1E9"`W-#,L,S,R(&]P=&EO;G,@=&\@96UP;&]Y965S(&%N9"!C;VYS
M=6QT86YT<R!H879I;F<@86X@87!P<F]X:6UA=&4@9F%I<B!V86QU92!O9B`D
M-3DW+#`P,"!B87-E9"!U<&]N('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P
M<FEC:6YG(&UO9&5L+CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!T(#`[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\=&%B
M;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L
M;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C
M96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
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M.B!B;W1T;VT[)SX-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A
M<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I
M9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
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M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C
M96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^5V5I9VAT960\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P
M/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG
M:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/E)E;6%I;FEN9SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@
M8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^06=G<F5G871E/"]T9#X-"CQT
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M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/D%V97)A9V4F(S$V,#M%>&5R8VES93PO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@
M8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^0V]N=')A8W1U86P\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O
M;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/DEN=')I;G-I8SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
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M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W
M<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW
M96EG:'0Z(&)O;&0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@
M8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^4')I
M8V4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^3&EF93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H
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M96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`T,"4[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/D)A;&%N8V4@)B,X,C$Q
M.R!$96-E;6)E<B`S,2P@,C`P.3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W
M:61T:#H@,3(E.R!P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ
M(')I9VAT.R<^,BPU-C$L,S,R/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!P861D:6YG
M+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L
M969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$R)3L@<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N,C8\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4[(&)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXW
M+C$V('EE87)S/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!P861D:6YG+6)O='1O;3H@
M,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$R)3L@8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/C,P-"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9#Y'<F%N
M=&5D/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^-S0S+#,S,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXP+C@P/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C9F9C8SLG/@T*/'1D/D5X97)C:7-E9#PO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@R-34L
M.34T/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXP+C0T/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R<^1F]R9F5I=&5D/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
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M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/C`N
M-CD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E
M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
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M<'0[)SY"86QA;F-E("8C.#(Q,3L@1&5C96UB97(@,S$L(#(P,3`\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^,BPU,SDL
M,#DQ/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T
M.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N,S(\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXV+CDW('EE87)S/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L
M969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$L,#(X+#`P
M,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[)SX-"CQT9#Y'<F%N=&5D/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-34W+#`P,CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXQ+C(V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D/D5X97)C
M:7-E9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/B@R,RPS,S,\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N-3<\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET93LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SY&
M;W)F96ET960\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/B@Y,RPW-3`\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[
M)SXI/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
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M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI
M9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/D)A;&%N8V4@)B,X,C$Q.R!$96-E;6)E
M<B`S,2P@,C`Q,2`F(S@R,3$[(&]U='-T86YD:6YG/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/C(L.3<Y+#`Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
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M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^-BXP,2!Y96%R<SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/D)A;&%N8V4@
M)B,X,C$Q.R!$96-E;6)E<B`S,2P@,C`Q,2`F(S@R,3$[(&5X97)C:7-A8FQE
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M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^-2XV,B!Y
M96%R<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M;&]R.B`C8V-F9F-C.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X-"CQT9`T*('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
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M.B`R+C5P=#LG/D=R86YT(&1A=&4@9F%I<B!V86QU92!O9B!O<'1I;VYS(&=R
M86YT960@)B,X,C$Q.R`R,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0[)SXV,#DL,#`P/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ
M(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^5V5I9VAT960@879E<F%G92!G<F%N="!D871E(&9A:7(@=F%L=64@
M)B,X,C$Q.R`R,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0[)SXQ+C`Y/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/D=R86YT(&1A=&4@9F%I<B!V86QU92!O9B!O<'1I;VYS
M(&=R86YT960@)B,X,C$Q.R`R,#$P/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXU.3<L,#`P/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI
M9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^5V5I9VAT960@879E<F%G92!G<F%N="!D871E(&9A:7(@=F%L
M=64@)B,X,C$Q.R`R,#$P/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT
M+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
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M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I9VAT
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/D]U='-T86YD:6YG(&]P=&EO;G,@:&5L9"!B>2!R
M96QA=&5D('!A<G1I97,@)B,X,C$Q.R`R,#$Q/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R!T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R!T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/D5X97)C
M:7-A8FQE(&]P=&EO;G,@:&5L9"!B>2!R96QA=&5D('!A<G1I97,@)B,X,C$Q
M.R`R,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
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M-C`[/"]T9#X-"CQT9`T*('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/D]U='-T86YD:6YG(&]P=&EO;G,@:&5L9"!B
M>2!R96QA=&5D('!A<G1I97,@)B,X,C$Q.R`R,#$P/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
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M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R!T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/D5X
M97)C:7-A8FQE(&]P=&EO;G,@:&5L9"!B>2!R96QA=&5D('!A<G1I97,@)B,X
M,C$Q.R`R,#$P/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/C@U."PQ-C`\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@<FEG
M:'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO
M9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[)SXF(S$V,#L\
M+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R<^
M5&AE(&]P=&EO;G,@;W5T<W1A;F1I;F<@86YD(&5X97)C:7-A8FQE(&%T($1E
M8V5M8F5R(#,Q+"`R,#$Q(&%R92!A<R!F;VQL;W=S.CPO<#X-"CPO9&EV/@T*
M/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[)SXF(S$V,#L\+W`^#0H\
M+V1I=CX-"CQD:78^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M)R!C;VQS<&%N/3-$,3$@;F]W<F%P/3-$;F]W<F%P/D]P=&EO;G,F(S$V,#M/
M=71S=&%N9&EN9SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O
M;&0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[)R!C;VQS<&%N/3-$.2!N;W=R87`],T1N;W=R87`^3W!T:6]N<R8C,38P
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M/E=E:6=H=&5D)B,Q-C`[079E<F%G93PO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/E=E:6=H
M=&5D/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^5V5I9VAT960F
M(S$V,#M!=F5R86=E/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#Y286YG928C,38P.V]F/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^079E<F%G93PO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
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M=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!N;W=R87`],T1N;W=R87`^17AE<F-I
M<V4F(S$V,#M0<FEC93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/D]P
M=&EO;G,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^17AE<F-I<V4F(S$V,#M0<FEC93PO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#LG(&YO=W)A<#TS1&YO=W)A<#Y#;VYT<F%C='5A;"8C,38P.TQI9F4\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
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M)B,Q-C`[4')I8V4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!N;W=R87`],T1N;W=R
M87`^0V]N=')A8W1U86PF(S$V,#M,:69E/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-"4[('1E>'0M
M86QI9VXZ(&-E;G1E<CLG/B0P+C`Y("T-"B`D-"XU-SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W
M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT.R<^,BPX
M.#DL,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$R
M)3L@=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C(P/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$T)3L@=&5X="UA;&EG;CH@<FEG:'0[)SXV+C$Q('EE
M87)S/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$R)3L@=&5X="UA
M;&EG;CH@<FEG:'0[)SXR+#,V-"PV,#@\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=W:61T:#H@,3(E.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N,CD\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,30E.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/C4N-S(@>65A<G,\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG/B0T+C4X("T@)#DN,#4\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
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M.3,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[)SXR+C<V('EE87)S/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXX.2PY.3D\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B0\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXU+CDS/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R<^,BXW-B!Y
M96%R<SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B0P+C`Y("T@)#DN,#4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^
M,BPY-SDL,#$P/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/C$N,S0\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R<^-BXP,2!Y96%R<SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@<FEG:'0[)SXR+#0U-"PV,#<\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R<^,2XT-CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[)SXU+C8R('EE
M87)S/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I
M=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[)SY4:&4@;W!T:6]N<R!O=71S
M=&%N9&EN9R!A;F0@97AE<F-I<V%B;&4@870@1&5C96UB97(@,S$L(#(P,3`@
M87)E(&%S(&9O;&QO=W,Z/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQT
M86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C
M;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#LG(&-O;'-P86X],T0Q,2!N
M;W=R87`],T1N;W=R87`^3W!T:6]N<R8C,38P.T]U='-T86YD:6YG/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([
M(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#LG(&-O;'-P86X],T0Y
M(&YO=W)A<#TS1&YO=W)A<#Y/<'1I;VYS)B,Q-C`[17AE<F-I<V%B;&4\+W1D
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M9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^5V5I9VAT960F(S$V,#M!
M=F5R86=E/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^5V5I9VAT960\+W1D/@T*/'1D(&YO
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M/3-$;F]W<F%P/E)A;F=E)B,Q-C`[;V8\+W1D/@T*/'1D(&YO=W)A<#TS1&YO
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M86=E/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^4F5M86EN:6YG
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^079E<F%G93PO=&0^#0H\=&0@;F]W<F%P/3-$
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M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^3W!T:6]N<SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A
M<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#LG(&-O;'-P86X],T0R#0H@;F]W<F%P/3-$;F]W<F%P/D5X97)C
M:7-E)B,Q-C`[4')I8V4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!N;W=R87`],T1N
M;W=R87`^0V]N=')A8W1U86PF(S$V,#M,:69E/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^3W!T:6]N<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
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M)B,Q-C`[3&EF93PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[)SX-
M"CQT9"!S='EL93TS1"=W:61T:#H@,30E.R!T97AT+6%L:6=N.B!C96YT97([
M)SXD,"XP.2`M("0T+C4W/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$R)3L@=&5X="UA;&EG;CH@<FEG:'0[)SXR+#0T.2PP.3(\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3(E.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/C$N,38\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,30E
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/C<N,#D@>65A<G,\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,3(E.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$L
M.3`P+#0T-3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X
M="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M,B4[('1E>'0M86QI9VXZ(')I9VAT.R<^,2XR.#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-"4[('1E>'0M86QI9VXZ(')I9VAT.R<^-BXT-R!Y
M96%R<SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG+6)O='1O;3H@,7!T
M.R<^)#0N-3@@+2`D.2XP-3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^.#DL.3DY/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
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M<G,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/C@Y+#DY.3PO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/C4N.3,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[)SXS+C<V('EE87)S/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)#`N,#D@+2`D
M.2XP-3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXR+#4S.2PP.3$\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,2XS,CPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
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M-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N-7!T(&1O=6)L93LG/C8N,S4@>65A<G,\+W1D/@T*/"]T<CX-
M"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M="`P.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'0@,#LG/E1H92!F;VQL;W=I;F<@:7,@82!S=6UM87)Y(&]F('1H
M92!#;VUP86YY)B,X,C$W.W,@;F]N+79E<W1E9"!S=&]C:R!O<'1I;VYS(&%T
M($1E8V5M8F5R(#,Q+"`R,#$Q.CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!T(#`[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^
M#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#@U)3L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@;6%R9VEN+6QE9G0Z(#`N-S5I;CLG(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
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M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P/E=E:6=H=&5D)B,Q-C`[079E<F%G93PO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
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M,T0G9F]N="UW96EG:'0Z(&)O;&0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^4W1O8VLF(S$V,#M/<'1I;VYS/"]T9#X-"CQT9"!S='EL93TS1"=P
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M(S$V,#M&86ER)B,Q-C`[5F%L=64\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$
M;F]W<F%P/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R#0H@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C
M8SLG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`V-"4[)SY.;VXM=F5S=&5D)B,Q
M-C`[)B,X,C$Q.R8C,38P.T1E8V5M8F5R)B,Q-C`[,S$L)B,Q-C`[,C`Q,#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ
M(')I9VAT.R<^-30X+#8T-SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ(')I9VAT.R<^,"XW-SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9#Y'<F%N
M=&5D/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^-34W+#`P,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$N,#D\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0^5F5S=&5D+T5X97)C
M:7-E9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/B@U,C@L,#$W/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$N,#<\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)SY&;W)F96ET960O0V%N8V5L;&5D/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
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M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^
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M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^-3(T+#0P,SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/E=E:6=H=&5D
M(&%V97)A9V4@<F5M86EN:6YG('!E<FEO9"!F;W(@=F5S=&EN9SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0[)SXQ+C8W('EE87)S/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D
M:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3LG/CQB/CQI/E-T;V-K(%=A<G)A;G1S(&%N9"!$97)I=F%T
M:79E($QI86)I;&ET:65S/"]I/CPO8CX\+W`^#0H\+V1I=CX-"CQD:78^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
M)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D]N($IU;'D@,BP@,C`Q,"P@
M=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@0V]M;6]N(%-T;V-K(%!U<F-H
M87-E($%G<F5E;65N="!W:71H(&$@<VEN9VQE(&EN=F5S=&]R+B!!<R!P87)T
M(&]F('1H:7,@86=R965M96YT+"!T:&4@0V]M<&%N>2!I<W-U960@=V%R<F%N
M=',@=&\@<'5R8VAA<V4@-C`L-C`V('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@
M=&\@=&AE('!L86-E;65N="!A9V5N="P@;W(@:71S('!E<FUI='1E9"!A<W-I
M9VYS+B!4:&4@=V%R<F%N=',@:&%V92!A;B!E>&5R8VES92!P<FEC92!O9B`D
M,2XS,B!A;F0@82!L:69E(&]F(#4@>65A<G,N(%1H92!W87)R86YT<R!V97-T
M960@;VX@2F%N=6%R>2`Q+"`R,#$Q(&%N9"!E>'!I<F4@1&5C96UB97(@,S$L
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M86YT<R!R96UA:6YE9"!O=71S=&%N9&EN9RX\+W`^#0H\+V1I=CX-"CQD:78^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D]N($IA;G5A<GD@,C@L
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M:7-A8FQE)B,Q-C`[9F]R('1H:7)T965N(&UO;G1H<R8C,38P.V%T("0R+C`P
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M('1H86X@)#(N,#`@<&5R('-H87)E+"!T:&4@=V%R<F%N="!H;VQD97)S('=I
M;&P@8F4@<F%T8VAE=&5D(&1O=VX@=&\@=&AE(&QO=V5R(&]F9F5R:6YG('!R
M:6-E+B!(;W=E=F5R+"!T:&4@0V]M<&%N>2!H860@:6YS=&ET=71E9"!A(&9L
M;V]R('!R:6-E(&]F("0Q+C0P('!E<B!S:&%R92!I;B!C;VYN96-T:6]N('=I
M=&@@=&AE('!R:6-E('!R;W1E8W1I;VXN/"]P/@T*/"]D:78^#0H\9&EV/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG
M/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY/;B!!<')I;"`V+"`R,#$Q
M+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@86YO=&AE<B!#;VUM;VX@4W1O
M8VL@4'5R8VAA<V4@06=R965M96YT('1H870@=')I9V=E<F5D('1H92!R871C
M:&5T('!R;W9I<VEO;B!A;F0@<F4M<V5T('1H92!P<FEC92!O9B!T:&5S92!W
M87)R86YT<R!T;R`D,2XT,"!P97(@<VAA<F4N($1U92!T;R!T:&4@<F4M<V5T
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M<R!R96UA:6YE9"!O=71S=&%N9&EN9RX\+W`^#0H\+V1I=CX-"CQD:78^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
M)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/E1H92!W87)R86YT<R!W97)E
M(&EN:71I86QL>2!R96-O<F1E9"!A<R!L:6%B:6QI=&EE<R!A="!T:&5I<B!E
M<W1I;6%T960@9F%I<B!V86QU92!O;B!T:&4@8V]M;6ET;65N="!D871E+"!W
M:&EC:"!W87,@)#<Q-BPP,#`@=VET:"!S=6)S97%U96YT(&-H86YG97,@:6X@
M97-T:6UA=&5D(&9A:7(@=F%L=64@<F5C;W)D960@87,@82!W87)R86YT(&5X
M<&5N<V4F(S$V,#MI;B!T:&4@0V]M<&%N>28C.#(Q-SMS('-T871E;65N="!O
M9B!O<&5R871I;VYS(&%T(&5A8V@@<W5B<V5Q=65N="!R97!O<G1I;F<@<&5R
M:6]D+B!/;B!!<')I;"`V+"`R,#$Q+"!T:&4@9F%I<B!V86QU92!O9B!T:&4@
M=V%R<F%N="!L:6%B:6QI='D@=V%S("0Q+C4@;6EL;&EO;BP@=VAI8V@@<F5P
M<F5S96YT960@86X@:6YC<F5A<V4@:6X@9F%I<B!V86QU92!O9B`D-S8U+#`P
M,"X@5&AE(&9A:7(@=F%L=64@=V%S(&UE87-U<F5D('5S:6YG('1H92!";&%C
M:RU38VAO;&5S('9A;'5A=&EO;B!M;V1E;"X@5&AE(&%S<W5M<'1I;VYS('5S
M960@8GD@=&AE($-O;7!A;GD@87)E('-U;6UA<FEZ960@:6X@=&AE(&9O;&QO
M=VEN9R!T86)L93H\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P="`P.R!T97AT+6%L:6=N.@T*(&IU<W1I9GD[)SXF(S$V,#L\+W`^
M#0H\+V1I=CX-"CQD:78^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#@U)3L@
M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z(#`N-S5I;CLG
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4]
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M9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A
M<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CLG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y#;VUM:71M96YT/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^1&%T
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M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^07!R:6PF(S$V,#LV+"8C,38P.S(P,3$\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`W,"4[)SY#;&]S:6YG('-T;V-K('!R:6-E/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT.R<^,2XS
M.3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG
M;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^,BXP.#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^17AP96-T960@9&EV:61E;F0@<F%T93PO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`\
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M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/C`N,C@\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXE
M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^,"XR.3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B4\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/D5X<&5C=&5D(&QI
M9F4@*'EE87)S*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$N,#@\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXP+C@U/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY/
M;B!!=6=U<W0@,3`L(#(P,3$L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A
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M)B,Q-C`[97AT96YD960@8GD@='=O(&UO;G1H<RX\+W`^#0H\+V1I=CX-"CQD
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D]N($%P<FEL(#8L
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M>&5R8VES86)L928C,38P.V9O<B!T:&ER=&5E;B!M;VYT:',F(S$V,#MA="`D
M,BXP-S(U('!E<B!S:&%R92X@5&AE('=A<G)A;G0@:&%D(&%N(&%N=&DM9&EL
M=71I;VX@<')I8V4@<')O=&5C=&EO;B!F96%T=7)E.R!T:&%T('!R;W9I9&5D
M(&EF('1H92!#;VUP86YY(&ES<W5E<R!S96-U<FET:65S(&%T(&$@<')I8V4@
M<&5R('-H87)E('1H870@:7,@;&5S<R!T:&%N("0R+C`W,C4@<&5R('-H87)E
M+"8C,38P.W1H928C,38P.V5X97)C:7-E('!R:6-E(&]F('1H92!W87)R86YT
M)B,Q-C`[=VEL;"!B92!R871C:&5T960@9&]W;B!T;R!T:&4@;&]W97(@;V9F
M97)I;F<@<')I8V4N)B,Q-C`[3VX@2G5L>2`R."P@,C`Q,2P@=&AE('=A<G)A
M;G0@=V%S(&5X8VAA;F=E9"!F;W(@82!N97<@=V%R<F%N="!W:71H('-U8G-T
M86YT:6%L;'D@<VEM:6QA<B!T97)M<R!E>&-E<'0@=&AA="!I;B!T:&4@;F5W
M('=A<G)A;G0@*&DI('1H92!A;G1I+61I;'5T:6]N('!R:6-E('!R;W1E8W1I
M;VX@=V%S(&5L:6UI;F%T960L("AI:2D@=&AE(&5X97)C:7-E('!R:6-E('=A
M<R!L;W=E<F5D('1O("0Q+C`P+"`H:6EI*2!T:&4@97AP:7)A=&EO;B!D871E
M('=A<R!E>'1E;F1E9"!F;W(@86X@861D:71I;VYA;"8C,38P.W1H<F5E(&UO
M;G1H<R!T;R!!=6=U<W0@,3(L(#(P,3(L)B,Q-C`[86YD("AI=BD@=&AE('=A
M<G)A;G0F(S@R,3<[<R!I;FET:6%L(&5X97)C:7-E(&1A=&4@=V%S(&-H86YG
M960@=&\@2F%N=6%R>2`R,#$R+B!$=64@=&\@=&AI<R!W87)R86YT(&5X8VAA
M;F=E+"!T:&4@=V%R<F%N="!L:6%B:6QI='D@=V%S(&UA<FME9"UT;RUM87)K
M970@86YD(')E8VQA<W-I9FEE9"!T;R!A9&1I=&EO;F%L('!A:60M:6X@8V%P
M:71A;"!S:6YC92!I="!C96%S960@=&\@8V]N=&%I;B!T:&4@<')O=FES:6]N
M<R!O9B!A(&1E<FEV871I=F4@;&EA8FEL:71Y+B!!<R!O9B!$96-E;6)E<B`S
M,2P@,C`Q,2P@86QL(&]F('1H97-E('=A<G)A;G1S(')E;6%I;F5D(&]U='-T
M86YD:6YG+CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I
M=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R<^5&AE('=A<G)A;G0@:7,F(S$V,#MI;FET:6%L;'D@<F5C
M;W)D960@87,@82!L:6%B:6QI='D@870F(S$V,#MI=',@97-T:6UA=&5D(&9A
M:7(@=F%L=64@;VX@=&AE(&-O;6UI=&UE;G0@9&%T92P@=VAI8V@@=V%S("0W
M-S8L,#`P('=I=&@@<W5B<V5Q=65N="!C:&%N9V5S(&EN(&5S=&EM871E9"!F
M86ER('9A;'5E(')E8V]R9&5D(&%S(&$@=V%R<F%N="!E>'!E;G-E)B,Q-C`[
M:6X@=&AE($-O;7!A;GDF(S@R,3<[<R!S=&%T96UE;G0@;V8@;W!E<F%T:6]N
M<R!A="!E86-H('-U8G-E<75E;G0@<&5R:6]D+B!/;B!*=6QY(#(X+"`R,#$Q
M+"!T:&4@9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N="!L:6%B:6QI='D@=V%S
M("0R-3,L,#`P+"!W:&EC:"!R97!R97-E;G1E9"!A(&1E8W)E87-E(&EN(&9A
M:7(@=F%L=64@;V8@)#4R,RPP,#`N(%1H92!F86ER('9A;'5E(&ES(&UE87-U
M<F5D('5S:6YG('1H92!";&%C:RU38VAO;&5S('9A;'5A=&EO;B!M;V1E;"X@
M5&AE(&%S<W5M<'1I;VYS('5S960@8GD@=&AE($-O;7!A;GD@87)E('-U;6UA
M<FEZ960@:6X@=&AE(&9O;&QO=VEN9R!T86)L93H\+W`^#0H\+V1I=CX-"CQD
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'1A8FQE('-T>6QE
M/3-$)W=I9'1H.B`X-24[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;BUL969T.B`P+C<U:6X[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M4F5M96%S=7)E;65N=#PO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/B8C,38P
M.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9`T*(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/'1D(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<#Y#;VUM:71M96YT/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^1&%T93PO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
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M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`^2G5L>28C,38P.S(X+"8C,38P.S(P,3$\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M9F9C8SLG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`W,"4[('1E>'0M:6YD96YT
M.B`M,"XR-6EN.R!P861D:6YG+6QE9G0Z(#`N,C5I;CLG/D-L;W-I;F<@<W1O
M8VL@<')I8V4\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L
M969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$R)3L@=&5X="UA
M;&EG;CH@<FEG:'0[)SXR+C`X/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,"XR-6EN
M.R!P861D:6YG+6QE9G0Z(#`N,C5I;CLG/D5X<&5C=&5D(&1I=FED96YD(')A
M=&4\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXP/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M9F9C8SLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`M,"XR-6EN.R!P861D:6YG+6QE9G0Z(#`N,C5I;CLG/D5X<&5C
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,"XR-6EN
M.R!P861D:6YG+6QE9G0Z(#`N,C5I;CLG/E)I<VL@9G)E92!I;G1E<F5S="!R
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M.R!T97AT+6EN9&5N=#H@+3`N,C5I;CL@<&%D9&EN9RUL969T.B`P+C(U:6X[
M)SY%>'!E8W1E9"!L:69E("AY96%R<RD\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C`X/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
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M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P="`P.R<^5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('1H
M92!E<W1I;6%T960@9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N="!L:6%B:6QI
M=&EE<R`\:3XH:6X@=&AO=7-A;F1S*3H\+VD^/"]P/@T*/"]D:78^#0H\9&EV
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV
M/@T*/&1I=CX-"CQT86)L92!S='EL93TS1"=W:61T:#H@.#4E.R!B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!M87)G:6XM;&5F=#H@,"XW-6EN.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TP+C(U:6X[('!A9&1I
M;F<M;&5F=#H@,"XR-6EN.R<^0F%L86YC92!A="!$96-E;6)E<B`S,2P@,C`Q
M,#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT
M9"!S='EL93TS1"=W:61T:#H@.#4E.R!T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@+3`N,C5I;CL@<&%D9&EN9RUL969T.B`P+C(U:6X[)SY787)R
M86YT(&QI86)I;&ET>3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M,B4[('1E>'0M86QI9VXZ(')I9VAT.R<^,2PT.3(\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[)SX-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3`N,C5I;CL@<&%D9&EN
M9RUL969T.B`P+C(U:6X[)SY#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W87)R
M86YT(&QI86)I;&ET>3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^*#$L
M-S,T/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T
M97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V9F8V,[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M('1E>'0M:6YD96YT.B`M,"XR-6EN.R!P861D:6YG+6QE9G0Z(#`N,C5I;CLG
M/D)A;&%N8V4@870@1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T
M86)L93X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^02!S=6UM87)Y(&]F('=A<G)A;G0@86-T:79I='D@9F]R('1H92!#
M;VUP86YY(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"!A
M;F0@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q(&ES(&%S
M(&9O;&QO=W,Z/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQT86)L92!S
M='EL93TS1"=W:61T:#H@.#4E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
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M=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
M9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/E=E:6=H=&5D)B,Q-C`[079E<F%G93PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
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M;W=R87`],T1N;W=R87`^3G5M8F5R)B,Q-C`[;V8F(S$V,#M787)R86YT<SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
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M;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#<P)3LG/D)A
M;&%N8V4@870@1&5C96UB97(@,S$L(#(P,#D\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,3(E.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$L,#<P+#0W
M,CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG
M;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^,RXR-SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9#Y'<F%N=&5D/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M-C`L-C`V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
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M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
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M;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V9F8V,[)SX-"CQT9#Y"86QA;F-E(&%S($1E8V5M8F5R(#,Q
M+"`R,#$P/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^,2PQ,S$L,#<X/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
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M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/C(L,C<R+#DV,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$N,C4\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0^17AE<F-I<V5D/"]T9#X-
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M=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C`S/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R<^1F]R9F5I=&5D/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXH,3(Y+#(T,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@
M;&5F=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/C(N,#@\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^0F%L86YC92!A<R!$
M96-E;6)E<B`S,2P@,C`Q,3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXS+#(U
M.2PQ.#8\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT
M.R<^,2XY-3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@
M,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!T(#`[)SY!('-U;6UA<GD@;V8@86QL(&]U='-T86YD:6YG(&%N9"!E
M>&5R8VES86)L92!W87)R86YT<R!A<R!O9B!$96-E;6)E<B`S,2P@,C`Q,2!I
M<R!A<R!F;VQL;W=S.CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!T(#`[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\=&%B
M;&4@<W1Y;&4],T0G=VED=&@Z(#@U)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL
M87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN+6QE9G0Z(#`N-S5I;CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R<@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/D5X97)C:7-E/&)R("\^4')I8V4\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^5V%R<F%N=',\
M8G(@+SY/=71S=&%N9&EN9SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#LG(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#Y787)R86YT<SQB<B`O/D5X97)C:7-A8FQE
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W
M<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P/E=E:6=H=&5D)B,Q-C`[079E<F%G93QB<B`O/E)E;6%I;FEN9SQB<B`O
M/D-O;G1R86-T=6%L)B,Q-C`[3&EF93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#LG(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y!9V=R96=A=&4@/&)R("\^26YT
M<FEN<VEC)B,Q-C`[5F%L=64\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q."4[('1E>'0M86QI9VXZ(')I9VAT.R<^,2XP,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$W)3L@=&5X="UA
M;&EG;CH@<FEG:'0[)SXX-#0L,SDQ/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.PT*('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-R4[('1E>'0M86QI9VXZ(')I9VAT.R<^
M.#0T+#,Y,3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$W)3L@=&5X="UA;&EG;CH@<FEG:'0[)SXP+C8Q('EE87)S/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T
M.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$W)3L@=&5X="UA;&EG
M;CH@<FEG:'0[)SXR,3DL,#`P/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
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M<FEG:'0[)SXT+C`P('EE87)S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V9F8V,[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXQ+C0P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PT,C@L-3<R/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PT
M,C@L-3<R/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^,"XS,R!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
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M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^-3$W+#(U-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/C0N.3$@>65A<G,\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/C,N,S`\+W1D/@T*/'1D('-T>6QE/3-$)W1E
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M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
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M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C4P+#`P,#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/C4P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
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M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
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M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXS,C<L
M-#4V/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXS,C<L
M-#4V/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXP+C@V
M('EE87)S/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXM
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[)SX-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^,2XY-3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
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M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
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M=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(')I9VAT.R<^,C$Y+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.@T*(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P="`P.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'0@,#LG/CQB/CQI/D]P=&EO;G,@;V8@4W5B
M<VED:6%R:65S/"]I/CPO8CX\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P="`P.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG
M/D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q+"!#1#0@0FEO<V-I96YC97,L($EN
M8RXL(&$@;6%J;W)I='DM;W=N960@<W5B<VED:6%R>2!O9B!3>6YT:&5T:6,@
M0FEO;&]G:6-S+"!H87,@82!T;W1A;"!O9B`R,"PP,#`@<W1O8VL@;W!T:6]N
M<R!O=71S=&%N9&EN9R!A;F0@97AE<F-I<V%B;&4N)B,Q-C`[)B,Q-C`[5&AE
M<V4@<W1O8VL@;W!T:6]N<R!H879E(&%N(&5X97)C:7-E('!R:6-E(&]F("0P
M+C(P(&%N9"!A(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E(&]F(#`N,S<@
M>65A<G,N/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV
M/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[)SY!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,2P@17!I=&]P92P@
M82!M86IO<FET>2UO=VYE9"!S=6)S:61I87)Y(&]F(%-Y;G1H971I8R!":6]L
M;V=I8W,L(&AA<R`U,"PP,#`@<W1O8VL@;W!T:6]N<R!O=71S=&%N9&EN9R!A
M;F0@,C`L,#`P('-T;V-K(&]P=&EO;G,@97AE<F-I<V%B;&4N(%1H97-E('-T
M;V-K(&]P=&EO;G,@:&%V92!A;B!E>&5R8VES92!P<FEC92!O9B`D,"XP,#$@
M86YD(&$@<F5M86EN:6YG(&-O;G1R86-T=6%L(&QI9F4@;V8@-BXU,"!Y96%R
M<RX\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%4T<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VL@
M4'5R8VAA<V4@5V%R<F%N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K(%!U<F-H
M87-E(%=A<G)A;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@4'5R8VAA<V4@5V%R<F%N=',@
M6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XM=&]P.B`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;BUL969T.B`P:6X[)SX\8CXW+B8C,38P.R8C,38P.R8C,38P.U-T
M;V-K(%!U<F-H87-E(%=A<G)A;G1S/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D]N($UA<F-H(#$U
M+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;VYS=6QT:6YG
M(&%G<F5E;65N="!F;W(@82!F:6YA;F-I86P@8V]M;75N:6-A=&EO;G,@<')O
M9W)A;2P@9F]R(&$@<&5R:6]D(&]F('1W96QV92!M;VYT:',@=&AA="!B96=A
M;B!O;B!&96)R=6%R>2`R,"P@,C`Q,BX@07,@8V]M<&5N<V%T:6]N(&9O<B!S
M=6-H('!R;V=R86TL('1H92!C;VYS=6QT86YT(&ES('!A:60@82!M;VYT:&QY
M(&9E92!A;F0@=VEL;"!B92!I<W-U960@82!P97)F;W)M86YC92!W87)R86YT
M(&5X97)C:7-A8FQE(&9O<B`R-3`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!B87-E9"!O;B!A8VAI979E;65N="!O
M9B!C97)T86EN(&UI;&5S=&]N97,N(%5P;VX@:6YI=&EA=&EO;B!O9B!T:&4@
M<')O9W)A;2P@-3`L,#`P(&]F('1H92!P97)F;W)M86YC92!W87)R86YT<R!V
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M=F%L=64@;V8@=&AE('=A<G)A;G0@87!P<F]X:6UA=&5D("0V,2PP,#`@86YD
M('=A<R!M96%S=7)E9"!U<VEN9R!T:&4@0FQA8VLM4V-H;VQE<R!V86QU871I
M;VX@;6]D96PN(%1H92!A<W-U;7!T:6]N<R!U<V5D(&)Y('1H92!#;VUP86YY
M(&%R92!S=6UM87)I>F5D(&EN('1H92!F;VQL;W=I;F<@=&%B;&4Z/"]P/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[)B,Q-C`[/"]P/@T*
M/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`X-24[(&)O<F1E<BUC;VQL87!S93H@
M8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@.#4E.R<^
M17AE<F-I<V4@<')I8V4\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[('=I9'1H.B`Q,B4[)SXR+C(P/"]T9#X-"CQT9"!S='EL93TS1"=T
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/C$P.#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B4\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SY2:7-K(&9R964@:6YT97)E<W0@<F%T93PO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/C`N,S<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
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M+"`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;VYS=6QT:6YG
M(&%G<F5E;65N="!F;W(@9FEN86YC:6%L(&%D=FES;W)Y('-E<G9I8V5S+"!F
M;W(@82!P97)I;V0@;V8@='=E;'9E(&UO;G1H<RX@07,@8V]M<&5N<V%T:6]N
M(&9O<B!S=6-H('-E<G9I8V5S+"!T:&4@8V]N<W5L=&%N="!I<R!P86ED(&$@
M;6]N=&AL>2!F964@86YD(&]N($9E8G)U87)Y(#(L(#(P,3(L('=A<R!I<W-U
M960@82!W87)R86YT(&5X97)C:7-A8FQE(&9O<B`Q,#`L,#`P('-H87)E<R!O
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M,#`L,#`P(&%N9"!W87,@;65A<W5R960@=7-I;F<@=&AE($)L86-K+5-C:&]L
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M<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-
M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#@U
M)3LG/D5X97)C:7-E('!R:6-E/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!W:61T:#H@,3(E.R<^,2XQ-#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-
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M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F
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M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#LF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/;B!!
M<')I;"`V+"`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!#;VUM
M;VX@4W1O8VL@4'5R8VAA<V4@06=R965M96YT('=I=&@@86X@:6YS=&ET=71I
M;VYA;"!I;G9E<W1O<BX@07,@<&%R="!O9B!T:&ES(&%G<F5E;65N="P@=&AE
M($-O;7!A;GD@:7-S=65D(&$@=V%R<F%N="!T;R!P=7)C:&%S92`X-#0L,SDQ
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VLN(%1H92!W87)R86YT<R!H879E(&%N
M(&5X97)C:7-E('!R:6-E(&]F("0Q+C`P(&%N9"!A(&QI9F4@;V8@9FEF=&5E
M;B!M;VYT:',N(%1H92!W87)R86YT<R!V97-T960@:6UM961I871E;'D@86YD
M(&5X<&ER92!!=6=U<W0@,3`L(#(P,3(N($%S(&]F($UA<F-H(#,Q+"`R,#$R
M+"`S-#0L,SDQ(&]F('1H97-E('=A<G)A;G1S(')E;6%I;F5D(&]U='-T86YD
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M8VES92!P<FEC92!O9B`D,2XT,"!A;F0@82!L:69E(&]F(&9I9G1E96X@;6]N
M=&AS+B!4:&4@=V%R<F%N=',@=F5S=&5D(&EM;65D:6%T96QY(&%N9"!E>'!I
M<F4@36%Y(#$L(#(P,3(N($%S(&]F($UA<F-H(#,Q+"`R,#$R+"`W-#8L-#(Y
M(&]F('1H97-E('=A<G)A;G1S(')E;6%I;F5D(&]U='-T86YD:6YG+CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+`T*('-E
M<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^3VX@2G5L>2`R+"`R,#$P+"!T:&4@0V]M
M<&%N>2!E;G1E<F5D(&EN=&\@82!#;VUM;VX@4W1O8VL@4'5R8VAA<V4@06=R
M965M96YT('=I=&@@82!S:6YG;&4@:6YV97-T;W(N($%S('!A<G0@;V8@=&AI
M<R!A9W)E96UE;G0L('1H92!#;VUP86YY(&ES<W5E9"!W87)R86YT<R!T;R!P
M=7)C:&%S92`V,"PV,#8@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!T;R!T:&4@
M<&QA8V5M96YT(&%G96YT+"!O<B!I=',@<&5R;6ET=&5D(&%S<VEG;G,N(%1H
M92!W87)R86YT<R!H879E(&%N(&5X97)C:7-E('!R:6-E(&]F("0Q+C,R(&%N
M9"!A(&QI9F4@;V8@-2!Y96%R<RX@5&AE('=A<G)A;G1S('9E<W1E9"!O;B!*
M86YU87)Y(#$L(#(P,3$@86YD(&5X<&ER92!$96-E;6)E<B`S,2P@,C`Q-2X@
M4VEN8V4@=&AE<V4@=V%R<F%N=',@=V5R92!G<F%N=&5D(&%S('!A<G0@;V8@
M86X@97%U:71Y(')A:7-E+"!T:&4@0V]M<&%N>2!H87,@=')E871E9"!T:&5M
M(&%S(&$@9&ER96-T(&]F9F5R:6YG(&-O<W0N(%1H92!R97-U;'0@;V8@=&AE
M('1R86YS86-T:6]N(&AA<R!N;R!A9F9E8W0@=&\@97%U:71Y+B!!<R!O9B!-
M87)C:"`S,2P@,C`Q,BP@,3@L,3@R(&]F('1H97-E('=A<G)A;G1S(')E;6%I
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M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE
M('-T>6QE/3-$)W=I9'1H.B`X-24[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P
M<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`^5V5I9VAT960\8G(@+SY!=F5R86=E)B,Q
M-C`[17AE<F-I<V4F(S$V,#M0<FEC93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F
M9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#<P)3LG/D)A;&%N8V4@)B,X,C$Q.R!$96-E;6)E<B`S,2P@,C`Q
M,#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W
M:61T:#H@,3(E.R<^,2PQ,S$L,#<X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,B4[)SXS+C0Y/"]T
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M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D/D5X97)C
M:7-E9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
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M;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^,BXP.#PO=&0^#0H\
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M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#Y'<F%N=&5D/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M,S4P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/C$N.3`\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG
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M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^17AP:7)E
M9#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
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M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,BPT
M,30L.3(R/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/C(N,S8\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/D)A;&%N8V4@)B,X,C$Q.R!-87)C:"`S,2P@,C`Q,B`F(S@R,3$[(&5X
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M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0-"B!S='EL93TS1"=P
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M;&4^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
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M<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^17AE<F-I<V4\
M8G(@+SY0<FEC93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<#Y787)R86YT<SQB<B`O/D]U='-T86YD:6YG/"]T9#X-
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M9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P
M/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^5V5I9VAT960F(S$V,#M!=F5R
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M<F%P/D%G9W)E9V%T93QB<B`O/DEN=')I;G-I8R8C,38P.U9A;'5E/"]T9#X-
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M=&@Z(#$X)3LG/C$N,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3<E.R<^,S0T+#,Y,3PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[('=I9'1H.B`Q-R4[)SXS-#0L,SDQ/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$W
M)3LG/C`N,S8@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$W)3LG/C0T,RPP,#`\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^,2XQ-#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$P,"PP,#`\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXQ,#`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-"XX-"!Y96%R<SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C$P-BPP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2XS,CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C$X+#$X,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$X+#$X,CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C,N-S4@
M>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXQ-BPP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$N-#`\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXW-#8L-#(Y/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-S(Q+#0R.3PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C`N,#@@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXU-S<L,#`P/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C(N,C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXR-3`L,#`P/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-3`L
M,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^,2XY-B!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
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M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M-3$W+#(U-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/C0N-C8@>65A<G,\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/C,N,S`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ#0H@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C8Q+#(P-SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C8Q+#(P-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C,N,S`@>65A<G,\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXS+C<U/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-3`L,#`P/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^-3`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,RXX."!Y96%R<SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@
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M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT.R<^,S(W+#0U-CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT.R<^,S(W+#0U-CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT.R<^/'4@<W1Y;&4],T0G=&5X="UD96-O<F%T:6]N
M.B!N;VYE.R<^,"XV,2!Y96%R<SPO=3X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[
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M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[)SX\9F]N="!S='EL93TS1"=T97AT+75N9&5R;&EN92US='EL93H@9&]U
M8FQE.R<^/'4@<W1Y;&4],T0G=&5X="UD96-O<F%T:6]N.B!N;VYE.R<^,2XX
M,2!Y96%R<SPO=3X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!R:6=H=#LG/C$L,30R+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\=&%B;&4@<W1Y;&4]
M,T0G;6%R9VEN+71O<#H@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!M87)G:6XM8F]T=&]M.B`P<'@[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX-"CQT9"!S
M='EL93TS1"=W:61T:#H@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[)SX\8CXX
M+CPO8CX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M)SX\8CY3=&]C:R!297!U<F-H87-E(%!R;V=R86T\+V(^/"]T9#X-"CPO='(^
M#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'0@,"`P<'0@,"XU:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SXF(S$V,#L\
M+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R<^3VX@07!R:6P@,RP@,C`P.2P@=&AE($-O
M;7!A;GDF(S@R,3<[<R!";V%R9"!O9B!$:7)E8W1O<G,@87!P<F]V960@82!3
M=&]C:R!297!U<F-H87-E(%!R;V=R86T@875T:&]R:7II;F<@=&AE($-O;7!A
M;GD@=&\@<F5P=7)C:&%S92P@9G)O;2!T:6UE+71O+71I;64@86YD('1H<F]U
M9V@@1&5C96UB97(@,S$L(#(P,#DL('5P('1O("0Q(&UI;&QI;VX@;V8@:71S
M(&-O;6UO;B!S=&]C:RP@=7`@=&\@82!M87AI;75M(&]F(&9O=7(@;6EL;&EO
M;B!S:&%R97,@870@<')I8V5S(&]F('5P('1O("0U('!E<B!S:&%R92X@07,@
M;V8@1&5C96UB97(@,S$L(#(P,3$L('1H92!#;VUP86YY(&AA9"!R97!U<F-H
M87-E9"`X,2PT.#(@<VAA<F5S(&9O<B!A<'!R;WAI;6%T96QY("0U,"PP,#`@
M*"0P+C8Q('!E<B!S:&%R92DL(&)A<V5D('5P;VX@=&AE('%U;W1E9"!C;&]S
M:6YG('1R861I;F<@<')I8V4N)B,Q-C`[)B,Q-C`[5&AE<V4@=')E87-U<GD@
M<VAA<F5S(&%R92!N;W0@:6YC;'5D960@:6X@=&AE(&-O;7!U=&%T:6]N(&]F
M(&5A<FYI;F=S("AL;W-S*2!P97(@<VAA<F4@86YD(&%R92!D965M960@=&\@
M8F4@8V%N8V5L960@86YD(')E=&ER960N/"]P/@T*/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-'/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3=&]C:VAO;&1E<G,@17%U:71Y($YO=&4@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:VAO;&1E<G,G($5Q=6ET>2!.;W1E($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XM=&]P.B`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUL969T
M.B`P:6X[)SX\8CXX+B8C,38P.R8C,38P.R8C,38P.U-T;V-K:&]L9&5R<R8C
M.#(Q-SL@17%U:71Y/"]B/CPO<#X-"CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN+71O<#H@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM;&5F=#H@,&EN.R<^
M1'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P,3(L
M('1H92!#;VUP86YY(&ES<W5E9"`R.#DL,S0S('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VLL(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@97AE<F-I<V4@;V8@<W1O
M8VL@;W!T:6]N<RP@9F]R('!R;V-E961S(&]F(&%P<')O>&EM871E;'D@)#8X
M+#`P,"X@5&AE($-O;7!A;GD@86QS;R!I<W-U960@,2PQ.30L,C8T('-H87)E
M<R!O9B!C;VUM;VX@<W1O8VL@:6X@8V]N;F5C=&EO;B!W:71H('1H92!E>&5R
M8VES92!O9B!W87)R86YT<RP@9F]R('!R;V-E961S(&]F(&%P<')O>&EM871E
M;'D@)#$N-2!M:6QL:6]N+CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\=&%B;&4@<W1Y;&4],T0G
M;6%R9VEN+71O<#H@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XM8F]T=&]M.B`P<'@[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX-"CQT9"!S='EL
M93TS1"=W:61T:#H@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[)SX\8CXV+CPO
M8CX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\
M8CY3=&]C:VAO;&1E<G,F(S@R,3<[($5Q=6ET>3PO8CX\+W1D/@T*/"]T<CX-
M"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M="`P(#!P="`P+C5I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/B8C,38P.SPO
M<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[)SX\:3Y996%R($5N9&5D($1E8V5M8F5R(#,Q
M+"`R,#$P/"]I/CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\
M+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R<^3VX@2G5L>2`R+"`R,#$P+"!T:&4@0V]M<&%N>2!S
M;VQD(#$L,C$R+#$R,2!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C
M;VUM;VX@<W1O8VL@870@82!C;&]S:6YG('!R:6-E(&]F("0P+C@R-2!F;W(@
M9W)O<W,@<')O8V5E9',@;V8@)#$@;6EL;&EO;BXF(S$V,#LF(S$V,#M4:&4@
M0V]M<&%N>2!P86ED(&1I<F5C="!O9F9E<FEN9R!C;W-T<R!O9B`D,3$U+#`P
M,"XF(S$V,#LF(S$V,#M3964@3F]T92`U(')E9V%R9&EN9R!W87)R86YT<R!G
M<F%N=&5D('=I=&@@=&AI<R!O9F9E<FEN9RX\+W`^#0H\+V1I=CX-"CQD:78^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D1U<FEN9R!T:&4@>65A
M<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"P@=&AE($-O;7!A;GD@:7-S=65D
M(#(U-2PY-30@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RP@:6X@8V]N;F5C=&EO
M;B!W:71H('1H92!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS+"!F;W(@<')O
M8V5E9',@;V8@)#$S,"PP,#`N(%1H92!#;VUP86YY(&%L<V\@:7-S=65D(#(W
M.2PW,C0@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!F;W(@8V]N<W5L=&EN9R!S
M97)V:6-E<RP@:&%V:6YG(&$@9F%I<B!V86QU92!O9B`D,C$T+#`P,"`H)#`N
M-S8@<&5R('-H87)E*2P@.#$L,#,U('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@
M9F]R(&QI8V5N<V4@9F5E<RP@:&%V:6YG(&$@9F%I<B!V86QU92!O9B`D-S`L
M,#`P("@D,"XX-R!P97(@<VAA<F4I+"!A;F0@-C`L-3(Q('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@9F]R(&5M<&QO>6UE;G0@<V5R=FEC92P@:&%V:6YG(&$@
M9F%I<B!V86QU92!O9B`D-#<L,#`P("@D,"XW-R!P97(@<VAA<F4I+B!4:&4@
M9F%I<B!V86QU92!O9B!T:&5S92!I<W-U86YC97,@=V5R92!B87-E9"!U<&]N
M('1H92!Q=6]T960@8VQO<VEN9R!T<F%D:6YG('!R:6-E<RX\+W`^#0H\+V1I
M=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQI/EEE
M87(@16YD960@1&5C96UB97(@,S$L(#(P,3$\+VD^/"]P/@T*/"]D:78^#0H\
M9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY$=7)I;F<@=&AE
M('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3$L('1H92!#;VUP86YY(&ES
M<W5E9"`R."PS,S,@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I;B!C;VYN96-T
M:6]N('=I=&@@=&AE(&5X97)C:7-E(&]F('-T;V-K(&]P=&EO;G,@86YD('=A
M<G)A;G1S(&9O<B!P<F]C965D<R!O9B`D,34L,#`P(&%N9"`Q,"PV,34@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!R96QA=&5D('1O(&$@8V%S:&QE<W,@97AE
M<F-I<V4@;V8@=V%R<F%N=',N(%1H92!#;VUP86YY(&ES<W5E9"`W,RPU.#4@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!F;W(@96UP;&]Y;65N="!S97)V:6-E
M+"!H879I;F<@82!F86ER('9A;'5E(&]F("0Y-"PP,#`@*"0Q+C(Y(&%V97)A
M9V4@<&5R('-H87)E*2!A;F0@,3<Q+#<Y-B!S:&%R97,@;V8@8V]M;6]N('-T
M;V-K(&9O<B!C;VYS=6QT:6YG('-E<G9I8V5S+"!H879I;F<@82!F86ER('9A
M;'5E(&]F("0Q-C4L,#`P("@D,"XY-B!A=F5R86=E('!E<B!S:&%R92DL(&)A
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M(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^3VX@
M2F%N=6%R>2`R."P@,C`Q,2P@=&AE($-O;7!A;GD@<V]L9"`R+#@U-RPQ-#0@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',@97AE<F-I<V%B
M;&4@9F]R)B,Q-C`[,2PT,C@L-3<R('-H87)E<R!O9B!C;VUM;VX@<W1O8VLF
M(S$V,#MF;W(@)#0@;6EL;&EO;BX@1&ER96-T(&]F9F5R:6YG(&-O<W1S('=E
M<F4@87!P<F]X:6UA=&5L>2`D,CDV+#`P,"X\+W`^#0H\+V1I=CX-"CQD:78^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D]N($%P<FEL(#8L(#(P
M,3$L('1H92!#;VUP86YY('-O;&0@,2PV.#@L-S@R('-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@86YD(&$@=V%R<F%N="!E>&5R8VES86)L92!F;W(@.#0T+#,Y
M,2!S:&%R97,@;V8@8V]M;6]N('-T;V-K)B,Q-C`[9F]R("0S+C4@;6EL;&EO
M;BX@1&ER96-T(&]F9F5R:6YG(&-O<W1S('=E<F4@87!P<F]X:6UA=&5L>2`D
M,C0S+#`P,"X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M3&EC96YS92P@0V]L;&%B;W)A=&EV92!A;F0@16UP;&]Y;65N="!!9W)E96UE
M;G1S(&%N9"!#;VUM:71M96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN
M9V5N8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD($-O
M;G1I;F=E;F-I97,@1&ES8VQO<W5R92!;5&5X="!";&]C:UT\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\=&%B;&4@<W1Y;&4],T0G
M;6%R9VEN+71O<#H@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XM8F]T=&]M.B`P<'@[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX-"CQT9"!S='EL
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M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T
M(#`N-6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN.R<^)B,Q-C`[/"]P/@T*/"]D
M:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3LG/CQI/DQI8V5N<V4@06=R965M96YT<SPO:3X\+W`^#0H\
M+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/E1H
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M+"`H8BD@97AP96YS92!R96EM8G5R<V5M96YT<RP@86YD("AC*2!A8VAI979E
M;65N="!O9B!S=6-C97-S(&UI;&5S=&]N97,N($%L;"!E>'!E;G-E<R!R96QA
M=&5D('1O('1H97-E(&%G<F5E;65N=',@:&%V92!B965N(')E8V]R9&5D(&%S
M(')E<V5A<F-H(&%N9"!D979E;&]P;65N="X\+W`^#0H\+V1I=CX-"CQD:78^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQI/E)E<V5A<F-H($%G
M<F5E;65N=#PO:3X\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*
M/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3LG/DEN(%-E<'1E;6)E<B8C,38P.V]F(#(P,#4L('1H
M92!#;VUP86YY(&5N=&5R960@:6YT;R!A('1H<F5E+7EE87(@<F5S96%R8V@@
M86=R965M96YT('=I=&@@=&AE(%5N:79E<G-I='D@;V8@36EC:&EG86XN(%!U
M<G-U86YT('1O('1H870@86=R965M96YT+"!T:&4@0V]M<&%N>2!S<&]N<V]R
M960@<F5S96%R8V@@;V8@87!P<F]X:6UA=&5L>2`D-#8P+#`P,"!P97(@>65A
M<BXF(S$V,#LF(S$V,#M/;B!-87)C:"`R,"P@,C`P."P@=&AE($-O;7!A;GD@
M=&5R;6EN871E9"!T:&4@86=R965M96YT+B8C,38P.R8C,38P.T]N($UA<F-H
M(#(T+"`R,#`Y+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!P87EM96YT
M('!L86X@=VET:"!T:&4@56YI=F5R<VET>2!O9B!-:6-H:6=A;B!T;R!P87D@
M=&AE(&]U='-T86YD:6YG(&)A;&%N8V4@;V8@)#$Y-RPP,#`N)B,Q-C`[)B,Q
M-C`[5&AE($-O;7!A;GD@86=R965D('1O('!A>2`D-2PP,#`@<&5R(&UO;G1H
M+"!U;G1I;"!T:&4@8F%L86YC92!I<R!P86ED(&EN(&9U;&PN($%T($1E8V5M
M8F5R(#,Q+"`R,#$Q+"!T:&4@8F%L86YC92!I<R!A<'!R;WAI;6%T96QY("0S
M,BPP,#`@86YD(&ES(')E8V]R9&5D(&%S(&$@<VAO<G0M=&5R;2!A8V-O=6YT
M<R!P87EA8FQE/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO
M9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[)SX\:3Y%;7!L;WEM96YT($%G<F5E;65N=',\+VD^/"]P
M/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M)SY/;B!&96)R=6%R>2`V+"`R,#$P+"!T:&4@0V]M<&%N>2!E>&5C=71E9"!A
M('1H<F5E+7EE87(@96UP;&]Y;65N="!A9W)E96UE;G0@=VET:"!*86UE<R!3
M+B!+=6\L($TN1"XL($-H86ER;6%N+"!#:&EE9B!%>&5C=71I=F4@3V9F:6-E
M<B!A;F0@4')E<VED96YT+B8C,38P.R8C,38P.U1H92!A9W)E96UE;G0@<')O
M=FED960@9F]R(&%N(&%N;G5A;"!B87-E('-A;&%R>2!O9B`D,3DY+#`P,"P@
M9&ES8W)E=&EO;F%R>2!P97)F;W)M86YC92!A;F0@=')A;G-A8W1I;VYA;"!B
M;VYU<R!P87EM96YT<RP@86YD(#0P,"PP,#`@<W1O8VL@;W!T:6]N<R!W:71H
M(&%N(&5X97)C:7-E('!R:6-E(&5Q=6%L('1O('1H92!M87)K970@<')I8V4@
M;VX@=&AE(&1A=&4@;V8@9W)A;G0N)B,Q-C`[)B,Q-C`[3V8@=&AE<V4@<W1O
M8VL@;W!T:6]N<RP@,3`P+#`P,"!V97-T960@:6UM961I871E;'D@=7!O;B!G
M<F%N="!A;F0@=&AE(')E;6%I;F1E<B!W:6QL('9E<W0@<')O(')A=&$L(&]N
M(&$@;6]N=&AL>2!B87-I<RP@;W9E<B!T:&4@9F]L;&]W:6YG('1H:7)T>2US
M:7@@;6]N=&AS+B!4:&4@9F%I<B!V86QU92!O9B!T:&4@;W!T:6]N<R!T;W1A
M;&5D("0S,C@L,#`P(&%N9"!W87,@9&5T97)M:6YE9"!U<VEN9R!T:&4@0FQA
M8VLM4V-H;VQE<R!M;V1E;"!W:71H('1H92!F;VQL;W=I;F<@87-S=6UP=&EO
M;G,Z(&5X<&5C=&5D(&1I=FED96YD('EI96QD(&]F(#`E+"!E>'!E8W1E9"!V
M;VQA=&EL:71Y(&]F(#(P-"XU)3L@<FES:R!F<F5E(&EN=&5R97-T(')A=&4@
M;V8@,RXU.24@86YD(&%N(&5X<&5C=&5D(&QI9F4@;V8@,3`@>65A<G,N/"]P
M/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M)SY%9F9E8W1I=F4@1F5B<G5A<GD@,RP@,C`Q,BP@1'(N($MU;R!R97-I9VYE
M9"!F<F]M(&AI<R!P;W-I=&EO;G,@87,@4')E<VED96YT(&%N9"!#:&EE9B!%
M>&5C=71I=F4@3V9F:6-E<BX@26X@8V]N;F5C=&EO;B!W:71H(&AI<R!R97-I
M9VYA=&EO;BP@1'(N($MU;R!E;G1E<F5D(&EN=&\@82!N:6YE+6UO;G1H(&-O
M;G-U;'1I;F<@86=R965M96YT('=I=&@@=&AE($-O;7!A;GD@*'1H92`F(S@R
M,C`[0V]N<W5L=&EN9R!!9W)E96UE;G0F(S@R,C$[*2X@4'5R<W5A;G0@=&\@
M=&AE($-O;G-U;'1I;F<@06=R965M96YT+"!$<BX@2W5O('=I;&P@8F4@96YT
M:71L960@=&\@82!C;VYS=6QT:6YG(&9E92!O9B`D,3<L,#`P('!E<B!M;VYT
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M92!#;VYS=6QT:6YG($%G<F5E;65N="X\+W`^#0H\+V1I=CX-"CQD:78^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
M)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D5F9F5C=&EV92!&96)R=6%R
M>2`S+"`R,#$R+"!*969F<F5Y(%)I;&5Y('=A<R!A<'!O:6YT960@=&\@<V5R
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M87)Y(&]F("0S-#@L,#`P(&%N9"!W:6QL(&)E(&5L:6=I8FQE(&9O<B!D:7-C
M<F5T:6]N87)Y('!E<F9O<FUA;F-E(&%N9"!T<F%N<V%C=&EO;F%L(&)O;G5S
M('!A>6UE;G1S+B!!9&1I=&EO;F%L;'DL($UR+B!2:6QE>2!W87,@9W)A;G1E
M9"!O<'1I;VYS('1O('!U<F-H87-E(#<U,"PP,#`@<VAA<F5S(&]F('1H92!#
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M-SMS(&]W;B!S=&]C:RX\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P
M/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3LG/D5F9F5C=&EV92!&96)R=6%R>2`V+"`R,#$R
M+"!#+B!%=F%N($)A;&QA;G1Y;F4@=V%S(&%P<&]I;G1E9"!T:&4@0V]M<&%N
M>28C.#(Q-SMS($-H:65F($9I;F%N8VEA;"!/9F9I8V5R+B!);B!C;VYN96-T
M:6]N('=I=&@@:&ES(&%P<&]I;G1M96YT+"!-<BX@0F%L;&%N='EN92!E;G1E
M<F5D(&EN=&\@82!T:')E92UY96%R(&5M<&QO>6UE;G0@86=R965M96YT('=I
M=&@@=&AE($-O;7!A;GD@*'1H92`F(S@R,C`[0F%L;&%N='EN92!%;7!L;WEM
M96YT($%G<F5E;65N="8C.#(R,3LI+B!0=7)S=6%N="!T;R!T:&4@0F%L;&%N
M='EN92!%;7!L;WEM96YT($%G<F5E;65N="P@37(N($)A;&QA;G1Y;F4@=VEL
M;"!B92!E;G1I=&QE9"!T;R!A;B!A;FYU86P@8F%S92!S86QA<GD@;V8@)#(Y
M."PP,#`@86YD('=I;&P@8F4@96QI9VEB;&4@9F]R(&1I<V-R971I;VYA<GD@
M<&5R9F]R;6%N8V4@86YD('1R86YS86-T:6]N86P@8F]N=7,@<&%Y;65N=',N
M($%D9&ET:6]N86QL>2P@37(N($)A;&QA;G1Y;F4@=V%S(&=R86YT960@;W!T
M:6]N<R!T;R!P=7)C:&%S92`T,C4L,#`P('-H87)E<R!O9B!O=7(@8V]M;6]N
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M:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!T(#`[#0H@=&5X="UA;&EG;CH@:G5S=&EF>3LG/E1H
M92!";&%C:RU38VAO;&5S(&%S<W5M<'1I;VYS('5S960@:6X@8V%L8W5L871I
M;F<@=&AE(&9A:7(@=F%L=64@;V8@=&AE('-T;V-K(&]P=&EO;G,@87)E(&%S
M(&9O;&QO=W,Z/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'0@,#LG/B8C,38P.R8C,38P.R8C,38P.SPO<#X-"CPO9&EV/@T*/&1I
M=CX-"CQT86)L92!S='EL93TS1"=W:61T:#H@-C`E.R!B;W)D97(M8V]L;&%P
M<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#4T)3L@
M<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SY%>&5R8VES92!P<FEC93PO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#0E.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#,Y)3L@<&%D9&EN
M9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/B0R+C,P("T@
M)#(N-#<\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@<&%D9&EN9RUR
M:6=H=#H@,"XX<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M93LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^17AP
M96-T960@9&EV:61E;F1S/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`P+CAP=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/C`E/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[)SX-"CQT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`P+CAP=#LG/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R<^,3<T)3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T
M.R<^4FES:R!F<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R<^,2XY,R4@+2`Q+CDW)3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@,"XX<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F
M9F-C.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SY%
M>'!E8W1E9"!L:69E(&]F(&]P=&EO;G,\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^
M,3`@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT
M9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#LG/D5X<&5C=&5D(&9O
M<F9E:71U<F5S/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P
M+CAP=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H
M=#H@,"XX<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/C`E/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\
M9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO
M9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[)SX\:3Y/=&AE<B!#;VUM:71M96YT<SPO:3X\+W`^#0H\
M+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D%S
M(&]F($1E8V5M8F5R(#,Q+"`R,#$Q+"!A;6]U;G1S(&1U92!F;W(@;&EC96YS
M92!A9W)E96UE;G1S(&%R92!A<R!F;VQL;W=S(#QI/BAI;B!T:&]U<V%N9',I
M/"]I/B`Z/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO9&EV
M/@T*/&1I=CX-"CQT86)L92!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=W:61T
M:#H@-C`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\
M=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&QE
M9G0[)SY996%R)B,Q-C`[16YD:6YG)B,Q-C`[1&5C96UB97(F(S$V,#LS,2P\
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M93LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`W.24[('1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M;&5F=#H@,3<N,W!T.R<^,C`Q,CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W
M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,3@E.R!T97AT+6%L:6=N.B!R:6=H=#LG/C,W/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Q-RXS
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M9&EN9RUL969T.B`Q-RXS<'0[)SXR,#$T/"]T9#X-"CQT9#XF(S$V,#L\+W1D
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M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T.R!P861D:6YG+6QE9G0Z(#$W+C-P=#LG/C(P,38\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/C4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
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M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV
M/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[)SX\:3Y/<&5R871I
M;F<@3&5A<V4\+VD^/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY$=7)I
M;F<@,C`P-RP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@;F]N+6-A;F-E
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M:6X@06YN($%R8F]R+"!-:6-H:6=A;BXF(S$V,#LF(S$V,#L\+W`^#0H\+V1I
M=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/D1U<FEN
M9R!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,3$@86YD(#(P,3`@
M=&AE($-O;7!A;GD@<F5C;V=N:7IE9"!R96YT(&5X<&5N<V4@;V8@)#8T+#`P
M,"!A;F0@)#(Q-"PP,#`L(')E<W!E8W1I=F5L>2X\+W`^#0H\+V1I=CX-"CQD
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQI/D-A<&ET86P@
M3&5A<V4\+VD^/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CPO
M9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[)SY);B!*=6YE(#(P,#8L('1H92!#;VUP86YY(&%C<75I
M<F5D("0V-2PP,#`@;V8@97%U:7!M96YT('5N9&5R(&$@;F]N+6-A;F-E;&%B
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M=&AE(&QE87-E('=A<R`X+C4Q)2XF(S$V,#L@4F5L871E9"!M;VYT:&QY('!A
M>6UE;G1S(&]F('!R:6YC:7!A;"!A;F0@:6YT97)E<W0@=V5R92`D,2PT,#`@
M;W9E<B!A('!E<FEO9"!O9B!S:7AT>2!M;VYT:',N)B,Q-C`[($EN(%-E<'1E
M;6)E<B`R,#`X+"!T:&4@;&5S<V]R(&5X=&5N9&5D('1H92!T97)M(&9O<B!R
M97!A>6UE;G0@8GD@96EG:'0@;6]N=&AS+"!W:71H(&$@9FEN86P@;6%T=7)I
M='D@9&%T92!O9B!*86YU87)Y(#(P,3(N)B,Q-C`[)B,Q-C`[5&AE(')E;6%I
M;FEN9R!B86QA;F-E(&]F('1H:7,@8V%P:71A;"!L96%S92!A="!$96-E;6)E
M<B`S,2P@,C`Q,"!W87,@)#(T+#`P,"X@26X@2F%N=6%R>2`R,#$Q+"!T:&ES
M(&-A<&ET86P@;&5A<V4@=V%S('!A:60@:6X@9G5L;"!A;F0@=&AE(&9U;F1S
M('=E<F4@<F5L96%S960@9G)O;2!E<V-R;W<N(%-E92!.;W1E(#,@)B,X,C$Q
M.R!$:7-C;VYT:6YU960@3W!E<F%T:6]N<R!O9B!!9&5O;F$@0VQI;FEC86P@
M3&%B;W)A=&]R>2X\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN8V]M92!487AE<SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY);F-O;64@5&%X($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X($1I
M<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV/@T*/'1A8FQE('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN+6)O='1O;3H@,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N
M-6EN.R!T97AT+6%L:6=N.B!L969T.R<^/&(^.2X\+V(^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&(^26YC;VUE(%1A>&5S
M/"]B/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=CX-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T(#`N-6EN.R!T97AT+6EN9&5N=#H@
M+3`N-6EN.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/E1H97)E('=A
M<R!N;R!I;F-O;64@=&%X(&5X<&5N<V4@9F]R('1H92!Y96%R<R!E;F1E9"!$
M96-E;6)E<B`S,2P@,C`Q,2!A;F0@,C`Q,"!D=64@=&\@=&AE($-O;7!A;GDF
M(S@R,3<[<R!N970@;&]S<V5S+CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V
M,#L\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^5&AE($-O;7!A;GDF(S@R,3<[<R!T
M87@@97AP96YS92!D:69F97)S(&9R;VT@=&AE("8C.#(R,#ME>'!E8W1E9"8C
M.#(R,3L@=&%X(&5X<&5N<V4@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q,2!A;F0@,C`Q,"P@*&-O;7!U=&5D(&)Y(&%P<&QY:6YG('1H
M92!&961E<F%L($-O<G!O<F%T92!T87@@<F%T92!O9B`S-"4@=&\@;&]S<R!B
M969O<F4@=&%X97,@86YD(#4N-24@9F]R($UI8VAI9V%N(%-T871E($-O<G!O
M<F%T92!T87AE<RP@=&AE(&)L96YD960@<F%T92!U<V5D('=A<R`S-RXV,R4I
M+"!A<R!F;VQL;W=S(#QI/BAI;B!T:&]U<V%N9',I.CPO:3X\+W`^#0H\+V1I
M=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D:78^#0H\9&EV/@T*/'1A8FQE
M('-T>6QE/3-$)W=I9'1H.B`X-24[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P
M<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;BUL969T.B`P+C<U:6X[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I
M9VAT.B!B;VQD.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!C;VQS
M<&%N/3-$,CXR,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B
M;VQD.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#LG(&-O;'-P86X],T0R/C(P,3`\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`W,"4[('1E>'0M86QI9VXZ(&QE9G0[)SY#;VUP
M=71E9"`F(S@R,C`[97AP96-T960F(S@R,C$[('1A>"!B96YE9FET("T@1F5D
M97)A;#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3(E.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/B@R+#8Q.#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,3(E.R!T97AT+6%L:6=N.B!R:6=H=#LG/B@U-3`\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SY#;VUP=71E9"`F(S@R,C`[97AP96-T960F(S@R,C$[
M('1A>"!B96YE9FET("T@4W1A=&4\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXH-#0X/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@Y
M-#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/DYO;BUT87AA8FQE(&9E9&5R86P@9W)A;G0\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
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M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[)SX-
M"CQT9#Y.;VXM9&5D=6-T:6)L92!S=&]C:RUB87-E9"!C;VUP96YS871I;VX\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXS-C8\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ-3`\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SY787)R86YT(&5X<&5N<V4\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXU-CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/D-H86YG92!I;B!F86ER('9A;'5E
M(&]F('=A<G)A;G0@97AP96YS93PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CDQ/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF
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M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/D-H86YG92!I;B!V
M86QU871I;VX@86QL;W=A;F-E/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXR+#`S-3PO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^-C<S/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO
M<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[)SY4:&4@969F96-T<R!O9B!T96UP;W)A<GD@
M9&EF9F5R96YC97,@=&AA="!G879E(')I<V4@=&\-"B!S:6=N:69I8V%N="!P
M;W)T:6]N<R!O9B!D969E<G)E9"!T87@@87-S971S(&%T($1E8V5M8F5R(#,Q
M+"`R,#$Q(&%N9"`R,#$P(&%R92!A<R!F;VQL;W=S(#QI/BAI;B!T:&]U<V%N
M9',I.CPO:3X\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/"]D
M:78^#0H\9&EV/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`X-24[(&)O<F1E
M<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`P+C<U:6X[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT+7=E
M:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW
M96EG:'0Z(&)O;&0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#LG(&-O
M;'-P86X],T0R/C(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z
M(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,#PO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\
M=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SY$969E<G)E9"8C,38P.W1A>"8C,38P.V%S<V5T<SH\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!P861D:6YG+6)O='1O
M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H
M=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UW96EG:'0Z(&)O;&0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT
M+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-
M"CQT9"!S='EL93TS1"=W:61T:#H@-S`E.R!T97AT+6%L:6=N.B!L969T.R<^
M4W1O8VL@:7-S=65D(&9O<B!S97)V:6-E<SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W
M:61T:#H@,3(E.R!T97AT+6%L:6=N.B!R:6=H=#LG/B@S,C$\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@
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M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY"860@9&5B="`F
M(S@R,3$[(&-H86YG92!I;B!A;&QO=V%N8V4\+W1D/@T*/'1D/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXH,C`U/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/B@T.3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SY.
M970@;W!E<F%T:6YG(&QO<W,@8V%R<GDM9F]R=V%R9#PO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R<^*#$P+#0R-3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
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M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/E1O
M=&%L(&=R;W-S(&1E9F5R<F5D('1A>"!A<W-E=',\+W1D/@T*/'1D/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXH,3`L
M.34Q/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/B@X+#DQ-CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SY,97-S('9A;'5A=&EO;B!A;&QO=V%N8V4\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R<^."PY,38\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^3F5T(&1E9F5R<F5D('1A
M>"!A<W-E=',\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'0@,#LG/B8C,38P.SPO<#X-"CPO9&EV/@T*
M/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SY!="!$96-E;6)E<B`S,2P@,C`Q,2P@=&AE($-O;7!A;GD@:&%S
M(&$@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y+69O<G=A<F0@;V8@87!P<F]X
M:6UA=&5L>2`D,C<N-R!M:6QL:6]N(&%V86EL86)L92!T;R!O9F9S970@9G5T
M=7)E('1A>&%B;&4@:6YC;VUE(&5X<&ER:6YG('1H<F]U9V@@,C`S,2X@571I
M;&EZ871I;VX@;V8@=&AE<V4@;F5T(&]P97)A=&EN9R!L;W-S97,@;6%Y(&)E
M(&QI;6ET960@9'5E('1O('!O=&5N=&EA;"!O=VYE<G-H:7`@8VAA;F=E<R!U
M;F1E<B!396-T:6]N(#,X,B!O9B!T:&4@26YT97)N86P@4F5V96YU92!#;V1E
M+CPO<#X-"CPO9&EV/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"CQD
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^5&AE('9A;'5A=&EO;B!A;&QO=V%N8V4@870@1&5C96UB97(@,S$L
M(#(P,3`@=V%S(&%P<')O>&EM871E;'D@)#@N.2!M:6QL:6]N+B!4:&4@;F5T
M(&-H86YG92!I;B!V86QU871I;VX@86QL;W=A;F-E(&1U<FEN9R!T:&4@>65A
M<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2!W87,@86X@:6YC<F5A<V4@;V8@
M87!P<F]X:6UA=&5L>2`D,B!M:6QL:6]N+B!);B!A<W-E<W-I;F<@=&AE(')E
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M<B`S,2P@,C`Q,2X\+W`^#0H\+V1I=CX-"CQD:78^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*
M/"]D:78^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3LG/D1U<FEN9R`R,#$P+"!T:&4@0V]M<&%N>2!R96-E
M:79E9"!G<F%N="!R979E;G5E(&]F("0T.#DL,#`P+B8C,38P.R8C,38P.U5N
M9&5R('1H92!T97)M<R!O9B!T:&4@9W)A;G0L('1H:7,@<F5V96YU92!I<R!N
M;W0@=&%X86)L92X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
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M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%4T<^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4W5B<V5Q=65N="!%=F5N=#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N
M="!%=F5N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT<R!;5&5X="!";&]C
M:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;BUT;W`Z(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6QE
M9G0Z(#!I;CLG/CQB/CDN)B,Q-C`[)B,Q-C`[)B,Q-C`[4W5B<V5Q=65N="!%
M=F5N=',\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^3VX@36%Y(#$L(#(P,3(L('1H92!#;VUP86YY
M('=A<R!I;F9O<FUE9"!B>2!"97)M86X@)F%M<#L@0V]M<&%N>2P@4"Y!+B`H
M)B,X,C(P.T)E<FUA;B`F86UP.R!#;VUP86YY)B,X,C(Q.RDL('1H92!#;VUP
M86YY)B,X,C$W.W,@:6YD97!E;F1E;G0@<F5G:7-T97)E9"!A8V-O=6YT:6YG
M(&9I<FTL('1H870@9'5R:6YG(&$@<F5G=6QA<B!0=6)L:6,@0V]M<&%N>2!!
M8V-O=6YT:6YG($]V97)S:6=H="!";V%R9"`H)B,X,C(P.U!#04]")B,X,C(Q
M.RD@:6YS<&5C=&EO;B!O9B!"97)M86X@)F%M<#L@0V]M<&%N>2P@=&AE(%!#
M04]"(&ES<W5E9"!A(&-O;6UE;G0@=&AA="!T:&4@875D:70@;W!I;FEO;B!I
M;F-L=61E9"!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS($%N;G5A;"!297!O<G0@
M;VX@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q,2!W87,@:7-S=65D(&)Y(&$@<&%R=&YE<B!A="!"97)M86X@)F%M<#L@
M0V]M<&%N>2!W:&\@=V%S(&YO="!A=71H;W)I>F5D('5N9&5R('1H92!00T%/
M0B!R=6QE<R!T;R!I<W-U92!T:&4@;W!I;FEO;B!O<B!A8W0@87,@;W5R(&YA
M;65D(&5N9V%G96UE;G0@<&%R=&YE<B!W:71H(')E<W!E8W0@=&\@=&AE($9O
M<FT@,3`M2R!A=61I="`H;W(@<')I;W(@,C`Q,2!&;W)M(#$P+5$@:6YT97)I
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M<RDN/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
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M="!I="!B96-O;65S(&YE8V5S<V%R>2X\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SY/;B!-87D@,3`L(#(P,3(L($IE9F9R97D@2BX@2W)A=W,@=V%S(&%P<&]I
M;G1E9"!A<R!T:&4@:6YD97!E;F1E;G0L(&YO;BUE>&5C=71I=F4@0VAA:7)M
M86X@;V8@=&AE($)O87)D+B!&;W(@:&ES('-E<G9I8V4@87,@:6YD97!E;F1E
M;G0L(&YO;BUE>&5C=71I=F4@0VAA:7)M86X@;V8@=&AE($)O87)D+"!-<BX@
M2W)A=W,@=VEL;"!R96-E:79E(&%N;G5A;"!C;VUP96YS871I;VX@;V8@)#$U
M,"PP,#`N($%D9&ET:6]N86QL>2P@37(N($MR87=S('=A<R!G<F%N=&5D(&]P
M=&EO;G,@=&\@<'5R8VAA<V4@,3`P+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@=VET:"!A;B!E>&5R8VES92!P<FEC
M92!E<75A;"!T;R!O=7(@<&5R('-H87)E(&UA<FME="!P<FEC92!O;B!T:&4@
M9&%T92!O9B!I<W-U92X@5&AE<V4@;W!T:6]N<R!W:6QL('9E<W0@<')O(')A
M=&$L('%U87)T97)L>2!O=F5R(&$@='=O('EE87(@<&5R:6]D('=I=&@@=&AE
M(&9I<G-T('%U87)T97)L>2!I<W-U86YC92!O9B`Q,BPU,#`@;W!T:6]N<R!V
M97-T:6YG(&EM;65D:6%T96QY+B!4:&4@0V]M<&%N>2!M96%S=7)E9"!T:&4@
M9F%I<B!V86QU92!O9B!T:&4@<W1O8VL@;W!T:6]N<R!A="!A<'!R;WAI;6%T
M96QY("0Q-C8L,#`P('5S:6YG(&$@0FQA8VLM4V-H;VQE<R!V86QU871I;VX@
M;6]D96P[('1H97-E('=A<G)A;G1S('=E<F4@:6YD97AE9"!T;R!T:&4@0V]M
M<&%N>28C.#(Q-SMS(&]W;B!S=&]C:RX\+W`^#0H\<"!S='EL93TS1"=M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
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M='EL93TS1"=W:61T:#H@-3`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#<W)3LG/D5X97)C:7-E
M('!R:6-E/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W
M:61T:#H@,C`E.R<^,2XW,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
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M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
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M;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3LG/CQB/C$P+B!3=6)S97%U96YT($5V96YT/"]B/CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^3VX@1&5C96UB97(@,C`L(#(P,3$L('1H92!#;VUP86YY(&5N=&5R
M960@:6YT;R!A(&-O;G-U;'1I;F<@86=R965M96YT(&9O<B!F:6YA;F-I86P@
M861V:7-O<GD@<V5R=FEC97,L(&9O<B!A('!E<FEO9"!O9B!T=V5L=F4@;6]N
M=&AS+B!!<R!C;VUP96YS871I;VX@9F]R('-U8V@@<V5R=FEC97,L('1H92!C
M;VYS=6QT86YT('=I;&P@8F4@<&%I9"!A(&UO;G1H;'D@9F5E(&]F("0Q,"PP
M,#`@86YD('=A<R!I<W-U960@82!W87)R86YT(&5X97)C:7-A8FQE(&9O<B`Q
M,#`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S
M=&]C:RX@5&AE('=A<G)A;G0@:7,@97AE<F-I<V%B;&4@=7!O;B!I<W-U86YC
M92!F;W(@82!P97)I;V0@;V8@9FEV92!Y96%R<R!F<F]M('1H92!D871E(&]F
M(&ES<W5E(&%T(&%N(&5X97)C:7-E('!R:6-E(&5Q=6%L('1O('1H92!P<FEC
M92!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!O;B!T:&4@
M9&%T92!O9B!I<W-U92X@5&AE(&ES<W5E(&1A=&4@;V8@=&AE('=A<G)A;G0@
M:7,@1F5B<G5A<GD@,BP@,C`Q,BX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/E1H92!F
M86ER('9A;'5E(&]F('1H92!W87)R86YT(&%P<')O>&EM871E9"`D,C`P+#`P
M,"!A;F0@=V%S(&UE87-U<F5D('5S:6YG('1H92!";&%C:RU38VAO;&5S('9A
M;'5A=&EO;B!M;V1E;"X@5&AE(&%S<W5M<'1I;VYS('5S960@8GD@=&AE($-O
M;7!A;GD@87)E('-U;6UA<FEZ960@:6X@=&AE(&9O;&QO=VEN9R!T86)L93H\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P.R<^)B,Q-C`[)B,Q-C`[/"]P
M/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`U,"4[(&)O<F1E<BUC;VQL87!S
M93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V9F8V,[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@-S4E
M.R<^17AE<F-I<V4@<')I8V4\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
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M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C$W-#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B4\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY2:7-K(&9R964@:6YT97)E<W0@<F%T
M93PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/C`N-S$\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
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M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
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M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#LF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^3VX@36%Y(#$L
M(#(P,3(L('1H92!#;VUP86YY('=A<R!I;F9O<FUE9"!B>2!"97)M86X@)F%M
M<#L@0V]M<&%N>2P@4"Y!+B`H)B,X,C(P.T)E<FUA;B`F86UP.R!#;VUP86YY
M)B,X,C(Q.RDL('1H92!#;VUP86YY)B,X,C$W.W,@:6YD97!E;F1E;G0@<F5G
M:7-T97)E9"!A8V-O=6YT:6YG(&9I<FTL('1H870@9'5R:6YG(&$@<F5G=6QA
M<B!0=6)L:6,@0V]M<&%N>2!!8V-O=6YT:6YG($]V97)S:6=H="!";V%R9"`H
M)B,X,C(P.U!#04]")B,X,C(Q.RD@:6YS<&5C=&EO;B!O9B!"97)M86X@)F%M
M<#L@0V]M<&%N>2P@=&AE(%!#04]"(&ES<W5E9"!A(&-O;6UE;G0@=&AA="!T
M:&4@875D:70@;W!I;FEO;B!I;F-L=61E9"!I;B!T:&4@0V]M<&%N>28C.#(Q
M-SMS($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E
M;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2!W87,@:7-S=65D(&)Y(&$@<&%R=&YE
M<B!A="!"97)M86X@)F%M<#L@0V]M<&%N>2!W:&\@=V%S(&YO="!A=71H;W)I
M>F5D('5N9&5R('1H92!00T%/0B!R=6QE<R!T;R!I<W-U92!T:&4@;W!I;FEO
M;B!O<B!A8W0@87,@;W5R(&YA;65D(&5N9V%G96UE;G0@<&%R=&YE<B!W:71H
M(')E<W!E8W0@=&\@=&AE($9O<FT@,3`M2R!A=61I="`H;W(@<')I;W(@,C`Q
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M:6]N<R!O9B!!8V-O=6YT86YT<RDN/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'0@,#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[)SY4:&4@0V]M<&%N>2!B96QI979E<R!T:&%T
M('1H92!P<F5V:6]U<VQY(&9I;&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&9O
M<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2!A<F4@86-C=7)A
M=&4N($EN(&%D9&ET:6]N+"!T:&4@0V]M<&%N>2!H87,@;F]T(&)E96X@:6YF
M;W)M960@8GD@0F5R;6%N("9A;7`[($-O;7!A;GD@;W(@=&AE(%!#04]"+"!T
M:&%T('1H92!P<F5V:6]U<VQY(&9I;&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S
M(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2!A<F4@;F]T
M(&%C8W5R871E(&]R(&]T:&5R=VES92!I;G9A;&ED+B!!<R!A(&UA='1E<B!O
M9B!P<F5C875T:6]N('1H92!N97<@96YG86=E;65N="!P87)T;F5R(&%T($)E
M<FUA;B`F86UP.R!#;VUP86YY(&AA<R!S:6YC93H@*&DI('1A:V5N(&9U;&P@
M<F5S<&]N<VEB:6QI='D@9F]R('1H92!A=61I="!A<R!T:&4@;&5A9"!E;F=A
M9V5M96YT('!A<G1N97(@;VX@=&AE(&%U9&ET+"`H:6DI('!E<F9O<FUE9"!A
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M('-T871E;65N=',@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R
M,#$Q+"!O=&AE<B!T:&%N('1H92!A9&1I=&EO;B!O9B!T:&4@36%Y(#$L(#(P
M,3(@86YD($UA>2`Q,"P@,C`Q,B!D:7-C;&]S=7)E<R!I;B!T:&ES('-U8G-E
M<75E;G0@979E;G0@;F]T92!T;R!T:&4@9FEN86YC:6%L('-T871E;65N=',N
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3LG/B8C,38P.R8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY/;B!-87D@,3`L(#(P,3(L($IE
M9F9R97D@2BX@2W)A=W,@=V%S(&%P<&]I;G1E9"!A<R!T:&4@:6YD97!E;F1E
M;G0L(&YO;BUE>&5C=71I=F4@0VAA:7)M86X@;V8@=&AE($)O87)D+B!&;W(@
M:&ES('-E<G9I8V4@87,@:6YD97!E;F1E;G0L(&YO;BUE>&5C=71I=F4@0VAA
M:7)M86X@;V8@=&AE($)O87)D+"!-<BX@2W)A=W,@=VEL;"!B92!I<W-U960@
M;W!T:6]N<R!E>&5R8VES86)L92!F;W(@,3`P+#`P,"!S:&%R97,@;V8@=&AE
M($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@86YD('=I;&P@<F5C96EV
M92!A;FYU86P@8V]M<&5N<V%T:6]N(&]F("0Q-3`L,#`P+B!4:&4@9F%I<B!V
M86QU92!O9B!T:&5S92!O<'1I;VYS('=I;&P@8F4@;65A<W5R960@=7-I;F<@
M=&AE($)L86-K+5-C:&]L97,@=F%L=6%T:6]N(&UO9&5L+CPO<#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,U,C1F-C=F7S(S
M,3A?-#8S.5]A83<W7S0Y.30Y-#8T86%B,@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\S-3(T9C8W9E\R,S$X7S0V,SE?86$W-U\T.3DT.30V-&%A
M8C(O5V]R:W-H965T<R]F:6QE;&ES="YX;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/'AM;"!X;6QN<SIO/3-$
M(G5R;CIS8VAE;6%S+6UI8W)O<V]F="UC;VTZ;V9F:6-E.F]F9FEC92(^#0H@
M/&\Z36%I;D9I;&4@2%)E9CTS1"(N+B]7;W)K8F]O:RYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,38N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3DN:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7S,U,C1F-C=F
@7S(S,3A?-#8S.5]A83<W7S0Y.30Y-#8T86%B,BTM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>1.&#160;&#160;&#160;Organization</b></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Synthetic Biologics, Inc. (the &#8220;Company&#8221; or &#8220;Synthetic Biologics&#8221;), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. In the area of synthetic biology, the Company is initially developing a product candidate to treat pulmonary arterial hypertension (PAH). The Company also intends to expand new and existing collaborations in the synthetic biology area. In addition, Synthetic Biologics has several clinical-stage programs that are being funded, or partially funded, by grants, charitable organizations and corporate partners. In this area we are developing, or have partnered the development of, product candidates to treat relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS).</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="border-bottom: black 1pt solid; text-align: center; width: 23%; font-weight: bold; text-decoration: none;"><b>Medical Indication</b></td>
<td style="text-align: center; padding-bottom: 1pt; width: 2%;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 23%; font-weight: bold; text-decoration: none;"><b>Product Candidate</b></td>
<td style="text-align: center; padding-bottom: 1pt; width: 2%;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 50%; font-weight: bold; text-decoration: none;"><b>Status</b></td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">PAH</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">Synthetic DNA-based therapy</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">Preclinical</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">Relapsing-remitting MS</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">Trimesta</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">All patients enrolled in Phase II clinical trial;</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">(oral estriol)</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">dosing and monitoring underway</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">Cognitive dysfunction in</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">Trimesta</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">Patient enrollment underway in Phase II</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">MS</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">(oral estriol)</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">clinical trial</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">Fibromyalgia</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">Effirma</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">Partnered with Meda AB</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">(oral flupirtine)</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">ALS</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">AEN-100</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">Phase II/III clinical trial preparation underway</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">(gastroretentive zinc acetate)</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E1NAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump">$ 6,802<span></span></td>
        <td class="nump">$ 6,678<span></span></td>
        <td class="nump">$ 2,649<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable net</a></td>
        <td class="nump">440<span></span></td>
        <td class="nump">405<span></span></td>
        <td class="nump">339<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
        <td class="nump">83<span></span></td>
        <td class="nump">16<span></span></td>
        <td class="nump">343<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets of discontinued operations</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">23<span></span></td>
        <td class="nump">214<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">7,325<span></span></td>
        <td class="nump">7,122<span></span></td>
        <td class="nump">3,545<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">303<span></span></td>
        <td class="nump">323<span></span></td>
        <td class="nump">475<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Long-term note receivable</a></td>
        <td class="nump">700<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
        <td class="nump">21<span></span></td>
        <td class="nump">31<span></span></td>
        <td class="nump">91<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">8,349<span></span></td>
        <td class="nump">7,476<span></span></td>
        <td class="nump">4,111<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">316<span></span></td>
        <td class="nump">388<span></span></td>
        <td class="nump">266<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
        <td class="nump">127<span></span></td>
        <td class="nump">29<span></span></td>
        <td class="nump">210<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities of discontinued operations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">24<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">443<span></span></td>
        <td class="nump">417<span></span></td>
        <td class="nump">500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long Term Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Accounts payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">32<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump">443<span></span></td>
        <td class="nump">417<span></span></td>
        <td class="nump">532<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized, 31,374,002 issued and 31,292,520 outstanding and 23,420,189 issued and 23,338,707 outstanding</a></td>
        <td class="nump">33<span></span></td>
        <td class="nump">31<span></span></td>
        <td class="nump">23<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">60,946<span></span></td>
        <td class="nump">58,901<span></span></td>
        <td class="nump">47,280<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(53,073)<span></span></td>
        <td class="num">(51,873)<span></span></td>
        <td class="num">(43,724)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
        <td class="nump">7,906<span></span></td>
        <td class="nump">7,059<span></span></td>
        <td class="nump">3,579<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
        <td class="nump">$ 8,349<span></span></td>
        <td class="nump">$ 7,476<span></span></td>
        <td class="nump">$ 4,111<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DepositsAndOtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DepositsAndOtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate value (measured at the lower of net carrying value or fair value less cost of disposal) for current assets (assets with expected useful life shorter than one year or one operating cycle, whichever is longer) of a disposal group, including a component of the entity (discontinued operation), to be sold or that has subsequently been disposed of through sale, as of the financial statement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 144<br><br><br><br> -Paragraph 46<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrestricted cash available for day-to-day operating needs, for an entity that has cash equivalents, but does not aggregate cash equivalents with cash on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of current obligations (due less than one year or one operating cycle, if longer) arising from the sale, disposal or planned sale in the near future (generally within one year) of a disposal group, including a component of the entity (discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 144<br><br><br><br> -Paragraph 46<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date more than one year from the balance sheet date, net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesAndLoansReceivableNetNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EJF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity [Parenthetical] (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuanceCost', window );">Stock Issuance Cost</a></td>
        <td class="nump">$ 539<span></span></td>
        <td class="nump">$ 115<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuanceCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issuance Cost during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuanceCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6GBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss</a></td>
        <td class="num">$ (1,849)<span></span></td>
        <td class="num">$ (2,223)<span></span></td>
        <td class="num">$ (7,626)<span></span></td>
        <td class="num">$ (1,195)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net Income (Loss) from Discontinued Operations</a></td>
        <td class="nump">649<span></span></td>
        <td class="nump">37<span></span></td>
        <td class="num">(523)<span></span></td>
        <td class="num">(516)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">508<span></span></td>
        <td class="nump">768<span></span></td>
        <td class="nump">973<span></span></td>
        <td class="nump">400<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedAsCompensation', window );">Stock issued as employee compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">76<span></span></td>
        <td class="nump">94<span></span></td>
        <td class="nump">47<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedForLicenseFee', window );">Stock issued for license fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">70<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssueOfStockForExclusiveChannelCollaborationAgreement', window );">Stock issued for exclusive channel collaboration agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,684<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedForConsultingFees', window );">Stock issued for consulting fees</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">58<span></span></td>
        <td class="nump">165<span></span></td>
        <td class="nump">214<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExpenses', window );">Warrant expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">716<span></span></td>
        <td class="nump">1,492<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">94<span></span></td>
        <td class="nump">242<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump">20<span></span></td>
        <td class="nump">80<span></span></td>
        <td class="nump">144<span></span></td>
        <td class="nump">346<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for uncollectible accounts receivable</a></td>
        <td class="nump">8<span></span></td>
        <td class="nump">21<span></span></td>
        <td class="nump">414<span></span></td>
        <td class="nump">130<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of premium on investments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">57<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Loss on sale of short-term investment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfProperty', window );">Gain (loss) on the sale of equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="nump">6<span></span></td>
        <td class="num">(3)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_EquipmentImpairmentLoss', window );">Impairment loss on equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">121<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfAccountsReceivable', window );">Gain on the settlement of accounts payable</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(63)<span></span></td>
        <td class="num">(63)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num">(43)<span></span></td>
        <td class="num">(111)<span></span></td>
        <td class="num">(480)<span></span></td>
        <td class="num">(438)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
        <td class="num">(67)<span></span></td>
        <td class="nump">268<span></span></td>
        <td class="nump">327<span></span></td>
        <td class="num">(335)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesReceivableCurrent', window );">Note receivable</a></td>
        <td class="num">(700)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseInDepositsAndOtherAssets', window );">Deposits and other assets</a></td>
        <td class="nump">10<span></span></td>
        <td class="nump">68<span></span></td>
        <td class="nump">60<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets of discontinued operations</a></td>
        <td class="nump">23<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="nump">191<span></span></td>
        <td class="nump">13<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="num">(72)<span></span></td>
        <td class="nump">154<span></span></td>
        <td class="nump">153<span></span></td>
        <td class="num">(196)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
        <td class="nump">98<span></span></td>
        <td class="num">(192)<span></span></td>
        <td class="num">(181)<span></span></td>
        <td class="nump">202<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Liabilities of discontinued operations</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(40)<span></span></td>
        <td class="num">(24)<span></span></td>
        <td class="num">(5)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
        <td class="num">(1,415)<span></span></td>
        <td class="num">(281)<span></span></td>
        <td class="num">(2,875)<span></span></td>
        <td class="num">(1,145)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of short-term investments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(4,370)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from short-term investments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,293<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(12)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">77<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided By (Used In) Investing Activities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="num">(75)<span></span></td>
        <td class="nump">65<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises', window );">Proceeds from issuance of common stock for stock option and warrant exercises</a></td>
        <td class="nump">68<span></span></td>
        <td class="nump">8<span></span></td>
        <td class="nump">15<span></span></td>
        <td class="nump">129<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises', window );">Proceeds from issuance of common stock for warrant exercises</a></td>
        <td class="nump">1,471<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedForExclusiveChannelCollaborationAgreement', window );">Proceeds from issuance of common stock for exclusive channel collaboration agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises', window );">Proceeds from the issuance of common stock</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">4,000<span></span></td>
        <td class="nump">7,500<span></span></td>
        <td class="nump">1,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Cash paid as direct offering costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(296)<span></span></td>
        <td class="num">(539)<span></span></td>
        <td class="num">(115)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
        <td class="nump">1,539<span></span></td>
        <td class="nump">3,712<span></span></td>
        <td class="nump">6,979<span></span></td>
        <td class="nump">1,014<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net increase (decrease) in cash</a></td>
        <td class="nump">124<span></span></td>
        <td class="nump">3,432<span></span></td>
        <td class="nump">4,029<span></span></td>
        <td class="num">(66)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at the beginning of period</a></td>
        <td class="nump">6,678<span></span></td>
        <td class="nump">2,649<span></span></td>
        <td class="nump">2,649<span></span></td>
        <td class="nump">2,715<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at the end of period</a></td>
        <td class="nump">6,802<span></span></td>
        <td class="nump">6,080<span></span></td>
        <td class="nump">6,678<span></span></td>
        <td class="nump">2,649<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">10<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ExchangeOfEquipment', window );">Exchange of equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">64<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital', window );">Reclassification of warrant liability to additional paid-in capital</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,734<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ChangeInFairValueOfWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ChangeInFairValueOfWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_EquipmentImpairmentLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Impairment loss on equipment during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_EquipmentImpairmentLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ExchangeOfEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equipment Exchanged during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ExchangeOfEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in assets of discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseInDepositsAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IncreaseDecreaseInDepositsAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in liabilities of discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IssueOfStockForExclusiveChannelCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued for exclusive channel collaboration agreement during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IssueOfStockForExclusiveChannelCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity excluding stock option and warrant exercised during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity for stock option exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity for warrant exercises.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reclassification of warrant liability to additional paid-in capital for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedAsCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncash expense that accounts for the value of stock options distributed to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedAsCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedForConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of restricted stock or stock options granted to nonemployees as payment for consulting fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedForConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedForExclusiveChannelCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued For Exclusive Channel Collaboration Agreement during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedForExclusiveChannelCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedForLicenseFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>issued of stock based on license fee During the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedForLicenseFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expenses incurred for warrant during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentForAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrestricted cash available for day-to-day operating needs, for an entity that has cash equivalents, but does not aggregate cash equivalents with cash on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) in cash, excluding cash equivalents, for an entity that has cash equivalents, but does not aggregate cash equivalents with cash on the balance sheet. For example, an entity that aggregates cash equivalents with investments discloses the balance of cash excluding cash equivalents on the balance sheet and the change in cash excluding cash equivalents on the statement of cash flows. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfProperty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gains (losses) included in results of operations resulting from the sale or disposal of property, plant and equipment, which do not qualify for treatment as discontinued operations. This item does not include any gain (loss) recognized on the sale of oil and gas property or timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390789&amp;loc=d3e2443-110228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 37, 41, 42, 43, 45<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfProperty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reflects the net positive or negative amount derived from subtracting from net proceeds of sale, the carrying amounts, net of allocated reserves, of accounts receivable transferred to a third party in a transaction that qualifies for sales treatment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 13<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6942082&amp;loc=d3e107425-111719<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the gain (loss) realized on the sale of held-to-maturity securities disposed of during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the parent which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4613673-111683<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph b(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the overall income (loss) from a disposal group apportioned to the parent that is classified as a component of the entity, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount which may be allocable to noncontrolling interests, if any. Includes the following (net of tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph b(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -Subparagraph f<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period of amounts due within one year (or one business cycle) from note holders for outstanding loans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInNotesReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherCurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.5)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProvisionForDoubtfulAccounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RecoveryOfDirectCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EFCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets [Parenthetical] (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">32,857,609<span></span></td>
        <td class="nump">31,374,002<span></span></td>
        <td class="nump">23,420,189<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">32,776,127<span></span></td>
        <td class="nump">31,292,520<span></span></td>
        <td class="nump">23,338,707<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>License, Collaborative and Employment Agreements and Commitments<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
        <td class="text"><div>
<table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in; text-align: left;"><b>7.</b></td>
<td style="text-align: justify;"><b>License, Collaborative and Employment Agreements and Commitments</b></td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>License Agreements</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company has entered into various option and license agreements for the use of patents and their corresponding applications. These agreements have been entered into with various educational institutions and hospitals. These agreements contain payment schedules or stated amounts due for (a) option and license fees, (b) expense reimbursements, and (c) achievement of success milestones. All expenses related to these agreements have been recorded as research and development.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>Research Agreement</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">In September&#160;of 2005, the Company entered into a three-year research agreement with the University of Michigan. Pursuant to that agreement, the Company sponsored research of approximately $460,000 per year.&#160;&#160;On March 20, 2008, the Company terminated the agreement.&#160;&#160;On March 24, 2009, the Company entered into a payment plan with the University of Michigan to pay the outstanding balance of $197,000.&#160;&#160;The Company agreed to pay $5,000 per month, until the balance is paid in full. At December 31, 2011, the balance is approximately $32,000 and is recorded as a short-term accounts payable</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>Employment Agreements</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On February 6, 2010, the Company executed a three-year employment agreement with James S. Kuo, M.D., Chairman, Chief Executive Officer and President.&#160;&#160;The agreement provided for an annual base salary of $199,000, discretionary performance and transactional bonus payments, and 400,000 stock options with an exercise price equal to the market price on the date of grant.&#160;&#160;Of these stock options, 100,000 vested immediately upon grant and the remainder will vest pro rata, on a monthly basis, over the following thirty-six months. The fair value of the options totaled $328,000 and was determined using the Black-Scholes model with the following assumptions: expected dividend yield of 0%, expected volatility of 204.5%; risk free interest rate of 3.59% and an expected life of 10 years.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Effective February 3, 2012, Dr. Kuo resigned from his positions as President and Chief Executive Officer. In connection with his resignation, Dr. Kuo entered into a nine-month consulting agreement with the Company (the &#8220;Consulting Agreement&#8221;). Pursuant to the Consulting Agreement, Dr. Kuo will be entitled to a consulting fee of $17,000 per month and retain the right to exercise the stock options held by him that have vested (324,999) as of the effective date of the Consulting Agreement for a period expiring on the date that is one year from the effective date of the Consulting Agreement.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Effective February 3, 2012, Jeffrey Riley was appointed to serve as the Company&#8217;s Chief Executive Officer and President. In connection with his appointment, Mr. Riley entered into a three-year employment agreement with the Company (the &#8220;Riley Employment Agreement&#8221;). Pursuant to the Riley Employment Agreement, Mr. Riley will be entitled to an annual base salary of $348,000 and will be eligible for discretionary performance and transactional bonus payments. Additionally, Mr. Riley was granted options to purchase 750,000 shares of the Company&#8217;s common stock with an exercise price equal to the per share market price on the date of issue. These options will vest pro rata, on a monthly basis, over thirty-six months. The Company measured the fair value of the stock options at approximately $1.7 million using a Black-Scholes valuation model; these warrants were indexed to the Company&#8217;s own stock.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Effective February 6, 2012, C. Evan Ballantyne was appointed the Company&#8217;s Chief Financial Officer. In connection with his appointment, Mr. Ballantyne entered into a three-year employment agreement with the Company (the &#8220;Ballantyne Employment Agreement&#8221;). Pursuant to the Ballantyne Employment Agreement, Mr. Ballantyne will be entitled to an annual base salary of $298,000 and will be eligible for discretionary performance and transactional bonus payments. Additionally, Mr. Ballantyne was granted options to purchase 425,000 shares of our common stock with an exercise price equal to our per share market price on the date of issue. These options will vest pro rata, on a monthly basis, over thirty-six months. The Company measured the fair value of the stock options at approximately $1 million using a Black-Scholes valuation model; these warrants were indexed to the Company&#8217;s own stock.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;
 text-align: justify;">The Black-Scholes assumptions used in calculating the fair value of the stock options are as follows:</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;&#160;&#160;</p>
</div>
<div>
<table style="width: 60%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; background-color: #ccffcc;">
<td style="width: 54%; padding-right: 0.8pt;">Exercise price</td>
<td style="width: 4%; padding-right: 0.8pt;">&#160;</td>
<td style="width: 39%; padding-right: 0.8pt; text-align: center;">$2.30 - $2.47</td>
<td style="width: 3%; padding-right: 0.8pt;">&#160;</td>
</tr>
<tr style="vertical-align: top; background-color: white;">
<td style="padding-right: 0.8pt;">Expected dividends</td>
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;">0%</td>
<td style="padding-right: 0.8pt;">&#160;</td>
</tr>
<tr style="vertical-align: top; background-color: #ccffcc;">
<td style="padding-right: 0.8pt;">Expected volatility</td>
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;">174%</td>
<td style="padding-right: 0.8pt;">&#160;</td>
</tr>
<tr style="vertical-align: top; background-color: white;">
<td style="padding-right: 0.8pt;">Risk free interest rate</td>
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;">1.93% - 1.97%</td>
<td style="padding-right: 0.8pt;">&#160;</td>
</tr>
<tr style="vertical-align: top; background-color: #ccffcc;">
<td style="padding-right: 0.8pt;">Expected life of options</td>
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;">10 years</td>
<td style="padding-right: 0.8pt;">&#160;</td>
</tr>
<tr style="vertical-align: top; background-color: white;">
<td style="padding-right: 0.8pt;">Expected forfeitures</td>
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;">0%</td>
<td style="padding-right: 0.8pt; text-align: center;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>Other Commitments</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">As of December 31, 2011, amounts due for license agreements are as follows <i>(in thousands)</i> :</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<table align="center" style="width: 60%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="font-weight: bold; text-align: left;">Year&#160;Ending&#160;December&#160;31,</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="width: 79%; text-align: left; padding-left: 17.3pt;">2012</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 18%; text-align: right;">37</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; padding-left: 17.3pt;">2013</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-left: 17.3pt;">2014</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; padding-left: 17.3pt;">2015</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 17.3pt;">2016</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt; padding-left: 8.65pt; text-align: left;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">57</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"><i>Operating Lease</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">During 2007, the Company entered into a non-cancelable operating lease for office, laboratory and production space in Ann Arbor, Michigan.&#160;This lease expired on February 28, 2011. In March 2011, the Company entered into a month-to-month lease, at a different location, in Ann Arbor, Michigan.&#160;&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">During the years ended December 31, 2011 and 2010 the Company recognized rent expense of $64,000 and $214,000, respectively.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>Capital Lease</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">In June 2006, the Company acquired $65,000 of equipment under a non-cancelable capital lease. The Company agreed to guarantee and to release the seller from the seller&#8217;s personal guarantee of the remaining balance and the amount was placed in
 escrow.&#160;&#160;The effective interest rate of the lease was 8.51%.&#160; Related monthly payments of principal and interest were $1,400 over a period of sixty months.&#160; In September 2008, the lessor extended the term for repayment by eight months, with a final maturity date of January 2012.&#160;&#160;The remaining balance of this capital lease at December 31, 2010 was $24,000. In January 2011, this capital lease was paid in full and the funds were released from escrow. See Note 3 &#8211; Discontinued Operations of Adeona Clinical Laboratory.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EGCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Synthetic Biologics, Inc.<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000894158<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">Other<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
         2012<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
        <td class="text"><div>
<table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in; text-align: left;"><b>9.</b></td>
<td style="text-align: justify;"><b>Income Taxes</b></td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">There was no income tax expense for the years ended December 31, 2011 and 2010 due to the Company&#8217;s net losses.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company&#8217;s tax expense differs from the &#8220;expected&#8221; tax expense for the years ended December 31, 2011 and 2010, (computed by applying the Federal Corporate tax rate of 34% to loss before taxes and 5.5% for Michigan State Corporate taxes, the blended rate used was 37.63%), as follows <i>(in thousands):</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2010</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 70%; text-align: left;">Computed &#8220;expected&#8221; tax benefit - Federal</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">(2,618</td>
<td style="width: 1%; text-align: left;">)</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">(550</td>
<td style="width: 1%; text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Computed &#8220;expected&#8221; tax benefit - State</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(448</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(94</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">Non-taxable federal grant</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(184</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Meals, entertainment and other</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td>Non-deductible stock-based compensation</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">366</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">150</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Warrant expense</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">56</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">Change in fair value of warrant expense</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">91</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Realized loss on debt securities</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">7</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; padding-bottom: 1pt;">Change in valuation allowance</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">2,035</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">673</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The effects of temporary differences that gave rise to
 significant portions of deferred tax assets at December 31, 2011 and 2010 are as follows <i>(in thousands):</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2010</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="font-weight: bold; padding-bottom: 1pt;">Deferred&#160;tax&#160;assets:</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="width: 70%; text-align: left;">Stock issued for services</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">(321</td>
<td style="width: 1%; text-align: left;">)</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">(223</td>
<td style="width: 1%; text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">Bad debt &#8211; change in allowance</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(205</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(49</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1pt;">Net operating loss carry-forward</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(10,425</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(8,644</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">Total gross deferred tax assets</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(10,951</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(8,916</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1pt;">Less valuation allowance</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">10,951</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">8,916</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; padding-bottom: 2.5pt;">Net deferred tax assets</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">At December 31, 2011, the Company has a net operating loss carry-forward of approximately $27.7 million available to offset future taxable income expiring through 2031. Utilization of these net operating losses may be limited due to potential ownership changes under Section 382 of the Internal Revenue Code.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The valuation allowance at December 31, 2010 was approximately $8.9 million. The net change in valuation allowance during the year ended December 31, 2011 was an increase of approximately $2 million. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, Management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2011.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">During 2010, the Company received grant revenue of $489,000.&#160;&#160;Under the terms of the grant, this revenue is not taxable.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E14AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenue, net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 2,125<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">489<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total Revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2,614<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Costs and Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">1,468<span></span></td>
        <td class="nump">1,233<span></span></td>
        <td class="nump">2,588<span></span></td>
        <td class="nump">2,117<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">386<span></span></td>
        <td class="nump">231<span></span></td>
        <td class="nump">3,340<span></span></td>
        <td class="nump">1,580<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Costs and Expenses</a></td>
        <td class="nump">1,854<span></span></td>
        <td class="nump">1,464<span></span></td>
        <td class="nump">5,928<span></span></td>
        <td class="nump">3,697<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from Continuing Operations</a></td>
        <td class="num">(1,854)<span></span></td>
        <td class="num">(1,464)<span></span></td>
        <td class="num">(5,928)<span></span></td>
        <td class="num">(1,083)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExpenses', window );">Warrant expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(716)<span></span></td>
        <td class="num">(1,492)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(94)<span></span></td>
        <td class="num">(242)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_EquipmentImpairmentLoss', window );">Impairment loss on equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(121)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on the sale of equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(5)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
        <td class="nump">5<span></span></td>
        <td class="nump">56<span></span></td>
        <td class="nump">22<span></span></td>
        <td class="nump">9<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense), net</a></td>
        <td class="nump">5<span></span></td>
        <td class="num">(759)<span></span></td>
        <td class="num">(1,698)<span></span></td>
        <td class="num">(112)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Loss from Continuing Operations</a></td>
        <td class="num">(1,849)<span></span></td>
        <td class="num">(2,223)<span></span></td>
        <td class="num">(7,626)<span></span></td>
        <td class="num">(1,195)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net Income (Loss) from Discontinued Operations</a></td>
        <td class="nump">649<span></span></td>
        <td class="nump">37<span></span></td>
        <td class="num">(523)<span></span></td>
        <td class="num">(516)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">$ (1,200)<span></span></td>
        <td class="num">$ (2,186)<span></span></td>
        <td class="num">$ (8,149)<span></span></td>
        <td class="num">$ (1,711)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Income (Loss) Per Share - Basic and Dilutive:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Continuing Operations (in dollars per share)</a></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (0.09)<span></span></td>
        <td class="num">$ (0.27)<span></span></td>
        <td class="num">$ (0.06)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Discontinued Operations (in dollars per share)</a></td>
        <td class="nump">$ 0.02<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net Loss Per Share</a></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="num">$ (0.09)<span></span></td>
        <td class="num">$ (0.29)<span></span></td>
        <td class="num">$ (0.08)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive', window );">Weighted average number of common shares outstanding during the year Basic and Dilutive (in shares)</a></td>
        <td class="nump">32,003,164<span></span></td>
        <td class="nump">25,220,694<span></span></td>
        <td class="nump">27,710,428<span></span></td>
        <td class="nump">22,393,568<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ChangeInFairValueOfWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ChangeInFairValueOfWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_EquipmentImpairmentLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Impairment loss on equipment during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_EquipmentImpairmentLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expenses incurred for warrant during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDilutedAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the parent which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4613673-111683<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph b(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 10<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the overall income (loss) from a disposal group apportioned to the parent that is classified as a component of the entity, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount which may be allocable to noncontrolling interests, if any. Includes the following (net of tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph b(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of income (loss) derived from discontinued operations during the period, net of related tax effect, per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Audit and Accounting Guide (AAG)<br><br> -Number AAG-BRD<br><br> -Chapter 4<br><br> -Paragraph 80<br><br> -Subparagraph Exhibit 4-4<br><br> -IssueDate 2006-05-01<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif;"><b>4.&#160;&#160;&#160;Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &#8220;Lab&#8221;) to Hartlab, LLC, an entity controlled by the Lab&#8217;s former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year non-recourse promissory note bearing interest at 5.7% per annum secured by all of the assets of the Lab. The note and all unpaid interest are due on March 1, 2014.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In accordance with ASC Topic 205-20 &#8220; <i>Presentation of Financial Statements&#8212;Discontinued Operations</i> &#8221; (ASC 205-20), the Company determined that all the criteria had been met and classified the Lab as discontinued operations and its results of operations, financial position and cash flows are separately reported for all periods presented. The assets of the discontinued operations are presented separately under the caption &#8220;Assets of discontinued operations&#8221; in the accompanying Consolidated Balance Sheets at March 31, 2012, and December 31, 2011, and consist of the following <i>(in thousands):</i></p>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<table style="width: 88%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-style: italic;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March 31, 2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31, 2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Assets of discontinued operations:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt; width: 70%;">Property and equipment, net</td>
<td style="padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 12%;">-</td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 12%;">23</td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;">Total assets</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">23</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The summarized statement of operations data for Adeona Clinical Laboratory for the three months ended March 31, 2012 and March 31, 2011 are as follows <i>(in thousands):</i></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p>
<table style="width: 88%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6">March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 70%;">Laboratory fees, net</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 12%;">115</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 12%;">323</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Operating Costs and Expenses:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align:
 right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0.24in;">General and administrative</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">27</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">35</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0.24in;">Cost of&#160; laboratory services</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">116</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">251</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0.24in;">Total operating costs and expenses</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">143</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">286</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Income (loss) from discontinued operations</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(28</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">37</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Other Income:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0.12in;">Gain on the sale of Adeona Clinical Laboratory</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">677</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Net income from discontinued operations</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">649</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">37</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span></td>
        <td class="text"><div>
<table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in; text-align: left;"><b>3.</b></td>
<td style="text-align: justify;"><b>Discontinued Operations of Adeona Clinical Laboratory</b></td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &#8220;Lab&#8221;) to Hartlab, LLC, an entity controlled by the Lab&#8217;s former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year non-recourse promissory note secured by all of the assets of the Lab.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">In accordance with ASC Topic 205-20 &#8220;<i>Presentation of Financial Statements&#8212;Discontinued Operations</i>&#8221; (ASC 205-20), the Company determined that the sale of the Lab should be classified as &#8220;held for sale&#8221; at December 31, 2011. In accordance with ACS 205-20 all of the following criteria must be met for an entity to be classified as &#8220;held for sale&#8221;:</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 6%; text-align: justify;">&#160;</td>
<td style="width: 6%; padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="width: 88%; padding-right: 0.8pt; text-align: justify;">Management, having the authority to approve the action, commits to a plan to sell the asset.</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt; text-align: justify;">The asset is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets.</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt; text-align: justify;">An active program to locate a buyer and other actions required to complete the plan to sell the asset have been initiated.</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt; text-align: justify;">The sale of the asset is probable, and transfer of the asset is expected to qualify for recognition as a complete sale within one year.</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt; text-align: justify;">The asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value.</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company determined that all the criteria had been met and has classified the Lab as discontinued operations and its results of operations, financial position and cash flows are separately reported for all periods presented. The assets and liabilities of the discontinued operations are presented separately under the captions &#8220;Assets of discontinued operations&#8221; and &#8220;Liabilities of discontinued operations,&#8221; respectively, in the accompanying Consolidated Balance Sheets at December 31, 2011, and December 31, 2010, and consist of the following <i>(in thousands</i> <i>):</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;">&#160;</p>
</div>
<div>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2010</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">Assets of discontinued operations:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="width: 64%; text-align: left; padding-left: 9pt;">Property and equipment, net</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">23</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">36</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 1pt; padding-left: 9pt;">Goodwill</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align:
 right;">-</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">178</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;">Total assets</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">23</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">214</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Liabilities of discontinued operations:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;">Current portion of capital lease</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">24</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;">Total liabilities</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">24</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">The summarized statement of operations data for Adeona Clinical Laboratory for the years ended December 31, 2011 and December 31, 2010 are as follows <i>(in thousands):</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2011</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2010</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 64%; text-align: left;">Laboratory fees, net</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">1,169</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">551</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">Operating Costs and Expenses:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-left: 9pt;">General and administrative</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">539</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">599</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; padding-left: 9pt;">Cost of&#160; laboratory services</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">975</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">468</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;">Impairment loss on
 goodwill</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">178</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;">Total operating costs and expenses</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">1,692</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">1,067</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; padding-bottom: 2.5pt;">Loss from discontinued operations</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(523</td>
<td style="padding-bottom: 2.5pt; text-align: left;">)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(516</td>
<td style="padding-bottom: 2.5pt; text-align: left;">)</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390789&amp;loc=d3e2443-110228<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 43-48<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1474-107760<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1020-107759<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1510-107760<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1012-107759<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>3.&#160;&#160;&#160;Summary of Significant Accounting Policies</b></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Principles of Consolidation</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">All inter-company transactions and accounts have been eliminated in consolidation.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Use of Estimates</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Accounts Receivable and Allowance for Doubtful Accounts</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Accounts receivable were reported at realizable value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded. The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables deemed uncollectible were charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Revenue Recognition</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&#160;&#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&#160;&#160;For the three months ended March 31, 2012 and 2011, the Company&#8217;s only stream of revenue was laboratory revenue.&#160;Laboratory revenues are a component of discontinued operations for the three months ended March 31, 2012 and 2011. <i>See Note 4 &#8211; Discontinued Operations of Adeona Clinical Laboratory and Note Receivable.</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>License Revenues</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date,
 the Company has not received any royalty revenues.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On May 6, 2010, the Company entered into the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&#160; As consideration for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment was recorded as license revenue in 2010. Pursuant to the Company&#8217;s license agreement with McLean Hospital, the Company paid 15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and $10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of 7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.&#160;The Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. Pursuant to the terms of the Company&#8217;s agreement with McLean Hospital, the Company is obligated to pay half of all future royalties the Company receives.&#160;&#160;Future milestone payments will be recorded as revenue when payment is received as there are no future deliverables, and it is non-refundable.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Laboratory Revenues</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company primarily recognized revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company maintained a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looked at several factors, the most significant of which is the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The allowance taken was the averaged yearly average adjustment amount for these prior periods and multiplied by the period&#8217;s actual gross sales to determine the actual sales allowance for each period.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company generated reimbursements from&#160;3 significant insurance providers in March 31, 2012 and 2011, as follows:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<table style="width: 88%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;">Customer</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; width: 33%;">A</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 34%;">68</td>
<td style="text-align: left; width: 1%;">%</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 33%;">69</td>
<td style="text-align: left; width: 1%;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">B</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">18</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center;">C</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5</td>
<td style="text-align: left;">%</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Risks and Uncertainties</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company's operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast and plan future business activities.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Cash and Cash Equivalents</i></b></p>
<p
 style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three months or less.&#160;&#160;At March 31, 2012 and 2011, respectively, the Company had no cash equivalents.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Goodwill</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Goodwill was not amortized, and was tested for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was assigned.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">ASC No. 350 requires a two-step approach to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit, and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially affected by changes in these estimates and assumptions.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">At December 31, 2011, in connection with the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired. <i>See Note 4 &#8211; Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</i>.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Net Earnings (Loss) per Share</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Net earnings (loss) per share is computed by dividing net earnings (loss) less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends by the weighted average number of common shares outstanding including the effect of common share equivalents.&#160;Since the Company reported a net loss for the three months ended March 31, 2012 and 2011, all common equivalent shares would be anti-dilutive; as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the three months ended March 31, 2012 were 3,843,465 and 2,414,922, respectively, and for the three months ended March 31, 2011 were 2,273,072 and 2,554,650, respectively.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Research and Development Costs</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company expenses research and development costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&#8217;s product candidates.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Stock-Based Payment Arrangements</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#8217; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Reclassifications</i></b></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">To conform prior period amounts to current year classifications, the Company has reclassified assets, liabilities, revenues and expenses associated with the sale of Adeona Clinical Laboratory to discontinued operations. These reclassifications had no impact on the Company&#8217;s previously reported financial condition, results of operations or cash
 flows.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p><span></span></td>
        <td class="text"><div>
<table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in; text-align: left;"><b>2.</b></td>
<td style="text-align: justify;"><b>Summary of Significant Accounting Policies</b></td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Principles of Consolidation</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">All inter-company transactions and accounts have been eliminated in consolidation.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Emerging from the Development Stage</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">During the second quarter of 2010, the Company emerged from the development stage.&#160;&#160;&#160;A development-stage enterprise is one in which planned principle operations have not commenced or if its operations have commenced, there has been no significant revenue.&#160;&#160; The Company&#8217;s strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration.&#160;&#160;On May 6, 2010, the Company entered into a Sublicense Agreement (the &#8220;Meda Agreement&#8221;) with Meda&#160;AB of Sweden (&#8220;Meda&#8221;) and received an up-front payment of $2.5 million. The execution of the Meda Agreement combined with revenues from Adeona Clinical Laboratory were an indication of the commencement of principal operations, and therefore development-stage reporting was no longer required.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Use of Estimates</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Accounts Receivable and Allowance for Doubtful Accounts</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Accounts receivable were reported at realizable value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded. The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables deemed uncollectible were charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Revenue Recognition</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&#160;&#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&#160;&#160;For the year ended December 31, 2011, the Company&#8217;s only stream of revenue was laboratory revenue. During the year ended December 31, 2010, the Company&#8217;s streams of revenue were license revenue, laboratory revenue and grant revenue.&#160;&#160;&#160;Laboratory revenues are a component of discontinued operations for the years ended December 31, 2011 and 2010. See
 Note 3 &#8211; Discontinued Operations of Adeona Clinical Laboratory.</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>License Revenues</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company&#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On May 6, 2010, the Company entered into the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&#160; As consideration for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment was recorded as license revenue in 2010. Pursuant to the Company&#8217;s license agreement with McLean Hospital, the Company paid 15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and $10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of 7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.&#160;The Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. Pursuant to the terms of the Company&#8217;s agreement with McLean Hospital, the Company is obligated to pay half of all future royalties the Company receives.&#160;&#160;Future milestone payments will be recorded as revenue when payment is received as there are no future deliverables, and it is non-refundable.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160; <i>Laboratory Revenues</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company primarily recognized revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company maintained a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looked at several factors, the most significant of which is the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The allowance taken was the averaged yearly average adjustment amount for these prior periods and multiplied by the period&#8217;s actual gross sales to determine the actual sales allowance for each period.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company generated reimbursement from&#160;three significant insurance providers in 2011 and 2010.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<table align="center" style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">Customer</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2010</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 31%; text-align: center;">A</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 31%; text-align: right;">70</td>
<td style="width: 1%; text-align: left;">%</td>
<td style="width:
 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 30%; text-align: right;">65</td>
<td style="width: 1%; text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: center;">B</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">11</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: center;">C</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">19</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">14</td>
<td style="text-align: left;">%</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"><i>Grant Revenues</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On November 4, 2010, the Company was awarded two grants totaling $489,000 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company&#8217;s clinical programs. The QTDP Grants Program was included in the healthcare reform legislation and established a one-time pool of $1 billion for grants to small biotechnology companies developing novel therapeutics which show potential to: (a)&#160;result in new therapies that either treat areas of unmet medical need, or prevent, detect, or treat chronic or acute diseases and conditions; (b)&#160;reduce long-term health care costs in the U.S.; or (c)&#160;significantly advance the goal of curing cancer within a 30-year period.&#160;&#160;All grant income was recognized in 2010 and there are no future obligations associated with these grants.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">During 2010 and March 2011, all amounts awarded under these grants had been received. See Note 9 regarding the taxability of grant revenues.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"><i>Revenues, net (in thousands)</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap">December&#160;31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">2010</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 64%; text-align: left;">License revenue</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">-</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">2,500</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1pt;">License fees</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(375</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">License revenue, net</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2,125</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1pt;">Grant revenue</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">489</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; padding-bottom: 2.5pt;">Total revenues, net</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,614</td>
<td style="padding-bottom:
 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Risks and Uncertainties</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company's operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast and plan future business activities.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Cash and Cash Equivalents</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three months or less.&#160;&#160;At December 31, 2011 and 2010, respectively, the Company had no cash equivalents.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Classification of Marketable Securities as Held to Maturity, Trading, and Available for Sale</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Debt securities are classified as held to maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available for sale. Held to maturity securities are recorded as either short-term or long-term on the balance sheet, based on contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held to maturity or as trading, are classified as available for sale, and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders&#8217; equity. At December 31, 2011 and 2010, respectively, the Company had no marketable securities.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">During the year ended December 31, 2011, the Company held investments in marketable securities that were classified as held to maturity and consisted of corporate bonds and certificates of deposits as follows <i>(in thousands)</i> :</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<table style="width: 60%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">December 31, 2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 78%; text-align: justify;">Purchase of short-term investments</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 19%; text-align: right;">(4,370</td>
<td style="width: 1%; text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: justify;">Amortization of premium on investments</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">57</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: justify;">Proceeds from short-term investments</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4,293</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: justify; padding-bottom: 1pt;">Loss on sale of short-term investments</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">20</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Fair value</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Property and Equipment</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated
 useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 49%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center;">Asset&#160;Description</td>
<td style="width: 4%; padding-right: 0.8pt; text-align: center;">&#160;</td>
<td style="width: 47%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center;">Estimated&#160;Useful&#160;Life</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt;">Office equipment and furniture</td>
<td style="padding-right: 0.8pt; text-align: center;">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;">5&#160;&#160;years</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt;">Laboratory equipment</td>
<td style="padding-right: 0.8pt; text-align: center;">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;">7-10 years</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt;">Manufacturing equipment</td>
<td style="padding-right: 0.8pt; text-align: center;">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;">10 years</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt;" nowrap="nowrap">Leasehold improvements and fixtures</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">Lesser of estimated useful or life of lease</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Depreciation expense was approximately $144,000 and $346,000 for the years ended December 31, 2011 and 2010, respectively. When assets are disposed of, the cost and accumulated depreciation are removed from the accounts. Repairs and maintenance are charged to expense as incurred.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">During 2010, the Company reviewed property and equipment for impairment and determined that certain items had been impaired due to obsolescence. As a result of this review, the Company recorded an impairment loss of approximately $121,000. For the year ended December 31, 2011, there were no significant events or changes in circumstances identified by the Company that would indicate that the carrying value of an asset was not recoverable.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Long-Lived Assets</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Goodwill</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Goodwill was not amortized, and was tested for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was assigned.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">ASC No. 350 requires a two-step approach to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit, and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially affected by changes in these estimates and assumptions.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">At December 31, 2011, in connection with the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired. See Note 3 &#8211; Discontinued Operations of Adeona Clinical Laboratory.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Beneficial Conversion Feature</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">For conventional convertible debt where the rate of conversion is below market value, the Company records a "beneficial conversion feature" (BCF) and related debt
 discount.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">When the Company records a BCF, the relative fair value of the BCF would be recorded as a debt discount against the face amount of the respective debt instrument. The discount would be amortized to interest expense over the life of the debt.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Derivative Liabilities</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In&#160;determining the appropriate fair value, the Company uses the Black-Scholes option pricing model. In&#160;assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In&#160;addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option pricing model.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Debt Issue Costs and Debt Discount</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company may pay debt issue costs, and record debt discounts in connection with raising funds through the issuance of convertible debt.&#160;&#160;These costs are amortized over the life of the debt to interest expense. If&#160;a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Original Issue Discount</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">For certain convertible debt issued, the Company may provide the debt holder with an original issue discount.&#160;&#160;&#160;The original issue discount was recorded to debt discount reducing the face amount of the note and is being amortized to interest expense over the life of the debt.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Net Earnings (Loss) per Share</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Net earnings (loss) per share is computed by dividing net earnings (loss) less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends by the weighted average number of common shares outstanding including the effect of common share equivalents.&#160;Since the Company reported a net loss for the years ended December 31, 2011 and 2010, all common equivalent shares would be anti-dilutive; as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the year ended December 31, 2011 were 2,979,010 and 3,259,186, respectively, and for the year ended December 31, 2010 were 1,990,444 and 1,070,472, respectively.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Research and Development Costs</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company expenses research and development costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&#8217;s product candidates.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Fair Value of Financial Instruments</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market
 participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 3%;">&#160;</td>
<td style="width: 3%; padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="width: 94%; padding-right: 0.8pt; text-align: justify;">Level 1 inputs: Quoted prices (unadjusted)&#160;for identical assets or liabilities in active markets;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in;">&#160;</p>
</div>
<div>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 3%;">&#160;</td>
<td style="width: 3%; padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="width: 94%; padding-right: 0.8pt; text-align: justify;">Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in;">&#160;</p>
</div>
<div>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 3%;">&#160;</td>
<td style="width: 3%; padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="width: 94%; padding-right: 0.8pt; text-align: justify;">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The carrying amounts of the Company&#8217;s short-term financial instruments, including accounts receivable, other current assets, accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Stock-Based Payment Arrangements</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#8217; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Income Taxes</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company accounts for income taxes in accordance with accounting guidance now codified as FASB ASC Topic 740, &#8220; <i>Income Taxes</i> ,&#8221; which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Accounting guidance now codified as FASB ASC Topic 740-20, <i>&#8220;Income Taxes &#8211; Intraperiod Tax Allocation,&#8221;</i> clarifies the accounting for uncertainties in income taxes recognized in accordance with FASB ASC Topic 740-20 by prescribing guidance for the recognition, de-recognition and measurement in financial statements of income tax positions taken in previously filed tax returns or tax positions expected to be taken in tax returns, including a decision whether to file or not to file in a particular jurisdiction. FASB ASC Topic 740-20 requires that any liability created for unrecognized tax benefits is disclosed. The application of FASB ASC Topic 740-20 may also affect the tax bases of assets and liabilities and therefore may change or create deferred tax liabilities or assets. The Company would recognize interest and penalties related to unrecognized tax benefits in income tax expense. At December 31, 2011 and 2010, respectively, the Company did not record any liabilities for uncertain tax positions.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Recent Accounting
 Pronouncements</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">In May 2011, the FASB issued guidance in regard to fair value measurement. The new guidance results in a consistent definition of fair value and common requirements for measurement of and disclosure about fair value between GAAP and International Financial Reporting Standards (IFRS). This guidance is effective for interim and annual periods beginning after December 15, 2011. The adoption of this guidance is not expected to have a material impact on the Company&#8217;s financial position or results of operations.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">In September 2011, the FASB issued guidance in regard to goodwill impairment. The new guidance is intended to reduce the cost and complexity of the annual goodwill impairment test by providing entities with the option of performing a "qualitative" assessment to determine whether further impairment testing is necessary. An entity can choose to perform the qualitative assessment on none, some, or all of its reporting units. Moreover, an entity can bypass the qualitative assessment for any reporting unit in any period and proceed directly to step one of the impairment test, and then perform the qualitative assessment in any subsequent period. The new guidance is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company&#8217;s financial position or results of operations.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"><b><i>Reclassifications</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">To conform prior period amounts to current year classifications, the Company has reclassified assets, liabilities, revenues and expenses associated with the sale of Adeona Clinical Laboratory to discontinued operations. These reclassifications had no impact on the Company&#8217;s previously reported financial condition, results of operations or cash flows.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Event<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif; margin-left: 0in;"><b>9.&#160;&#160;&#160;Subsequent Events</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On May 1, 2012, the Company was informed by Berman &amp; Company, P.A. (&#8220;Berman &amp; Company&#8221;), the Company&#8217;s independent registered accounting firm, that during a regular Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) inspection of Berman &amp; Company, the PCAOB issued a comment that the audit opinion included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011 was issued by a partner at Berman &amp; Company who was not authorized under the PCAOB rules to issue the opinion or act as our named engagement partner with respect to the Form 10-K audit (or prior 2011 Form 10-Q interim reviews) after the original engagement partner rotated off the account under the Securities and Exchange Commission&#8217;s independence rules as it pertains to partner rotation (S-X Rule 2-01 - Qualifications of Accountants).</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company received funds from the exercise of warrants but will not issue any shares under any of its outstanding registration statements on Form S-3 until such time as it receives guidance from the SEC whether the issue disclosed herein affects the Company&#8217;s ability to continue to issue securities thereunder. The Company intends to return all of the funds to the warrant holders. The Company has sought guidance from the SEC staff regarding this matter and intends to file a waiver request to the extent it becomes necessary.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On May 10, 2012, Jeffrey J. Kraws was appointed as the independent, non-executive Chairman of the Board. For his service as independent, non-executive Chairman of the Board, Mr. Kraws will receive annual compensation of $150,000. Additionally, Mr. Kraws was granted options to purchase 100,000 shares of the Company&#8217;s common stock with an exercise price equal to our per share market price on the date of issue. These options will vest pro rata, quarterly over a two year period with the first quarterly issuance of 12,500 options vesting immediately. The Company measured the fair value of the stock options at approximately $166,000 using a Black-Scholes valuation model; these warrants were indexed to the Company&#8217;s own stock.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Black-Scholes assumptions used in calculating the fair value of the stock options are as follows:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 50%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 77%;">Exercise price</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 20%;">1.70</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Expected dividends</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Expected volatility</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">171</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Risk free interest rate</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.28</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Expected life of options</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">7 years</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Expected forfeitures</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
</table><span></span></td>
        <td class="text"><p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b>10. Subsequent Event</b></p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On December 20, 2011, the Company entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services, the consultant will be paid a monthly fee of $10,000 and was issued a warrant exercisable for 100,000 shares of the Company&#8217;s common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal to the price of the Company&#8217;s common stock on the date of issue. The issue date of the warrant is February 2, 2012.</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The fair value of the warrant approximated $200,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;&#160;</p>
<table style="width: 50%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 75%;">Exercise price</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 22%; text-align: right;">1.14</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Expected dividends</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">Expected volatility</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">174</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Risk free interest rate</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.71</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">Expected life of warrant</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5 years</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Expected forfeitures</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
</table>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On May 1, 2012, the Company was informed by Berman &amp; Company, P.A. (&#8220;Berman &amp; Company&#8221;), the Company&#8217;s independent registered accounting firm, that during a regular Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) inspection of Berman &amp; Company, the PCAOB issued a comment that the audit opinion included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011 was issued by a partner at Berman &amp; Company who was not authorized under the PCAOB rules to issue the opinion or act as our named engagement partner with respect to the Form 10-K audit (or prior 2011 Form 10-Q interim reviews) after the original engagement partner rotated off the account under the Securities and Exchange Commission&#8217;s independence rules as it pertains to partner rotation (S-X Rule 2-01 - Qualifications of Accountants).</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company believes that the previously filed financial statements for the year ended December 31, 2011 are accurate. In addition, the Company has not been informed by Berman &amp; Company or the PCAOB, that the previously filed financial statements for the year ended December 31, 2011 are not accurate or otherwise invalid. As a matter of precaution the new engagement partner at Berman &amp; Company has since: (i) taken full responsibility for the audit as the lead engagement partner on the audit, (ii) performed a detailed review of all audit procedures related to the original audit for sufficiency and (iii) reissued the audit opinion. The review performed by the new audit partner did not result in any changes to the Company&#8217;s financial statements or notes to the financial statements for the year ended December 31, 2011, other than the addition of the May 1, 2012 and May 10, 2012 disclosures in this subsequent event note to the financial statements.</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On May 10, 2012, Jeffrey J. Kraws was appointed as the independent, non-executive Chairman of the Board. For his service as independent, non-executive Chairman of the Board, Mr. Kraws will be issued options exercisable for 100,000 shares of the Company&#8217;s common stock and will receive annual compensation of $150,000. The fair value of these options will be measured using the Black-Scholes valuation model.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockPurchaseWarrantsAbstract', window );"><strong>Stock Purchase Warrants [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockPurchaseWarrantsTextBlock', window );">Stock Purchase Warrants [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif; margin-left: 0in;"><b>7.&#160;&#160;&#160;Stock Purchase Warrants</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On March 15, 2012, the Company entered into a consulting agreement for a financial communications program, for a period of twelve months that began on February 20, 2012. As compensation for such program, the consultant is paid a monthly fee and will be issued a performance warrant exercisable for 250,000 shares of the Company&#8217;s common stock based on achievement of certain milestones. Upon initiation of the program, 50,000 of the performance warrants vested. The performance warrant is exercisable for a period of two years from the date the agreement was executed for an exercise price equal to the price of the Company&#8217;s common stock on the date of execution. The fair value of the warrant approximated $61,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 85%;">Exercise price</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 12%;">2.20</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Expected dividends</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Expected volatility</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">108</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Risk free interest rate</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.37</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Expected life of warrant</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2 years</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Expected forfeitures</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 20, 2011, the Company entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services, the consultant is paid a monthly fee and on February 2, 2012, was issued a warrant exercisable for 100,000 shares of the Company&#8217;s common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal to the price of the Company&#8217;s common stock on the date of issue. The fair value of the warrant approximated $200,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 85%;">Exercise price</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 12%;">1.14</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Expected dividends</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Expected volatility</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">174</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Risk free interest rate</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.71</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Expected life of warrant</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5 years</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Expected forfeitures</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On April 6, 2011, the Company entered into a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase 844,391 shares of common stock. The warrants have an exercise price of $1.00 and a life of fifteen months. The warrants vested immediately and expire August 10, 2012. As of March 31, 2012, 344,391 of these warrants remained outstanding.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On January 28, 2011, the Company entered into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants to purchase 1,428,572 shares of common stock. The warrants have an exercise price of $1.40 and a life of fifteen months. The warrants vested immediately and expire May 1, 2012. As of March 31, 2012, 746,429 of these warrants remained outstanding.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times,
 serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On July 2, 2010, the Company entered into a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.32 and a life of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As of March 31, 2012, 18,182 of these warrants remained outstanding.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">A summary of warrant activities as of March 31, 2012, and for the year ended December 31, 2011, is as follows:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Warrants</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Weighted<br />Average&#160;Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 70%;">Balance &#8211; December 31, 2010</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 12%;">1,131,078</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 12%;">3.49</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2,272,963</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.25</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(15,615</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.03</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt;">Expired</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(129,240</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">2.08</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>Balance &#8211; December 31, 2011</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">3,259,186</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.95</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">350,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.90</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(1,194,264</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.24</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt;">Expired</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;">Balance &#8211; March 31, 2012 - outstanding</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,414,922</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2.36</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;">Balance &#8211; March 31, 2012 &#8211; exercisable</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,214,922</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td
 style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2.37</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The warrants outstanding as of March 31, 2012, are as follows:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Exercise<br />Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Warrants<br />Outstanding</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Warrants<br />Exercisable</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Weighted&#160;Average<br />Remaining<br />Contractual&#160;Life</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Aggregate<br />Intrinsic&#160;Value</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 18%;">1.00</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 17%;">344,391</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 17%;">344,391</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 17%;">0.36 years</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 17%;">443,000</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">$</td>
<td style="text-align: right;">1.14</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">100,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">100,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4.84 years</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">106,000</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">$</td>
<td style="text-align: right;">1.32</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">18,182</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">18,182</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">3.75 years</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">16,000</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">$</td>
<td style="text-align: right;">1.40</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">746,429</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">721,429</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.08 years</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">577,000</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">$</td>
<td style="text-align: right;">2.20</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">250,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">50,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.96 years</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">$</td>
<td style="text-align: right;">2.22</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">517,257</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">517,257</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4.66 years</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">$</td>
<td style="text-align: right;">3.30</td>
<td style="text-align:
 left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">61,207</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">61,207</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">3.30 years</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">$</td>
<td style="text-align: right;">3.75</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">50,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">50,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">3.88 years</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">$</td>
<td style="text-align: right; padding-bottom: 1pt;">6.36</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">327,456</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">327,456</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;"><u style="text-decoration: none;">0.61 years</u></td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,414,922</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,214,922</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="text-underline-style: double;"><u style="text-decoration: none;">1.81 years</u></font></td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,142,000</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span></td>
        <td class="text"><div>
<table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in; text-align: left;"><b>8.</b></td>
<td style="text-align: justify;"><b>Stock Repurchase Program</b></td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On April 3, 2009, the Company&#8217;s Board of Directors approved a Stock Repurchase Program authorizing the Company to repurchase, from time-to-time and through December 31, 2009, up to $1 million of its common stock, up to a maximum of four million shares at prices of up to $5 per share. As of December 31, 2011, the Company had repurchased 81,482 shares for approximately $50,000 ($0.61 per share), based upon the quoted closing trading price.&#160;&#160;These treasury shares are not included in the computation of earnings (loss) per share and are deemed to be canceled and retired.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockPurchaseWarrantsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockPurchaseWarrantsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockPurchaseWarrantsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for stock purchase warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockPurchaseWarrantsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Disclosures [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif;"><b>5.&#160;&#160;&#160;Selected Balance Sheet Information</b>&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">Accounts receivable consisted of the following at March 31, 2012 and December 31, 2011 <i>(in thousands):</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 88%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March 31, 2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31, 2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 70%;">Accounts receivable</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 12%;">736</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 12%;">692</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Bad debt allowance - customer</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(296</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(287</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Accounts receivable, net</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">440</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">405</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Property and Equipment consisted of the following at March 31, 2012, and December 31, 2011 <i>(in thousands)</i> :</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 88%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March&#160;31,&#160;2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December&#160;31, 2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 70%;">Manufacturing equipment</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 12%;">400</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 12%;">400</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Computer and office equipment</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">159</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">159</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Laboratory equipment</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">136</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">136</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 9pt;">Total</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">695</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">695</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Less accumulated depreciation</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(392</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(372</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;
 padding-bottom: 2.5pt;">Property and equipment, net</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">303</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">323</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">Depreciation expense for the three months ended March 31, 2012 and 2011 was $20,000 and $80,000, respectively.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<div>&#160;</div><span></span></td>
        <td class="text"><table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in; text-align: left;"><b>4.</b></td>
<td style="text-align: justify;"><b>Selected Balance Sheet Information</b></td>
</tr>
</table>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;">&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>Accounts receivable (in thousands)</i></p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
<table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2010</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 64%; text-align: justify;">Accounts receivable</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">692</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">472</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1pt;">Bad debt allowance - customer</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(287</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(133</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">405</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">339</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>&#160;Other current assets (in thousands)</i></p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
<table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" border="0" cellspacing="0" cellpadding="0"  >
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2010</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 64%; text-align: justify;">Grant receivable</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">-</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">320</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1pt;">Prepaid expenses</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">16</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">23</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">16</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">343</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>&#160;</i></p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>Property and equipment (in thousands)&#160;</i></p>
<p style="font: 10pt">&#160;</p>
<table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2010</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 64%; text-align: justify;">Leasehold improvements</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">-</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">863</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: justify;">Manufacturing equipment</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">400</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">333</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: justify;">Computer and office equipment</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">159</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">160</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: justify; padding-bottom: 1pt;">Laboratory equipment</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">136</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">214</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: justify;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">695</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,570</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1pt;">Less accumulated depreciation</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(372</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(1,095</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">323</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">475</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>&#160;</i></p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"><i>Accrued expenses (in thousands)&#160;</i></p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
<table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2010</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 64%; text-align: justify;">Accrued vendor payments</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">1</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">105</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Bonus</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">100</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 1pt;">Compensation</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">28</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">29</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">210</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureTextBlockSupplementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif;"><b>6.&#160;&#160;&#160;Stock-Based Compensation</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During 2001, Pipex Therapeutics&#8217; board of directors and stockholders adopted the 2001 Stock Incentive Plan (the &#8220;2001 Stock Plan&#8221;). This plan was assumed by Pipex in the October 2006 merger with Sheffield. As of the date of the merger, there were 1,489,353 options issued and outstanding under the 2001 plan. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &#8220;Awards&#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of March 31, 2012, there were 1,066,007 options issued and outstanding under the 2001 Stock Plan.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On March 20, 2007, the Company&#8217;s board of directors approved the Company&#8217;s 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2012, there are 1,031,394 options issued and outstanding under the 2007 Stock Plan.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On November 2, 2010, the board of directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire seven to ten years after the grant date. As of March 31, 2012, there are 1,746,064 options issued and outstanding under the 2010 Stock Plan.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used in the months ended March 31, 2012 and 2011 are as follows:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<table style="width: 88%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6">Three&#160;Months&#160;Ended&#160;March&#160;31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2012</td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td nowrap="nowrap">Exercise price</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$1.14 &#8211; $2.47</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$1.21 &#8211; $2.22</td>
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align:
 left; width: 64%;" nowrap="nowrap">Expected dividends</td>
<td style="width: 1%;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; width: 1%;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; width: 15%;" nowrap="nowrap">0%</td>
<td style="text-align: center; width: 1%;" nowrap="nowrap"></td>
<td style="text-align: center; width: 1%;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; width: 1%;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; width: 15%;" nowrap="nowrap">0%</td>
<td style="text-align: left; width: 1%;" nowrap="nowrap"></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">Expected volatility</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">108% &#8211; 174%</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">185% &#8211; 188%</td>
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">Risk free interest rates</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">0.37% &#8211; 1.98%</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">2.81% &#8211; 3.58%</td>
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">Expected life options</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">10 years</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">5 years &#8211; 7 years</td>
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">Expected forfeitures</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">0%</td>
<td style="text-align: center;" nowrap="nowrap"></td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">0%</td>
<td style="text-align: left;" nowrap="nowrap"></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company records stock-based compensation based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 3%;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 3%;"><font style="font-size: 10pt;">&#9679;</font></td>
<td style="width: 94%;"><font style="font-size: 10pt;">immediate vesting,</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font-size: 10pt;">&#160;</font></td>
<td><font style="font-size: 10pt;">&#9679;</font></td>
<td><font style="font-size: 10pt;">one-half vesting immediately and the remainder over three years</font></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 3%;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 3%;"><font style="font-size: 10pt;">&#9679;</font></td>
<td style="width: 94%;"><font style="font-size: 10pt;">monthly over three years,</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font-size: 10pt;">&#160;</font></td>
<td><font style="font-size: 10pt;">&#9679;</font></td>
<td><font style="font-size: 10pt;">quarterly over three years,</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font-size: 10pt;">&#160;</font></td>
<td><font style="font-size: 10pt;">&#9679;</font></td>
<td><font style="font-size: 10pt;">annually over three years,</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font-size: 10pt;">&#160;</font></td>
<td><font style="font-size: 10pt;">&#9679;</font></td>
<td><font style="font-size: 10pt;">one-third immediate vesting and remaining annually over two years,</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font-size: 10pt;">&#160;</font></td>
<td><font style="font-size: 10pt;">&#9679;</font></td>
<td><font style="font-size: 10pt;">one-eighth immediate vesting with remaining vesting over two years,</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font-size: 10pt;">&#160;</font></td>
<td><font style="font-size: 10pt;">&#9679;</font></td>
<td><font style="font-size: 10pt;">one-half immediate vesting with remaining vesting over nine months; and</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font-size: 10pt;">&#160;</font></td>
<td><font style="font-size: 10pt;">&#9679;</font></td>
<td><font style="font-size: 10pt;">one quarter immediate vesting with the remaining over three years.</font></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During the three months ended March 31, 2012, the Company granted 1,300,000 options to employees and consultants having a fair value of approximately $3 million based upon the Black-Scholes option pricing model.&#160; During the same period of 2011, the Company granted 324,502 options to employees having a fair value of approximately $433,000 based upon the Black-Scholes option pricing model.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">A summary of stock option
 activities as of March 31, 2012, and for the year ended December 31, 2011, is as follows:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Options</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Weighted<br />Average<br />Exercise<br />Price</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Weighted<br />Average<br />Remaining<br />Contractual<br />Life</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Aggregate<br />Intrinsic<br />Value</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 52%;">Balance &#8211; December 31, 2010</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 9%;">2,539,091</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 9%;">1.32</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 9%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 9%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">557,002</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.26</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(23,333</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.57</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Forfeited or expired</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(93,750</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">0.59</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>Balance &#8211; December 31, 2011</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2,979,010</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.34</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,300,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2.35</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(289,343</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.23</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Forfeited or expired</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(146,202</td>
<td style="text-align: left; padding-bottom:
 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">0.80</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;">Balance &#8211; March 31, 2012 &#8211; outstanding</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">3,843,465</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.79</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="text-underline-style: double;">7.18 years</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,230,000</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;">Balance &#8211; March 31, 2012 &#8211; exercisable</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,323,320</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.62</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="text-underline-style: double;">5</font>.73 years</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,814,000</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The options outstanding and exercisable as of March 31, 2012, are as follows:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="13">Options&#160;Outstanding</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="10">Options&#160;Exercisable</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Weighted</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Weighted&#160;Average</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Weighted</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Weighted&#160;Average</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;">Range&#160;of</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Average</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Remaining</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Average</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Remaining</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center;">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Options</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Contractual&#160;Life</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Options</td>
<td style="padding-bottom:
 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Contractual&#160;Life</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; width: 16%;">$0.09 - $4.57</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 11%;">3,753,466</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 11%;">1.69</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: center; width: 11%;">7.29 years</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 11%;">2,233,321</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 11%;">1.44</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: center; width: 11%;">5.86 years</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 1pt;">$4.58 - $9.05</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">89,999</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5.93</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;">2.51 years</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">89,999</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5.93</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;">2.51 years</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 2.5pt;">$0.09 - $9.05</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">3,843,465</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.79</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: center;"><font style="text-underline-style: double;">7.18 years</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,323,320</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.62</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: center;"><font style="text-underline-style: double;">5.73 years</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The options outstanding and exercisable as of March 31, 2011, are as follows:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="13">Options&#160;Outstanding</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="10">Options&#160;Exercisable</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Weighted</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Weighted&#160;Average</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Weighted</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Weighted&#160;Average</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;">Range&#160;of</td>
<td>&#160;</td>
<td style="text-align: center;"
 colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Average</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Remaining</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Average</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">Remaining</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center;">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Options</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Contractual&#160;Life</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Options</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Contractual&#160;Life</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; width: 16%;">$0.09 - $4.57</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 11%;">2,721,921</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 11%;">1.22</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: center; width: 11%;">6.75 years</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 11%;">2,183,073</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 11%;">1.32</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: center; width: 11%;">6.27 years</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 1pt;">$4.58 - $9.05</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">89,999</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5.93</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;">3.51 years</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">89,999</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5.93</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;">3.51 years</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 2.5pt;">$0.09 - $9.05</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,811,926</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.37</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: center;"><font style="text-underline-style: double;">6.65 years</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,273,072</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.50</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: center;"><font style="text-underline-style: double;">6.16 years</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<div style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Options of Subsidiary</i></b></div>
<div style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</div>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times,
 serif;">During 2004 and 2007, CD4 granted 30,000 options. On August 5, 2009, 10,000 of these options expired. As of March 31, 2012, a total of 20,000 options were outstanding and exercisable with an exercise price of $0.20 and a remaining contractual life of 0.12 years.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of March 31, 2012, Epitope has 50,000 options outstanding and 20,000 options exercisable with an exercise price of $0.001 and a remaining contractual life of 6.25 years.&#160;&#160;These options were granted during 2008, vest annually over 5 years, and have a fair value of $50, which was determined using the Black-Scholes model with the following assumptions: expected dividend yield of 0%; expected volatility of 200%, risk free interest rate of 2.47% and an expected life of 10 years.</p><span></span></td>
        <td class="text"><div>
<table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in; text-align: left;"><b>5.</b></td>
<td style="text-align: justify;"><b>Stock-Based Compensation</b></td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"><b><i>Stock Incentive Plan</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">During 2001, the Company&#8217;s Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the &#8220;2001 Stock Plan&#8221;). As of the date of the merger, there were 1,489,353 options issued and outstanding under the 2001 plan. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &#8220;Awards&#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of December 31, 2011, there were 1,320,354 options issued and outstanding under the 2001 Stock Plan.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On March 20, 2007, the Company&#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of December 31, 2011, there are 1,201,156 options issued and outstanding under the 2007 Stock Plan.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various period from the date of grant, and generally expire ten years after the grant date. As of December 31, 2011, there are 457,500 options issued and outstanding under the 2010 Stock Plan.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes assumptions used in the years ended December 31, 2011 and 2010 are as follows:</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6">Year&#160;ended&#160;December&#160;31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: center;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt; text-align: center;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2">2010</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align:
 bottom; background-color: #ccffcc;">
<td>Exercise price</td>
<td>&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">$0.49 - $2.22</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">$0.56 - $0.87</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="width: 64%; text-align: left;">Expected dividends</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: center;">&#160;</td>
<td style="width: 15%; text-align: center;">0%</td>
<td style="width: 1%; text-align: center;">&#160;</td>
<td style="width: 1%; text-align: center;">&#160;</td>
<td style="width: 1%; text-align: center;">&#160;</td>
<td style="width: 15%; text-align: center;">0%</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">Expected volatility</td>
<td>&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">175% - 188%</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">187% - 207%</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Risk fee interest rate</td>
<td>&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">1.30% - 3.58%</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">2.54% - 3.63%</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">Expected life of option</td>
<td>&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">5 - 7 years</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">10 years</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Expected forfeitures</td>
<td>&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">0%</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">0%</td>
<td style="text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The Company records stock-based compensation based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.75in;">&#160;</td>
<td style="width: 0.5in; padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt;">immediate vesting,</td>
</tr>
<tr style="vertical-align: top;">
<td>&#160;</td>
<td style="padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt;">half vesting immediately and the remainder over three years,</td>
</tr>
<tr style="vertical-align: top;">
<td>&#160;</td>
<td style="padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt;">quarterly over three years,</td>
</tr>
<tr style="vertical-align: top;">
<td>&#160;</td>
<td style="padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt;">annually over three years,</td>
</tr>
<tr style="vertical-align: top;">
<td>&#160;</td>
<td style="padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt;">one-third immediate vesting and remaining annually over two years,</td>
</tr>
<tr style="vertical-align: top;">
<td>&#160;</td>
<td style="padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt;">one half immediate vesting with remaining vesting over nine months,</td>
</tr>
<tr style="vertical-align: top;">
<td>&#160;</td>
<td style="padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt;">one quarter immediate vesting with the remaining over three years</td>
</tr>
<tr style="vertical-align: top;">
<td>&#160;</td>
<td style="padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt;">one quarter immediate vesting with the remaining over 33 months; and</td>
</tr>
<tr style="vertical-align: top;">
<td>&#160;</td>
<td style="padding-right: 0.8pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="padding-right: 0.8pt;">monthly over three years.</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">During 2011, the Company granted 557,002 options to employees and consultants having an approximate fair value of $609,000 based upon the Black-Scholes option pricing model.&#160; During 2010, the Company granted 743,332 options to employees and consultants having an approximate fair value of $597,000 based upon the Black-Scholes option pricing model.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2"
 nowrap="nowrap">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">Remaining</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">Aggregate</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">Average&#160;Exercise</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">Contractual</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">Intrinsic</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Options</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Price</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Life</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Value</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 40%; padding-bottom: 2.5pt;">Balance &#8211; December 31, 2009</td>
<td style="width: 1%; padding-bottom: 2.5pt;">&#160;</td>
<td style="width: 1%; padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="width: 12%; padding-bottom: 2.5pt; text-align: right;">2,561,332</td>
<td style="width: 1%; padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="width: 1%; padding-bottom: 2.5pt;">&#160;</td>
<td style="width: 1%; padding-bottom: 2.5pt; text-align: left;">$</td>
<td style="width: 12%; padding-bottom: 2.5pt; text-align: right;">1.26</td>
<td style="width: 1%; padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="width: 1%; padding-bottom: 2.5pt;">&#160;</td>
<td style="width: 1%; border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="width: 12%; border-bottom: black 2.5pt double; text-align: right;">7.16 years</td>
<td style="width: 1%; padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="width: 1%; padding-bottom: 2.5pt;">&#160;</td>
<td style="width: 1%; border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="width: 12%; border-bottom: black 2.5pt double; text-align: right;">304,000</td>
<td style="width: 1%; padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">743,332</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.80</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td>Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(255,954</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.44</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 1pt;">Forfeited</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align:
 right;">(509,619</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">0.69</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt;">Balance &#8211; December 31, 2010</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">2,539,091</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">$</td>
<td style="padding-bottom: 2.5pt; text-align: right;">1.32</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">6.97 years</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,028,000</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">557,002</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1.26</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td>Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(23,333</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.57</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 1pt;">Forfeited</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(93,750</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">0.59</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt;">Balance &#8211; December 31, 2011 &#8211; outstanding</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,979,010</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.34</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">6.01 years</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 2.5pt;">Balance &#8211; December 31, 2011 &#8211; exercisable</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,454,607</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.46</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">5.62 years</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td
 style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 2.5pt;">Grant date fair value of options granted &#8211; 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">609,000</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt;">Weighted average grant date fair value &#8211; 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.09</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 2.5pt;">Grant date fair value of options granted &#8211; 2010</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">597,000</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt;">Weighted average grant date fair value &#8211; 2010</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">0.80</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 2.5pt;">Outstanding options held by related parties &#8211; 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,283,160</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; padding-bottom: 2.5pt;">Exercisable options held by related parties &#8211; 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,070,660</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td
 style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 2.5pt;">Outstanding options held by related parties &#8211; 2010</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,083,160</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; padding-bottom: 2.5pt;">Exercisable options held by related parties &#8211; 2010</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">858,160</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">The options outstanding and exercisable at December 31, 2011 are as follows:</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="11" nowrap="nowrap">Options&#160;Outstanding</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="9" nowrap="nowrap">Options&#160;Exercisable</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Weighted</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Weighted&#160;Average</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Weighted</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Weighted&#160;Average</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap">Range&#160;of</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Average</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Remaining</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Average</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Remaining</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; border-bottom: black 1pt solid;" nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Options</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" nowrap="nowrap">Contractual&#160;Life</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Options</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" nowrap="nowrap">Contractual&#160;Life</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 14%; text-align: center;">$0.09 -
 $4.57</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 12%; text-align: right;">2,889,011</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">1.20</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 14%; text-align: right;">6.11 years</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 12%; text-align: right;">2,364,608</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">1.29</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 14%; text-align: right;">5.72 years</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: center; padding-bottom: 1pt;">$4.58 - $9.05</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">89,999</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5.93</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; border-bottom: black 1pt solid;">2.76 years</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">89,999</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5.93</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; border-bottom: black 1pt solid;">2.76 years</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: center; padding-bottom: 2.5pt;">$0.09 - $9.05</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,979,010</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.34</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; border-bottom: black 2.5pt double;">6.01 years</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,454,607</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.46</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; border-bottom: black 2.5pt double;">5.62 years</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">The options outstanding and exercisable at December 31, 2010 are as follows:</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="11" nowrap="nowrap">Options&#160;Outstanding</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="9" nowrap="nowrap">Options&#160;Exercisable</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Weighted</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Weighted&#160;Average</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Weighted</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Weighted&#160;Average</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap">Range&#160;of</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Average</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Remaining</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Average</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Remaining</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; border-bottom: black 1pt solid;" nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Options</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2"
 nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" nowrap="nowrap">Contractual&#160;Life</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Options</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" nowrap="nowrap">Contractual&#160;Life</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 14%; text-align: center;">$0.09 - $4.57</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 12%; text-align: right;">2,449,092</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">1.16</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 14%; text-align: right;">7.09 years</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 12%; text-align: right;">1,900,445</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">1.28</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 14%; text-align: right;">6.47 years</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: center; padding-bottom: 1pt;">$4.58 - $9.05</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">89,999</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5.93</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; border-bottom: black 1pt solid;">3.76 years</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">89,999</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5.93</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; border-bottom: black 1pt solid;">3.76 years</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: center; padding-bottom: 2.5pt;">$0.09 - $9.05</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,539,091</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.32</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; border-bottom: black 2.5pt double;">6.97 years</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,990,444</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.48</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; border-bottom: black 2.5pt double;">6.35 years</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">The following is a summary of the Company&#8217;s non-vested stock options at December 31, 2011:</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">Weighted&#160;Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><b>Unvested</b>&#160;&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><b>Grant</b>&#160;&#160;</td>
<td nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Stock&#160;Options</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Date&#160;Fair&#160;Value</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr
 style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 64%;">Non-vested&#160;&#8211;&#160;December&#160;31,&#160;2010</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 15%; text-align: right;">548,647</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 15%; text-align: right;">0.77</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">557,002</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.09</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td>Vested/Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(528,017</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.07</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 1pt;">Forfeited/Cancelled</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(53,229</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">0.57</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt;">Non-vested &#8211; December 31, 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">524,403</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">0.82</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 2.5pt;">Weighted average remaining period for vesting</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.67 years</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Stock Warrants and Derivative Liabilities</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On July 2, 2010, the Company entered into a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.32 and a life of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As of December 31, 2011, 30,303 of these warrants remained outstanding.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On January 28, 2011, the Company entered into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants to purchase 1,428,572 shares of common stock. Each warrant was exercisable&#160;for thirteen months&#160;at $2.00 per share and subsequently exchanged for new warrants with substantially the same&#160;terms as the original warrants except that the expiration date was extended for two months. The original warrants had an anti-dilution price protection feature; if the Company issues securities at a price per share that is less than $2.00 per share, the warrant holders will be ratcheted down to the lower offering price. However, the Company had instituted a floor price of $1.40 per share in connection with the price protection.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On April 6, 2011, the Company entered into another Common Stock Purchase Agreement that triggered the ratchet provision and re-set the price of these warrants to $1.40 per share. Due to the re-set to the floor price, the warrant liability was marked-to-market and reclassified to additional paid-in capital since it ceased to contain the provisions of a derivative liability. As of December 31, 2011, all of these warrants remained outstanding.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The warrants were initially recorded as liabilities at their estimated fair value on the commitment date, which was $716,000 with subsequent changes in estimated fair value recorded as a warrant expense&#160;in the Company&#8217;s statement of operations at each subsequent reporting period. On April 6, 2011, the fair value of the warrant liability was $1.5 million, which represented an increase in fair value of $765,000. The fair value was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align:
 justify;">&#160;</p>
</div>
<div>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Remeasurement</td>
<td nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Commitment</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Date</td>
<td nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Date</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">April&#160;6,&#160;2011</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 70%;">Closing stock price</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">1.39</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">2.08</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Expected dividend rate</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">Expected stock price volatility</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">117.1</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">104.6</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Risk free interest rate</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.28</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.29</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">Expected life (years)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.08</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.85</td>
<td style="text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On August 10, 2011, the Company entered into an agreement to exchange the warrants issued in connection with the January 28, 2011 financing for new warrants with substantially the same terms as the original warrants except that in the new warrants the expiration date was&#160;extended by two months.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On April 6, 2011, the Company entered into a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase 844,391 shares of common stock. The warrant was initially exercisable&#160;for thirteen months&#160;at $2.0725 per share. The warrant had an anti-dilution price protection feature; that provided if the Company issues securities at a price per share that is less than $2.0725 per share,&#160;the&#160;exercise price of the warrant&#160;will be ratcheted down to the lower offering price.&#160;On July 28, 2011, the warrant was exchanged for a new warrant with substantially similar terms except that in the new warrant (i) the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00, (iii) the expiration date was extended for an additional&#160;three months to August 12, 2012,&#160;and (iv) the warrant&#8217;s initial exercise date was changed to January 2012. Due to this warrant exchange, the warrant liability was marked-to-market and reclassified to additional paid-in capital since it ceased to contain the provisions of a derivative liability. As of December 31, 2011, all of these warrants remained outstanding.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">The warrant is&#160;initially recorded as a liability at&#160;its estimated fair value on the commitment date, which was $776,000 with subsequent changes in estimated fair value recorded as a warrant expense&#160;in the Company&#8217;s statement of operations at each subsequent period. On July 28, 2011, the fair value of the warrant liability was $253,000, which represented a decrease in fair value of $523,000. The fair value is measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Remeasurement</td>
<td nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td
 nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Commitment</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Date</td>
<td nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Date</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">July&#160;28,&#160;2011</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 70%; text-indent: -0.25in; padding-left: 0.25in;">Closing stock price</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">2.08</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">0.84</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;">Expected dividend rate</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;">Expected stock price volatility</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">112.1</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">105.6</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;">Risk free interest rate</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.29</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.21</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;">Expected life (years)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.08</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.04</td>
<td style="text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">The following table summarizes the estimated fair value of the warrant liabilities <i>(in thousands):</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-indent: -0.25in; padding-left: 0.25in;">Balance at December 31, 2010</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="width: 85%; text-align: left; text-indent: -0.25in; padding-left: 0.25in;">Warrant liability</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 12%; text-align: right;">1,492</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;">Change in fair value of warrant liability</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">242</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;">Reclassification to additional paid-in capital</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(1,734</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.25in;">Balance at December 31, 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">A summary of warrant activity for the Company for the year ended December 31, 2010 and for the year ended December 31, 2011 is as follows:</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" colspan="2" nowrap="nowrap">Weighted&#160;Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2"
 nowrap="nowrap">Number&#160;of&#160;Warrants</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 70%;">Balance at December 31, 2009</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 12%; text-align: right;">1,070,472</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">3.27</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">60,606</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.32</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td>Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 1pt;">Forfeited</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td>Balance as December 31, 2010</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,131,078</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">3.49</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2,272,963</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.25</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td>Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(15,615</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.03</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 1pt;">Forfeited</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(129,240</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">2.08</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt;">Balance as December 31, 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">3,259,186</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.95</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">A summary of all outstanding and exercisable warrants as of December 31, 2011 is as follows:</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Exercise<br />Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Warrants<br />Outstanding</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Warrants<br />Exercisable</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Weighted&#160;Average<br />Remaining<br />Contractual&#160;Life</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap">Aggregate <br />Intrinsic&#160;Value</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 18%; text-align: right;">1.00</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 17%; text-align: right;">844,391</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;
 text-align: left;">&#160;</td>
<td style="width: 17%; text-align: right;">844,391</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 17%; text-align: right;">0.61 years</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 17%; text-align: right;">219,000</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">$</td>
<td style="text-align: right;">1.32</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">30,303</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">30,303</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4.00 years</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">$</td>
<td style="text-align: right;">1.40</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,428,572</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,428,572</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.33 years</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">$</td>
<td style="text-align: right;">2.22</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">517,257</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">517,257</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4.91 years</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;">$</td>
<td style="text-align: right;">3.30</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">61,207</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">61,207</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">3.41 years</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">$</td>
<td style="text-align: right;">3.75</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">50,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">50,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4.13 years</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">6.36</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">327,456</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">327,456</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">0.86 years</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.95</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">3,259,186</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">3,259,186</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.33 years</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">219,000</td>
<td style="padding-bottom: 2.5pt; text-align:
 left;">&#160;</td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"><b><i>Options of Subsidiaries</i></b></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">As of December 31, 2011, CD4 Biosciences, Inc., a majority-owned subsidiary of Synthetic Biologics, has a total of 20,000 stock options outstanding and exercisable.&#160;&#160;These stock options have an exercise price of $0.20 and a remaining contractual life of 0.37 years.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">As of December 31, 2011, Epitope, a majority-owned subsidiary of Synthetic Biologics, has 50,000 stock options outstanding and 20,000 stock options exercisable. These stock options have an exercise price of $0.001 and a remaining contractual life of 6.50 years.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif; margin-left: 0in;"><b>8.&#160;&#160;&#160;Stockholders&#8217; Equity</b></p>
<div style="text-align: justify; margin-top: 0px; font: 10pt times new roman, times, serif; margin-left: 0in;">During the three months ended March 31, 2012, the Company issued 289,343 shares of common stock, in connection with the exercise of stock options, for proceeds of approximately $68,000. The Company also issued 1,194,264 shares of common stock in connection with the exercise of warrants, for proceeds of approximately $1.5 million.</div><span></span></td>
        <td class="text"><div>
<table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in; text-align: left;"><b>6.</b></td>
<td style="text-align: justify;"><b>Stockholders&#8217; Equity</b></td>
</tr>
</table>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>Year Ended December 31, 2010</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On July 2, 2010, the Company sold 1,212,121 shares of the Company&#8217;s common stock at a closing price of $0.825 for gross proceeds of $1 million.&#160;&#160;The Company paid direct offering costs of $115,000.&#160;&#160;See Note 5 regarding warrants granted with this offering.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">During the year ended December 31, 2010, the Company issued 255,954 shares of common stock, in connection with the exercise of stock options, for proceeds of $130,000. The Company also issued 279,724 shares of common stock for consulting services, having a fair value of $214,000 ($0.76 per share), 81,035 shares of common stock for license fees, having a fair value of $70,000 ($0.87 per share), and 60,521 shares of common stock for employment service, having a fair value of $47,000 ($0.77 per share). The fair value of these issuances were based upon the quoted closing trading prices.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><i>Year Ended December 31, 2011</i></p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">During the year ended December 31, 2011, the Company issued 28,333 shares of common stock in connection with the exercise of stock options and warrants for proceeds of $15,000 and 10,615 shares of common stock related to a cashless exercise of warrants. The Company issued 73,585 shares of common stock for employment service, having a fair value of $94,000 ($1.29 average per share) and 171,796 shares of common stock for consulting services, having a fair value of $165,000 ($0.96 average per share), based on the quoted closing trading prices. The Company also issued 3,123,558 shares of common stock as consideration for the Channel Agreement with Intrexon, having a fair value of $1.7 million ($0.54 average per share), based on the quoted closing trading price.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On January 28, 2011, the Company sold 2,857,144 shares of common stock and warrants exercisable for&#160;1,428,572 shares of common stock&#160;for $4 million. Direct offering costs were approximately $296,000.</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
</div>
<div>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On April 6, 2011, the Company sold 1,688,782 shares of common stock and a warrant exercisable for 844,391 shares of common stock&#160;for $3.5 million. Direct offering costs were approximately $243,000.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPWBI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital [Member]</div>
        </th>
        <th class="th">
          <div>Retained Earnings [Member]</div>
        </th>
        <th class="th">
          <div>Subscription Receivable [Member]</div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2009</a></td>
        <td class="nump">$ 22<span></span></td>
        <td class="nump">$ 45,553<span></span></td>
        <td class="num">$ (42,013)<span></span></td>
        <td class="num">$ (17)<span></span></td>
        <td class="nump">$ 3,545<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2009</a></td>
        <td class="nump">21,449,352<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">400<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">400<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for employee compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">47<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">47<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for employee compensation (in shares)</a></td>
        <td class="nump">60,521<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueLicenseFees', window );">Issuance of common stock for license fees</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">70<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">70<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesLicenseFees', window );">Issuance of common stock for license fees (in shares)</a></td>
        <td class="nump">81,035<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueConsultingFees', window );">Issuance of common stock for consulting fees</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">213<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">213<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesConsultingFees', window );">Issuance of common stock for consulting fees (in shares)</a></td>
        <td class="nump">279,724<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for options exercised</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">113<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">17<span></span></td>
        <td class="nump">130<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for options exercised (in shares)</a></td>
        <td class="nump">255,954<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">884<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">885<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
        <td class="nump">1,212,121<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,711)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,711)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2010</a></td>
        <td class="nump">23<span></span></td>
        <td class="nump">47,280<span></span></td>
        <td class="num">(43,724)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3,579<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2010</a></td>
        <td class="nump">23,338,707<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">973<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">973<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for employee compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">94<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">94<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for employee compensation (in shares)</a></td>
        <td class="nump">73,585<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement', window );">Issuance of common stock for exclusive channel collaboration agreement</a></td>
        <td class="nump">3<span></span></td>
        <td class="nump">1,684<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,687<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement', window );">Issuance of common stock for exclusive channel collaboration agreement (in shares)</a></td>
        <td class="nump">3,123,558<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueConsultingFees', window );">Issuance of common stock for consulting fees</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">165<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">165<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesConsultingFees', window );">Issuance of common stock for consulting fees (in shares)</a></td>
        <td class="nump">171,796<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised', window );">Issuance of common stock for options and warrants exercised</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">15<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">15<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised', window );">Issuance of common stock for options and warrants exercised (in shares)</a></td>
        <td class="nump">38,948<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
        <td class="nump">5<span></span></td>
        <td class="nump">6,956<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">6,961<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
        <td class="nump">4,545,926<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified', window );">Warrant liability reclassified to stockholders' equity</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,734<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,734<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(8,149)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(8,149)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2011</a></td>
        <td class="nump">$ 31<span></span></td>
        <td class="nump">$ 58,901<span></span></td>
        <td class="num">$ (51,873)<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 7,059<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2011</a></td>
        <td class="nump">31,292,520<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in additional paid in capital due to warrants liability reclassified to stockholders equity during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of consulting fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodSharesConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period For Exclusive Channel Collaboration Agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesLicenseFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of licence fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodSharesLicenseFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options and warrants exercised during the current period..</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodValueConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued during the period as a result of consulting fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodValueConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued during the period For Exclusive Channel Collaboration Agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodValueLicenseFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued during the period as a result of licence fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodValueLicenseFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value stock issued during the period as a result of the stock options and warrants exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value stock issued during the period as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Nature of Operations and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
        <td class="text"><table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in; text-align: left;"><b>1.</b></td>
<td style="text-align: justify;"><b>Organization and Nature of Operations and Basis of Presentation</b></td>
</tr>
</table>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;">&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Description of Business</i></b></p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">Synthetic Biologics, Inc. (the &#8220;Company&#8221; or &#8220;Synthetic Biologics&#8221;), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. In the area of synthetic biology, the Company is initially developing a product candidate to treat PAH. The Company also intends to expand new and existing collaborations in the synthetic biology area. In addition, Synthetic Biologics has several clinical-stage programs that are being funded, or partially funded, by grants, charitable organizations and corporate partners. In this area we are developing, or have partnered the development of, product candidates to treat relapsing-remitting MS, cognitive dysfunction in MS, fibromyalgia and ALS.</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 24%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center;" nowrap="nowrap">Medical Indication</td>
<td style="width: 2%; padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="width: 24%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center;" nowrap="nowrap">Product Candidate</td>
<td style="width: 2%; padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="width: 48%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center;" nowrap="nowrap">Status</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">PAH</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">Synthetic DNA-based therapy</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">Preclinical</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">Relapsing-remitting MS</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">Trimesta</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">All patients enrolled in Phase II clinical trial;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;(estriol)</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">dosing and monitoring underway</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">Cognitive dysfunction in</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">Trimesta</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">Patient enrollment underway in Phase II</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">MS</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;(estriol)</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">clinical trial</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">Fibromyalgia</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">Effirma</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">Partnered with Meda AB</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;"
 nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">(oral flupirtine)</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">ALS</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">AEN-100</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">Clinical trial preparation underway</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">(gastroretentive zinc acetate)</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
<td style="padding-right: 0.8pt; text-align: center;" nowrap="nowrap">&#160;</td>
</tr>
</table>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0;">&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On December 21, 2011, Synthetic Biologics announced that the Board of Directors had taken several actions to prioritize its focus on our entry into the emerging field of synthetic biology. The Company also announced that it intends to seek marketing partners for its zinc-based products <i>reaZin</i> &#8482; and <i>wellZin</i> &#8482;.</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"><b><i>Basis of Presentation and Corporate Structure</i></b></p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">As of December 31, 2011, the Company had eight active subsidiaries, Pipex Therapeutics, Inc. (&#8220;Pipex Therapeutics&#8221;), Adeona Clinical Laboratory (formerly Hart Lab, LLC), Effective Pharmaceuticals, Inc. (&#8220;EPI&#8221;), Solovax, Inc. (&#8220;Solovax&#8221;), CD4 Biosciences, Inc. (&#8220;CD4&#8221;), Epitope Pharmaceuticals, Inc. (&#8220;Epitope&#8221;), Healthmine, Inc. (&#8220;Healthmine&#8221;) and Putney Drug Corp. (&#8220;Putney&#8221;). As of December 31, 2011, EPI, Adeona Clinical Laboratory, Healthmine and Putney are wholly owned and Pipex Therapeutics, Solovax, CD4 and Epitope are majority-owned.</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">For financial reporting purposes, the outstanding common stock of the Company is that of Synthetic Biologics, Inc. All statements of operations, stockholders&#8217; equity and cash flows for each of the entities are presented as consolidated. All subsidiaries were formed under the laws of the State of Delaware on January 8, 2001, except for EPI, which was incorporated in Delaware on December 12, 2000, Epitope which was incorporated in Delaware in January of 2002, Putney which was incorporated in Delaware in November of 2006, Healthmine which was formed in Delaware in December of 2007 and Adeona Clinical Laboratory which was incorporated in Illinois as a limited liability company on August 8, 2005.</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">&#160;&#160;</p>
<p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;">On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &#8220;Lab&#8221;) to Hartlab, LLC, an entity controlled by the Lab&#8217;s former owner, in consideration for (i) the immediate assignment of the Lab&#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year non-recourse promissory note secured by all the assets of the Lab. Accordingly, this business has been presented in the consolidated financial statements as discontinued operations. This transaction is described in more detail in Note 3 &#8211; Discontinued Operations of Adeona Clinical Laboratory.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6970148&amp;loc=SL6228881-111685<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS140-4/FIN46(R)-8<br><br> -Paragraph 8, C1, C7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name FASB Interpretation (FIN)<br><br> -Publisher FASB<br><br> -Number 46R<br><br> -Paragraph 4, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359553&amp;loc=d3e288-107754<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>29</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>4</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/Balancesheetparenthetical</Role>
      <ShortName>Consolidated Balance Sheets [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StatementOfIncomeAlternative</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Changes in Stockholders' Equity [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Organization and Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Organization and Nature of Operations and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable</Role>
      <ShortName>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Selected Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/SelectedBalanceSheetInformation</Role>
      <ShortName>Selected Balance Sheet Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Stock Purchase Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StockPurchaseWarrants</Role>
      <ShortName>Stock Purchase Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - License, Collaborative and Employment Agreements and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitments</Role>
      <ShortName>License, Collaborative and Employment Agreements and Commitments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 002 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Consolidated Balance Sheets [Parenthetical]</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - Consolidated Statements of Changes in Stockholders' Equity [Parenthetical]</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>syn-20120331.xml</File>
    <File>syn-20120331.xsd</File>
    <File>syn-20120331_cal.xml</File>
    <File>syn-20120331_def.xml</File>
    <File>syn-20120331_lab.xml</File>
    <File>syn-20120331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
